BIOTECHPERLE: AASTROM 905286!!! - 500 Beiträge pro Seite

[RichManMaker]

In Kürze sollen GUTE News von AASTROM kommen, WKN 905286!

Der Wert ist aktuell auf ATL bei ca. 0,75€. bzw. 0,65$ angelangt.

Das letzte Mal als News kamen explodierte der Wert auf über 2$.

Aussichtsreich!

RichManMaker

[RichManMaker]

AASTROM ( WKN 905286 ) steht unmittelbar vor Ausbruch:

Schaut auf en Chart!

KZ 1,25$ = 1,4€.

RichManMaker

Letzte News:

Aastrom testet SC-I an europäischen Krebszentren

Das in der Stammzellenforschung tätige US-Unternehmen Aastrom Biosciences, Inc. (Nasdaq: ASTM) wird gemäß eigener Angaben in
einem europaweiten Netzwerk von Krebszentren sein Produkt SC-I testen. Das multinationale europäische Netzwerk wird in enger
Zusammenarbeit die klinische Evaluierung von Aastroms SC-I Knochenmarkstammzellen durchführen. SC-I wird hierbei bei
Krebspatienten zum Einsatz kommen, die nicht über ausreichend Zellmaterial für ein PBSC (Periphere Blutstammzellen) Transplantat
verfügen. Jedes Krebszentrum wird nach einem standardisierten klinischen Protokoll drei bis fünf Patienten mit Hilfe von SC-I
behandeln, die erhaltenen Daten sollen gemeinsam publiziert werden. Nach erfolgreicher Beendigung dieser klinischen Phase werden
die europäischen Krebszentren in der Lage sein, das Aastrom Produkt erfolgreich routinemäßig einzusetzen. Aastrom wird sein Produkt
im Anschluss an die klinische Testung allen beteiligten Krebszentren kommerziell zur Verfügung stellen.

[Junkers87DStuka]

VERP,SS DICH
HIER

STRONGEST SELL!!!

DER WERT IST TOT

PUSH LIEBER DEINE RHOMBIC !!!

[RichManMaker]

Auf Spinner wie oben gehe ich nicht ein...

AASTROM WKN 905286:
Gerade zu 0,74$ = ca. 0,82€. zwei DICKE Käufe in USA!!!

Hier könnte was gehen, es stehen News zu den Studien hinsichtlich der Krebsforschung an.

Fast auf ATL...würde erste Position aufbauen.

Frankfurt taxt noch 0,78€. im ask...

Meine Meinung!

RMM

[meislo]

Your requested Equity Alert on ASTM,
follows below.

===============================================





Aastrom Biosciences Receives $0.9 Million Grant From DARPA for Immune System Research - Collaborative Grant Funds Research for New Cell Therapy Application -

ANN ARBOR, Mich., Sep 18, 2002 /PRNewswire-FirstCall via COMTEX/ -- Aastrom
Biosciences, Inc. (Nasdaq: ASTM) announced that it was awarded approximately
$897,000 of a collaborative grant by the Defense Advanced Research Projects
Agency (DARPA) providing funding over an 18 month period for the research and
development of a system to engineer human stem cells into an artificial immune
system. In addition to Aastrom, the multi-disciplinary team working on this
project includes researchers from Florida State University and Tulane
University, and is being led by scientists at the Ohio State University Research
Foundation. A total grant of approximately $3.7 million was awarded to support
the efforts of the collaborative scientific and engineering team involved in
this research project, subject to appropriate progress as determined by DARPA.

DARPA structured this Engineered Tissue Constructs program into two phases. The
current grant supports Phase I, intended to establish the reliable
differentiation of human stem cells into multiple immune functions within a 3-D
culture system. Under a separate request, Phase II of the program will focus on
the continuation of Phase I technologies.

"Aastrom is pleased to be a part of this diverse team of experienced
investigators, and looks forward to working with these respected institutions to
develop an automated, clinical-scale culture system for the Department of
Defense based on our current AastromReplicell(TM) System platform technology,"
said Steven N. Wolff, M.D., Vice President Medical Research of Aastrom. "We
believe Aastrom`s cell therapy technologies will benefit this project, and have
the potential to lead to advances in the fields of immunotherapy, vaccine
development and tissue regeneration."

The immune system is the body`s internal natural defense to fight infectious
agents, including viruses. The potential outcome of this DARPA project is the
development of an effective tissue engineering approach to generate an immune
system outside of the body. It is intended that this system will be used to test
new vaccines that may provide better protection against agents of bio-terrorism.

Dr. Wolff continued, "Aastrom has been conducting clinical studies demonstrating
the successful biological outcomes of ex vivo-expanded adult bone marrow stem
cells using Aastrom`s patented technologies. Due to the hard work and effort of
Aastrom`s team of researchers and engineers, this collaborative grant presents
an important opportunity to use our technologies in the fight against biological
terrorism."

About DARPA

DARPA (Defense Advanced Research Projects Agency), the central research and
development organization for the Department of Defense, is charged with pursuing
research and technology that could provide dramatic advances for traditional
military roles and missions. The Defense Sciences Office (DSO), one of eight
DARPA technical offices, seeks the most promising discoveries and innovations in
science and engineering to enhance defense capabilities. To accelerate reliable
science and technology methodologies necessary to achieve 3-D tissue
engineering, the DSO established a special focus area through the formation of
the Engineered Tissue Constructs program.

About Aastrom Biosciences, Inc.

Aastrom develops unique cell-based products through proprietary technologies for
stem cell tissue repair, and the treatment of cancer and infectious disease.
These competencies are based on dual-technology platforms: patented single-pass
perfusion (SPP) providing cells with excellent biological function, and patented
GMP-compliant system automation facilitating the delivery of cells for
therapeutic use into medical practice. These technologies are integrated into
the AastromReplicell(TM) System, to uniquely standardize and automate the
processes involved in producing high quality Tissue Repair Cells (TRCs) and
Therapeutic Cells (TCs). Aastrom`s growing pipeline of TRC products, derived
from bone marrow and cord blood, target the reconstruction of normal tissues.
These TRCs are intended for use in stem cell transplants, the treatment of
severe osteoporosis and in bone grafting procedures. Aastrom also has an
expanding line of potential TC products. These TCs are intended to function
similar to drugs in causing a therapeutic action. Aastrom`s TC products under
development include the Dendricell(TM) dendritic cell products for the cancer
vaccine market. In addition, Aastrom has developed a proprietary cell
manufacturing device, the AastromReplicell(TM) System. These products are not
available for sale at this time in the U.S., except for research or
investigational use. The SC-I, CB-I, DC-I, DCV-I cell production products and
the AastromReplicell(TM) System are CE Mark approved for European marketing and
sales, and the System is also available to clinical research programs and
companies developing cell therapies.


Please visit our website at http://www.aastrom.com

This document contains forward-looking statements, including without limitation,
statements regarding product development objectives, potential product
applications and potential advantages of the AastromReplicell(TM) System and
related cell therapy kits, which involve certain risks and uncertainties. The
forward-looking statements are also identified through use of the words
"intend," "potential," "could," "believe," "may," and other words of similar
meaning. Actual results may differ significantly from the expectations contained
in the forward-looking statements. Among the factors that may result in
differences are the results obtained from clinical trial and development
activities, research activities being conducted by others, regulatory approval
requirements, the availability of resources, competitive developments and the
allocation of resources among different potential uses. These and other
significant factors are discussed in greater detail in Aastrom`s Annual Report
on Form 10-K, and other filings with the Securities and Exchange Commission.


CONTACT:
Kris M. Maly
Investor Relations Manager
Aastrom Biosciences, Inc.
Phone: [phone]

Noonan Russo Presence Euro RSCG
Brian Ritchie, Phone: [phone] (media)
David Walsey, Phone: [phone] (investors)

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X87530214

SOURCE Aastrom Biosciences, Inc.


CONTACT: Kris M. Maly, Investor Relations Manager of Aastrom
Biosciences, [phone]; or Media, Brian Ritchie, [phone], or
Investors, David Walsey, [phone], all of Noonan Russo Presence Euro
RSCG

URL: http://www.aastrom.com
http://www.prnewswire.com

Copyright (C) 2002 PR Newswire. All rights reserved.

-0-


KEYWORD: Michigan
INDUSTRY KEYWORD: HEA
MTC





****************** TO EDIT YOUR EQUITY ALERTS *********************
To unsubscribe or edit your alerts, visit
http://www.equityalert.com/alerts.asp?uid=meislo&xid=72594

*******************************************************************
** IMPORTANT NOTICE AND DISCLAIMER REGARDING THIS COURTESY EMAIL **
*******************************************************************

PLEASE VISIT: http://www.equityalert.com/home/disclaim.asp FOR
ACCESS TO OUR COMPLETE "EQUITYALERT SUBSCRIBER AGREEMENT AND
DISCLAIMER".

*******************************************************************

[meislo]

Your requested Equity Alert on ASTM,
follows below.

===============================================





Aastrom Biosciences Receives $0.9 Million Grant From DARPA for Immune System Research - Collaborative Grant Funds Research for New Cell Therapy Application -

ANN ARBOR, Mich., Sep 18, 2002 /PRNewswire-FirstCall via COMTEX/ -- Aastrom
Biosciences, Inc. (Nasdaq: ASTM) announced that it was awarded approximately
$897,000 of a collaborative grant by the Defense Advanced Research Projects
Agency (DARPA) providing funding over an 18 month period for the research and
development of a system to engineer human stem cells into an artificial immune
system. In addition to Aastrom, the multi-disciplinary team working on this
project includes researchers from Florida State University and Tulane
University, and is being led by scientists at the Ohio State University Research
Foundation. A total grant of approximately $3.7 million was awarded to support
the efforts of the collaborative scientific and engineering team involved in
this research project, subject to appropriate progress as determined by DARPA.

DARPA structured this Engineered Tissue Constructs program into two phases. The
current grant supports Phase I, intended to establish the reliable
differentiation of human stem cells into multiple immune functions within a 3-D
culture system. Under a separate request, Phase II of the program will focus on
the continuation of Phase I technologies.

"Aastrom is pleased to be a part of this diverse team of experienced
investigators, and looks forward to working with these respected institutions to
develop an automated, clinical-scale culture system for the Department of
Defense based on our current AastromReplicell(TM) System platform technology,"
said Steven N. Wolff, M.D., Vice President Medical Research of Aastrom. "We
believe Aastrom`s cell therapy technologies will benefit this project, and have
the potential to lead to advances in the fields of immunotherapy, vaccine
development and tissue regeneration."

The immune system is the body`s internal natural defense to fight infectious
agents, including viruses. The potential outcome of this DARPA project is the
development of an effective tissue engineering approach to generate an immune
system outside of the body. It is intended that this system will be used to test
new vaccines that may provide better protection against agents of bio-terrorism.

Dr. Wolff continued, "Aastrom has been conducting clinical studies demonstrating
the successful biological outcomes of ex vivo-expanded adult bone marrow stem
cells using Aastrom`s patented technologies. Due to the hard work and effort of
Aastrom`s team of researchers and engineers, this collaborative grant presents
an important opportunity to use our technologies in the fight against biological
terrorism."

About DARPA

DARPA (Defense Advanced Research Projects Agency), the central research and
development organization for the Department of Defense, is charged with pursuing
research and technology that could provide dramatic advances for traditional
military roles and missions. The Defense Sciences Office (DSO), one of eight
DARPA technical offices, seeks the most promising discoveries and innovations in
science and engineering to enhance defense capabilities. To accelerate reliable
science and technology methodologies necessary to achieve 3-D tissue
engineering, the DSO established a special focus area through the formation of
the Engineered Tissue Constructs program.

About Aastrom Biosciences, Inc.

Aastrom develops unique cell-based products through proprietary technologies for
stem cell tissue repair, and the treatment of cancer and infectious disease.
These competencies are based on dual-technology platforms: patented single-pass
perfusion (SPP) providing cells with excellent biological function, and patented
GMP-compliant system automation facilitating the delivery of cells for
therapeutic use into medical practice. These technologies are integrated into
the AastromReplicell(TM) System, to uniquely standardize and automate the
processes involved in producing high quality Tissue Repair Cells (TRCs) and
Therapeutic Cells (TCs). Aastrom`s growing pipeline of TRC products, derived
from bone marrow and cord blood, target the reconstruction of normal tissues.
These TRCs are intended for use in stem cell transplants, the treatment of
severe osteoporosis and in bone grafting procedures. Aastrom also has an
expanding line of potential TC products. These TCs are intended to function
similar to drugs in causing a therapeutic action. Aastrom`s TC products under
development include the Dendricell(TM) dendritic cell products for the cancer
vaccine market. In addition, Aastrom has developed a proprietary cell
manufacturing device, the AastromReplicell(TM) System. These products are not
available for sale at this time in the U.S., except for research or
investigational use. The SC-I, CB-I, DC-I, DCV-I cell production products and
the AastromReplicell(TM) System are CE Mark approved for European marketing and
sales, and the System is also available to clinical research programs and
companies developing cell therapies.


Please visit our website at http://www.aastrom.com

This document contains forward-looking statements, including without limitation,
statements regarding product development objectives, potential product
applications and potential advantages of the AastromReplicell(TM) System and
related cell therapy kits, which involve certain risks and uncertainties. The
forward-looking statements are also identified through use of the words
"intend," "potential," "could," "believe," "may," and other words of similar
meaning. Actual results may differ significantly from the expectations contained
in the forward-looking statements. Among the factors that may result in
differences are the results obtained from clinical trial and development
activities, research activities being conducted by others, regulatory approval
requirements, the availability of resources, competitive developments and the
allocation of resources among different potential uses. These and other
significant factors are discussed in greater detail in Aastrom`s Annual Report
on Form 10-K, and other filings with the Securities and Exchange Commission.


CONTACT:
Kris M. Maly
Investor Relations Manager
Aastrom Biosciences, Inc.
Phone: [phone]

Noonan Russo Presence Euro RSCG
Brian Ritchie, Phone: [phone] (media)
David Walsey, Phone: [phone] (investors)

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X87530214

SOURCE Aastrom Biosciences, Inc.


CONTACT: Kris M. Maly, Investor Relations Manager of Aastrom
Biosciences, [phone]; or Media, Brian Ritchie, [phone], or
Investors, David Walsey, [phone], all of Noonan Russo Presence Euro
RSCG

URL: http://www.aastrom.com
http://www.prnewswire.com

Copyright (C) 2002 PR Newswire. All rights reserved.

-0-


KEYWORD: Michigan
INDUSTRY KEYWORD: HEA
MTC





****************** TO EDIT YOUR EQUITY ALERTS *********************
To unsubscribe or edit your alerts, visit
http://www.equityalert.com/alerts.asp?uid=meislo&xid=72594

*******************************************************************
** IMPORTANT NOTICE AND DISCLAIMER REGARDING THIS COURTESY EMAIL **
*******************************************************************

PLEASE VISIT: http://www.equityalert.com/home/disclaim.asp FOR
ACCESS TO OUR COMPLETE "EQUITYALERT SUBSCRIBER AGREEMENT AND
DISCLAIMER".

*******************************************************************

[meislo]

Neue Behandlungsmethode gegen Hautkrebs erforscht
- Laborgezüchtete Immunzellen werden Patienten eingepflanztLaborgezüchtete Immunzellen können nach neuen Forschungsergebnissen aus den USA erfolgreich gegen den Hautkrebs eingesetzt werden. Wie die Zeitschrift "Science" in ihrer Internet-Ausgabe berichtet, konnten mit Hilfe solcher Zellen bei mehreren Patienten so genannte Melanome, also rasch wachsende bösartige Tumore, deutlich verringert werden. Die Zellen waren im Labor präpariert worden, um den jeweiligen spezifischen Tumor des Patienten zu bekämpfen.
Bei den Untersuchungen am Nationalen Krebs-Institut der USA waren insgesamt 13 Patienten die so genannten T-Lymphozyten eingespritzt worden. Bei zwei von ihnen konnte das Melanom um mehr als 95 beziehungsweise 99 Prozent reduziert werden, in vier weiteren Fällen um mehr als 50 Prozent. Bei vier Patienten waren die Ergebnisse gemischt, bei dreien war die
Behandlung wirkungslos.
Die Forscher sehen in laborgezüchteten Immunzellen ein mögliches Behandlungsmittel auch gegen andere Krebsarten
und Infektionskrankheiten wie etwa Aids.

Könnte AASTROM mit seinem Ripicellsystem von dieser Meldung profitieren .Wenn ja dann könnte es bald Richtung Norden mit dem Kurs gehen. Was meint IHR,das wäre doch eine Bombemsache

[meislo]

Schnelle Antwort auf Posting Nr. 7 gibt AASTROM heute selbst
bekannt


Aastrom Biosciences and Stanford University Collaborate on Experimental Treatment For Multiple Myeloma - Clinical Study Uses New Dendritic Cell Vaccine Approach -

ANN ARBOR, Mich., Oct 2, 2002 /PRNewswire-FirstCall via COMTEX/ -- Aastrom
Biosciences, Inc. (Nasdaq: ASTM) announced today the initiation of a
collaborative agreement with Leland Stanford Junior Aastrom Biosciences and Stanford University Collaborate on Experimental Treatment For Multiple Myeloma - Clinical Study Uses New Dendritic Cell Vaccine Approach -

ANN ARBOR, Mich., Oct 2, 2002 /PRNewswire-FirstCall via COMTEX/ -- Aastrom
Biosciences, Inc. (Nasdaq: ASTM) announced today the initiation of a
collaborative agreement with Leland Stanford Junior University (Stanford) for an
immunotherapeutic vaccine clinical study for multiple myeloma cancer patients.
The collaboration will combine Aastrom`s dendritic cell vaccine technology with
Stanford`s cancer antigen technology to produce a cell-based treatment for
multiple myeloma.

The clinical study will be conducted at Stanford University Medical Center under
the direction of Ronald Levy, M.D., Chief, Division of Oncology at Stanford
University Medical Center. Dr. Levy is the principal investigator and received a
grant supporting this study from the National Institutes of Health, Grant Number
CA49605, Project 6, titled, "Idiotype Vaccination Following Allogeneic
Transplantation For the Treatment of Multiple Myeloma."

"This collaboration represents an important development for Aastrom, as it moves
our dendritic cell technology forward into the clinic in a very interesting
format," stated Steven Wolff, M.D., Vice President Medical Research at Aastrom.
"Dr. Levy`s protocol will attempt to harness the power of the immune system to
attack a serious form of cancer. Aastrom`s dendritic cell technology has been
developed to provide the cells for this type of clinical approach."

Dendritic cells are found in the skin, lymphoid tissues and the blood, and are
the most potent antigen-presenting cell serving to initiate an immune reaction.
Antigens are biological molecules that combine with dendritic cells. These
antigen-loaded dendritic cells "educate" immune system T-cells to recognize
antigens on target cells. This approach can be used to form a tumor-specific
vaccine, by first producing a specific class of dendritic cells using cell
culture, and then loading these cells with antigen that is specific to a
patient`s tumor. Once administered to cancer patients, these dendritic cell
vaccines are intended to work by triggering a T-cell immune system response
against the patient`s tumor cells. Recent research publications have shown
encouraging data and results with these new therapeutic vaccines in renal cell
carcinoma, melanoma, prostate and other cancers. The Aastrom/Stanford
collaboration will extend this approach to multiple myeloma.

About Aastrom Biosciences, Inc.

Aastrom develops unique cell-based products through proprietary technologies for
stem cell tissue repair, and the treatment of cancer and infectious disease.
These competencies are based on dual-technology platforms: patented single-pass
perfusion (SPP), providing cells with excellent biological function, and
patented GMP-compliant system automation facilitating the delivery of cells for
therapeutic use in medical practice. These technologies are integrated into the
AastromReplicell(TM) System, to uniquely standardize and automate the processes
involved in producing high quality Tissue Repair Cells (TRCs) and Therapeutic
Cells (TCs). Aastrom`s growing pipeline of TRC products, derived from bone
marrow and cord blood, target the reconstruction of normal tissues. These TRCs
are intended for use in stem cell transplants, the treatment of severe
osteoporosis and in bone grafting procedures. Aastrom also has an expanding line
of potential TC products. These TCs are intended to function similarly to drugs
in causing a therapeutic action. Aastrom`s TC products under development include
the Dendricell(TM) dendritic cell products for the cancer vaccine market. In
addition, Aastrom has developed a proprietary cell manufacturing device, the
AastromReplicell(TM) System. These products are not available for sale at this
time in the U.S., except for research or investigational use. The SC-I, CB-I,
DC-I, DCV-I cell production products and the AastromReplicell(TM) System are CE
Mark approved for European marketing and sales, and the System is also available
to clinical research programs and companies developing cell therapies.


kanntUniversity (Stanford) for an
immunotherapeutic vaccine clinical study for multiple myeloma cancer patients.
The collaboration will combine Aastrom`s dendritic cell vaccine technology with
Stanford`s cancer antigen technology to produce a cell-based treatment for
multiple myeloma.

The clinical study will be conducted at Stanford University Medical Center under
the direction of Ronald Levy, M.D., Chief, Division of Oncology at Stanford
University Medical Center. Dr. Levy is the principal investigator and received a
grant supporting this study from the National Institutes of Health, Grant Number
CA49605, Project 6, titled, "Idiotype Vaccination Following Allogeneic
Transplantation For the Treatment of Multiple Myeloma."

"This collaboration represents an important development for Aastrom, as it moves
our dendritic cell technology forward into the clinic in a very interesting
format," stated Steven Wolff, M.D., Vice President Medical Research at Aastrom.
"Dr. Levy`s protocol will attempt to harness the power of the immune system to
attack a serious form of cancer. Aastrom`s dendritic cell technology has been
developed to provide the cells for this type of clinical approach."

Dendritic cells are found in the skin, lymphoid tissues and the blood, and are
the most potent antigen-presenting cell serving to initiate an immune reaction.
Antigens are biological molecules that combine with dendritic cells. These
antigen-loaded dendritic cells "educate" immune system T-cells to recognize
antigens on target cells. This approach can be used to form a tumor-specific
vaccine, by first producing a specific class of dendritic cells using cell
culture, and then loading these cells with antigen that is specific to a
patient`s tumor. Once administered to cancer patients, these dendritic cell
vaccines are intended to work by triggering a T-cell immune system response
against the patient`s tumor cells. Recent research publications have shown
encouraging data and results with these new therapeutic vaccines in renal cell
carcinoma, melanoma, prostate and other cancers. The Aastrom/Stanford
collaboration will extend this approach to multiple myeloma.

About Aastrom Biosciences, Inc.

Aastrom develops unique cell-based products through proprietary technologies for
stem cell tissue repair, and the treatment of cancer and infectious disease.
These competencies are based on dual-technology platforms: patented single-pass
perfusion (SPP), providing cells with excellent biological function, and
patented GMP-compliant system automation facilitating the delivery of cells for
therapeutic use in medical practice. These technologies are integrated into the
AastromReplicell(TM) System, to uniquely standardize and automate the processes
involved in producing high quality Tissue Repair Cells (TRCs) and Therapeutic
Cells (TCs). Aastrom`s growing pipeline of TRC products, derived from bone
marrow and cord blood, target the reconstruction of normal tissues. These TRCs
are intended for use in stem cell transplants, the treatment of severe
osteoporosis and in bone grafting procedures. Aastrom also has an expanding line
of potential TC products. These TCs are intended to function similarly to drugs
in causing a therapeutic action. Aastrom`s TC products under development include
the Dendricell(TM) dendritic cell products for the cancer vaccine market. In
addition, Aastrom has developed a proprietary cell manufacturing device, the
AastromReplicell(TM) System. These products are not available for sale at this
time in the U.S., except for research or investigational use. The SC-I, CB-I,
DC-I, DCV-I cell production products and the AastromReplicell(TM) System are CE
Mark approved for European marketing and sales, and the System is also available
to clinical research programs and companies developing cell therapies.

[meislo]

Mir war garnicht bewust was die Stanford Universität für einen guten Ruf in Sachen Forschung besitzt bis ich heute zufällig uber dieses Interview gestossen bin.

Bitte lest selber

Die entscheidende Passage stelle ich am Anfang ins Board und dann das ganze Interview

Ich habe einmal daran gedacht, Dekan einer Universität zu werden. Aber da ist man nur damit beschäftigt, Geld zu beschaffen. Die eine Stelle, die ich gerne hätte, wäre Präsident der Stanford University zu sein, trotz der Mängel, die man mit den Universitäten verbindet. Ich habe einen enormen Respekt vor der Forschung.


Die New Economy lebt


Die Fragen stellte Stuart Crainer, Handelsblatt


Tom Peters, der erste Berater in den USA, der als „Management-Guru“ bezeichnet wurde, sagt voraus, dass in zehn Jahren 90 % der heutigen Bürojobs verschwunden sind. Das Gespräch führte Stuart Crainer.





HB DÜSSELDORF. Herr Peters, Ihr Bestseller „In Search of Excellence“ feiert in diesem Jahr seinen zwanzigsten Geburtstag. Hält das Buch nach so vielen Jahren einer genauen Prüfung stand?

Mich interessiert es nicht besonders, ob es standhält. Ich denke nie darüber nach, ob „In Search of Excellence“ überhaupt überzeugt. Es war zu seiner Zeit inspirierend und nützlich, und ich war begeistert, an dem Erfolg teilzuhaben. Es hat zum Jahr 1982 gepasst wie die Faust aufs Auge. Das Buch war ein Freibrief für mich. Es hat seinen Zweck erfüllt, und das ist das Beste, was man erhoffen kann. Es sind Löcher drin – vielleicht nicht ganz so groß wie schwarze Löcher, aber fast!

Haben Sie jemals ernsthaft daran gedacht, eine Fortsetzung zu schreiben?

Ich habe nie daran gedacht, weiter daran zu stricken, auch wenn man mich hundert Mal gebeten hat, es doch zu tun. Mich faszinieren Bücher über turbulente Zeiten und Persönlichkeiten, die mit der Doppeldeutigkeit umgehen müssen.

Es scheint, als hätten Sie sich vom klar umgrenzten Weltbild eines Ingenieurs zu einer Anschauung weiterbewegt, die die komplexen Vorgänge in der Welt akzeptiert und feiert. Trifft das in etwa zu?

Ich war bei „In Search of Excellence“ mit seiner McKinsey-Logik überorganisiert. Jetzt sage ich: Hüten Sie sich vor den Meistern der Ordnung, den Leuten, die „Regeln“ anbieten für ein geordnetes und rechtes Leben. So funktioniert das nicht. Komplexe Angelegenheiten schwarz und weiß zu sehen, ist töricht. Das Leben ist einziges Durcheinander.

Im richtigen Leben muss man seinen Spaß am Durcheinander finden. Das gilt besonders für die Zeiten des Abschwungs. Man muss den Fluss der Dinge als Chance begreifen, als eine Möglichkeit, kühne Initiativen, von denen man schon immer geträumt hat, ins Leben zu rufen.

Sie haben sich der neuen Technik mit mehr Enthusiasmus zugewandt als die meisten Ihrer Wettbewerber.

Ich habe immer Angst zurückzufallen. Dies ist das Zeitalter des permanenten Rummels, also muss man Wege finden, um das Feuer zu schüren. Ich kenne niemanden in meiner Branche, der im Internet wäre. Ich halte immer noch 80 bis 90 Reden pro Jahr und liebe es, dass ich meinen Zuhörern Power-Point-Präsentationen auf dem neuesten Stand vorlegen kann.

Ich bin entzückt, dass ich Leuten, die an meiner Arbeit interessiert sind, solch einen direkten und unmittelbaren Zugang gewähren kann. Ich will ja nur mit den Leuten reden. Und das ist der große Vorteil des Internet. Es verschafft Dir einen Zugang zum Publikum wie nie zuvor. Aber jetzt, da jeder im Web ist, muss man auf die Verpackung achten. Wir haben mit unserem Internet-Geschäft einen Fehler nach dem anderen gemacht. Die Web-Site vertraglich weiterzuvergeben, hat nicht funktioniert – ironischerweise, da ich doch ein Meister der Weitervergabe bin.

Unsere Pläne waren zu hochfliegend, zu schnell und sind dauernd auseinandergefallen. Ich habe gelernt, dass Web-Sites Lebewesen sind. Es ist ein spielerisches Medium: Wenn Du deine Meinung änderst, kannst Du sie einfach auslöschen.

Dann betrachten Sie den Abschwung der US-Wirtschaft nicht als das Ende der New Economy?

Alles ist anders, und doch ist alles gleich. Das Internet bleibt sicher bestehen, und der technische Wandel beschleunigt sich immer noch. Also gibt es mehr New Economy als je zuvor. Es ist jetzt nicht der richtige Zeitpunkt, sich zu ducken und die Investitionen in neue Technik zu kürzen. Man sollte wie verrückt in das neue Zeug investieren.

Aber Sie sind immer noch der Meinung, dass die Technik uns vor noch mehr beunruhigende Herausforderungen stellen wird?

Ja, die Dinge verändern sich dank des Wettbewerbs, der Unternehmens-Software – die Werkzeuge, die jeden Aspekt des Innenlebens einer Firma aneinanderkoppeln, das Outsourcing, das Internet, das Geschäft zwischen den einzelnen Unternehmen und die Zeitverdichtung – das Tempo, mit dem neue Technik wie das Internet aufgenommen wird.

Erinnern Sie sich daran, was mit den Arbeitern passiert ist. Im Jahr 1970 brauchten 108 Männer etwa fünf Tage, um ein Schiff mit Holzbalken zu entladen. Dann kamen die Container. Dieselbe Arbeit wird heute von acht Leuten an nur einem Tag erledigt. Nun stellen Sie sich vor, eine vergleichbare Veränderung vollzieht sich bei den Angestellten. Und genau das geschieht zur Zeit: die Dekonstruktion der Büroarbeit. Ich gehe davon aus, dass in den kommenden zehn bis 15 Jahren 90 % der Bürojobs in den USA entweder verschwunden oder bis zur Unkenntlichkeit umgewandelt sein werden.

Da 90 Prozent von uns in irgendeiner Weise als Angestellte tätig sind, ist das eine ziemlich katastrophale Prognose.

Aber es ist etwas, über das wir alle nachdenken müssen. Eine häufige Kritik an Gurus ist, dass sie nichts taugen würden, wenn sie tatsächlich ein Unternehmen führen müssten.

Haben Sie sich jemals als für den Chefposten tauglich empfunden?

Ich habe es genossen, eine Militäreinheit mit 435 Personen zu führen, aber das, was ich jetzt tue, macht mir auch Spaß. Peter Drucker hat einmal gesagt, es würde ihn langweilen, ein Unternehmen zu leiten. Der Gedanke, der Boss von GE zu sein, gibt mir nichts. Das habe ich noch nie gewollt.

Mit den Bossen herumzuhängen, war nie mein Ding. Aber eine Neugründung zu leiten, ein Unternehmen auf einem ganz anderen Gebiet zu gründen, das ist ein Fest, ob es nun darum geht, Deinen eigenen Marketing-Ansatz zu erfinden oder was auch immer. Auch wenn das harte und psychologisch anspruchsvolle Arbeit ist.

Ich habe einmal daran gedacht, Dekan einer Universität zu werden. Aber da ist man nur damit beschäftigt, Geld zu beschaffen. Die eine Stelle, die ich gerne hätte, wäre Präsident der Stanford University zu sein, trotz der Mängel, die man mit den Universitäten verbindet. Ich habe einen enormen Respekt vor der Forschung.

Haben Sie je daran gedacht, bei ihren vielen Seminaren und Reisen kürzer zu treten?

Ich mache weiter, so lange ich daran Spaß habe. Und ich genieße es, vor dem Publikum zu stehen. Außerdem bin ich im tiefsten Inneren sehr wettbewerbsorientiert. In den Seminaren stehe ich mit mir selbst im Wettkampf.

Wenn ich sieben Stunden lang zu einigen hundert Leuten spreche, dann trägt mich das zu neuen Ufern. Ich bin kein Perfektionist, aber intellektuell sehr neugierig. Meine Mission ist es, mich zu amüsieren.

[meislo]

Dendritic Cell Vaccination Can Induce Regression Of B-Cell NHL


By Faith Reidenbach

NEW YORK Mar 27, 2002 (Reuters Health) - In patients with stage III or IV follicular B-cell non-Hodgkin`s lymphoma, a novel idiotypic vaccination procedure can induce cellular and antibody responses and durable tumor regression.

"The vaccine maneuver consisted of obtaining both the idiotype from the patient`s tumor and the dendritic cells from the patient`s blood, incubating them together and then reinfusing those dendritic cells into the patient," Dr. Ronald Levy, Chief of the Division of Oncology at Stanford University in California, noted in an interview with Reuters Health.

In a pilot study, he and colleagues vaccinated 10 patients who had relapsed or residual disease. Dendritic cells were divided and pulsed (incubated) separately with idiotype or with keyhole limpet hemocyanin (KLH), a carrier protein that Dr. Levy`s group observed to be highly immunogenic in earlier vaccination studies of patients with follicular NHL. Idiotype and KLH were injected at different sites.

Eight of the 10 patients developed T-cell proliferative responses to idiotype, two showed serum anti-idiotype antibodies, and all patients developed humoral and cellular proliferative responses to KLH, the researchers report in the March 1st issue of Blood. Moreover, they observed antitumor activity in four patients, including three who had a complete response.

Encouraged, they vaccinated 25 additional patients after an attempt at remission induction with chemotherapy. For the last 13 patients in this group, dendritic cells were pulsed with both idiotype and KLH and injected at a single site.

Of the 23 patients who completed the vaccination series, 15 showed T-cell or humoral responses to idiotype, the research team determined. Sixteen were progression-free at a median follow-up of 43 months after chemotherapy. There was one death. In a subgroup of 18 patients who had less than a complete response to chemotherapy when vaccination began, four showed sustained regression of tumor.

Of the 13 patients who received the idiotype-KLH conjugate, 12 were evaluable, of whom four showed cellular responses to idiotype and six mounted humoral responses.

"We are now conducting a national phase III trial of idiotype vaccination, without the dendritic cells, to test the efficacy of this approach to delay or prevent the recurrence of lymphoma after standard chemotherapy," Dr. Levy told Reuters Health.

"All patients with newly diagnosed lymphoma should be screened for eligibility in clinical trials," he urged. "This is the only way that we will be able to change the outcomes for this disease and change our standard practices."

In the journal, the Stanford investigators also suggest the findings "may herald a shift in our view of the optimal timing of idiotypic vaccination." Eight to 33 months after original vaccination, they gave idiotype-KLH conjugate booster vaccinations to six patients who had persistent or relapsing disease. They detected immune responses in three of these patients, who showed complete or partial tumor regression.

This finding "provides rationale for further study of idiotype-KLH vaccination in patients with relapsed or even untreated follicular NHL," they propose.

SOURCE:

[meislo]

Hier die zugegeben etwas schlechte Übersetzung

So ganz schlau geworden bin ich nun auch nicht aber vielleicht versteht hier irgendwer aus dem Board was genau gemeint ist. Vielleicht kann Er/Sie sich hierzu äussern.

Dendritic Zellenschutzimpfung kann Rückbildung der B-Zelle NHL durch Faith Reidenbach NEUES YORK Mrz 27, 2002 verursachen (Gesundheit Reuters) - bei Patienten mit Stadium III, oder IV kann Lymphom der follicular B-Zellennon-Hodgkins, ein idiotypic Schutzimpfungverfahren des Romans die zellulare und Antikörperantworten und haltbare Tumorrückbildung verursachen. "das vaccine Manöver bestand aus dem Erreichen des idiotype vom Tumor des Patienten und die dendritic Zellen vom Blut des Patienten, sie zusammen ausbrütend und jene dendritic Zellen in den Patienten dann reinfusing," Dr. Ronald Levy, Leiter der Abteilung von Onkologie an der Stanforduniversität in Kalifornien, merkten in einem Interview mit Gesundheit Reuters. In einer Versuchsstudie impften er und Kollegen 10 Patienten, die oder Restkrankheit zurückgefallen waren. Dendritic Zellen wurden (ausgebrütet worden) separat mit idiotype oder mit Schlüssellochlimpethemocyanin (KLH), ein Fördermaschineprotein geteilt und pulsiert, das die Gruppe des Dr. Levys beobachtet, um in den früheren Schutzimpfungstudien der Patienten mit follicular NHL in hohem Grade immunisierend zu sein. Idiotype und KLH wurden an den unterschiedlichen Aufstellungsorten eingespritzt. Acht der 10 Patienten entwickelten proliferative Antworten der T-Zelle zum idiotype, zeigten zwei Serumanti-idiotypeantikörper, und alle Patienten entwickelten humorales und zellulare proliferative Antworten zu KLH, die Forscher berichten in der Ausgabe Märzes 1. des Bluts. Außerdem beobachteten sie Antitumortätigkeit bei vier Patienten, einschließlich drei, wer eine komplette Antwort hatte. Angeregt, impften sie 25 zusätzliche Patienten nach einem Versuch an der Erlaßinduktion mit Chemotherapie. Für die letzten 13 Patienten in dieser Gruppe, wurden dendritic Zellen mit idiotype und KLH pulsiert und eingespritzt an einem einzelnen Aufstellungsort. Von den 23 Patienten, die die Schutzimpfung-Reihe durchführten, zeigten 15 T-Zelle oder humorale Antworten zum idiotype, die festgestellte Forschungsmannschaft. Sechzehn waren an einem mittleren Anschluß von 43 Monaten nach Chemotherapie Weiterentwicklung-frei. Es gab einen Tod. In einer Untergruppe von 18 Patienten, die kleiner als eine komplette Antwort zur Chemotherapie hatten, als Schutzimpfung anfing, vier unterstützte Rückbildung des Tumors gezeigt. Von den 13 Patienten, die das idiotype-KLHparonym empfingen, waren 12 evaluable, von denen vier darstellten, daß zellulare Antworten zu idiotype und sechs humorale Antworten anbrachten. "wir leiten jetzt einen nationalen Versuch der Phase III der idiotypeschutzimpfung, ohne die dendritic Zellen, um die Wirksamkeit dieser Annäherung zu zu prüfen verzögern oder verhindern das Wiederauftreten des Lymphoms nach Standardchemotherapie," Dr. Levy erklärte Gesundheit Reuters. "alle Patienten mit eben bestimmtem Lymphom sollten für Eignung in den klinischen Versuchen aussortiert werden," er drängten. "dieses ist die einzige Weise, daß wir in der LageSIND, die Resultate für diese Krankheit zu ändern und unsere gängigen Praxen zu ändern.", Im Journal schlagen die Stanfordforscher auch vor, daß die Entdeckungen "eine Verschiebung in unserer Ansicht des optimalen TIMINGS der idiotypic Schutzimpfung ankündigen können.", Acht bis 33 Monate nach ursprünglicher Schutzimpfung, gaben sie idiotype-KLH verbundene Zusatzschutzimpfungen zu sechs Patienten, die hartnäckiges oder Zurückfallenkrankheit hatten. Sie ermittelten immune Antworten in drei dieser Patienten, die komplette oder teilweise Tumorrückbildung zeigten. Dieses, das "findet, versieht Grundprinzip für weitere Studie der idiotype-KLHschutzimpfung bei Patienten mit zurückgefallen, oder sogar unbehandeltes follicular NHL," schlagen sie vor. QUELLE

[meislo]

Eine Studie die ich nal ins Board stellen möchte für diesen Schrotttt bezahlt man 25 Dollar

Market Guide / ProVestor Plus Company Report
Aastrom Biosciences, Inc.
Saturday, October 5, 2002
© 2002 Market Guide Inc. Data Provided by Market Guide Inc.
This report is provided for information purposes only. Under no circumstances is it
to be used or considered as an offer to sell, or a solicitation to buy any security.
While the information contained herein has been obtained from sources deemed
reliable, neither Market Guide nor any party through whom the reader obtains this
Report guarantees that it is accurate or complete or make any warranties with regard
to the results to be obtained from its use. All rights reserved. This report and its
contents may not be resold or otherwise used in commerce without the permission
of Market Guide, Inc.
2001 Marcus Ave. Suite South 200
Lake Success, NY 11042-1011
Tel: [phone] Fax: [phone]
Web Site: www.marketguide.com
Overview Market Guide / ProVestor Plus Company Report
Aastrom Biosciences,
Inc. (NASD:ASTM)
Fiscal Year ends June 30. All data are on a fiscal year basis except where noted. All financials are
reported to conform to the current year presentation and may reflect certain reclassifications made
in prior years.
Prepared Saturday, October 5, 2002 Page 2
Business Summary
ASTM is developing automated clinical systems designed to enable therapeutic
procedures using living cells in the treatment of cancer and other diseases and in the
restoration of normal tissues.
Year-To-Date Results
For the 9 months ended 3/31/02, revenues fell less than 1% to $650K. Net loss rose
48% to $6M. Revenues reflect a decrease in product sales and rentals. Higher loss
reflects a $146K excess inventory charge and higher research, development and
marketing costs.
Earnings Announcement
For the 3 months ended 03/31/2002, revenues were 232; after tax earnings were
-2,072. (Thousands)
Share Information
Market Capitalization $11.8 Mil.
Shares Outstanding 43.7 Mil.
Trading Float 43.3 Mil.
Monthly Trading Volume 5.9 Mil.
Beta 1.6
Indicated Annual Dividend $0.00
Five Year Monthly Stock Performance History
O N D J F M A M J J A S O N D J F M A M J J A S O N D J F M A M J J A S O N D J F M A M J J A S O N D J F M A M J J A S O
1998 1999 2000 2001 2002 1997
$8
$6
$4
$2
$8
$6
$4
$2
Charted in logarithmic format to illustrate true percent changes in price
Price History (Calendar Year)
High Price High
Low Price Low
Year End Price Close
Year End P/E P/E
Dividend Yield
High P/E High P/E
Low P/E Low P/E
2001
$2.60
$0.75
$0.98
NM
0.0%
NM
NM
2000
$9.06
$0.72
$0.88
NM
0.0%
NM
NM
1999
$3.63
$0.31
$0.78
NM
0.0%
NM
NM
1998
$6.75
$1.81
$2.88
NM
0.0%
NM
NM
1997
$9.94
$3.25
$4.38
NM
0.0%
NM
NM
YTD ’02
$1.10
$0.24
$0.27
NM
NA
NA
Current Price
Price (10/4/2002) $0.27
52 Week High (11/26/2001) $1.25
52 Week Low (9/26/2002) $0.24
Per Share Statistics & Current Price Multiples
Per Share Multiple
Earnings (TTM) ($0.18)¹ NM
Book Value (MRQ) $0.29 0.9x
Cash Flow (TTM) NA NM
Revenues (TTM) $0.02¹ 13.5x¹
Employees
Employees 40
Sales Per Employee (TTM) $21,925¹
Net Income Per Employee (TTM) NM
TTM = Trailing Twelve Months, MRQ = Most Recent Quarter, NA = Not Available, NM = Not Meaningful, NAR = Not Available Due To A Restatement.
¹ Uses recent earnings announcement data
Stock Price Performance Market Guide / ProVestor Plus Company Report
Aastrom Biosciences,
Inc. (NASD:ASTM)
Prepared Saturday, October 5, 2002 Page 3
Institutional Ownership
22 Institutions own 1.17% of the 43.7 million common shares
outstanding. The average institutional ownership of the
Biotechnology & Drugs Industry is 44.3%, and the average
institutional ownership of the S&P 500 as a whole is 61.4%.
Insider Trading
Insiders hold 427 thousand shares. In the last 6
months, there have been no insider purchases, and
there have been no insider sales.
Daily Trading Activity During Last Four Months
8 15 22 29 6 13 20 27 3 10 17 24 31 7 14 21 28
June July August September Oct
$0.875
0.750
0.625
0.500
0.375
0.250
0.125
$0.875
0.750
0.625
0.500
0.375
0.250
0.125
0
2
4
6
0
2
4
6
Daily Trading Volume (Millions)
60 Day Moving Average
Equity and Debt Composition
Common Stock no Par, 5/02, 60M auth., 43,726,5575 issd. Insiders
control approx. 3% (includes 900K options). IPO: 2/97, 3M shares @
$7 by Cowen & Company.
Analyst Footnotes
All share amounts prior to IPO are pro forma. 1991, Company changed
name from Ann Arbor Stomal. Upon completion of IPO, Company
converted all Pfd. Stock to Common.
Dividends
ASTM does not currently pay a dividend.
Officers
R. Douglas Armstrong, Chmn./Pres./CEO
Michael Durski, VP-Fin. & Admin./CFO
Brian Hampson, VP
Bruce Husel, VP
Audrey Hutter, VP.
Headquarters
24 Frank Lloyd Wright Drive
P.O. Box 376
Ann Arbor, MI 48106
Company incorporated 1989 in MI
Phone [phone]
Fax [phone]
The quick brown fox jumped over the lazy dog
The quick brown fox jumped over the lazy dog
The quick brown fox jumped over the lazy dog
The quick brown fox jumped over the lazy dog
The quick brown fox jumped over the lazy dog
Quarterly Trends Market Guide / ProVestor Plus Company Report
Aastrom Biosciences,
Inc. (NASD:ASTM)
Years are Fiscal Years
Prepared Saturday, October 5, 2002 Page 4
NA
NA
NA
$232
$267
$151
$246
$191
$295
$167
$149
$212
$404
$385
$260
$251
$207
$163
$104
$80
$49
2003 2002 2001 2000 1999 1998
Quarterly Revenue
$ USD Thousands
NA
NA
NA
($0.05)
($0.05)
($0.05)
($0.05)
($0.05)
($0.03)
($0.04)
($0.04)
($0.09)
($0.13)
($0.21)
($0.13)
($0.20)
($0.16)
($0.27)
($0.29)
($0.41)
($0.60)
2003 2002 2001 2000 1999 1998
Quarterly EPS
Primary
Price/TTM Sales Bands
8.3 - 236.6 x Sales (TTM)
Price/TTM Earnings Bands
Dashed lines represent a band off the chart
Industry Overview Market Guide / ProVestor Plus Company Report
Aastrom Biosciences,
Inc. (NASD:ASTM)
Prepared Saturday, October 5, 2002 Page 5
Miravant Medical Technolo (MRVT) $14.7 $2.62 NM NM $0.78 $11.98 $0.19
Cadus Pharmaceutical Corp (KDUS) $14.5 $0.60 NM NM $1.10 $1.50 $0.81
IntraBiotics Pharmaceut. (IBPI) $14.3 $0 NM NM $0.38 $4.96 $0.33
Immune Response Corp. (IMNR) $14.3 $7.91 NM NM $0.36 $1.81 $0.32
CardioTech International, (CTE) $14.1 $3.21 (60.2)% NM $1.53 $3.50 $1.10
AutoImmune Inc. (AIMM) $14.0 $1.36 47.5% 23.1x $0.83 $1.40 $0.46
Axonyx Inc. (AXYX) $13.8 $0 NM NM $0.80 $6.17 $0.50
Synthetic Blood Int’l Inc (SYBD) $13.7 $0 NM NM $0.16 $0.51 $0.12
Cortex Pharmaceuticals (COR) $13.6 $6.45 (20.8)% NM $0.81 $3.44 $0.51
Bioanalytical Systems,Inc (BASI) $13.5 $26.6 5.7% 9.0x $2.95 $9.52 $2.65
Natrol, Inc. (NTOL) $13.5 $73.2 (29.8)% NM $1.05 $3.44 $0.95
BioTime, Inc. (BTX) $13.4 $0.21 NM NM $0.99 $6.30 $0.95
Sheffield Pharmaceuticals (SHM) $13.3 $0.01 NM NM $0.45 $4.75 $0.30
Hycor Biomedical, Inc. (HYBD) $13.3 $17.9 2.2% 35.9x $1.65 $7.16 $1.57
Viragen International, In (VGNI) $13.0 $1.28 NM NM $0.28 $1.47 $0.21
Pharmaceutical Formulatio (PHFR) $12.8 $51.0 (23.8)% NM $0.15 $0.23 $0.01
Insmed Incorporated (INSM) $12.3 $0.30 NM NM $0.37 $4.76 $0.35
Zonagen, Incorporated (ZONA) $12.2 $3.20 NM NM $1.07 $8.74 $0.90
Aastrom Biosciences, Inc. (ASTM) $11.8 $0.88 NM NM $0.27 $1.25 $0.24
Genaissance Pharm. Inc. (GNSC) $11.6 $7.06 NM NM $0.51 $6.13 $0.36
Argonaut Technologies (AGNT) $11.6 $20.7 (96.1)% NM $0.58 $4.49 $0.51
Anika Therapeutics, Inc. (ANIK) $11.5 $12.0 (39.5)% NM $1.16 $1.54 $0.83
Nutrition 21, Inc. (NXXI) $11.5 $14.6 (40.9)% NM $0.35 $0.98 $0.24
Progen Industries Limited (PGLAF) $11.2 $2.43 (47.1)% NM $0.46 $0.96 $0.45
BioDelivery Sciences Int’ (BDSI) $10.9 $0.91 NM NM $1.55 $5.50 $1.25
OXiGENE, Inc. (OXGN) $10.8 $8.24 (62.7)% NM $0.85 $3.90 $0.85
RegeneRx Biopharmaceut. (RGRX) $10.8 $0 NM NM $0.40 $0.72 $0.15
Ergo Science Corporation (ERGO) $10.5 $0 NM NM $1.47 $2.50 $1.45
Cyanotech Corporation (CYAN) $10.4 $7.95 (37.2)% NM $0.59 $1.43 $0.40
Protein Polymer Technolog (PPTI) $10.2 $1.96 NM NM $0.37 $1.27 $0.22
Forbes Medi-Tech Inc. (FMTI) $9.76 $5.62 (62.5)% NM $0.46 $2.50 $0.28
SIGA Technologies, Inc. (SIGA) $9.63 $0.31 NM NM $0.95 $5.21 $0.65
NeuroCorp., Ltd. (NURC) $9.55 $0.74 NM NM $0.75 $1.35 $0.01
Vion Pharmaceuticals,Inc. (VION) $9.53 $0.41 NM NM $0.33 $5.61 $0.26
Carrington Laboratories, (CARN) $9.38 $16.7 (10.8)% NM $0.95 $3.75 $0.46
Northwest Biotherapeutics (NWBT) $9.35 $0.08 NM NM $0.55 $5.92 $0.45
Biotechnology & Drugs Industry
Following is a list of companies in the Biotechnology &
Drugs industry not appearing in the chart above. They
are listed in order of descending market capitalization:
AMGN, CAH, SRA, DNA, FRX, NVO, TEVA, ABC, AGN,
CHIR, ESALY, GILD, IDPH, AHM, MEDI, AAA, GENZ,
BGEN, MYL, KG, SHPGY, BVF, CLL, BRL, MLNM, WPI,
IVX, CEPH, MDZ, CRL, SCRI, IVGN, EW, HGSI, VRTX,
ADRX, SCIO, TECH, NBIX, RDY, ICOS, ..., MRVT, ...,
NWBT, ....
ASTM is in the Biotechnology & Drugs Industry of the Healthcare Sector. Below is a list of the
35 companies most similar to ASTM’s market capitalization in the Biotechnology & Drugs
Industry listed in descending order. There are 482 companies in this industry.
ASTM Price Performance vs. Biotechnology & Drugs Industry
ASTM vs. Co. Rank Industry
Period Actual S&P 500 In Industry Rank
4 Week (27.0)% (18.5)% 21 89
13 Week (22.9)% (4.7)% 47 99
26 Week (59.7)% (43.5)% 32 54
52 Week (76.5)% (68.6)% 22 19
YTD (72.4)% (60.5)% 29 23
Ranks are Percentile Ranks ranging from 0 to 99, with 99 = best.
Company Name Market TTM Net P/E Price 52-Week 52-Week
(Ticker Symbol) Cap. Revenue Margin 10/4/02 10/4/02 High Low
(Millions) (Millions)
Industry Valuation Market Guide / ProVestor Plus Company Report
Aastrom Biosciences,
Inc. (NASD:ASTM)
S&P 500 Industry
Low
Industry
High
Industry
Average
ASTM
Prepared Saturday, October 5, 2002 Page 6
Price / Earnings Ratios
Current P/E NM 33.3x 225.5x 0.0x 23.2x
High P/E - Last 5 Years NA 63.2x 259.4x 26.4x 50.0x
Low P/E - Last 5 Years NA 20.9x 50.6x 2.2x 17.4x
Beta - 5 Yr. Monthly Avg. 1.6 0.9 4.6 (19.2) 1.0
Other Valuation Multiples
Price to Cash Flow (TTM) NM 29.4x 392.8x 0.0x 15.8x
Price to Free Cash Flow (TTM) NM 37.3x 368.3x 0.0x 26.9x
¹ Price to Sales (TTM) 13.6x 7.9x 408.5x 0.0x 2.6x
Price to Book (MRQ) 0.9x 5.7x 67.8x 0.0x 4.2x
Price to Tangible Book (MRQ) 0.9x 6.8x 70.0x 0.0x 7.1x
Dividends
Dividend Yield 0.0% 0.3% 4.2% 0.0% 2.4%
5 Year Average Yield 0.0% 0.1% 3.1% 0.0% 1.4%
5 Year Dividend Growth Rate NM 8.3% 38.0% (100.0)% 7.8%
Payout Ratio (TTM) 0.0% 1.4% 216.2% 0.0% 29.7%
Revenue Growth (TTM)
-100% 0% 100% 200% 300%
Earnings (TTM) / Price
-30% -15% 0% 15% 30%
PROA
LDNA
HEMA ICCC
POLXF
PHLI
GORX
CYTR
CARN
NURC
CYAN
ERGO RGRX
PGLAF
HYBD
BTX
BASI
COR
SYBD
CTE KDUS
EPMN
BBII
DRUG
CYPB
UG
NAII
PRCY
AKRN
SNUS(389%)
SNT
IMMTC
ONCY
EBIO
BIORY
CVGR
APPA
Industry Comparison of Revenue
Growth and Earnings Yield
Companies that exhibit both a high
earnings yield and high revenue growth
are generally more attractive than
companies with low revenue growth and
low earnings yield.
Companies for this scatter plot have a
market capitalization between $2 million
and $30 million. Companies with NA or
NM values do not appear.
IHTC has been excluded because of
Earnings Yield greater than 30%.
HAUS, CYME, BIOHF, SBIO, HXBM,
NEOT, BSTI, MLSC, NEOP, AEMD,
PURW, INIS, AVXT, XTRN, ALLP, IOX,
HMGN, ORG, ETOP, BSTC, DBSY,
HMYD, VLTS, ACEL, EXTI, RZYM, IG,
ISTA, DATA, CVM, ANX, DOR, EXEG,
NERX, GNT, NWBT, VION, SIGA, FMTI,
PPTI, OXGN, NXXI, ANIK, AGNT, GNSC,
ASTM, ZONA, INSM, PHFR, VGNI, SHM,
NTOL, AXYX, IMNR, IBPI, MRVT, STEM,
DIAGF, VITX, UGNE, DCRN, ETRX,
VGNX, LYNX, GZMO, GENR, PDGM,
BCRX, TGEN, DUSA, GBI, AKC, CLPA,
PHGN, HSKA, VRA, PVLS, VPHM, GLGS,
MCHM, AMRN, ISV, HDGC, BLSI, GTCB,
CGEN, CRIS, GENE, KERX, PTN, GNBT,
DYAX, BIOM, HMSL have been excluded
TTM Revenue Quintile
0-20 21-40 41-60 61-80 81-100
Ratios for Aastrom
Biosciences, Inc. use the
October 4 closing price of
$0.27.
Aastrom Biosciences, Inc.
trades at a higher
multiple of sales than the
industry average.
This page compares selected valuation measures for ASTM with other companies in the
Biotechnology & Drugs Industry as well as the S&P 500.
¹ Uses recent earnings announcement data
Industry Profitability Market Guide / ProVestor Plus Company Report
Aastrom Biosciences,
Inc. (NASD:ASTM)
S&P 500 Industry
Low
Industry
High
Industry
Average
ASTM
Prepared Saturday, October 5, 2002 Page 7
Growth Rates
Revenue (MRQ) vs. Qtr 1 Yr. Ago 21.5% 26.3% 453.4% (100.0)% 3.7%
¹ Revenue (TTM) vs. TTM Last Year (2.4)% 27.7% 5,352.0% (226.3)% 1.6%
Revenue 5 Year Growth Rate (11.0)% 28.2% 281.4% (100.0)% 11.3%
EPS (MRQ) vs. Qtr 1 Yr. Ago 3.9% 25.8% 900.0% (975.7)% 11.9%
EPS (TTM) vs. TTM 1 Yr. Ago NM 18.6% 368.7% (100.0)% 4.2%
EPS - 5 Yr. Growth Rate NM 22.8% 186.8% (52.1)% 8.7%
Dividend - 5 Yr. Growth Rate NM 8.3% 38.0% (100.0)% 7.8%
Capital Spending - 5 Yr. Growth (33.5)% 23.4% 686.1% (100.0)% 10.3%
Revenue Growth (TTM)
-100% 0% 100% 200% 300% 400%
EBITD Margin (TTM)
-12000 -8000 -4000 0 4000
HAUS
BIOHF
SBIO
IHTC
BSTI
NEOP
PURW
INIS
AVXT
XTRN
PROA
ALLP(456%)
IOX
HMGN
ORG
LDNA
HEMA ICCC
BSTC
POLXF
DBSY
VLTS
ACEL(-54900)
PHLI
GORX
EXTI
RZYM
CYTR
IG
DATA
CVM
ANX
EXEG
NERX
GNT
NWBT(-16008)
CARN
VION
NURC
SIGA
FMTI
PPTI
CYAN
OXGN
PGLAF
NXXI ANIK
AGNT
GNSC
ASTM
ZONA
INSM
PHFR
VGNI
HYBD
SHM(-116960)
BTX
NTOL
BASI
COR
CTE
IMNR
KDUS
MRVT
STEM
DIAGF
VITX
UGNE
EPMN
BBII
DRUG
CYPB
UG
DCRN
ETRX
VGNX
LYNX
GZMO
NAII
PRCY
GENR(493%)
PDGM
AKRN
BCRX
TGEN
DUSA
AKC
CLPA
SNUS
SNT
HSKA
IMMTC
VRA
ONCY
PVLS
EBIO
BIORY
VPHM
CVGR
AMRN
APPA
ISV(-55484)
HDGC
GTCB
CGEN CRIS
GENE
PTN
DYAX
BIOM
Industry Comparison of Revenue
Growth and EBITD Margin (Earnings
Before Interest, Taxes, and
Depreciation / Revenues)
Companies with higher than average
EBITD margin and revenue growth are
doing well. Companies with a low
EBITD margin and revenue growth are
suffering.
Companies for this scatter plot have a
market capitalization between $2 million
and $30 million. Companies with NA or
NM values do not appear.
ISTA has been excluded because of
EBITD Margin less than -12,000%.
CYME, NEOT, AIMM, MCHM have been
excluded because of Revenue Growth
greater than 400%.
TTM Revenue Quintile
81-100% > $15.6 million
61-80% $8.24-15.6 million
41-60% $3.78-8.24 million
21-40% $0.96-3.78 million
0-20% < $0.96 million
ASTM’s 5-year revenue
growth is slower than the
industry average.
¹ Uses recent earnings announcement data
Industry Returns Market Guide / ProVestor Plus Company Report
Aastrom Biosciences,
Inc. (NASD:ASTM)
S&P 500 Industry
Low
Industry
High
Industry
Average
ASTM
Prepared Saturday, October 5, 2002 Page 8
Financial Strength
Aastrom Biosciences, Inc.
is less leveraged than the
average for the
Biotechnology & Drugs
industry.
Quick Ratio (MRQ) 13.2 4.9 137.8 0.0 1.1
Current Ratio (MRQ) 14.7 5.8 138.0 0.0 1.6
LT Debt/Equity (MRQ) 0.0 0.4 547.3 0.0 0.7
Total Debt/Equity (MRQ) 0.0 0.4 547.8 0.0 1.0
Interest Coverage (TTM) NM (1.3) 1,833.3 (5,842.2) 9.5
Management Effectiveness
ASTM’s TTM return on
assets is lower than the
industry average.
¹ Return On Assets (TTM) (56.4)% 2.6% 189.4% (2,138.5)% 6.4%
Return On Assets - 5 Yr. Avg. (86.6)% 2.6% 322.9% (12,389.1)% 8.0%
Return On Investment (TTM) (63.4)% 3.9% 485.2% (775.0)% 10.1%
Return On Investment - 5 Yr. Avg. (96.6)% 5.8% 193.4% (774.9)% 12.8%
¹ Return On Equity (TTM) (60.4)% 8.6% 127.8% (399.2)% 18.1%
Return On Equity - 5 Yr. Avg. (264.3)% 9.3% 471.4% (1,390.9)% 21.9%
Profit Margin (TTM)
-60% -30% 0% 30% 60%
Effective Tax Rate (TTM)
0% 25% 50% 75%
IHTC
LDNA
ICCC
POLXF
CYTR
NXXI
HYBD
BASI
AIMM
UG
PRCY
CVGR
Industry Comparison of Profit
Margin vs. Effective Tax Rate
Earnings of companies with below
average tax rates might erode if the tax
rate increases.
Companies for this scatter plot have a
market capitalization between $2 million
and $30 million. Companies with NA or
NM values do not appear.
ASTM does not appear because of an
NA or NM value.
TTM Revenue Quintile
81-100% > $17.9 million
61-80% $12.2-17.9 million
41-60% $8.87-12.2 million
21-40% $6.80-8.87 million
0-20% < $6.80 million
¹ Uses recent earnings announcement data
Industry Growth Rates Market Guide / ProVestor Plus Company Report
Aastrom Biosciences,
Inc. (NASD:ASTM)
S&P 500 Industry
Low
Industry
High
Industry
Average
ASTM
Prepared Saturday, October 5, 2002 Page 9
Profitability Ratios
Gross Margin (TTM) 83.7% 65.4% 114.0% (86.7)% 47.7%
Gross Margin - 5 Yr. Avg. 77.8% 63.8% 100.0% (78.7)% 48.9%
EBITD Margin (TTM) NM 21.7% 94.4% (100.0)% 21.1%
EBITD Margin - 5 Yr. Avg. NM 16.6% 60.5% (98.0)% 22.1%
Operating Margin (TTM) NM 17.1% 94.4% (100.0)% 17.7%
Operating Margin - 5 Yr. Avg. NM 9.0% 51.3% (99.3)% 18.2%
Pretax Margin (TTM) NM 20.1% 94.5% (100.0)% 14.9%
Pretax Margin - 5 Yr. Avg. NM 10.8% 57.4% (97.8)% 17.1%
Profit Margin (TTM) NM 13.7% 107.6% (96.1)% 10.6%
Profit Margin - 5 Yr. Avg. NM 5.2% 37.0% (98.4)% 11.2%
Effective Tax Rate (TTM) NM 32.5% 225.5% 0.0% 33.3%
Effective Tax Rate - 5 Yr. Avg. NM 30.5% 73.0% 0.0% 35.8%
Operating Efficiency
ASTM’s revenue per
employee is lower than
the industry average.
¹ Revenue/Employee (TTM) $21,925 $562,911 $13,802,000 $168 $632,831
Net Income/Employee (TTM) NM $97,506 $900,291 $0 $76,597
¹ Receivable Turnover (TTM) 6.3x 11.1x 1,178.3x 0.0x 9.4x
Inventory Turnover (TTM) 0.2x 3.1x 1,538.5x (1.5)x 11.5x
¹ Asset Turnover (TTM) 0.1x 1.0x 5.4x 0.0x 1.0x
Profit Margin (TTM)
-120% -90% -60% -30% 0% 30%
Profit Margin (5-Yr. Avg.)
-120% -90% -60% -30% 0% 30%
HAUS
SBIO
IHTC
PURW
PROA
IOX
HMGN
LDNA
HEMA
ICCC
BSTC
POLXF
PHLI
GORX
IG
CARN
CYAN
NXXI
ANIK
AGNT
PHFR
HYBD
NTOL
BASI
CTE
BBII
UG
NAII
AKRN
HSKA
CVGR
AMRN
GENE
DYAX
Industry Comparison of Profit
Margin (TTM) vs. Profit Margin
(5-Yr. Avg)
Companies with TTM profit margins
above their 5-year average are
improving their profitability.
Companies for this scatter plot have a
market capitalization between $2 million
and $30 million. Companies with NA or
NM values do not appear.
ASTM does not appear because of an
NA or NM value.
TTM Revenue Quintile
81-100% > $37.3 million
61-80% $22.2-37.3 million
41-60% $12.2-22.2 million
21-40% $8.87-12.2 million
0-20% < $8.87 million
ASTM’s TTM gross
margin is higher than the
average for the industry.
¹ Uses recent earnings announcement data
Annual Income Statement
Annual Financials Market Guide / ProVestor Plus Company Report
Aastrom Biosciences,
Inc. (NASD:ASTM)
Years are Fiscal Years
In Thousands, Except Per Share Amounts (Currency is U.S. Dollars)
12 Months
Jun 30 1997
1997
12 Months
Jun 30 1998
1998
12 Months
Jun 30 1999
1999
12 Months
Jun 30 2000
2000
12 Months
Jun 30 2001
2001
Prepared Saturday, October 5, 2002 Page 10
Product Sales $0 $0 $34 $169 $85
Research & Develop. 230 3 0 0 0
Grants 148 246 847 981 814
Total Revenue $378 $249 $881 $1,150 $899
Cost of Production $0 $0 $6 $1,251 $13
Research & Devel. 13,357 15,498 10,871 6,289 4,983
General & Administration 1,953 2,858 2,836 3,364 2,482
Total Expenses $15,310 $18,356 $13,713 $10,904 $7,478
Interest Expense (32) (12) (4) 0 0
Other, Net 676 886 1,808 364 653
Income Before Taxes ($14,288) ($17,233) ($11,028) ($9,390) ($5,926)
Income After Taxes ($14,288) ($17,233) ($11,028) ($9,390) ($5,926)
Preferred Dividends 0 (351) (409) (208) 0
Issuance Prfd. Stock 0 (3,439) (70) 0 0
EPS Reconciliation
Adjusted Income Available to Common ($14,288) ($21,023) ($11,507) ($9,598) ($5,926)
Primary/Basic Average Sh 11,228 13,363 15,342 23,344 34,030
Pri/Bas EPS Ex. Extraordinary Items ($1.27) ($1.57) ($0.75) ($0.41) ($0.17)
Net Income ($14,288) ($21,023) ($11,507) ($9,598) ($5,926)
Pri/Bas EPS In. Extraordinary Items ($1.27) ($1.57) ($0.75) ($0.41) ($0.17)
Diluted Average Shs. 11,228 13,363 15,342 23,344 34,030
Diluted EPS Excl Extraordinary Items ($1.27) ($1.57) ($0.75) ($0.41) ($0.17)
Diluted EPS Incl Extraordinary Items ($1.27) ($1.57) ($0.75) ($0.41) ($0.17)
Gross Margin
97
100.0%
98
100.0%
99
99.3%
00
(8.8)%
01
98.6%
Revenue
97
$378
98
$249
99
$881
00
$1,150
01
$899
EPS Fully Diluted
97
($1.27)
98
($1.57)
99
($0.75)
00
($0.41)
01
($0.17)
Excl. Extraordinary Items
Fully Diluted Avg. Shrs.
Millions
97
11.2
98
13.4
99
15.3
00
23.3
01
34.0
Pretax Margin
97
(3,779.9)%
98
(6,920.9)%
99
(1,251.8)%
00
(816.5)%
01
(659.2)%
Preferred Dividend
97
$0
98
$351
99
$409
00
$208
01
$0
Annual Balance Sheet
Annual Financials Market Guide / ProVestor Plus Company Report
Aastrom Biosciences,
Inc. (NASD:ASTM)
Years are Fiscal Years
In Thousands (Currency is U.S. Dollars)
As of
Jun 30 1997
1997
As of
Jun 30 1998
1998
As of
Jun 30 1999
1999
As of
Jun 30 2000
2000
As of
Jun 30 2001
2001
Prepared Saturday, October 5, 2002 Page 11
Assets
Cash/Equivalents $1,943 $2,078 $7,528 $2,064 $10,659
ST Investments 15,064 9,134 0 10,681 0
Receivables 229 167 113 242 129
Inventory 0 0 1,144 0 725
Prepaid Expenses 126 270 253 158 213
Total Current Assets $17,362 $11,649 $9,038 $13,145 $11,726
Machinery/Equipment $1,425 $1,473 $1,477 $1,483 $1,381
Office Equipment 733 903 883 886 918
Leasehold Imprv. 605 621 622 622 622
Equip/Lease 0 0 0 120 120
Depreciation (1,715) (2,272) (2,480) (2,819) (2,862)
Total Assets $18,410 $12,374 $9,540 $13,437 $11,905
Liabilities
Payable/Accrued $1,508 $1,313 $836 $837 $856
Employee Expense 130 150 193 165 155
Cur.Port.Leases 124 65 0 0 0
Total Current Liabs $1,762 $1,528 $1,029 $1,002 $1,011
Total Long Term Debt $65 $0 $0 $0 $0
Total Liabilities $1,827 $1,528 $1,029 $1,002 $1,011
Shareholder Equity
Preferred Stock $0 $9,930 $6,588 $0 $0
Common Stock 58,073 59,474 72,257 92,367 96,752
Accum. Deficit (41,313) (58,897) (70,334) (79,932) (85,858)
Notes Receivable (167) 0 0 0 0
Stock Purch. Rts. 0 335 0 0 0
Investment Loss (10) 4 0 0 0
Total Equity $16,583 $10,846 $8,511 $12,435 $10,894
Total Liab. & Sh. Equity $18,410 $12,374 $9,540 $13,437 $11,905
Shares Outstanding 13,275 13,640 16,980 33,608 37,681
Total Cash and Equivs.
Millions
97
$1.9
98
$2.1
99
$7.5
00
$2.1
01
$10.7
Total Liabilities
Millions
97
$1.83
98
$1.53
99
$1.03
00
$1.00
01
$1.01
Total Equity
Millions
97
$16.6
98
$10.8
99
$8.5
00
$12.4
01
$10.9
Shares Outstanding
Millions
97
13.3
98
13.6
99
17.0
00
33.6
01
37.7
Annual Cash Flow Statement
Annual Financials Market Guide / ProVestor Plus Company Report
Aastrom Biosciences,
Inc. (NASD:ASTM)
Years are Fiscal Years
In Thousands of U.S. Dollars
12 Months
Jun 30 1997
1997
12 Months
Jun 30 1998
1998
12 Months
Jun 30 1999
1999
12 Months
Jun 30 2000
2000
12 Months
Jun 30 2001
2001
Prepared Saturday, October 5, 2002 Page 12
Cash From (Used By) Operations
Net Income ($14,288) ($17,233) ($11,028) ($9,390) ($5,926)
Depreciation 564 557 296 346 171
Amort./Investments (84) (180) (70) (21) (69)
Stock Compensation 120 398 11 5 120
Inv Write Down 0 0 0 1,027 0
Stock Issued 0 1,100 1,100 1,100 0
Receivables (148) 38 54 (129) 113
Inventory 0 0 (1,144) 117 (725)
Prepaid Expenses 311 (144) 17 95 (55)
Payable/Accrued 316 (195) (477) 1 19
Accrd. Empl. Expense 33 20 43 (28) (10)
Deferred Revenue (122) 0 0 0 0
Cash From Operations ($13,298) ($15,639) ($11,198) ($6,877) ($6,362)
Plus: Cash From (Used by) Investment Activities
Purch.-ST Investment ($19,190) ($12,326) ($1,000) ($10,660) ($1,500)
Matur.-St Investment 4,200 18,450 10,200 0 12,250
Capital Expenditures (424) (234) (73) (136) (58)
Cash From Investing ($15,414) $5,890 $9,127 ($10,796) $10,692
Plus: Cash From (Used By) Financing Activities
Prfd. Stock, Issd. $0 $9,930 $7,499 $0 $0
Common Stock, Issd. 19,911 127 87 12,209 4,265
Capital Lease Oblig. (223) (124) (65) 0 0
Repurchase Common 0 (49) 0 0 0
Cash From Financing $19,688 $9,884 $7,521 $12,209 $4,265
Equals: Increase (Decrease) In Cash
Net Change In Cash ($9,024) $135 $5,450 ($5,464) $8,595
Free Cash Flow ($13,722) ($15,873) ($11,271) ($7,013) ($6,420)
Cash From Operations
97
($13,298)
98
($15,639)
99
($11,198)
00
($6,877)
01
($6,362)
Total Capital Expend.
97
($424)
98
($234)
99
($73)
00
($136)
01
($58)
Cash From Financing
97
$19,688
98
$9,884
99
$7,521
00
$12,209
01
$4,265
Net Change In Cash
97
($9,024)
98
$135
99
$5,450
00
($5,464)
01 $8,595
Quarterly Income Statement
Quarterly Financials Market Guide / ProVestor Plus Company Report
Aastrom Biosciences,
Inc. (NASD:ASTM)
Years are Fiscal Years
In Thousands, Except Per Share Amounts (Currency is U.S. Dollars)
3 Months
Mar 31 2001
Q3 ’01
3 Months
Jun 30 2001
Q4 ’01
3 Months
Sep 30 2001
Q1 ’02
3 Months
Dec 31 2001
Q2 ’02
3 Months
Mar 31 2002
Q3 ’02
Prepared Saturday, October 5, 2002 Page 13
Product Sales $0 $0 $0 $80 $0
Grants 191 246 151 187 232
Total Revenue $191 $246 $151 $267 $232
Cost of Product Sale $0 $0 $40 $66 $40
Research & Devel. 1,455 1,543 1,207 1,396 1,439
General & Administration 599 710 919 931 886
Total Expenses $2,054 $2,253 $2,166 $2,393 $2,365
Other, Net 148 118 122 106 61
Income Before Taxes ($1,715) ($1,889) ($1,893) ($2,020) ($2,072)
Income After Taxes ($1,715) ($1,889) ($1,893) ($2,020) ($2,072)
EPS Reconciliation
Adjusted Income Available to Common ($1,715) ($1,889) ($1,893) ($2,020) ($2,072)
Primary/Basic Average Sh 33,846 34,761 39,934 42,343 42,506
Pri/Bas EPS Ex. Extraordinary Items ($0.05) ($0.05) ($0.05) ($0.05) ($0.05)
Net Income ($1,715) ($1,889) ($1,893) ($2,020) ($2,072)
Pri/Bas EPS In. Extraordinary Items ($0.05) ($0.05) ($0.05) ($0.05) ($0.05)
Diluted Average Shs. 33,846 34,761 39,934 42,343 42,506
Diluted EPS Excl Extraordinary Items ($0.05) ($0.05) ($0.05) ($0.05) ($0.05)
Diluted EPS Incl Extraordinary Items ($0.05) ($0.05) ($0.05) ($0.05) ($0.05)
Gross Margin
Q3
01
100.0%
Q4
01
100.0%
Q1
02
73.5%
Q2
02
75.3%
Q3
02
82.8%
Revenue
Q3
01
$191
Q4
01
$246
Q1
02
$151
Q2
02
$267
Q3
02
$232
EPS Fully Diluted
Q3
01
($0.05)
Q4
01
($0.05)
Q1
02
($0.05)
Q2
02
($0.05)
Q3
02
($0.05)
Excl. Extraordinary Items
Fully Diluted Avg. Shrs.
Millions
Q3
01
33.8
Q4
01
34.8
Q1
02
39.9
Q2
02
42.3
Q3
02
42.5
EBITD Margin
Q3
01
(872.8)%
Q4
01
(725.6)%
Q1
02
(1,313.2)%
Q2
02
(773.0)%
Q3
02
(878.9)%
Pretax Margin
Q3
01
(897.9)%
Q4
01
(767.9)%
Q1
02
(1,253.6)%
Q2
02
(756.6)%
Q3
02
(893.1)%
Quarterly Balance Sheet
Quarterly Financials Market Guide / ProVestor Plus Company Report
Aastrom Biosciences,
Inc. (NASD:ASTM)
Years are Fiscal Years
In Thousands (Currency is U.S. Dollars)
As of
Mar 31 2001
Q3 ’01
As of
Jun 30 2001
Q4 ’01
As of
Sep 30 2001
Q1 ’02
As of
Dec 31 2001
Q2 ’02
As of
Mar 31 2002
Q3 ’02
Prepared Saturday, October 5, 2002 Page 14
Assets
Cash/Equivalents $4,052 $10,659 $10,660 $8,781 $10,953
ST Investments 4,509 0 4,508 4,502 1,000
Receivables 155 129 110 172 145
Inventories 0 725 859 846 994
Prepaid Expenses 931 213 424 348 350
Total Current Assets $9,647 $11,726 $16,561 $14,649 $13,442
Property/Equip., Net $183 $179 $165 $161 $233
Total Assets $9,830 $11,905 $16,726 $14,810 $13,675
Liabilities
Payable/Accrued $920 $856 $736 $764 $741
Employee Expense 126 155 140 222 176
Total Current Liabs $1,046 $1,011 $876 $986 $917
Total Liabilities $1,046 $1,011 $876 $986 $917
Shareholder Equity
Common Stock 92,734 96,752 103,593 103,593 104,601
Accumulated Deficit (83,969) (85,858) (87,751) (89,771) (91,843)
Other Comprehensive 19 0 8 2 0
Total Equity $8,784 $10,894 $15,850 $13,824 $12,758
Total Liab. & Sh. Equity $9,830 $11,905 $16,726 $14,810 $13,675
Shares Outstanding 33,608 37,681 42,343 42,343 43,727
Total Cash and Equivs.
Q3
01
$4,052
Q4
01
$10,659
Q1
02
$10,660
Q2
02
$8,781
Q3
02
$10,953
Total Liabilities
Q3
01
$1,046
Q4
01
$1,011
Q1
02
$876
Q2
02
$986
Q3
02
$917
Total Equity
Q3
01
$8,784
Q4
01
$10,894
Q1
02
$15,850
Q2
02
$13,824
Q3
02
$12,758
Shares Outstanding
Millions
Q3
01
33.6
Q4
01
37.7
Q1
02
42.3
Q2
02 42.3
Q3
02
43.7
Quarterly Cash Flow Statement
Quarterly Financials Market Guide / ProVestor Plus Company Report
Aastrom Biosciences,
Inc. (NASD:ASTM)
Years are Fiscal Years
In Thousands of U.S. Dollars
9 Months
Mar 31 2001
Q3 ’01
12 Months
Jun 30 2001
Q4 ’01
3 Months
Sep 30 2001
Q1 ’02
6 Months
Dec 31 2001
Q2 ’02
9 Months
Mar 31 2002
Q3 ’02
Prepared Saturday, October 5, 2002 Page 15
Cash From (Used By) Operations
Net Income ($4,037) ($5,926) ($1,893) ($3,913) ($5,985)
Depreciation 135 171 32 62 94
Amort./Investments (59) (69) 0 0 0
Stock/Options Granted 120 120 0 0 0
Inventory Write Down 0 0 40 106 146
Receivables 87 113 19 (43) (16)
Inventory 0 (725) (174) (227) (415)
Other Current Assets 0 0 (211) (135) (137)
Payable/Accrued 83 19 (120) (92) (115)
Accrd. Empl. Expense (39) (10) (15) 67 21
Prepaid Expenses (773) (55) 0 0 0
Cash From Operations ($4,483) ($6,362) ($2,322) ($4,175) ($6,407)
Plus: Cash From (Used by) Investment Activities
Purch.-ST Investment ($1,500) ($1,500) ($4,500) ($4,500) ($5,500)
Matur.-St Investment 7,750 12,250 0 0 4,500
Capital Expenditures (26) (58) (18) (44) (148)
Cash From Investing $6,224 $10,692 ($4,518) ($4,544) ($1,148)
Plus: Cash From (Used By) Financing Activities
Common Stock Issued $247 $4,265 $6,841 $6,841 $7,849
Cash From Financing $247 $4,265 $6,841 $6,841 $7,849
Equals: Increase (Decrease) In Cash
Net Change In Cash $1,988 $8,595 $1 ($1,878) $294
Free Cash Flow ($4,509) ($6,420) ($2,340) ($4,219) ($6,555)
Cash From Operations
Q3
01
($4,483)
Q4
01
($6,362)
Q1
02
($2,322)
Q2
02
($4,175)
Q3
02
($6,407)
Total Capital Expend.
Q3
01
($26)
Q4
01
($58)
Q1
02
($18)
Q2
02
($44)
Q3
02
($148)
Cash From Financing
Q3
01
$247
Q4
01
$4,265
Q1
02
$6,841
Q2
02
$6,841
Q3
02
$7,849
Net Change In Cash
Q3
01
$1,988
Q4
01
$8,595
Q1
02
$1
Q2
02
($1,878)
Q3
02
$294

[meislo]

Ich stelle Euch einmal eine Zusammenfassung der wichtigsten Punkte eines Interview mit Dr. Amstrong von Oktober 2002


Add www to the beginning of the link above.
Exciting time developing for an exciting company.
Proprietary cell therapeutic.
Focused on three product areas.
1) TRC -tissue repair cells -cell mixtures to grow outside the body and reconstruct bone and cartiledge.
2) Therapeutic cells - vaccines for cancer or other types of infections.
3) Aastrom Devices - automated clinical level cell production instruments and related kits. Originally developed for Tissue repair and TRCs.
Multiple paths to revenue as the company and are now moving towards those pathways.
Different franchises and addressible market.
TRCs-begin with small sample of patients own bone marrow. Take small sample and grow large quantity. Clinical tests have shown successfully regeneration of tissue inside the patient (OC line of cell products). Major market opportunities. Use to generate bone. Used in severe osteoporosis patients. Bone regeneration, bone grafting (spinal fusions, repair large bone fractures of the leg and arms where you need bone graft material, bone repair. Planning initial clinical trials at this time.
How plan to achieve milestones?
Devices CE mark several products in Europe. Key milestone to establish customers and book revenue principly out of Europe.
Key 12-month milestones are >
Projecting over 8-12 new customers out of European marketplace and from these we should begin to book revenue.
Looking to go into Asia.
Another milestone is to gain regulatory approval to initiate and complete bone grafting clinical trials in US and Europe. Well over $1 billion market.
Last point-very active in area to produce dendricell (dendritic cells-important milestone coming up in the near term months).
TRC area- dentric cell vaccine -initiate first clinical trial with dendricell in the US in the near term months.
Challenges investors might be missing out-Company has been involved in stem therapy over 10 years. Investment in tech is now behind us. Demonstrated successful clinical results. Completed investment into devices of the systems to produce these cells. Risk of technology is behind us. Now is the time to put the successful tech to work to gain access to important markets.
Institutional investors-why should they look at aastrom. Aastrom share price dropped not due to any adverse situtations within Aastrom.
Low market cap relative to definable risk.
Generate revenues over the coming months. Large therapeutic opportnuties market moving into clinical trials.
Orphan product status.
Pipelines of products.
Long term investors - relates to multiple paths to revenue-long time opportunities.
Immediate revenue from device business 2-4 year range from cell therapeutics from Europe. 4-7 from U.S market. Near term growth and subsequent pipeline flowout to drive long term growth.
Mgmt team has unique balance of business and scientific background. Dr. A. since 1991.
Brian Hanson - over 9 years.
Dr. Steven Wolf -stem cell transplant program 20years at Vanderbelt.
Al Wright -financial community. Saavy business executive -help improve communications and performance with the investment community.
Watch us deliver and perform against these milestones.

[meislo]

Deutshe Übersetzung mittels Übersetzungsprogramm. Zugegeben
nicht die beste Übersetzung aber hilfreich

Aufregende Zeit, die für eine aufregende Firma sich entwickelt. Eigene Zelle therapeutisch. Konzentriert auf drei Produktbereiche. 1) TRC - Gewebereparaturzellen - Zellenmischungen zum Wachsen außerhalb des Körpers und Wieder aufbauen des Knochens und des cartiledge. 2) therapeutische Zellen - Impfstoffe für Krebs oder andere Arten Infektion. 3) Vorrichtungen Aastrom - automatisierte klinische waagerecht ausgerichtete Zellenproduktionsinstrumente und bezogene Installationssätze. Ursprünglich sich entwickelt für Gewebereparatur und -TRCs. Mehrfache Wege zum Einkommen als der Firma und bewegen jetzt in Richtung zu jenen Bahnen. Unterschiedliche Vorrechte und addressible Markt. TRCs-fangen Sie mit kleiner Probe der Patienten besitzen Knochenmark an. Nehmen Sie kleine Probe und wachsen Sie große Quantität. Klinische Tests haben erfolgreich Regeneration des Gewebes innerhalb des Patienten gezeigt (OC-Linie der Zellenprodukte). Hauptmarktgelegenheiten. Gebrauch, Knochen zu erzeugen. Verwendet bei strengen osteoporosispatienten. Knochenregeneration, verpflanzender Knochen (spinale Schmelzverfahren, reparieren große Knochenbrüche des Beines und der Arme, in denen Sie Knochentransplantationmaterial benötigen, Knochenreparatur. Planende klinische zuerstversuche diesmal. Wie planen Sie, Meilensteine zu erzielen? VorrichtungscCer-Markierung einige Produkte in Europa. Schlüsselmeilenstein zum principly Herstellen der Kunden und des Bucheinkommens aus Europa heraus. 12-month Schlüsselmeilensteine sind >, projizierend über 8-12 neue Kunden aus europäischem Markt heraus und von diesen sollten wir anfangen, Einkommen anzumelden. Schauen zum Einsteigen in Asien. Ein anderer Meilenstein soll Genehmigung durch die zuständige Aufsichtsbehörde gewinnen, um Knochenverpflanzens in US und in Europa einzuleiten und durchzuführen klinische Versuche. Gut über Markt $1 Milliarde. Letzter Punkt-sehr aktiv im Bereich zum Produzieren von dendricell (dendritic Zelle-wichtiger Meilenstein, der oben in naher Zukunft die Monate kommt). Dentric Zellenimpfstoff des TRC-Bereichs - leiten Sie ersten klinischen Versuch mit dendricell in den US in naher Zukunft die Monate ein. Herausforderungsinvestoren konnten fehlende HerausFirma sein ist mit.einbezogen worden in Stammtherapie über 10 Jahren. Investition im Tech ist jetzt hinter uns. Demonstrierte erfolgreiche klinische Resultate. Abgeschlossene Investition in Vorrichtungen der Systeme zum Produzieren dieser Zellen. Gefahr der Technologie ist hinter uns. Ist jetzt die Zeit, den erfolgreichen Tech zu setzen, um zu arbeiten, um zu den wichtigen Märkten Zutritt zu erhalten. Institutionell, Investor-warum wenn sie aastrom betrachten. Anteilpreis Aastrom ließ nicht wegen aller nachteiligen situtations innerhalb Aastrom fallen. Relative.to definierbare Gefahr der Baissekappe. Erzeugen Sie Einkommensover die kommenden Monate. Große therapeutische opportnuties vermarkten das Bewegen in klinische Versuche. Orphan Produktstatus. Rohrleitungen der Produkte. Lange Bezeichnungsinvestoren - bezieht auf mehrfachen Wegen auf Einkommen-langen Zeitgelegenheiten. Sofortig Einkommen von der Jahrstrecke des Vorrichtungsgeschäfts 2-4 von der Zellentherapeutik von Europa. 4-7 vom US-Markt. Nahe dem Bezeichnungswachstum und folgendem Rohrleitungflowout zum Fahren des langen Bezeichnungswachstums. Mannschaft Mgmt hat einzigartige Abgleichung des Geschäfts und des wissenschaftlichen Hintergrundes. Dr. A. seit 1991. Brian Hanson - über 9 Jahren. Dr. Steven Wolf - Stammzelletransplantprogramm 20years bei Vanderbelt. Al Wright - finanzielle Gemeinschaft. Unternehmensleiter Saavy - Hilfe verbessern Kommunikationen und Leistung mit der Investitiongemeinschaft. Passen Sie uns, gegen diese auf Meilensteine zu liefern und durchzuführen.

[t.1]

@meislo
danke für deine arbeit zu aastrom.bin in der aktie noch drin sehe aber die gefahr des delisting und und für mich am schlimmsten die dünne finanzdecke . kann aastrom am ende den kopf kosten.übernahme oder pleite im juni 2003 ?
grüße t.1

[meislo]

Hallo 1.1
Deine Bedenken verstehe ich voll und ganz. Um dem noch die Mütze aufzuziehen stelle ich noch einen Artikel ins Board auf den ich am Sonntag gestossen bin. Aastrom stellt doch den Kern auf zukünftig zu erwartende Einnahmen in den Bereich Gewebeeneuerung bzw. Knochenheilung,sprich Ostepporose.Dazu ein Artikel

Neuer Typ von Vitamin D kann Osteoporose heilen
Versuche mit einer künstlich erzeugten Substanz zeigen, dass altersbedingter Knochenabbau umkehrbar ist
Von Rolf H. Latusseck
Madison - Damit der Mensch sich mit einem gesunden Skelett bewegen kann, braucht er von der Geburt bis zum Lebensende unbedingt Vitamin D. Es reguliert den Kalzium- und Phosphatstoffwechsel und spielt deshalb eine wichtige Rolle für den Knochenaufbau. Knochenerweichungen, die mit Skelettdeformationen einhergehen, wie Rachitis bei Kindern und Osteomalazie bei Erwachsenen, sind selten geworden, seitdem die Rolle des Vitamins erkannt wurde. Außerdem ist es in Fisch reichlich enthalten, einige Grundnahrungsmittel werden sogar zusätzlich angereichert und unter UV-Einstrahlung auf die Haut wird es vom Körper selbsttätig synthetisiert.

Bei Frauen kann Vitamin-D-Mangel nach den Wechseljahren allerdings zur Entwicklung einer Osteoporose beitragen. Grundlagenforschungen auf diesem Gebiet erbrachten jetzt erste Hinweise, dass das Vitamin eine Osteoporose nicht nur aufhalten, sondern möglicherweise sogar umkehren kann. Hector DeLuca von der University of Wisconsin in Madison experimentierte mit einem künstlichen Abkömmling von Vitamin D3, das in seinem molekularen Aufbau leicht verändert war und die Bezeichnung 2MD erhielt. Im Reagenzglasversuch zeigte sich, dass 2MD so genannte Osteoblasten (Knochenbildungszellen) dazu anregt, Knochensubstanz zu bilden.

Daraufhin wurde die Substanz weiblichen Ratten verabreicht, die an Osteoporose litten. Schon sehr geringe Konzentrationen von 2MD führten bei den Tieren innerhalb von 23 Wochen zu einem Anstieg der Knochenmasse von neun Prozent. Besonders stark zeigte sich der Effekt an den einzelnen Wirbeln des Rückgrats, deren Substanzgewinn sogar 25 Prozent betrug. Eine vermehrte Zufuhr des natürlichen Vitamin D3 stoppte bei den Ratten zwar das weitere Fortschreiten der Osteoporose, führte aber nicht zu einer Zunahme der Knochendichte.

Das langsame Zusammenbrechen der Wirbel im Verlauf einer Osteoporose ist besonders häufig und führt zum typischen "Altersbuckel". "Mit 2MD haben wir eine Substanz gefunden, die selektiv auf Knochen wirkt", kommentiert DeLuca die Versuchsergebnisse. "Es ist der viel versprechendste Vitamin-D-Typ, der mir je untergekommen ist." Gleichzeitig betont der Vitamin-Experte jedoch, dass die Ergebnisse sich ausschließlich auf Tierversuche stützen. Die Wirkung der Substanz auf Menschen muss erst noch getestet werden, und es wird noch einige Jahre in Anspruch nehmen, bis 2MD als Medikament - wenn überhaupt - auf den Markt kommt. "Wir glauben zwar, dass die Substanz eine große Zukunft hat, aber Versuche mit Menschen haben wir noch nicht unternommen", so DeLuca.

Bisher wird Osteoporose bei Frauen mit einer Hormonersatztherapie behandelt. Doch die eingesetzten Östrogene stehen im Verdacht, langfristig an der Entstehung von Brustkrebs beteiligt zu sein. Ein Alternativmedikament ohne solche Nebenwirkungen, das zudem den Knochenschwund nicht nur anhält, sondern die Anlagerung neuer Knochensubstanz fördert, wäre deshalb äußerst wünschenswert. Bevor ein medizinischer Einsatz von 2MD erfolgen kann, sind jedoch noch weitere Grundlagenforschungen und langwierige klinische Versuche zu absolvieren.

[meislo]

Ein Interview mit Dr. Amstrong ist kostenlos abhörbar bei www.wallstreetreporter.com
Man muss sich aber vorher registrieren lassen.

audio interview is available wallstreetreporter .com, first time users need to register which is free, thanks

[meislo]

Wer weiss vielleicht hilft es etwas

Bush Signs Health Measures Into Law
Sat Oct 26, 4:47 PM ET

CABO SAN LUCAS, Mexico (AP) - President Bush (news - web sites) signed bills Saturday to accelerate development of high-tech medical devices and to renew government support for hundreds of community health centers that serve millions of uninsured patients.


AP Photo



Bush, taking action on the hot-button campaign issue of health care, announced in his weekly radio address Saturday that he was approving the measures. He signed the bills on a day when he traveled from his Texas ranch to an economic summit in Mexico.


The first bill reauthorizes federal programs for the 1,000 community health centers that provide care each year for about 12 million people, half of whom have no medical insurance.


The bill allows health centers to form networks for purchasing and technical services to save money. It also lets the centers participate in the National Health Service Corps, which pays off doctors` medical school loans in return for service in needed areas.


It establishes several new rural health programs to bolster emergency medical services and place more dental health providers in underserved communities.


Lawmakers must still approve money to finance the measure. The authorizing legislation Bush signed sets the rules for how the money should be spent.


The White House has said the president wants to add or expand centers at 1,200 sites over five years, doubling the number of people served.


"The quality of American medicine is excellent, yet too many Americans live in communities lacking good clinics and basic health care," Bush said in his radio remarks. "Community health centers are America`s health care safety net, providing prenatal care, checkups and preventative treatments to anyone who walks in the door."


Also getting the president`s signature was a bill that requires medical device manufacturers to pay tens of thousands of dollars in new user fees in return for speedier government review of their products.


Sen. Edward M. Kennedy, D-Mass., has said that because the Food and Drug Administration (news - web sites) lacks adequate resources, too many critical devices are unnecessarily slowed.


The proposal mirrors an existing user fee system financed by drug companies for speedier review of medications by the FDA.

Under the bill, manufacturers of medical devices such as catheters, pacemakers and MRI machines will pay just over $25 million in fees over the next year. In exchange, the government would hire more staff and improve systems to allow for speedier reviews of products.

The measure also gives small device manufacturers a break in the amount of fees they would have to pay.

"Medical devices are often very complex and require careful testing before they`re approved by the Food and Drug Administration, but the FDA is overwhelmed by the volume of new technologies, making delays more frequent, and undermining the quality of device reviews," Bush said.

"Under the new law, we`re going to speed up and improve the approval process," he said. "The entire nation will benefit from a faster approval of lifesaving innovations."

[meislo]

===============================================

Your requested Equity Alert on ASTM,
follows below.

===============================================





Aastrom Biosciences, Inc. Reports First Quarter 2003 Financial Results - Sales and Marketing Efforts Drive Aastrom`s Cell Therapy Pipeline Forward -

ANN ARBOR, Mich., Oct 30, 2002 /PRNewswire-FirstCall via COMTEX/ -- Aastrom
Biosciences, Inc. (NasdaqSC: ASTM), announced today financial results for the
first fiscal quarter ended September 30, 2002. The Company also summarized its
most recent operational achievements, including management appointments, and
significant clinical and financial milestones that have moved its cell-based
therapeutics further along the commercialization path.

For the quarter ended September 30, 2002, the Company reported a net loss of
$2.5 million, or $.05 per common share, up from a net loss of $1.9 million, or
$.05 per common share for the same period in 2001. Revenues generated by grant
funding, for the quarter ended September 30, 2002 were $86,000, compared to
$151,000 in 2001, as a result of decreased grant program activity this quarter.
With the award of the Department of Defense grant during the quarter, Aastrom
expects grant funding to increase throughout the fiscal year. The sales and
marketing effort showed progress with the number of customer sites increasing
from three to five. The Company expects revenue from these sites in the coming
months. Costs and expenses for the quarter ended September 30, 2002 increased to
$2.6 million, compared to $2.2 million for the same period in 2001. Increases in
costs and expenses include an increase in research and development expenses to
$1.4 million for the quarter ended September 30, 2002, from $1.2 million in
2001, and an increase in selling, general and administrative expenses to $1.1
million from $0.9 million. These increased expenses resulted from an expansion
of the Company`s program development and increased marketing opportunities,
especially in the area of dendritic cell-based vaccines in the European market,
and in preparation for the Company`s pending clinical bone grafting trials.

"Aastrom has taken great strides toward fulfilling its business strategies and
in developing its product pipeline during the last quarter, despite the general
adversity occurring within the biotechnology industry," said Alan M. Wright,
Senior Vice President Administrative and Financial Operations and Chief
Financial Officer of Aastrom. "We continue to partner with major research
institutions to explore applications of our technology and therapeutic products,
and have strengthened both our senior management team and our sales and
marketing capabilities in anticipation of further progress on the part of the
Company over the next fiscal year. In addition, we have successfully completed
the necessary steps to secure the funding needed to support that progress. The
milestones we have achieved have set the stage for continuing progress."


Aastrom`s Recent Operational Highlights
-- Aastrom recently announced the initiation of a collaborative agreement
with Stanford University to conduct an immunotherapeutic vaccine
clinical study. The collaboration will combine Aastrom`s dendritic
cell vaccine technology with Stanford`s cancer antigen technology to
produce an experimental cell-based treatment for cancer patients with
multiple myeloma.
-- The U.S. Food and Drug Administration granted orphan product status to
Aastrom`s SC-I autologous bone marrow stem cells, produced in the
AastromReplicell(TM) System, for use in cancer patients requiring a
stem cell transplant following high-dose chemotherapy, when they are
unable to obtain sufficient numbers of blood stem cells for adequate
treatment using current transplant methods.
-- In August, Aastrom announced that Alan M. Wright was appointed to the
position of Senior Vice President Administrative and Financial
Operations after serving as a member of Aastrom`s Board of Directors
for two years. Additionally, Mr. Wright has also assumed the position
of Chief Financial Officer of Aastrom previously held by Michael S.
Durski, who will be leaving the Company to pursue other opportunities.
-- The Company was awarded approximately $0.9 million of a collaborative
grant by the Defense Advanced Research Projects Agency, providing
funding over an 18-month period for the research and development of a
bioreactor system to engineer human stem cells into an artificial
immune system. Aastrom is one of four organizations comprising this
multi-disciplinary team that combines scientific and engineering
expertise in research to support the Department of Defense`s initiative
to fight biological terrorism.
-- During the quarter, the Company raised approximately $0.9 million from
the sale of common stock through a series of financing transactions.
These proceeds will be used to continue moving Aastrom`s tissue repair
and dendritic cell programs forward to commercialization.
-- In October, Aastrom appointed Robert J. Bard, JD, to its management
team as Vice President Regulatory Affairs and Quality Systems. Mr.
Bard will be responsible for all regulatory and quality matters
pertaining to the Company`s current and future therapeutic and device
products.

About Aastrom Biosciences, Inc.

Aastrom Biosciences Inc. (NasdaqSC: ASTM) is a late-stage development company
focused on human cell-based therapies. Aastrom intends to leverage its
proprietary ex vivo cell production technology to produce patient-specific cell
therapeutics for stem cell tissue repair and regeneration, and the treatment of
cancer and other infectious diseases. Aastrom`s core technology is based on its
proprietary AastromReplicell(TM) System, a patented, integrated system of
instrumentation and single-use consumable kits for the commercial production of
human cells. The AastromReplicell(TM) System is used by the Company to
manufacture its stem cell-based Tissue Repair Cell and its Therapeutic Cell
proprietary products, and is also sold independently as a platform for dendritic
cell vaccine production. Aastrom recently initiated marketing of its CE-Marked
dendritic cell production and bone marrow transplant products in Europe.
Aastrom`s strategy allows for multiple paths to revenue, with the immediate
device business generating revenue to support a series of planned therapeutic
products.

Please visit our website at www.aastrom.com

This document contains forward-looking statements, including without limitation,
statements regarding the receipt of grant funding, expected revenue from
customer sites, product development objectives, commercial introduction plans,
potential product applications, advantages of the AastromReplicell(TM) System
and related cell therapy kits, and financing plans which involve certain risks
and uncertainties. The forward-looking statements are also identified through
use of the words "intend," "expect," "pending," and other words of similar
meaning. Actual results may differ significantly from the expectations contained
in the forward-looking statements. Among the factors that may result in
differences are the results obtained from clinical trial and development
activities, regulatory approval requirements, the availability of resources,
financial market conditions, competitive products and technologies, the degree
to which the Company`s products achieve market acceptance, and the allocation of
resources among different potential uses. These and other significant factors
are discussed in greater detail in Aastrom`s Annual Report on Form-10K, and
other filings with the Securities and Exchange Commission.


- Financial Table Follows -
AASTROM BIOSCIENCES, INC.
(Unaudited)

CONSOLIDATED STATEMENT OF OPERATIONS DATA:

Quarter ended September 30,
2001 2002
REVENUES:
Product sales and rentals $- $7,000

Grants and other 151,000 86,000

Total revenues 151,000 93,000

COSTS AND EXPENSES:
Cost of product sales and rentals 40,000 88,000
Research and development 1,207,000 1,385,000

Selling, general and administrative 919,000 1,113,000

Total costs and expenses 2,166,000 2,586,000


OTHER INCOME 122,000 41,000

NET LOSS $(1,893,000) $(2,452,000)

COMPUTATION OF NET LOSS
APPLICABLE TO COMMON SHARES:

NET LOSS $(1,893,000) $(2,452,000)


NET LOSS PER COMMON SHARE
(Basic and Diluted) $(.05) $(.05)


Weighted average number of common
shares outstanding 39,934,000 44,886,000


CONSOLIDATED BALANCE SHEET DATA:
June 30, September 30,
2002 2002

ASSETS
Cash and investments $9,605,000 $7,930,000
Other current assets 1,742,000 2,106,000
Property, net 206,000 178,000
Total assets $11,553,000 $10,214,000

LIABILITIES AND SHAREHOLDERS` EQUITY
Current liabilities $750,000 $835,000
Shareholders` equity 10,803,000 9,379,000
Total liabilities and shareholders` equity $11,553,000 $10,214,000


CONTACTS:
Kris Maly
Investor Relations Manager
Aastrom Biosciences, Inc.
Phone: [phone]

Susan Ladue
The Scottsdale Group
Phone: [phone]

Make Your Opinion Count - Click Here
http://tbutton.prnewswire.com/prn/11690X84536400

SOURCE Aastrom Biosciences, Inc.


CONTACT: Kris Maly, Investor Relations Manager of Aastrom Biosciences,
Inc., [phone]; or Susan Ladue of The Scottsdale Group,
[phone]

URL: http://www.aastrom.com
http://www.prnewswire.com

Copyright (C) 2002 PR Newswire. All rights reserved.

-0-


KEYWORD: Massachusetts
INDUSTRY KEYWORD: HEA
BIO
MTC
SUBJECT CODE: ERN





****************** TO EDIT YOUR EQUITY ALERTS *********************
To unsubscribe or edit your alerts, visit
http://www.equityalert.com/alerts.asp?uid=meislo&xid=72594

*******************************************************************
** IMPORTANT NOTICE AND DISCLAIMER REGARDING THIS COURTESY EMAIL **
*******************************************************************

PLEASE VISIT: http://www.equityalert.com/home/disclaim.asp FOR
ACCESS TO OUR COMPLETE "EQUITYALERT SUBSCRIBER AGREEMENT AND
DISCLAIMER".

*******************************************************************

[meislo]

Viel Spass beim Lesen


Aastrom Biosciences, Inc. Sherry Grisewood, CFA
October 31, 2002

Symbol (NasdaqSC): ASTM Fiscal Year Ending:
June 30

Recent Price: $0.23 Year EPS P/E
REV`s PSR
Price Range: $1.25 - $0.22 2000A $(0.41) ---
$1.15 ---
Avg. Daily Vol. (30 day): 140,000 2001A $(0.17) ---
$0.89 ---
Industry: Biotech/Cell‑based Therapies 2002A $(0.19) ---
$0.87 ---
12 Month Target Price: $.65 2003E $(0.19) ---
$1.83 5.3x
Market Capitalization (000): $9,688 2004E $(0.22) ---
$4.64 2.1x

Capitalization (000): 6/30/02 Est. 2001‑2003 Annualized Current Rating History*
Shares O/S: 42,120 Growth Rate: 200% Date Assigned: 10/31/02
Cash & Equiv.: $9,605 Dividend: --- Price at Rating: $.23
Net Working Capital: $8,850 Yield: --- Orig. Price Target: $0.65
Long-Term Debt: $0 Inside Ownership: 1% Time Frame: 12 mos.
Shareholders Equity: $$10,803 *Rating as of this initial report

--------------------------------------------------------------------------------



Rating: Speculative Buy



Basis for Rating



Aastrom Biosciences, Inc., is a late-stage development company focused on human cell-based therapies. The Company intends to leverage its commercial cell production technology to produce cell-based therapeutics for tissue repair and regeneration, and for cell-mediated immunogenic therapies associated with treating certain cancers and viral diseases.

Proprietary technology underlies the Company`s commercial cell production platform, the AastromReplicell™ Cell Production System, the first clinical-scale human ex vivo (outside the body) cell production platform to meet cGMP and ISO9001/9002 requirements for commercial-scale cell production.


The AastromReplicell System and associated cell line specific single-use kits have received the CE-Mark for European Union marketing and are now being sold commercially. The Company`s lead stem cell products are in late stage clinical trials for marketing approval in the US.


The Company is utilizing specialized cells produced by the AastromReplicell System for the development of its own therapeutic products. Aastrom`s therapeutic pipeline is focused on cellular-based therapies derived from dendritic cells and from stroma (mesenchymal) stem cells.

Like so many biotechs during the course of the last year, Aastrom has experienced a significant decline in its share price, despite continued progress on building market presence for its approved products and developing a strategic plan leveraging the Company`s technology into cell-based therapeutics. Our research indicates that there are few companies which have garnered any marketing approval whatsoever for commercial products focusing on human cell-based therapeutics and associated clinical tools and devices. In this regard, Aastrom is unique. While we believe cell therapies represent an important new treatment modality for certain cancers, and infectious or degenerative diseases, controversy surrounding embryonic stem cell therapies and a plethora of technical and other ethical issues are currently holding back valuations for this group. It will take time for these issues to be resolved and for a market to develop in cell-based therapies beyond blood cell transplantation. We consider Aastrom to be a leader in this group, and consider the shares a Speculative Buy at current levels for speculative investors accustomed to the risks and timelines associated with development stage biotechnology.

Key Investment Considerations

Aastrom Biosciences has a patented platform-enabling technology, which is applicable to a range of cell-based therapies and products. Although Aastrom`s enabling technology can be applied to any cell type, all of Aastrom`s current cell-based products are derived from adult bone marrow stem cells or cord blood cells. Aastrom intends to become a leader in novel cell-based immunotherapies and regenerative tissue therapies. None of Aastrom`s current or proposed products involve the use of embryonic stem cells.


Successful commercial cell therapy requires, among other things, reliable, process-controlled ex vivo cell production that insures the viability and efficacy of a desired cell population. The AastromReplicell System utilizes proprietary Single-Pass Perfusion (SPP) and integrated automated systems to accomplish this goal. The System is already being sold commercially in the European marketplace, along with four specific cell line kit products. The Company is the first to offer such a commercial cGMP culturing system, and in October 2001, was the first company to receive CE Mark approval for a dendritic cell therapy product.


The Company`s core cell replication and automated expansion technology is protected by a broad array of methods, composition and use patents covering biological processes involved with ex vivo cell production, nutrient flow, regulation of cell lineages, the enhancement of ex vivo cultured cells, cell bioreactor devices and other cell-culture related apparatus. In addition, the Company has broadened its intellectual property base to now include the application of its technology to gene therapy.


The Company`s core automated cell expansion technology is applicable to the production of tissue repair cells (TRCs) which reconstruct diseased or damaged tissues, and to therapeutic cells (TCs) which are intended to be administered as "drugs". Aastrom intends to leverage its core technology in two therapeutic areas: cancer vaccines based on dendritic cells, and bone repair and regeneration products based on progenitor bone cells. These potential markets aggregate into billion dollar plus opportunities and provide multiple paths to revenue generation.
Summary

Generally speaking, in their simplest form, cell-based therapies involve harvesting or collecting living cells from the body, isolating therapy target cells, culturing those cells until they reach sufficient numbers to achieve a therapeutic effect and then infusing the cultured cells into the patient to effect tissue repair or a desired therapeutic action such as immune system regeneration. Familiar cell-based therapies include platelet transfusion, bone marrow transplantation, articular cartilage repair (Genzyme Corporation`s Carticel) and wound (burn) healing (Advanced Tissue Sciences` DermaGraft).

In recent years the understanding of the biology of cells, particularly undifferentiated or stem cells, as well as cell culturing process development (better isolation, culturing and expansion techniques) have sparked many new and exciting cell-based therapeutic opportunities which hold the promise of treating diseases where traditional pharmaceuticals have been unsuccessful. Some of the therapeutic areas where stem cell-based products are now being developed include immunological conditioning for the treatment of cancer (cancer vaccines), autoimmune disease treatment, the treatment of degenerative diseases such as Parkinson`s disease and Alzheimer`s disease, tissue regeneration and certain applications in gene therapy.

A significant limiting factor to increasing the market for cell-based therapies has been major technical hurdles involved in growing adequate numbers of viable and functioning cells ex vivo. Aastrom`s Biosciences, Inc. is a leader in the development of products for cell-based therapies. Aastrom`s proprietary enabling technology provides for the commercial manufacturing of therapeutic cell populations from small starting populations of donated human cells or tissues. Aastrom is commercializing this technology through the sale of ex vivo cell replication systems, while developing specific and proprietary therapeutics utilizing its enabling technology. None of the Company`s products involve embryonic stem cells (ES), nor does the Company conduct any research in ES cells.

Currently, the Company has five culturing system device products approved for sale on the European market and one tissue repair cell product is in late-stage clinical trials in the US. All of the Company`s cell replication products incorporate the Company`s patented Single-Pass Perfusion technology and "hands-off" cell culture system automation. All of the Company`s cell replication system products are manufactured to cGMP and ISO 9001/9002 standards.

Aastrom has validated its technical capabilities in cell replication and expansion with an early product focus on bone marrow-derived cell therapeutic products, one of which has received Orphan Drug Product designation by the FDA. Bone marrow stem cells are used largely to restore the blood and immune systems of leukemia and lymphoma patients who have compromised or myleoablated systems. The Company`s initial products enable the controlled replication of patient-derived (autologous) or donor-derived (allogeneic) bone marrow cells and umbilical cord blood cells for use in transplantation therapies. Clinical use of these products in over 125 patients has confirmed the safety of cells produced by the AastromReplicell System. The Company is now expanding its market opportunities by commercializing products that replicate and expand other types of bone marrow-derived cells, such as dendritic cells and stroma stem cells. From these products, the Company intends to build an in-house therapeutics pipeline in the areas of dendritic cell cancer vaccines and bone graft substitutes/bone regeneration therapies for the restoration of normal bone and other connective tissue.

Milestones and Objectives for 2003
In setting the Company`s objectives for the next fiscal and calendar years, management has focused on optimizing current resources and maximizing the opportunities to create revenue. As such, resources will be expended to develop markets for the Company`s approved products, while research and development will focus on proof-of-principle programs for the Company`s therapeutic cell products. Key objectives for 2003 and FY2004 are as follows:

Generate material sales of the AastromReplicell System in Europe; scale-up manufacturing to commercial volume levels.

Complete new manufacturing supplier agreements.

Pursue strategic and business collaborations; complete an Asian distributor agreement.

File PMA/BLA for the SC-I product in the US.

Generate preclinical data on Dendicell-based vaccines.

Develop evaluable clinical data on the Company`s bone-grafting product and move towards marketing approval in Europe.

Complete an additional financing and increase Company visibility with investors.
Aastrom, The Company
Aastrom was incorporated in 1989 and commenced operations as a development-stage company in 1991. The Company in-licensed core cell-culturing technology developed at the University of Michigan and began developing hematopoietic (blood) stem cell therapy products for breast cancer. Therapeutic approaches to breast cancer have since moved away from the utilization of salvage bone marrow transplantation as a treatment strategy. During 2001 and 2002, management reoriented the Company`s technology strengths and assets to pursue market opportunities in novel cell-based therapeutics such as dendritic cell-derived cancer vaccines and non-hematopoietic tissue regeneration.

During fiscal year 2002, Aastrom added management depth by bringing in additional highly experienced professionals. Mr. Alan Wright recently assumed the position of Senior Vice President, Administration and Financial Operations. Prior to assuming his Senior Vice President position, Mr. Wright served as a member of the Board of Directors. On October 24, Aastrom accounted the appointment of Robert S. Bard as Vice President of Regulatory Affairs and Quality Systems. Mr. Bard has over 28 years of domestic and international healthcare products manufacturing regulatory experience. Aastrom also established a Technology Review Board whose members include Michael Ehrenreich of Techvest, LLC and Dr. Susan Wyant, president and founder of The Dominion Group, a medical products research and consulting firm, as well as other prominent medical scientists, including James J. Mulé, Ph.D., Director Tumor Immunology & Immunotherapy, University of Michigan; Armand Keating, M.D., Head, Medical Oncology & Hematology, Princess Margaret Hospital; and Gunnar Kyalheim, M.D., Head, Clinical Stem Cell Laboratory, Norwegian Radium Hospital.

Aastrom is headquartered in Ann Arbor, Michigan, where the Company leases 22,000sq ft of laboratory and office space. During 2002, the Company activated its wholly owned subsidiary domiciled in Berlin, Germany, Zellera AG. Zellera has its own managing director who is mandated with establishing and executing Aastrom`s product operations and sales and marketing for Europe. The Company currently has 42 employees. The Company`s website is at www.aastrom.com.

Stem Cell Therapy
A stem cell is a unique cell in the body which can both replicate itself (unlike most cells in an adult) or give rise ultimately to a number of specialized tissue- or organ-specific functional cells. Certain stem cells retain these characteristics--the ability to self-replicate and non-specificity--virtually indefinitely, while others mature into highly specialized tissue and organ cells. Because of the capability to eventually become any of several specialized cells, stem cells are referred to as pluripotent or multipotent, depending on their source and specific capabilities. Hematopoietic stem cells are naturally found in the blood, bone marrow, or in umbilical cord blood. A more complete discussion of stem cells is found later in this report.

New Directions for Stem Cells
Cell therapy can be looked upon as an evolution of the practice of giving whole blood transfusions to diseased or injured patients. From whole blood to blood components, such as platelets, the practice of infusing a patient with healthy cells to augment a damaged or insufficient blood and immune system has been a standard medical practice for decades. Our increased knowledge of developmental biology has led to a fuller knowledge of the complexities in cell populations and specifically of the role and capabilities of stem cells. Exciting new applications, which exploit the fact that a given undifferentiated stem cell may give rise to a number of highly specialized cells, are being researched. Stem cells found in the bone marrow, for instance, may be progenitors of the hematopoietic system or of skeletal tissues such as bone. Within the hematopoietic system, the stem cell may eventually become a red blood cell or any of several kinds of white blood cells such as lymphocytes which provide the basis of the immune system. The capability to identify, isolate and expand certain stem and progenitor cells to become specific mature cells has led to the development of new strategies to fight cancer or regenerate damaged tissues.

Commercial Product Development Plan
The AastromReplicell System is capable of supplanting manual procedures now used to provide research quantities of therapeutic cellular products based on T-cells, dendritic cells, chondrocytes, mesenchymal stem cells, keratinocytes, neurons and other cell types. To secure FDA approval and commercial viability, cGMP procedures for cell expansion will likely be required. Aastrom believes its cell production systems already fulfill this requirement, and will garner commercial demand from others interested in developing these products and from clinical sites charged with administering these therapies. In addition, Aastrom is leveraging its cell expansion technology in a therapeutics development pipeline of its own, focused on two specific areas: dendritic cell-based cancer vaccines, and tissue repair cells, such as bone cells. The Company is currently developing direct cell-based therapeutics utilizing specific cell lines produced in-house. The Company`s cell-based products have potential in a variety of gene therapy applications, as well.

Dendritic Cell-Based Vaccines
Dendritic cells are crucial "initial mobilizers" of the immune response in the body and are derived from hematopoietic stem cells. The immune system is comprised of a variety of specialized cells that produce proteins capable of recognizing specific chemical structures, antigens, which are not naturally found within the body. Antigens are signature structures found on most disease-causing agents. Removing these foreign antigens is the purpose of the immune system.

Dendritic cells, one of several "antigen-presenting" cell types, play the primary role in activating the immune system. They are fairly rare, comprising less than 0.5% of nucleated cells in the blood, and are derived from CD34 positive hematopoietic bone marrow stem cells, or blood monocytes. Immature dendritic cells migrate from the bone marrow into the circulatory system, where they become part of the monocyte cell population. When signaled by the presence of a foreign antigen, they migrate to the spleen and lymph nodes, and initiate the critical first steps in the body`s immune response by proteolytically processing the foreign antigen into fragments and then presenting those fragments on their cell surfaces in association with molecules known as MHC molecules. This process causes the dendritic cell to mature and when specialized lymphocytes, T-cells with receptors specific to that antigen, encounter such a modified dendritic cell, the T-cell proliferates and it too begins a differentiation process. T-cells, one of the body`s ultimate defenders, eliminate antigen-bearing cells directly and thus are capable of eliminating antigen-bearing cancer cells or virally infected tissues. This form of immunity is referred to as cell-mediated immunity, and is different from B-cell lymphocytic activity, which relies upon the production of antibodies. Capturing and targeting the immunostimulatory aspects of the antigen-modified dendritic cell is at the heart of dendritic cell-based anti-cancer and anti-viral therapies under development.

Cancer vaccines are being designed to awaken the body`s own immune system to subtle or sub-stimulatory antigens, either by providing the body with clearer "antigen" signals or by manipulating dendritic cells to spark a vigorous cell-medicated immune response. A cancer vaccine may be comprised of a specific cancer antigen or whole cancer cell fused with an appropriate dendritic cell. Dendritic cells incubated under the right conditions with antigen become activated and then are infused into the patient to trigger T-cells and the rest of the cell-medicated immune cascade. Many cancer vaccines so designed require multiple infusions over a period of time to achieve a sufficient immune response. This fact implies the need for a reproducible supply of cultured dendritic cells. Aastrom`s DC-I and DCV-I cell kits, already CE-Marked, produce dendritic cells from progenitors found in the blood and can enhance specific characteristics suitable in cancer vaccines depending upon the presence of specific cytokines. Companies developing cancer vaccines could then take the expanded population of immature dendritic cells and expose them to specific antigens on demand for therapeutic applications.

Because of the Company`s Single-Pass Perfusion technology, dendritic cells are replicated with highly potent antigen-presenting activity. Other significant advantages of Aastrom`s DC-I Therapy Kit are that the System is contained in a single biochamber compared to current culturing methods which require multiple T225 flasks, thus reducing set-up time, product release tests and the number of open process steps. In addition, there is a marked increase in process control and GMP documentation is electronic. Several beta site evaluations of the DC-I are ongoing here in the US and in Germany.

Aastrom itself intends to develop its own cancer vaccines in this manner. Two proof-of-concept studies are expected to get under way during this current calendar quarter. The first, to be conducted at Stanford University, will focus on DC-I cells in a myeloma vaccine, and the other, to be conducted at Duke University, will apply DC-I cells in a colorectal cancer vaccine strategy. Both studies are funded by third party grants. Pre-clinical work using Aastrom`s T-cell therapeutic cells against Epson-Barr virus (EBV) is also underway.

Aastrom`s DCV-I product takes the same DendricellsTM that are produced in the DC-I System and loads them with a specific tumor antigen. In this manner, antigen from tumor-presenting patients can be loaded onto their own cultured dendritic cells and used as a patient-specific immunotherapy product. Aastrom believes that dendritic cell-based patient-specific treatments are an emerging therapeutic strategy in treating cancer, and as such, its DCV-I System would be suitable to any organization or researcher developing antigen-loaded dendritic cancer vaccines. In addition, Aastrom intends to develop its own dendritic cancer vaccines utilizing the DCV-I platform.

Bone Regeneration
In addition to hematopoietic stem cells, bone marrow also contains mesenchymal or stromal stem cells (MSCs). MSCs ultimately differentiate into osteoblasts, osteoclasts, myoblasts, chondrocytes and adipocytes or cells of bone, cartilage, muscle, and fat. Early preclinical and compassionate use of Aastrom`s SC-I, a bone marrow product, suggested that bone marrow-derived osteogenic progenitor cells were expanded along with blood and immune progenitor cells, which could benefit patients with bone-related disorders. Aastrom reasoned that bone cell therapy products derived from these cells might be more efficacious, patient-friendly and cheaper for a variety of bone-related disorders than current treatments.

Aastrom`s OC-I product has been found to contain large numbers of bone cell progenitor cells that could treat specific metabolic diseases of bone, such as osteoporosis, and conditions where bone cells either have lost function or there are too few bone cells to maintain function, as in genetic bone disorders like osteogenesis imperfecta or hypophosphatasia. The Company anticipates that its bone cell product could also be useful in a variety of procedures that require bone augmentation, such as non-healing long bone fractures and spinal fusions. Spinal fusions, the fastest growing segment in orthopedics, largely rely on the harvest of bone from the patient`s own iliac crest to "fuse" damaged vertebrae into a solid, non-moving mass. Because harvesting bone from a patient`s iliac crest can be a painful and at times, risky procedure, and using allograft (cadaver) bone carries the risk of disease and/or rejection upon implantation, medical researchers have been actively seeking an alternative approach that creates fused bone. Aastrom will be initiating proof-of-concept studies in Germany for OC-I cells` use in non-healing long bones, and expects to be filing with the FDA for a Phase I/II trial in the US for the non-healing long bone indication.

Aastrom Core Technology: A Proprietary Cell Culture System Platform

The goal of all stem cell-based products, including those from Aastrom, is to transplant as large a number of viable, biologically functioning stem cells as possible in order to maximize cell repopulation and minimize the time for the patient`s innate system to return to normal functionality. Aastrom`s core technology resides in its SPP and automated cell expansion system, which through cGMP-controlled processes, accomplishes this goal.

The AastromReplicell System is a sophisticated multi-component device that marries proprietary computer-control and robotics automation to the traditionally hands-on, labor-intensive and highly user-dependent process of cell culture. The AastromReplicell System incorporates proprietary software-controlled Application Keys, which direct the critical aspects of cell incubation with pre-determined and optimized culturing instructions. These instructions control oxygen and nutrient flow, temperature, physical agitation and the like. All of the culture media, growth factors and reagents for each particular cell type are supplied in sterile, filtered, customized packaging that allows for the closed aseptic transfer of reagents and growth factors into the culture cassette. Once prepared and introduced into the proprietary cell cassette of the AastromReplicell System, culturing is fully automated and requires no further intervention from the operator until harvest. The system produces tissue regeneration cells in about 12 days, compared to 20 to 40 for traditional methods. Aastrom cell products have been administered to over 125 patients.

The System incorporates two primary proprietary features: SPP, and a fully automated, closed-loop culturing system. SPP refers to the method by which Aastrom exposes cells to nutrients and "air" (oxygen, nitrogen and carbon dioxide) for growth, and removes waste products. All cells require the correct oxygen mixture, a specific set of nutrients, the correct exposure to those nutrients, and the removal of metabolic waste products for viability and growth. Minute changes or miscalculations in any of these factors can slow cell growth, push cells to differentiate in an unintended manner, or cause cells to become "sick" and die. Aastrom`s proprietary SPP strategy optimizes cell growth and viability by matching oxygen flow across a semi-permeable membrane with the optimal exposure to specific nutrients in a medium, thus recreating the flow rate of plasma and nutrients that occurs in the body. Importantly, cell media and oxygen are decoupled into two separate streams and the media is perfused through the cells in a linear fashion, unlike typical bioreactors.

Significant advantages of this approach are that the Aastrom System allows for the selection of the optimal nutrient/oxygen supply/waste removal ratio, as different cell types have different rates of metabolism and nutrient requirements. Secondly, the Aastrom System allows operators to slow cell growth rates to preserve an optimal microenvironment metabolite or cell stage. Finally, the Aastrom`s SPP approach provides uniform fluid and oxygenation dynamics for uniform cell growth. Overall, Aastrom`s SPP encourages superior cell biology, replicative potential and biological functionality compared to traditional cell culturing methods. The integration of patented automated components into a system of electronically controlled instrumentation and single-use consumable kits provides the ability to commercially produce any class of human cell in a cGMP and ISO compliant process. From a business model perspective, the AastromReplicell System provides a great deal of sales flexibility (lease, buy) in the hardware components (cell loading deck, incubation station, cell harvesting deck), while also generating a single-use consumables revenue stream from cell cassettes, application keys, liquid media, supplements and reagent products.

The Company is the exclusive licensee to core patents related to this technology and has broadened its intellectual property estate with subsequent Company-owned patents. Additionally, the Company has been issued several patents in the area of gene therapy and vector transfection. Aastrom was awarded two patents in 2002, the most recent, award of US Patent No. 6,326,198, entitled, "Methods and Compositions for the Ex Vivo Replication of Stem Cells, for the Optimization of Hematopoietic Progenitor Cell Cultures, and for Increasing the Metabolism, GM-CSF Secreting and/or IL-6 Secretion in Human Stromal Cells."

The AastromReplicell System: Major Advantages

Decreased cell variability from run to run.

Increased homogeneity in terms of phenotype, function/biological activity and replicative potential.

Increased yields.

Cells are produced in a standardized, controlled fashion.

Cells are cultured in closed-loop system; sterility is preserved.

Elimination of key human technician issues (scope of training, expertise, methodology)

Reduced failure rates from contamination, technician mistakes, etc.

These advantages overcome many of the crucial technical problems of conventional cell culturing methods, which include:

Loss of stem cell replicative potential due to unintended differentiation. Differentiated cells can rapidly overgrow the stem cell population and deplete the culture system of nutrients necessary for the survival and viability of stem cells.


Difficulty in characterizing expanded cell population because of mixed starting cell populations. The Aastrom approach produces a more homogeneous expanded cell product.


Costly culturing methods due to rapidly dividing mixed cell populations, where space and nutrients are lost to undesired cells. The AastromReplicell System is automated and optimized for target cell production.
Bone Marrow Transplantation
The Company`s early cell products are being utilized in bone marrow transplantation procedures, usually administered as second- or third-line salvage therapy for lymphoma and leukemia patients. Although products which stimulate the production of mature white blood cells from progenitor cells in the circulation are widely used, many patients have such depleted bone marrow due to treatment or disease that they may not have sufficient progenitor cells left to rebuild the hematopoietic and immune systems in a timely fashion.

Cells for transplantation can be derived from the bone marrow itself, the peripheral blood supply and umbilical cord blood. Stem cell collection from bone marrow is intensive, with the patient undergoing general anesthesia, enduring as many as 100 needle aspirations to collect a sufficient amount of marrow for cell expansion, and requiring a hospital stay. Pain and an attendant risk of infection and/or complication from the anesthesia are not uncommon. Cells collected from the peripheral blood supply require the donor to receive a series of injections of cellular growth factors and mobilizers to cause stem and progenitor cells to move into the circulating blood. Cells are then collected by passing the blood through an aphaeresis device (similar concept to kidney dialysis). While collection procedures can take several hours over several consecutive days, advancements in peripheral blood stem cell procedures (PBSC) are rapidly shortening collection times. Because PBSC takes less time and the patient has a faster recovery time over bone marrow aspiration, PBSC has become the preferred method of stem cell collection. Cord blood, which contains neonatal stem cells, is derived (by consent) from the neonatal umbilical cord shortly after birth and is "banked". The amount of blood collected from cord blood is relatively small, therefore the number of cells are low, although stem cells in cord blood are typically more numerous than in bone marrow. Furthermore, cord blood is banked and the process of cryopreservation can cause a significant rate of cell death. Thus, cord blood transplantation has been fairly limited, being used in about 2000 transplants, according to industry literature. However, if sufficient cells could be expanded for cord blood transplantation procedures, there may be a larger market to treat certain patient populations.

Bone Marrow Transplant Market
Approximately 20,000 stem cell transplantations are performed each year, with most occurring in patients with leukemia, lymphoma or myeloma cancer. While the number of stem cell transplants for lymphoma has continued to rise during the past four years, statistics from the International Bone Marrow Transplant and the American Bone Marrow Transplant Registries indicate the number of transplants in leukemia patients has remained relatively flat. The average age for bone marrow transplant has risen, primarily as a result of improved initial therapeutic approaches and better disease identification. A small number of bone marrow transplants continue to be performed as salvage therapy for some breast cancer patients, but the practice has declined sharply over two years.

Leukemia and lymphoma are both cancers of blood cells in which blood stem cells destined to become white blood cells fail to mature properly. According to the 2002 Cancer Facts & Figures report from the American Cancer Society, an estimated 30,800 new cases of leukemia will be diagnosed this year in the US and approximately 21,700 deaths will occur as a result of the disease. Leukemia affects lymphocytes and myleocytes, which fail to mature properly and accumulate in the bone marrow. The accumulation of diseased cells eventually destroys and crowds out normal blood cells. The disease is classified into five types and its exact origins are unknown. However, viruses, including AIDS, certain genetic factors and exposure to radiation and chemicals such as benzene have all been implicated with the development of the disease. Acute lymphocytic leukemia is the most prevalent cancer in children.

Lymphomas are cancers of the lymphatic system where white blood cells, or lymphocytes, are "frozen" in a state of immaturity in the lymph and lymph nodes and thus unable to perform their immune response function. Classifying lymphomas is complex and has changed dramatically in recent years. In general, however, lymphomas are classified broadly as either Hodgkin`s disease, a disease primarily occurring in adults and affecting Reed-Sternberg cells (a form of B-lymphocyte) and certain other inflammatory cells; or non-Hodgkin`s disease. About 7,000 new cases of Hodgkin`s disease will be diagnosed in the US this year, according to the American Cancer Society. Many Hodgkin`s disease patients are curable. Non-Hodgkin`s lymphoma is diagnosed in about 53,000 Americans each year, and results in about 24,400 deaths annually. It is the fifth most prevalent cancer in the US and its incidence has risen 82% during the last 25 years, in part due to the AIDS epidemic. There are additional classifications of non-Hodgkin`s disease according to cell type and clinical behavior. Aastrom estimates the market for its products in these indications is about $15 million. Industry sources estimate the total stem cell transplantation market in the range of $70-$100 million.

Aastrom Marketed Products

The AastromReplicell System SC-I Therapy and CB-I Therapy Kits were the Company`s first products to address the bone marrow transplant market and are now CE-Marked in Europe, where they are classified as medical laboratory equipment. Both the SC-I and CB-I systems incorporate the Company`s proprietary stand-alone automated cell-culturing system and produce therapeutic cell populations from relatively small aspirates of patient- or donor-derived stem cells. The SC-I expands hematopoietic stem cells and related progenitor cells as well as mesenchymal stem cells (MSCs). The SC-I cell product is intended to be used either as an alternative method to obtain stem cells or to augment PBSC procedures.

The CB-I Therapy Kit is designed to expand stem and progenitor cells derived from umbilical cord blood, and is largely used to assist in cell engraftment in children and adults when there is a subtherapeutic amount of cord blood available for transplantation. Supplementation with CB-I Kit expanded cells may allow even large adult patients to achieve engraftment from subtherapeutic amounts of cord blood. Allogeneic cord blood stem cell transplantation is used in the treatment of some patients receiving chemotherapy or radiation treatment for leukemia, since the immune response resulting from an allogeneic transplant (graft vs. host response) seems to have a beneficial effect in certain transplant patients. Cord blood is banked at institutions around the world.

Aastrom`s most recently CE-Marked products are the DC-I and DCV-I Therapy Kits. These kits are designed to provide dendritic cells for direct use in the production of dendritic cell vaccines. Recently, the ability to culture and manipulate dendritic cells has provided researchers with the opportunity to develop a more specific and potentially more highly active patient immune response to abnormal, invading cancer cells. Dendritic cell manipulation could become the "next generation" to many monoclonal antibody-based immunotherapies. Aastrom`s dendritic cell production system consistently produces blood monocyte-derived dendritic cells at any desired stage in a predictable and reliable fashion using typical laboratory equipment and methods.

Table 1. Aastrom Product Summary

Product Cell Source Tissue Target Therapeutic Application

SC-I Bone Marrow Bone Marrow, Blood, Immune (lymph) system Autologous stem cell transplantation for lymphoma
CB-I Cord Blood Bone Marrow, Immune System Allogeneic stem cell transplantation for leukemia
OC-I Bone Marrow Bone Osteoporosis - post menopausal women
OCG-I Bone Marrow Bone Bone Grafting
OCC-I Bone Marrow Bone/Cartilage Osteoarthritis
DC-I Bone Marrow Immune System Cancer/viral therapeutics
DCV-I Bone Marrow Immune System Antigen-loaded patient-specific anti-cancer/viral

Source: Aastrom Biosciences, Inc.

Clinical Support

Aastrom supports its product development and product marketing with ongoing clinical trials. Data from key Aastrom clinical trials has been published in such peer-reviewed journals as Bone Marrow Transplantation and Blood. For the SC-I product, multi-center trials demonstrated that Aastrom`s SC-I cells were safe and efficacious in a manner similar to standard bone marrow transplantation, and that in combination with peripheral blood stem cell (PBSC) transplantation, SC-I cells improved engraftment success in cases where PBSC dosages were well below optimal levels. The data generated in the Low Dose PBSC Study strongly suggest a synergistic effect that optimizes engraftment rates. However, SC-I expanded neutrophil and platelet recovery times have been observed to lag that of PBSC alone. Aastrom is continuing clinical research to improve the rate at which these blood cells reach normal levels and to determine the best PBSC/SC-I combination therapy. Recently, the FDA granted the SC-I Orphan Drug status for use in PBSC transplantation augmentation.

Aastrom`s CB-I product is undergoing Phase III clinical trials in both pediatric and adult patients in the US. Patients are receiving ex vivo expanded cord blood to augment unmanipulated cord blood cell transplantation. In a 28-patient pediatric leukemia study, CB-I demonstrated safety and possibly superior survival in patients with malignancies (p=0.032, statistically significant at 100 days). An adult leukemia study supported the observation that CB-I ex vivo cells aided engraftment even in large patients, where sufficient therapeutic cord blood cell numbers are difficult to obtain. With cord blood banks now established at several institutions and research supporting allogeneic cord blood cell transplantation for certain leukemias, cord blood cell transplantation may come into wider therapeutic use.

Aastrom is also supporting clinical research in Europe. In February 2002, the Company announced the formation of a European Cancer Center network consisting of centers of excellence established to collaborate in the clinical validation of Aastrom`s SC-I bone marrow stem cells in PBSC transplant augmentation. Clinical protocols and data collection will be standardized among the network participants, and upon successful completion, the resulting data is expected to be published. In a trial being supported by the Italian Government, Aastrom and the Azienda Unita Sanitaria Locale Di Ravenna, Oncologica Medica (AUSL-Ravenna) signed an agreement which calls for AUSL-Ravenna to purchase and use the SC-I therapy product in an experimental protocol for breast cancer. AUSL-Ravenna will lease the AastromReplicell System and purchase SC-I consumables.

Regulatory Status

Stem cell products and therapies are subject to a variety of regulations, which vary widely according to jurisdiction. In general, foreign jurisdictions such as the EU have taken a more liberal stance on classifying these products, and Aastrom`s cell replicating system and cell product kits are regulated as Class I or Class IIb medical laboratory equipment and supplies under the authority of the Medical Device Directives (MDD). Some reagents used as part of the AstromReplicell System are classified as Class III medical devices under the European system.

In the US, the regulatory path has been far less certain. To the Company`s knowledge, it is the first to submit a GMP-compliant cell culture system for the ex vivo production of human cell populations. The FDA is still in the process of drafting approval requirements for somatic cell and gene-related cell-based therapies. Presently, the FDA has classified Aastrom products as a combined IDE/BLA. The Company has filed several IDE`s for its products and is conducting clinical trials to support those filings. Cellular products are being submitted for approval under BLA regulations, which may also require an IND filing. Under present regulations, facilities manufacturing biological products must also file a BLA and be licensed.

Stem Cells, A Controversial Conduit to New Potentially Life-Saving Technologies

Humans and other mammalians are comprised of more than 200 cell types, all of which are derived from the zygote, or the single-cell fertilized egg. Along the way, unspecialized cells are cued and directed in the early stages following fertilization to develop into functional elements of tissues and organs. Stem cells are a broad class of cells which contain the "master" information that relates to an organism`s tissue and organ developmental process. As the developmental process proceeds, cells become less "unspecialized" and more characteristic of the specific tissues and organs they are to become, until they only possess the characteristics and functionality of a specific organ or tissue. This is the process of cell differentiation. Researchers are hopeful that by exploiting the ability of certain "unspecialized" cells to become "specialized" cells, or by tricking "unspecialized" cells into remaining undifferentiated until directed by the patient`s own body (as in bone marrow transplantation), dramatic new therapeutic technologies can be developed.

Stem cells have two specific classifications: embryonic and adult. Embryonic stem cells can self-replicate and give rise to cells from all three germ layers of embryo. Out of the 200-250 cells that make up the preimplantation human embryo, only about 30-34 comprise the inner pluripotent cell mass. It is believed that once implanted, the cells of the embryo go through further differentiation and lose their pluripotent characteristics. Adult stem cells are undifferentiated cells that reside within a mature differentiated tissue, such as blood. They can self-replicate and or become specialized only according to the tissue in which they are found. Adult stem cells reside in the bone marrow, circulatory system, gastrointestinal tract, pancreas, liver, skin and dental pulp, and their main function is to replace worn-out or damaged cells of those systems. At this point, there is no conclusive evidence as to whether adult stem cells are truly pluripotent--that is, capable of differentiating into tissues derived from an embryonic germ layer other than the one from which they originated--or simply multipotent, capable of producing a variety of cells from one embryonic germ layer.

Pluripotent cells derived from the blastula (a preimplantation embryo about 3-4 days old) or epiblast are also known as embryonic stem cells (ES cells). Human ES cells are derived from embryos that result from in vitro fertilization procedures. These embryos are not yet implanted into the uterus and some scientists argue, would not actually exist but for in vitro fertilization procedures. It is because embryonic stem cells can give rise to virtually any tissue or organ that they have received so much research focus. Because the blastocyst, a human embryo, dies when these cells are harvested, the use of embryonic stem cells has created much controversy.

Figure 1. Cell Differentiation Potential



Source: JM Dutton & Associates

Table 2. Cell Layers of the Gastrula and Corresponding Mature Tissue

Embryonic cell layer Differentiated Tissue

Ectoderm (external layer) Skin/epidermis, pigmentation cells, neuronal tissue, pituitary and adrenal medula glands, eyes, ears, connective tissue of the head

Mesoderm (middle layer) Bone marrow, muscle, bone, cartilage, vascular and cardiac vessels, urogenital system, lymphatic tissue, adrenal cortex

Endoderm (inner layer) Gastrointestinal organs, endothelial tissue?such as GI and respiratory system linings, urinary bladder, vagina, urethra, the larynx, trachea, lungs, thyroid, parathyroid and thymus glands

Source: Adapted from Chandross, KJ and Mezey, E. (2001), Plasticity of Adult Bone Marrow Cells,
Mattson, M.P. and Van Zant, G., eds. (Greenwich, CT: JAI Press)



Adult Stem Cells
In the adult, a reservoir of multipotent cells is maintained in certain tissues, such as the bone marrow, to replace or repair worn-out or damaged cells. Three primary classes of multipotent adult stem cells are hematopoietic stem cells (HSCs), found in the bone marrow and which give rise to all the component cells of blood; neuronal stem cells (NSCs), which form the brain and central nervous system; and mesenchymal stem cells (MHCs) which form bone, cartilage, muscle and fat. These groups of multipotent cells are referred to as adult stem cells or somatic stem cells.

Hematopoietic Stem Cells
Research in HSCs began nearly 40 years ago with the discovery that a single precursor cell from the bone marrow of adult mammals could both self-replicate and differentiate into any of several mature cell types found in the blood. This process, carefully controlled and regulated by complex cell signaling and cellular microenvironmental factors, governs the production of mature blood cells and enables the body to maintain hemostasis and respond to physiological stresses such as infection, injury and blood loss.

The HSC pool is very small compared to the number of mature blood cells found in the body, only about 1 in 2-10 million bone marrow cells is a stem cell. HSCs are found in pediatric and adult bone marrow, and to a lesser degree, in circulating blood or the fetal liver, and are comprised of distinct populations based upon cell type (phenotype) and function. HSCs are considered to be multipotent, as they go through a series of successive differentiations to eventually become one of eight known blood cell types. The various stages of differentiation can be identified by, among other things, specific markers on the cell`s surface.

In the adult, two types of HSCs are found; the first, referred to as long-term HSCs (LT-HSCs) have the capability of giving rise to all of the hematopoietic cell lines and have the greatest clonagenic (self-replicating) capacity. The immediate progeny of LT-HSCs, and also circulating in the stem cell pool, are short-term HSCs (ST-HSCs), which retain a similar capacity for generating all of the various blood cell types, but can only do so for 8-10 weeks. ST-HSCs give rise to two cell types which are lineage-restricted. These intermediary cells, the common lymphoid progenitor cell (CLP), and the common myeloid cell (CMP) are considered oligopotent, with the CMP further capable of becoming either a granulocyte-monocyte progenitor cell (GMP) or a megakaryocyte-erythrocyte progenitor cell (MEP). These progenitor cells in turn give rise to specific blood cells such as T-cells, B-cells, dendritic cells and monocytes. In the adult, most of the stem cell pool is comprised of ST-HSCs and their multipotent progenitors. This is in contrast to the stem cell pool found in the fetal liver, which consist primarily of LT-HSCs. Adult bone marrow HSCs differ in capabilities from those of fetal liver HSCs in phenotype and functionality as well as in ways which have therapeutic importance. Unlike adult HSCs, fetal HSCs divide rapidly and seem to be capable of reconstituting blood cell populations in irradiated hosts faster than adult HSCs, thus potentially providing a faster recovery to hemostasis for patients undergoing myleoablative chemo or radiation therapy.

HSCs and progenitor cells are also found circulating in the bloodstream. Bone marrow HSCs and their related progenitor cells rapidly enter the bloodstream and are found not only in the bone marrow, but also in other hematopoietic tissues such as the spleen, thymus, lymph nodes and the like, as well as non-hematopoietic tissues such as the brain, liver, lungs, kidneys, pancreas, muscles, heart, and skin. This suggests that HSCs present the key source of multipotent cells that repair damaged or degenerating tissues.

Figure 2. Hematopoietic Stem Cell Differentiation



Source: JM Dutton & Associates, Morrison, SJ, et al, Identification of a lineage of multipotent hematopoietic progenitors. Development, 1997; 124: 1929-1939

Understanding the complexity of these processes has proven daunting as evidenced by the difficulty of expanding HSCs in vitro while maintaining their clonagenic or self-renewal capacity.

Aastrom`s Market Opportunities

While the market for cell-based devices and tools is relatively small currently, estimated by the Company at about $15 million, we believe that in the near term, this will be an important revenue generator for the Company, especially if the Company`s DC-I and DCV-I products garner market favor. Bone marrow transplant augmentation procedures are currently only done in limited numbers, but with a growing acceptance of cord blood stem cell use in non-myleoablated patients, Aastrom could benefit as its CB-I product is the only commercial-grade product in late-stage US trials which expands cord blood cells. Cancer vaccines are potentially billion-dollar products, and the size of the market for solid tumor cancer therapeutics (breast, colo-rectal and prostate cancer) is well documented. We believe that a growing number of cell-based cancer vaccine product candidates entering Phase III clinical trials should spark demand for cGMP cell products such as those produced by Aastrom.

Aastrom management is especially excited about the market opportunity in bone regeneration products. The orthopedics market is huge, reaching $12 billion in total sales in 2001. Reconstructive procedures dominate sales, but the spinal market remains the fastest growing segment. Spinal market sales in 2001 reached $1.8 billion, up over 20% from 2000. Growth was driven by an estimated 7-8% rise in the number of spinal procedures, a 6-7% price increase, and the trend towards using an ever-increasing amount of hardware. The orthopedic market is dominated by Medtronic`s Sofamor Danek division and Stryker Corporation, with Biomet, JNJ, Zimmer, Sulza Medica and Smith & Nephew possessing much smaller market shares. The US spinal market is largely controlled by Sofamor Danek.

About 550,000-600,000 bone graft procedures are performed each year in the US, with most of those grafts utilizing a patient`s own bone, usually harvested from his hip. Although generally successful, pain, morbidity due to infection and additional surgery are all common drawbacks to patient-harvested bone. As many as 25-40% of autograft patients experience chronic pain at the harvest site. Allograft bone, processed from cadavers, has provided a competitive approach, but here again, safety and significant supply issues have limited the availability and use of allograft. Developing an orthobiological bone graft substitute has become a "Holy Grail" in orthopedics. However, to date, the success rate of a large number of candidate products has been very poor, and even with extraordinary amounts of R&D and clinical trial expenditures, there is still no stand-alone orthobiologic producer approved for the largest market segments. Instead approvals have been narrowly focused into niche applications. Strkyer has received limited European marketing approval for its OP-1 product in non-healing long bone fractures, and only obtained a Humanitarian Device Exemption in the US for use in up to 4,000 patients for this indication. Medtronic`s Danek, in collaboration with Wyeth Ayerst`s Genetics Institute, recently received FDA approval for its INFUSE bone morphogenic protein-infused interbody fusion cage. This approval, which took nearly five years to secure, was significantly narrower than contemplated by Danek or Genetics Institute at the start of the clinical process. Aastrom`s cell-based approach would represent a totally new treatment modality and perhaps overcome some of the technical issues confronted by others developing bone repair and regeneration products.

Research and License Agreements

Aastrom signed a research agreement in 1989 with the University of Michigan for technology related to the ex vivo production of human cells. In 1992, Aastrom entered an exclusive license agreement with the University of Michigan in connection with core technology developed under a research agreement. Under the license agreement, the University will receive a royalty equal to 2% of the net sales of products sold by Aastrom containing the licensed technology and covered by the University of Michigan`s patents. This agreement remains in force until the latest expiration date of the underlying patents.

Financial Highlights

In the past three years (2001, 2000, and 1999), Aastrom has generated revenue of $899,000, $1,150,000 and $881,000, respectively. The primary source of revenue was research grants, which contributed $814,000 to revenue in 2001, $981,000 in 2000 and $847,000 in 1999. The remainder of revenue was generated from product sales.

In the recently reported fiscal year 2002, Aastrom had revenues of $877,000, virtually the same as fiscal 2001. Research grant revenue totaled $800,000. SG&A and R&D costs rose to $9.2 million from $7.5 million the prior year, reflecting planned increases in sales and marketing expenses and operations expansion in Europe. Approximately $400,000 of the year-over-year increase was attributable to increased product development expense associated with dendritic cell vaccine and tissue regeneration products. During 2002, the Company partnered with the Barbara Ann Karmanos Cancer Institute at Wayne State University in Detroit to establish a Center for Cell Therapy. The Center received an initial $2.2 million award by the Michigan Economic Development Corporation to accelerate the development of cell-based therapies for cancer and other diseases. Also, during fiscal year 2002, the Company completed a 7.7 million share secondary offering, raising approximately $11 million, and filed a shelf registration in November 2001 for the sale of up to 8.4 million shares. As of June 30, approximately 1.4 million shares were sold under the November registration, raising approximately $1 million.

Competition

Stem cell therapy has created much excitement in the scientific and medical communities. Despite the controversy and restrictions placed on embryonic stem cell therapy, there are a number of early-stage companies here and abroad pursuing the development of stem cell-based products, or products which facilitate stem cell therapy. Few of these companies are exclusively focused on stem cell-based products and many are private. However, with generally less restrictive policies and more balanced public opinion, stem cell research and embryonic stem cell research in particular is especially active outside the US.

In addition, many companies are pursuing the development of non-stem cell-based products which could address similar markets to those targeted by Aastrom. Alternative strategies include gene therapy, antisense, non-dendritic cell cancer immunotherapy, cell cycle mediation, and cell signaling pathway mediation, to name a few. In the area of cancer vaccines, leading companies such as Cell Genesys, Inc., Genzyme Molecular Oncology and Immunex are established and well-financed competitors. Other companies such as Cell Therapeutics, Inc. and Genta, Inc. have developed and are selling other types of salvage therapies for leukemia and lymphoma patients. On the instrumentation side, the market for clinical research instrumentation and tools is dominated by large, well-established companies like Invitrogen, and Techne Corp (R&D Systems). The orthopedics market is dominated by "instrument" companies. "Non-instrument" companies developing or selling bone graft substitute products include public companies such as Osteotech and Interpore Cross, and a host of private companies such as Etex Corporation, Norian, Orquest, Orthovita, Osiris and Tissue Engineering Inc.

Comparables/Valuation

There are virtually no public companies directly comparable to Aastrom. Therefore, we have compiled a hybrid universe comprising instrumentation and research tools companies and therapeutics companies. Most comparable candidates are either private companies or divisions of larger companies.

Table 3. Aastrom Comparables

Company Recent Price Market Cap* TTM Rev* Px/S P/E Cash/Shr

Clinical Research Instrumentation, Tools, Culture Systems
AnorMED $2.10 $53.90 $5.00 2.3x --- 1.15
Ciphergen $2.06 $90.00 $28.20 3.1x --- 2.34
CytoGenix $0.15 $10.60 $0 --- --- 0.001
Sciclone $1.97 $112.60 $15.70 6.4x --- 0.66
Thermogenesis $1.42 $55.30 $8.40 6.0x --- 0.2
Average $64.48 $11.50 3.6x

Cell-based Therapeutics
Biomira, Inc** $2.06 $119.00 $4.70 24.7x --- 0.72
Chromos Molecular Systems** $0.39 $6.48 $0.20 32.3x --- 1.3
Theratechnologies, Inc.** $3.08 $93.60 $4.50 20.8x --- 1.9
(CellMed Biosciences, Inc.)
Curis $0.65 $21.00 $1.00 21.3x --- 0.95
Dendreon $1.26 $89.70 $13.80 6.4x --- 2.4
Diacrin, Inc. $1.21 $23.30 $2.50 9.4x --- 2.55
MultiCell Tech (Exten Ind) $0.04 $4.90 $0.54 7.8x --- 0
GenStar Therapeutics $0.20 $14.10 $0.67 20.0x --- 0.44
Geron Corporation $3.55 $111.30 $1.98 53.6x --- 2.49
Incara Pharmaceuticals $0.13 $2.30 $0.07 29.5x --- 0.1
Nexell Therapeutics*** $0.09 $1.90 $0.31 0.3x --- 0.21
Stem Cells, Inc. $1.00 $27.00 $0.64 40.0x --- 0.32
Bone, cartilage cell/ BGS
IsoTis (Netherlands) $2.60 $51.00 $2.10 24.3x --- 3.37
GenSci** $0.14 $6.81 $22.80 0.30x --- 0.1
Ortec International $0.45 $4.46 $0.23 18.9x --- 0.08

Average Ý
$38.45 Ý
$3.73 0.6xÝ
Aastrom Biosciences, Inc. $0.27 $11.80 $0.88 18.1x --- 0.27
*000`s omitted
** Canadian company, px converted to $US if not dual listed
***in reorganization
Note: Theratechnologies and IsoTis revenue is primarily research and government grants and interest income

Source: J.M. Dutton & Associates

Risks

Aastrom is a development-stage biotechnology company with limited financial resources. The Company will continue to require outside funding to support operations and clinical development programs for the foreseeable future. In addition, ASTM`s products are subject to FDA approval, and although marketing approval has been secured in Europe for several of the Company`s products, there can be no assurances that marketing approval will be granted in the US, which the Company considers its primary market. In addition to the general risks inherent in development stage biotechnology companies, investors in ASTM should consider the following company-specific risks:

Cell-based therapies, in general, continue to be subject to extensive ethical and regulatory controversy, which has been heightened by the debate over the use of embryonic stem cells. These issues have impacted virtually all cell-based therapy companies. Furthermore, many cell-based therapies are currently considered second-line or salvage therapies and as such, market opportunities remain niche-oriented. The entire cell-based therapy industry is subject to large swings in investor interest as a result of these issues. At the present, Aastrom`s products produce "single patient" therapies, which ultimately may or may not be competitive economically with current practice. Additionally, medical reimbursement issues may impact market acceptance.


A key component of Aastrom`s strategy for the future relies upon the development of a successful cell-based bone grafting/regeneration product to address the bone fracture and spinal fusion markets. To date, no company, including large, well-established companies, have been successful in developing a stand-alone biological-based bone regeneration product for the spinal fusion market. Complex technical and clinical approval issues remain unresolved. Without significant additional financial resources and a development partner, the Company may not be able to achieve this objective.


Aastrom may face manufacturing issues. The FDA is classifying its cell products as biologics, and may require additional licensing under a Biological License Application for any customer producing cell products in-house as a therapeutic. Some of the Company`s products require the use of fetal calf serum and/or equine serum for cell-culture media. Currently, the European Union maintains a highly cautious view of bovine-derived products as a result of BSE. The spread of West Nile Fever virus in horses may carry the same negatives. The lack of a serum-free media may hamper the European market acceptance as a result. Furthermore, Aastrom relies upon certain sole source suppliers, one of whom has given notice to cancel its supplier agreement. Although Aastrom does not anticipate any problems in securing a new supplier, increased lead times for products could occur.
Conclusion

We are convinced that stem cell therapies will eventually find their place in the commercial marketplace. However, fixing the time horizon for getting these next-generation products to market is complicated by a host of regulatory, technical and ethical issues surrounding "stem cells" as a therapeutic modality. Companies which have multi-faceted business models, like Aastrom, will fare relatively better during this period of uncertainty, as research activity in stem cell and other cell-based therapy continues around the world, and in fact, is far less fettered in countries such as Canada, UK, Israel and others. Aastrom is ahead of its competitors with a suite of approved GMP and ISO 9001/9002 compliant cell products. In this environment, we would expect market acceptance of the AastromReplicell System over time. Commercial sales of these products is critical for Aastrom to drive the Company`s therapeutic program, which holds significant promise. We rate Aastrom shares a Speculative Buy for high-risk-oriented investors familiar with the speculative nature of early stage biotechnology and who have multi-year investment time horizons. Our target price is $0.65 in 12 months.

Table 4. Aastrom Biosciences, Inc.
Selected Financial Informationfor the Year Ended June 30
(000`s)

2001 2002
Current Assets
Cash and Equivalents $10,659 $8,605
Short term investments --- 1,000
Receivables, net 129 120
Inventory, net 725 1,397
Other current assets 213 225

Total Current Assets 11,726 11,347

Property, net 179 206
Total Assets 11,905 11,553

Current Liabilities
Accts payable & accrued expenses 856 589
Accrued employee expenses 155 161

Total Current Liabilities 1,011 750

Accumulated deficit (85,858)Ý -93,797
Total Liabilities and Shareholders` Equity $11,905 $11,553

Income Statement Data
2001 2002 2003E 2004E
Revenues
Product sales and rentals $85 $80 $625 $3,440
Research and Development agreements
Grants 814 797 1,200 1,200
Total Revenues 899 877 1,825 4,640

Costs and Expenses
Cost of Sales 13 202 500 2,750
Research and Development 4,983 5,428 5,971 6,866
Selling, General & Administration 2,482 3,528 4,410 5,292
Total Operating Expenses 7,478 9,158 10,881 14,908

Operating profit (loss) -6,579 -8,281 -9,056 -10,268

Other Income
Interest, net 653 342 400 400
Other income
Total Other Income 653 342 400 400

Net Loss ($5,926) ($7,939) ($8,656) ($9,868)
Net Loss per Share, basic and diluted ($0.17) ($0.19) ($0.19) ($0.22)
Wgtd Avg Shares Outstanding 34,030 42,121 45,000 45,000


Source: Company SEC filings and J.M. Dutton & Associates estimates


--------------------------------------------------------------------------------

Analyst:
Analyst
Sherry Grisewood, CFA
Ms. Sherry Grisewood, CFA, has had extensive experience as a sell-side analyst, primarily in small cap stocks, and has worked for such firms as DLJ and EF Hutton. She has over 16 years experience as an independent special situations and small cap analyst, and has written a cash and futures market commentary since 1982. She has performed extensive analysis for investment banking projects and currently has her own practice working on securities analysis. Ms. Grisewood holds a B.S. degree with Highest Honors from Ramapo College of New Jersey and is a member of The New York Society of Security Analysts.


--------------------------------------------------------------------------------

Contact:
Aastrom Biosciences, Inc. 24 Frank Lloyd Wrig

[meislo]

Press Release Source: Aastrom Biosciences, Inc.


Analyst Coverage Initiated on Aastrom Biosciences
Friday November 1, 6:25 pm ET


BOSTON, Nov. 1 /PRNewswire-FirstCall/ -- Analyst coverage was initiated today on Aastrom Biosciences, Inc. (NasdaqSC: ASTM), a late-stage development company focused on human cell-based therapies for stem cell tissue repair and regeneration, and the treatment of cancer and other infectious diseases. The initial research report was issued by Sherry Grisewood, CFA, of J.M. Dutton & Associates, an investment research firm that does not provide investment- banking services to Aastrom Biosciences. The report can be viewed free of charge at www.jmdutton.com.
About J.M. Dutton & Associates

J.M. Dutton & Associates is an investment research firm offering fundamental research on public companies. Dutton & Associates provides economically bias-free, continuing analyst coverage of enrolled companies, and its research has wide distribution. For more information on J.M. Dutton & Associates, please visit their website at www.jmdutton.com.

Disclaimer

J.M. Dutton & Associates research does not require or connote endorsement or approval of any of the analysts` evaluations, ratings, opinions, or projections by the enrolled company. As have other companies enrolled in the Dutton & Associates continuing research program, Aastrom has paid Dutton & Associates a fee of $25,000, but does not have any control over the content or timing of the research produced.

CONTACT:

Susan Ladue
The Scottsdale Group
Phone: [phone]

Make Your Opinion Count - Click Here

[fonx]

@alle ,astm interesiert mich auch!!! Aber habe gelesen die haben einen Reservesplitt von 4-1 vor,um nicht von der Nasdaq zu fliegen,stimmt dies jetzt? Eine Antwort wäre echt nett!!Fonx

[meislo]

Davon ist nichts bekannt,auszuschliessen ist es aber nicht.
Der mögliche Reverse Split könnte aber wie in Amerika üblich auch höher ausfallen, wie im Fall Comerce One, nähmlich 1:10 . Das macht eher Sinn damit man nicht so schnell unter die 1 Dollar-Marke abstürtzt. Auch reicht ohne zusätzliche Einnahmen die Kapitaldecke nur noch bis ca. Ende Juni 2003 . Also ,ein Investment sollte nur der wagen, der ein Totalverlust auch verkraften kann.

[meislo]

Na Hoffentlich wird was daraus, damit wäre ein Reverse Splitt wohl vom Tisch

Nasdaq to decide on $1 listing rule next quarter
Friday November 8, 2:38 pm ET
By Nicole Maestri


BOCA RATON, Fla, Nov 8 (Reuters) - The Nasdaq Stock Market (OTC BB:NDAQ.OB - News) will likely decide whether it will waive its $1 minimum listing requirement for shares that list on the Nasdaq in the next quarter, Nasdaq Chairman Hardwick Simmons said on Friday.

In October, Simmons said the No. 2 U.S. stock market was considering waiving its minimum listing requirement since roughly 13 percent of its 3,800 stocks trade below $1.
...
...
...

http://biz.yahoo.com/rf/021108/markets_nasdaq_listing_1.html

[meislo]

Haben da gestern schon einige was gewusst

AASTROM BIOSCIENCES INC (ASTM)
Quarterly Report (SEC form 10-Q)
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Overview of Aastrom

We are pioneering the development of human cell therapy technologies intended for a broad range of medical applications based on our patented process and device capabilities for manufacturing proprietary cell mixtures. Our lead cell therapeutic product areas under development include: Tissue Repair Cells (TRCs), Therapeutic Cells (TCs), and Cell Culture Devices. TRCs are cells that lead to the construction of normal tissue such as bone. TCs are cells that can act like drugs, such as a therapeutic vaccine for cancer or viruses. Cell culture devices have been developed by Aastrom to produce our TRCs and TCs, but they can also be sold to authorized third parties as stand-alone products.

Our business model builds on two complementary components: (i) proprietary procedures and devices to enable certain types of stem cells and other types of human cells to be produced with excellent biological capabilities as compared with standard cell culture approaches; and (ii) the AastromReplicell™ System clinical platform that is designed to standardize and enable an effective commercialization pathway for bringing therapeutic cell production to medical practice. The AastromReplicell™ System consists of an instrumentation platform, to be either sold to a hospital or other centralized facility, or alternatively, used by Aastrom, that can operate a variety of single-use cell production kits that are specific to the desired medical application. Each cell product is produced using a specific type of kit. The kit and the cell product produced with the kit share a common identifying nomenclature such as DC-I, DCV-I, OC-I, OCG-I, SC-I and CB-I. Through this product configuration, we intend either directly to commercialize cells for therapeutic use, or to enable customers or potential collaborators with the capability to produce cells for therapeutic applications through sale of the AastromReplicell™ System instruments and kits. This approach is intended to provide a product pathway for each cell therapy that is similar to a pharmaceutical product including regulatory approval, reimbursement, marketing and pricing. We believe that the design of the AastromReplicell™ System will allow us to develop additional cell therapy products to provide standardization for a number of emerging cell therapies being developed by other researchers.

We have different TRC products in active development, including: SC-I bone marrow cells for bone marrow transplantation application; CB-I cells for cord blood stem cell transplantation application; OC-I cells for severe osteoporosis; and OCG-I cells for bone grafting applications. For the TC product areas, we are investigating immune system dendritic cells, a type of blood cell that has the ability to stimulate an immune response against specific targets as a potential new treatment for cancer and viral diseases. We have developed the DC-I and DCV-I device products, and intend to use them for our own TC products, as well as to sell them to many clinical researchers and centers that are developing dendritic cell-based vaccines designed to treat cancer and other disorders. We have obtained approval to affix the CE Mark to the DC-I and DCV-I kits, as well as the AastromReplicell™ System, allowing us to market and sell these products in Europe, through our German subsidiary, Zellera AG. We also are marketing


Table of Contents

the DC-I and DCV-I device products to U.S. clinical and research groups that are developing dendritic cell-based cancer vaccines. The development of our own proprietary vaccines may be pursued pending additional grant funding or strategic partnerships.

Our SC-I and CB-I TRC products have received CE Mark approval allowing us to begin commercialization activities in Europe, through our German subsidiary, Zellera AG, and are in Phase III-Type clinical studies in the U.S. However, we do not believe there is a current market for the CB-I product in Europe, and will be several years before any U.S. approvals may be received, or for the markets to develop for this product. Although able to be sold in Europe, the SC-I product will have to undergo various clinical evaluations at initial customer sites in order to generate the data necessary for reimbursement of the product. This year we established relationships at several European centers for these sites to generate this clinical data.

More recently we have initiated a development program for the production of bone-forming TRCs in the AastromReplicell™ System (our “OC” line of TRCs). The OC-I cell product is being developed for the treatment of patients with degenerative bone diseases such as osteoporosis, for which a Phase I/II-Pilot clinical study is in process in the U.S. Our OCG-I cell product is being developed for bone grafting applications, and we are developing a clinical trial plan for this product

Our therapeutic cell development efforts to date have focused on using our technology to grow larger quantities of the desired therapeutic cells from small starting amounts of cells or a tissue. Our cell production processes are based on using the natural reproductive capabilities of cells outside the body (ex vivo), without various cloning approaches. Our programs currently use bone marrow, cord blood and blood cells as starting sources of cells. As such, federal support or other factors relating to embryonal research have no direct impact on our current product programs.

Since our inception, we have been in the development stage and engaged in research and product development, conducted principally on our own behalf, but also in connection with various collaborative research and development agreements with others. We commenced our initial pilot-scale product launch in Europe of the AastromReplicell™ Cell Production System with the SC-I kit in April 1999. At approximately this same time, data was released at international meetings that resulted in the majority of the patients who would otherwise have been candidates for the SC-I product, to no longer require the use of the product. This loss of market for the SC-I caused us to reorganize our operations and suspend all marketing activities in October 1999, pending the receipt of additional financing and reorganization. While we’ve initiated marketing activities for the CE Marked SC-I, DC-I and the DCV-I products, we do not expect to generate positive cash flows from our consolidated operations for at least the next several years and then only if more significant product sales commence. Until that time, we expect that our revenue sources will be limited to grant revenue and research funding, milestone payments and licensing fees from potential future corporate collaborators. To date, we have financed our operations through public and private sales of our equity securities. As a development-stage company, we have never been profitable and do not anticipate having net


Table of Contents

income unless and until significant product sales commence, which is unlikely to occur until we obtain significant additional funding. Through September 30, 2002, we have accumulated losses of approximately $95 million. There can be no assurance that we will be able to achieve profitability on a sustained basis, if at all, obtain the required funding, or complete a corporate partnering or acquisition transaction.

Critical Accounting Policies

There are several accounting policies that we believe are significant to the presentation of our consolidated financial statements. The most significant accounting policies include those related to inventory and revenue recognition.

Inventory. We value our inventory that consists primarily of finished components of our lead product, the AastromReplicell™ Cell Production System, at the lower of cost (specific identification using first in, first out) or market. Furthermore, we regularly review inventory quantities on hand and record a provision to write down obsolete and excess inventory to its estimated net realizable value. Based on the aging of inventory at each period end, we utilize a systematic approach to determine our reserve for obsolete and excess inventory. Under this systematic approach, inventory that is less than twelve months old, based on the receipt date, will be carried at full value. Inventory quantities in excess of twelve months old are reserved over a six-month period, until the items are either sold or fully reserved. We feel this approach is appropriate given our limited product sales history and the risk associated with our ability to recover the inventory as we are still in the process of establishing our product market. Future technological changes, new product development and actual sales results could result in additional obsolete and excess inventory on hand. This could have a significant impact on the value of our inventory and our reported operating results.

Revenue recognition. We generate revenue from grants and research agreements, collaborative agreements and product sales. Revenue from grants and research agreements is recognized on a cost reimbursement basis consistent with the performance requirements of the related agreements. Revenue from collaborative agreements is recognized when the scientific or clinical results stipulated in the agreement have been met and there are no other ongoing obligations on our part. Revenue from product sales is recognized when title to the product transfers and there are no remaining obligations that will affect the customer’s final acceptance of the sale, generally after installation and training. If there are remaining obligations, including training or installation, revenue is recognized upon completion of these obligations. Revenue from licensing fees under licensing agreements is recognized as revenue when there are no future performance obligations remaining with respect to such fees. Payments received before all obligations are fulfilled are classified as deferred revenue.

Accounts receivable. We make estimates evaluating collectibility of accounts receivable. We continuously monitor collections and payments from our customers and maintain an allowance for estimated credit losses based on any specific customer collection issues we have identified. While such credit issues have not been significant, there is no assurance that we will continue to experience the same credit losses in the future.


Table of Contents

The summary of significant accounting policies should be read in conjunction with our consolidated financial statements and related notes and this discussion of our results of operations.

Results of Operations

Revenues for the quarter ended September 30, 2002 were $93,000, which consisted of grant revenues and product sales and rentals, compared to revenues of $151,000 for the same period in 2001. Grant revenues have decreased from the prior year as a result of reduced grant program activity. With the award of a collaborative grant by the Defense Advanced Research Projects Agency, for $886,000 over an eighteen-month period that began September 2002, we are anticipating that grant revenues will increase throughout the fiscal year. We continue to pursue grant-funded programs as well as European sales and marketing opportunities.

Costs and expenses for the quarter ended September 30, 2002 increased to $2,586,000, compared to $2,166,000 for the same period in 2001. Increases in costs and expenses include an increase in research and development expense to $1,385,000 for the quarter ended September 30, 2002, from $1,207,000 for the same period in 2001, and an increase in selling, general and administrative expenses to $1,113,000 from $919,000. These increased costs and expenses are the result of expanding our program development activities and increased marketing opportunities in the areas of dendritic cell-based vaccines in the European market and in preparation of our pending bone grafting trials.Selling, general and administrative expense for the quarter ended September 30, 2002 includes a non-cash charge of $159,000 relating to certain warrants issued in August 2002. These warrants were issued in a private transaction to an accredited investor for investment banking services and entitle the holder to purchase 2,000,000 shares of our common stock. Cost of product sales and rentals for the quarter ended September 30, 2002 and 2001 include charges of $88,000 and $40,000, respectively, relating to the provision for obsolete and excess AastromReplicellTM inventory.

Interest income was $41,000 for the quarter ended September 30, 2002 compared to $122,000 for the same period in 2001. The fluctuations in interest income are due primarily to corresponding changes in the level of cash, cash equivalents and short-term investments during the periods and decreases in yields from our investments.

Aastrom’s net loss was $2,452,000, or $.05 per common share for the quarter ended September 30, 2002 compared to $1,893,000, or $.05 per common share for the same period in 2001. This increase in net loss is primarily the result of increased costs and expenses offset on a per share basis by an increase in the weighted average number of common shares outstanding resulting from additional equity financing.


Table of Contents

Liquidity and Capital Resources

We have financed our operations since inception primarily through public and private sales of equity securities, which, from inception through September 30, 2002, have totaled approximately $106 million and, to a lesser degree, through grant funding, payments received under research agreements and collaborations and interest earned on cash, cash equivalents, and short-term investments. These financing sources have historically allowed us to maintain adequate levels of cash and other liquid investments.

Our combined cash, cash equivalents and short-term investments totaled $7,930,000 at September 30, 2002, a decrease of $1,675,000 from June 30, 2002. The primary uses of cash, cash equivalents and short-term investments during the quarter ended September 30, 2002 included $2,544,000 to finance our operations and working capital requirements. The primary source of cash, cash equivalents and short-term investments was from the equity financing transactions, of which $869,000 was raised during the quarter. This equity financing was transacted under our November 16, 2001 shelf registration and the Employee Stock Purchase Plan.

Our future cash requirements will depend on many factors, including continued scientific progress in our research and development programs, the scope and results of clinical trials, the time and costs involved in obtaining regulatory approvals, the costs involved in filing, prosecuting and enforcing patents, competing technological and market developments and the cost of product commercialization. We do not expect to generate a positive cash flow from operations for at least the next several years due to the expected spending for research and development programs and the cost of commercializing our product candidates. We intend to seek additional funding through research and development, or distribution and marketing, agreements with suitable corporate collaborators, grants and through public or private financing transactions. Successful future operations are subject to several technical and business risks, including our continued ability to obtain future funding, satisfactory product development, obtaining regulatory approval and market acceptance for our products. We expect that our available cash will be sufficient to finance currently planned activities into the first quarter of fiscal year 2004. We are currently pursuing additional sources of financing. If we cannot obtain additional funding prior to the end of the third quarter of fiscal year 2003, we will make substantial reductions in the scope and size of our operations, and may curtail activities currently planned to be resumed, in order to conserve cash until such funding is obtained. These estimates are forward-looking statements based on certain assumptions which could be negatively impacted by the matters discussed under this heading and under the caption “Business Risks” in our 2002 Annual Report on Form 10-K. In order to grow and expand our business, and to introduce our product candidates into the marketplace, we will need to raise additional funds. We will also need additional funds or a collaborative partner, or both, to finance the research and development activities of our product candidates for the expansion of additional cell types. We expect that our primary sources of capital for the foreseeable future will be through collaborative arrangements and through the public or private sale of our debt or equity securities. There can be no assurance that such collaborative arrangements, or any public or private financing, will be available on acceptable terms, if at all, or can be sustained.


Table of Contents

Several factors will affect our ability to raise additional funding, including, but not limited to, market volatility of our common stock and economic conditions affecting the public markets generally or some portion or all of the technology sector. If adequate funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our research and development programs, which may have a material adverse affect on our business. See “Business Risks” and “Notes to Consolidated Financial Statements” in our 2002 Annual Report on Form 10-K and “Notes to Consolidated Financial Statements” included herein.


Table of Contents

Certain Business Considerations

Our past losses and expected future losses cast doubt on our ability to operate profitably.

We were incorporated in 1989 and have experienced substantial operating losses since inception. As of September 30, 2002, we have incurred net losses totaling approximately $95 million. These losses have resulted principally from costs incurred in the research and development of our cell culture technologies and the AastromReplicell™ System, general and administrative expenses, and the prosecution of patent applications. We expect to incur significant operating losses until product sales increase, primarily owing to our research and development programs, including pre-clinical studies and clinical trials, and the establishment of marketing and distribution capabilities necessary to support commercialization efforts for our products. We cannot predict with any certainty the amount of future losses. Our ability to achieve profitability will depend, among other things, on successfully completing the development of our product candidates, obtaining regulatory approvals, establishing manufacturing, sales and marketing arrangements with third parties, and raising sufficient funds to finance our activities. We may not be able to achieve or sustain profitability.

Our inability to complete our product development activities successfully would severely limit our ability to operate or finance operations.

Commercialization in the United States of our lead product candidate, the AastromReplicell™ Cell Production System, will require additional research and development as well as substantial clinical trials. While we have commenced initial marketing on a limited basis of the AastromReplicell™ System in Europe, we believe that the United States will be the principal market for our products. We may not be able to successfully complete development of the AastromReplicell™ System or our other product candidates, or successfully market our technologies or product candidates. We, and any of our potential collaborators, may encounter problems and delays relating to research and development, regulatory approval and intellectual property rights of our technologies and product candidates. Our research and development programs may not be successful, and our cell culture technologies and product candidates may not facilitate the production of cells outside the human body with the expected result. Our technologies and product candidates may not prove to be safe and efficacious in clinical trials, and we may not obtain the intended regulatory approvals for our technologies or product candidates and the cells produced in such products. If any of these events occur, we may not have adequate resources to continue operations for the period required to resolve the issue delaying commercialization and we may not be able to raise capital to finance our continued operation during the period required for resolution of that issue.


Table of Contents

We may not be able to raise the required capital to conduct our operations and develop our products.

We will require substantial capital resources in order to conduct our operations and develop our products. In October 1999, we were forced to reduce operations based on our declining level of capital resources and our limited financing alternatives available at that time. The previous reduction in our operating activities has delayed our product development programs. We expect that our available cash and expected interest income will be sufficient to finance currently planned activities through the first quarter of fiscal year 2004. We are currently pursuing additional sources of financing. If we cannot obtain additional funding prior to the end of third quarter of fiscal year 2003, we will make substantial reductions in the scope and size of our operations, and may curtail activities currently planned to be resumed, in order to conserve cash until such funding is obtained. In order to grow and expand our business, and to introduce our new product candidates in to the marketplace, we will need to raise additional funds. We will also need additional funds or a collaborative partner, or both, to finance the research and development activities of our product candidates for the expansion of additional cell types.

Our future capital requirements will depend upon many factors, including:


• continued scientific progress in our research and development programs;

• costs and timing of conducting clinical trials and seeking regulatory
approvals and patent prosecutions;

• competing technological and market developments;

• our ability to establish additional collaborative relationships; and

• the effect of commercialization activities and facility expansions if and as
required.

Because of our long-term funding requirements, we are likely to access the public or private equity markets if and whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time. Further, we may enter into financing transactions at rates, which are at a substantial discount to market. This additional funding may not be available to us on reasonable terms, or at all. If adequate funds are not available, we may be required to further delay or terminate research and development programs, curtail capital expenditures, and reduce business development and other operating activities.

The issuance of additional common stock for funding has the potential for substantial dilution.

As noted above, we will need additional equity funding to provide us with the capital to reach our objectives. At current market prices, such an equity issuance would cause a substantially larger number of shares to be outstanding and would dilute the ownership interest of existing stockholders. Pursuant to previously approved shareholder resolutions, the Board of Directors has the authority to increase the maximum number of authorized shares from 100 million to 150 million.


Table of Contents

The warrants have the potential for substantial dilution.

As of September 30, 2002 we had warrants outstanding to purchase 2,614,386 shares of common stock at $1.44 per share and 2,000,000 shares of common stock at $0.75 per share. As of that date, we also had outstanding options to purchase 3,997,072 shares at a weighted average price of $1.43 per share. Holders of common stock could therefore experience dilution of their investment upon exercise of these warrants and options.

Our stock price has been volatile and future sales of substantial numbers of our shares could have an adverse affect on the market price of our shares.

The market price of shares of our common stock has been volatile ranging in closing price between $0.36 and $2.40, for fiscal year 2002. The price of our common stock may continue to fluctuate in response to a number of events and factors, such as:


• clinical trial results;

• the amount of our cash resources and our ability to obtain additional
funding;

• announcements of research activities, business developments, technological
innovations or new products by us or our competitors;

• changes in government regulation;

• disputes concerning patents or proprietary rights;

• changes in our revenues or expense levels;

• public concern regarding the safety, efficacy or other aspects of the
products or methodologies we are developing; and

• changes in potential recommendations by securities analysts.

Any of these events may cause the price of our shares to fall, which may adversely affect our business and financing opportunities. In addition, the stock market in general and the market prices for biotechnology companies in particular have experienced significant volatility that often has been unrelated to the operating performance or financial conditions of such companies. These broad market and industry fluctuations may adversely affect the trading price of our stock, regardless of our operating performance or prospects. For example, within the last fiscal year, our stock price has experienced a day where it closed at approximately 26% over the previous day’s closing price and another day when it dropped by over 19% from the previous day’s closing price.

Our stock may be delisted from Nasdaq that could affect its market price and liquidity.

We are required to meet certain financial tests (including, but not limited to, a minimum bid price of our common stock of $1.00) to maintain the listing of our common stock on the Nasdaq Stock Market. As a result of recent price fluctuations, our common stock price has traded below the $1.00 minimum level and we were notified that our common stock would be delisted if we did not regain compliance with this listing requirement prior to February 24, 2003. If we do not remain listed on Nasdaq, the market price and liquidity of our common


Table of Contents

stock could be impaired. Further, the National Association of Securities Dealers has recently adopted a change in minimum listing requirements to include a new $2.5 million of minimum net equity requirement for the SmallCap Market, which we currently meet. This new standard will replace the minimum tangible net worth requirement and becomes effective for us in November 2002. The result of such a change, or further changes, may be that it could be more difficult for us to maintain compliance with the listing standards, the result of which would be that our stock may be delisted.

We must successfully complete our clinical trials to be able to market our products.

To be able to market products in the United States, we must demonstrate, through extensive preclinical studies and clinical trials, the safety and efficacy of our processes and product candidates, together with the cells produced by such processes in such products, for application in the treatment of humans. We are currently conducting clinical trials to demonstrate the safety and biological activity of patient-derived cells produced in the AastromReplicell™ System. Depending on the availability of resources, we intend to commence at least one additional clinical trial to demonstrate the safety and biological activity of umbilical cord blood cells produced in the AastromReplicell™ System. If our clinical trials are not successful, our products may not be marketable.

Our ability to complete our clinical trials in a timely manner depends on many factors, including the rate of patient enrollment. Patient enrollment can vary with the size of the patient population, the proximity of suitable patients to clinical sites, perceptions of the utility of stem cell therapy for the treatment of certain diseases and the eligibility criteria for the study. We have experienced delays in patient accrual in our previous and current clinical trials. If we experience future delays in patient accrual, we could experience increased costs and delays associated with clinical trials, which would impair our product development programs and our ability to market our products. Furthermore, the FDA monitors the progress of clinical trials and it may suspend or terminate clinical trials at any time due to patient safety or other considerations.

Failure to obtain and maintain required regulatory approvals would severely limit our ability to sell our products.

We must obtain the approval of the FDA before commercial sales of our product candidates may commence in the United States, which we believe will be the principal market for our products. We may also be required to obtain additional approvals from foreign regulatory authorities to continue or increase our sales activities in those jurisdictions. If we cannot demonstrate the safety, reliability and efficacy of our product candidates, or of the cells produced in such products, we may not be able to obtain required regulatory approvals. Many of the patients enrolled in the clinical trials will have previously undergone extensive treatment which will have substantially weakened the patients and may have irreparably damaged the ability of their blood and immune system to recover. Some patients undergoing the transplant recovery process have died, from causes that were, according to the physicians involved, unrelated to the AastromReplicell™ System procedure, and it is possible that other patients


Table of Contents

may die or suffer severe complications during the course of either the current or future clinical trials. In addition, patients receiving cells produced with our technologies and product candidates may not demonstrate long-term engraftment in a manner comparable to cells obtained from current stem cell therapy procedures. If we cannot demonstrate the safety or efficacy of our technologies and product candidates, including long-term sustained engraftment, or if one or more patients die or suffer severe complications, the FDA or other regulatory authorities could delay or withhold regulatory approval of our product candidates.

Finally, even if we obtain regulatory approval of a product, that approval may be subject to limitations on the indicated uses for which it may be marketed. Even after granting regulatory approval, the FDA, other regulatory agencies, and governments in other countries continue to review and inspect marketed products, manufacturers and manufacturing facilities. Later discovery of previously unknown problems with a product, manufacturer or facility may result in restrictions on the product or manufacturer, including a withdrawal of the product from the market. Further, governmental regulatory agencies may establish additional regulations which could prevent or delay regulatory approval of our products.

Even if we obtain regulatory approvals to sell our products, lack of commercial acceptance would impair our business.

We are seeking to obtain regulatory approval to market the AastromReplicell™ System as an alternative to, or as an improvement for, the bone marrow harvest and peripheral blood progenitor cell stem cell collection methods. These stem cell collection methods have been widely practiced for a number of years, and our technologies or product candidates may not be accepted by the marketplace as readily as these or other competing processes and methodologies. Additionally, our technologies or product candidates may not be employed in all potential applications being investigated, and any reduction in applications would limit the market acceptance of our technologies and product candidates and our potential revenues. As a result, even if we obtain all required regulatory approvals, we cannot be certain that our products and processes will be adopted at a level that would allow us to operate profitably.

Failure of third parties to manufacture component parts or provide limited source supplies would impair our new product development and our sales activities.

We rely solely on third parties such as Plexus, Moll, Biowhittaker and Amgen to manufacture our product candidates, their component parts and growth factors and other materials used in the cell expansion process. We would not be able to obtain alternate sources of supply for many of these items on a short-term basis. Plexus has elected to exercise its right to terminate our Manufacturing Supply Agreement effective in February 2004. As a result, we are negotiating with another supplier for continued supply on commercially reasonable terms. However, we may not reach agreement with this new supplier and the new agreement may be on less favorable terms. If any of our key manufacturers or suppliers fail to perform their respective obligations or if our supply of growth factors, components or other materials is limited or interrupted, we would not be able to conduct clinical trials or market our product candidates on a timely and cost-competitive basis, if at all.


Table of Contents

On September 10, 2002 a major creditor of Moll filed an involuntary petition for Bankruptcy against Moll. On September 19, 2002 Moll announced that it had converted the case to a voluntary Chapter 11 reorganization case and had received preliminary approval for a $50 million debtor-in-possession financing. These factors may affect our supply of components. However, to date, there has been no impact on our supply of components from Moll.

Furthermore, some of the compounds used by us in our current bone marrow or cord blood cell expansion processes involve the use of animal-derived products. Suppliers or regulatory authorities may limit or restrict the availability of such compounds for clinical and commercial use. Any restrictions on these compounds would impose a potential competitive disadvantage for our products. Our inability to develop or obtain alternative compounds would harm our product development and commercialization efforts.

Finally, we may not be able to continue our present arrangements with our suppliers, supplement existing relationships, establish new relationships or be able to identify and obtain the ancillary materials that are necessary to develop our product candidates in the future. Our dependence upon third parties for the supply and manufacture of these items could adversely affect our ability to develop and deliver commercially feasible products on a timely and competitive basis.

Given our limited internal sales and marketing capabilities, we need to develop collaborative relationships to sell, market and distribute our products.

While we have commenced initial marketing on a limited basis of the AastromReplicell™ System and SC-I, CB-I, DC-I and DCV-I therapy kits in Europe, we have only limited internal sales, marketing and distribution capabilities. We intend to market our products through collaborative relationships with companies with established sales, marketing and distribution capabilities. Our inability to develop and maintain those relationships would limit our ability to market, sell and distribute our products. Our inability to enter into successful, long-term relationships could require us to develop alternate arrangements at a time when we need sales, marketing or distribution capabilities to meet existing demand.

Any changes in the governmental regulatory classifications of our products could prevent, limit or delay our ability to market or develop our products.

The FDA establishes regulatory requirements based on the classification of a product. The AastromReplicell™ System may be regulated as a Class III medical device, or the FDA may ultimately choose to regulate the AastromReplicell™ System under another category. Because our product development programs are designed to satisfy the standards applicable to Class III medical devices, a change in the regulatory classification would affect our ability to obtain FDA approval of our products. The AastromReplicell™ System is capable of producing different cell mixtures, and at least some of these cell mixtures will, under current regulations be regulated as biologic products, which require a completely different strategy.


Table of Contents

If we do not keep pace with our competitors and with technological and market changes, our products may become obsolete and our business may suffer.

The market for our products is very competitive, is subject to rapid technological changes and varies for different individual products. For each of our potential products, we believe that there are potentially many competitive approaches being pursued, including some by private companies for which information is difficult to obtain.

Many of our competitors have significantly greater resources, more product candidates and have developed product candidates and processes that directly compete with our products. Our competitors may have developed, or could in the future develop, new technologies that compete with our products or even render our products obsolete. As an example, in the past, published studies have suggested that stem cell therapy may have limited clinical benefit in the treatment of breast cancer, which was a significant portion of the overall stem cell transplant market. This has resulted in a substantial decline in the market for the AastromReplicell™ System with our SC-I kit. Our products are designed to improve and automate the processes for producing cells used in therapeutic procedures. Even if we are able to demonstrate improved or equivalent results, researchers and practitioners may not use our products and we will suffer a competitive disadvantage. As a result, we may be unable to recover the net book value of our inventory. Finally, to the extent that others develop new technologies that address the targeted application for our products, our business will suffer.

If we cannot attract and retain key personnel, then our business will suffer.

Our success depends in large part upon our ability to attract and retain highly qualified scientific and management personnel. We face competition for such personnel from other companies, research and academic institutions and other entities. Further, in an effort to conserve financial resources, we have implemented reductions in our work force on two separate occasions. As a result of these and other factors, we may not be successful in hiring or retaining key personnel. The Company has a key man life insurance policy for R. Douglas Armstrong, the Chairman, Chief Executive Officer and President of Aastrom. Our inability to replace any other lost key employee could harm our operations.

If our patents and proprietary rights do not provide substantial protection, then our business and competitive position will suffer.

Our success depends in large part on our ability to develop or license and protect proprietary products and technologies. However, patents may not be granted on any of our pending or future patent applications. Also, the scope of any of our issued patents may not be sufficiently broad to offer meaningful protection. In addition, our issued patents or patents licensed to us could be successfully challenged, invalidated or circumvented so that our patent rights would not create an effective competitive barrier. Furthermore, we rely on three exclusive, world-wide licenses relating to the production of human cells granted to us by the University of Michigan for certain of our patent rights. If we materially breach such agreements


Table of Contents

or otherwise fail to materially comply with such agreements, or if such agreements expire or are otherwise terminated by us, we may lose our rights under the patents held by the University of Michigan. At the latest, these licenses will terminate when the patent underlying the license expires. The first of these underlying patents will expire on March 21, 2012. We also rely on trade secrets and unpatentable know-how that we seek to protect, in part, by confidentiality agreements with our employees, consultants, suppliers and licensees. These agreements may be breached, and we might not have adequate remedies for any breach. If this were to occur, our business and competitive position would suffer.

Intellectual property litigation could harm our business.

Our success will also depend in part on our ability to develop commercially viable products without infringing the proprietary rights of others. Although we have not been subject to any filed infringement claims, other patents could exist or could be filed which would prohibit or limit our ability to market our products or maintain our competitive position. In the event of an intellectual property dispute, we may be forced to litigate. Intellectual property litigation would divert management’s attention from developing our products and would force us to incur substantial costs regardless of whether we are successful. An adverse outcome could subject us to significant liabilities to third parties, and force us to curtail or cease the development and sale of our products and processes.

The government maintains certain rights in technology that we develop using government grant money and we may lose the revenues from such technology if we do not commercialize and utilize the technology pursuant to established government guidelines.

Certain of our, and our licensors’, research has been or is being funded in part by government grants. As a result of such funding, the U.S. Government has certain rights in the technology developed with the grant. These rights include a non-exclusive, paid-up, worldwide license to use the technology for any governmental purpose. In addition, the government has the right to require us to grant an exclusive license to use the developed technology to a third party if the government determines that:


• we have not taken adequate steps to commercialize such technology;

• such action is necessary to meet public health or safety needs; or

• such action is necessary to meet requirements for public use under federal
regulations.

In these instances, we would not receive revenues on the products we developed. Additionally, technology that was partially funded by a federal research grant is subject to the following government rights:

• products using the technology which are sold in the United States are to be manufactured substantially in the United States, unless a waiver is obtained;



Table of Contents

• the government may force the granting of a license to a third party who will

make and sell the needed product if we do not pursue reasonable
commercialization of a needed product using the technology; and

• the U.S. Government may use the technology for its own needs.

If we fail to meet these guidelines, we would lose our exclusive rights to these products and we would lose potential revenue derived from the sale of these products.

The market for our products will be heavily dependent on third party reimbursement policies.

Our ability to successfully commercialize our product candidates will depend on the extent to which government healthcare programs, such as Medicare and Medicaid, as well as private health insurers, health maintenance organizations and other third party payors will pay for our products and related treatments. Reimbursement by third party payors depends on a number of factors, including the payor’s determination that use of the product is safe and effective, not experimental or investigational, medically necessary, appropriate for the specific patient and cost-effective. Reimbursement in the United States or foreign countries may not be available or maintained for any of our product candidates. If we do not obtain approvals for adequate third party reimbursements, we may not be able to establish or maintain price levels sufficient to realize an appropriate return on our investment in product development. Any limits on reimbursement available from third party payors may reduce the demand for, or negatively affect the price of, our products. For example, in the past, published studies have suggested that stem cell transplantation in breast cancer that constitute a significant portion of the overall stem cell therapy market, at the time, may have limited clinical benefit. The lack of reimbursement for these procedures by insurance payors would negatively affect the marketability of our products.

Potential product liability claims could affect our earnings and financial condition.

We face an inherent business risk of exposure to product liability claims in the event that the use of the AastromReplicell™ System during research and development efforts, including clinical trials, or after commercialization results in adverse affects. As a result, we may incur significant product liability exposure, which could exceed existing insurance coverage. We may not be able to maintain adequate levels of insurance at reasonable cost and/or reasonable terms. Excessive insurance costs or uninsured claims would increase our operating loss and affect our financial condition.

Our corporate documents and Michigan law contain provisions that may make it more difficult for us to be acquired.

Our board of directors has the authority, without shareholder approval, to issue additional shares of preferred stock and to fix the rights, preferences, privileges and restrictions of these shares without any further vote or action by our shareholders. This authority, together with certain provisions of our charter documents, may have the affect of making it more difficult for a third party to acquire, or of discouraging a third party from attempting to acquire control of


Table of Contents

our company. This affect could occur even if our shareholders consider the change in control to be in their best interest.

Forward-looking statements

This report contains certain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. These forward-looking statements include statements regarding:

• potential strategic collaborations with others;


• future capital needs;

• product development and marketing plan;

• clinical trial plans and anticipated results;

• anticipation of future losses; and

• replacement of manufacturing sources.

These statements are subject to risks and uncertainties, including those set forth in this Business Risks section, and actual results could differ materially from those expressed or implied in these statements. All forward-looking statements included in this registration statement are made as of the date hereof. We assume no obligation to update any such forward-looking statement or reason why actual results might differ.

These business considerations, and others, are discussed in more detail and should be read in conjunction with the “Business Risks” discussed in our 2002 Annual Report of Form 10-K.

[meislo]

Hier die Übersetzung für alle die es noch interessiert

Vierteljährliches Einzelteil 2 des Reports DER AASTROM-BIOSCIENCES Inc. (ASTM) (sek-Form 10-Q). Diskussion Management?s und Analyse des finanziellen Zustandes und Resultate des Betriebsüberblicks über Aastrom gehen wir mit der Entwicklung der menschlichen Zellentherapietechnologien voran, die für eine ausgedehnte Strecke der medizinischen Anwendungen bestimmt sind, die auf unseren patentierten Prozess- und Vorrichtungsfähigkeiten für die Produktion der eigenen Zellenmischungen basieren. Unsere therapeutischen Produktbereiche der Leitungzelle unter Entwicklung umfassen: Gewebereparaturzellen (TRCs), therapeutische Zellen (TCs) und Zellkulturvorrichtungen. TRCs sind Zellen, die zu den Aufbau des normalen Gewebes wie Knochen führen. TCs sind Zellen, die wie Drogen, wie ein therapeutischer Impfstoff für Krebs oder Viren fungieren können. Zellkulturvorrichtungen sind von Aastrom entwickelt worden, um unser TRCs und TCs zu produzieren, aber sie können an autorisierte dritte Beteiligte als alleinstehende Produkte auch verkauft werden. Unsere Geschäftsmodellbauten auf zwei ergänzenden Bestandteilen: (i) eigene Verfahren und Vorrichtungen zum Ermöglichen bestimmter Arten der Stammzellen und anderer Arten menschliche mit ausgezeichneten biologischen Fähigkeiten zu produzierende Zellen verglichen mit Standardzellkulturannäherungen; und (ii) das AastromReplicell? Klinische Plattform des Systems, die entworfen wird, um eine wirkungsvolle Kommerzialisierungbahn für das Holen der therapeutischen Zellenproduktion zur medizinischen Praxis zu standardisieren und zu ermöglichen. Das AastromReplicell? System besteht aus einer Instrumentenausrüstungsplattform, entweder, an ein Krankenhaus oder anderer zentralisierter Service verkauft zu werden, oder wechselweise, benutzt worden von Aastrom, kann das eine Vielzahl der Einwegzellenproduktionsinstallationssätze laufen lassen, die zur gewünschten medizinischen Anwendung spezifisch sind. Jedes Zellenprodukt wird mit einer spezifischen Art Installationssatz produziert. Der Installationssatz und das Zellenprodukt produzierten mit dem Installationssatzanteil eine allgemeine kennzeichnende Bezeichnung wie DC-ich, Dcv-i, Oc-i, Ocg-i, Sc-ich und Columbium-ich. Durch diese Produktkonfiguration beabsichtigen wir entweder, Zellen für therapeutischen Gebrauch direkt in den Handel zu bringen, oder Kunden oder Potentialmitarbeiter mit der Fähigkeit zu ermöglichen, Zellen für therapeutische Anwendungen durch Verkauf des AastromReplicell zu produzieren? Systeminstrumente und -installationssätze. Diese Annäherung soll eine Produktbahn für jede Zellentherapie zur Verfügung stellen, die einem pharmazeutischen Produkt einschließlich der Genehmigung durch die zuständige Aufsichtsbehörde, Vergütung, Marketing und Preiskalkulation ähnlich ist. Wir glauben daß das Design des AastromReplicell? System erlaubt uns, zusätzliche Zellentherapieprodukte zu entwickeln, um Normierung für eine Anzahl von den auftauchenden Zellentherapien zur Verfügung zu stellen, die von anderen Forschern sich entwickelt werden. Wir haben unterschiedliche TRC-Produkte in der aktiven Entwicklung und umfassen: Sc-ich Knochenmarkzellen für Knochenmark-Versetzunganwendung; Columbium-ichzellen für Netzkabelblut-Stammzelle-Versetzunganwendung; Zellen Oc-i für strenges osteoporosis; und Zellen Ocg-i für Knochenverpflanzenanwendungen. Für die TC-Produktbereiche forschen wir dendritic Zellen des immunen Systems, eine Art Blutzelle nach, die die Fähigkeit hat, eine immune Antwort gegen spezifische Ziele als mögliche neue Behandlung für Krebs und Virenkrankheiten anzuregen. Wir haben Produkte der DC--ich und Dcv-ivorrichtung entwickelt und beabsichtigen, sie für unsere eigenen TC-Produkte, sowie zu benutzen, um sie an viele klinische Forscher und Mitten zu verkaufen, die die dendritic auf Zellenbasisimpfstoffe entwickeln, die entworfen werden, um Krebs und andere Störungen zu behandeln. Wir haben Zustimmung erreicht, um die CER-Markierung zu den DC--ich und Dcv-iinstallationssätzen, sowie das AastromReplicell hinzuzufügen? System, uns erlaubend, diese Produkte in Europa, durch unsere deutsche Tochtergesellschaft, Zellera AG zu vermarkten und zu verkaufen. Wir sind auch Marketing-Inhaltsverzeichnis Produkte der DC--ich und Dcv-ivorrichtung zu klinischen VEREINIGTEN STAATEN und zu den Forschungsgruppen, die dendritic auf Zellenbasiskrebsimpfstoffe entwickeln. Die Entwicklung unserer eigenen eigenen Impfstoffe kann während zusätzliche Bewilligung ausgeübt werden finanzierend oder der strategischen Teilhaberschaften. Unsere Sc--ich und Columbium-ichcTrc Produkte haben CER-Markierungszustimmung empfangen, uns erlaubend, Kommerzialisierungtätigkeiten in Europa, durch unsere deutsche Tochtergesellschaft, Zellera AG anzufangen, und in den klinischen Studien der PhasencIii-Art in den US sind. Jedoch glauben wir nicht, daß es einen gegenwärtigen Markt für das Columbium-ichprodukt in Europa gibt und einige Jahre sein wird, bevor alle mögliche STAATZUSTIMMUNGEN empfangen werden können, oder, damit die Märkte für dieses Produkt sich entwickeln. Obgleich fähig, zu erzeugen in Europa verkauft zu werden, muß das Produkt Sc-ich verschiedene klinische Auswertungen an den Ausgangskundenseiten durchmachen, um die Daten, die für Vergütung des Produktes notwendig sind. Dieses Jahr bauten wir Verhältnisse in einigen europäischen Mitte auf, damit diese Aufstellungsorte diese klinischen Daten erzeugen. Vor kurzem haben wir ein Entwicklungsprogramm für die Produktion der Knochen-Formung von TRCs im AastromReplicell eingeleitet? System (unser?OC? Linie von TRCs). Das Zellenprodukt Oc-i wird für die Behandlung der Patienten mit degenerativen Knochenkrankheiten wie osteoporosis entwickelt, für das eine klinische Studie der Phase I/II-Pilot im Prozeß in den VEREINIGTEN STAATEN ist, die, unser Zellenprodukt Ocg-i für Knochenverpflanzenanwendungen entwickelt wird und wir einen klinischen Probeplan für dieses Produkt entwickeln, unsere therapeutischen Zellenentwicklungsbemühungen bis jetzt auf das Verwenden unserer Technologie, um größere Quantitäten der gewünschten therapeutischen Zellen von beginnenden etwas der Zellen oder des Gewebes zu wachsen gerichtet haben. Unsere Zellenproduktionsprozesse basieren auf dem Verwenden der natürlichen reproduktiven Fähigkeiten der Zellen außerhalb des Körpers (ex Vivo), ohne verschiedene Klonenannäherungen. Unsere Programme benutzen z.Z. Knochenmark, Netzkabelblut und Blutzellen als beginnende Quellen der Zellen. Als solcher, haben Bundesunterstützung oder andere Faktoren in bezug auf sind embryonal Forschung keine direkte Auswirkung auf unsere gegenwärtigen Produktprogramme. Seit unserer Gründung sind wir im Entwicklungsstadium gewesen und engagiert uns in der Forschung und in Produktentwicklung, hauptsächlich geleitet worden in unserem eigenen Namen, aber auch in Zusammenhang mit verschiedenen gemeinschaftlichen Forschungs- und Entwicklungsvereinbarungen mit anderen. Wir begannen unsere auf Versuchsebene zuerstprodukteinführung in Europa des AastromReplicell? Zellenproduktionssystem mit dem Installationssatz Sc-ich im April 1999. Zu ungefähr diesem gleichen Mal wurden Daten bei den internationalen Sitzungen freigegeben, die die Majorität der Patienten, die anders Anwärter für das Produkt Sc-ich gewesen sein würden ergaben, um den Gebrauch des Produktes nicht mehr zu erfordern. Dieser Verlust des Marktes für das Sc-ich veranließ uns, unsere Betriebe zu reorganisieren und alle Marketing-Tätigkeiten im Oktober 1999, während den Empfang der zusätzlichen Finanzierung und der Reorganisierung zu verschieben. Während we?ve Marketing-Tätigkeiten für das CER gekennzeichnete Sc-ich, DC-ich und die Produkte Dcv-i einleitet, erwarten wir nicht, positive Bargeldumläufe von unseren vereinigten Betrieben für mindestens die folgenden einige Jahre zu erzeugen und dann, nur wenn bedeutendere Produktverkäufe beginnen. Bis diese Zeit erwarten wir, daß unsere Einkommensquellen begrenzt werden, um Einkommen zu bewilligen und die Finanzierung zu erforschen, Meilensteinzahlungen und Lizenzgebühren von den möglichen zukünftigen korporativen Mitarbeitern. Bis jetzt haben wir unsere Betriebe durch die allgemeinen und privaten Verkäufe unserer Dividendenpapiere finanziert. Als Entwicklung-Stadiumsfirma sind wir nie rentabel gewesen und nicht Haben des Nettoinhaltsverzeichniseinkommens es sei denn vorwegnehmen und bis bedeutende Produktverkäufe beginnen, das unwahrscheinlich aufzutreten ist, bis wir die bedeutende zusätzliche Finanzierung erreichen. Durch September 30, 2002, haben wir Verluste von ungefähr $95 Million angesammelt. Es kann keine Versicherung geben, daß wir in der LageSIND, Rentabilität auf einer unterstützten Grundlage zu erzielen, wenn an allen, die angeforderte Finanzierung, beschaffen Sie oder eine korporative Partnering oder Erwerbsverhandlung durchführen Sie. Kritische Methoden der Buchführung dort sind einige Methoden der Buchführung, denen wir sind bedeutend zur Darstellung von unseren Konzernabschluss glauben. Die bedeutendsten Methoden der Buchführung schließen die mit ein, die auf Warenbestand und Einbuchung der Umsatzerlöse bezogen werden. Warenbestand. Wir bewerten unseren Warenbestand, der hauptsächlich aus fertigen Bestandteilen unseres Leitungproduktes besteht, das AastromReplicell? Zellenproduktionssystem, am niedrigeren von Kosten (spezifische Kennzeichnung mit zuerst innen, zuerst heraus) oder von Markt. Ausserdem wiederholen wir regelmäßig Warenbestandquantitäten an Hand und notieren eine Bestimmung, überholten und überschüssigen Warenbestand zu seinem geschätzten realisierbaren Nettowert zu notieren. Gegründet auf dem Altern des Warenbestands an jedem Periodenende, verwenden wir eine systematische Annäherung, um unsere Reserve für überholten und überschüssigen Warenbestand festzustellen. Unter dieser systematischen Annäherung wird Warenbestand, der kleiner als zwölf Monate alt ist, gegründet auf dem Empfangsdatum, am vollen Wert getragen. Warenbestandquantitäten über zwölf Monaten alt sind über einen Sechsmonatszeitraum reserviert, bis die Einzelteile entweder verkauft sind oder völlig aufgehoben. Wir glauben, daß diese Annäherung unsere begrenzte Produktverkaufsgeschichte und die Gefahr gegeben, die mit unserer Fähigkeit, den Warenbestand zurückzugewinnen dazugehörig ist angebrachtes ist, da wir noch bei dem Herstellen unseres Produktmarktes sind. Zukünftige technologische Änderungen, Entwicklung neuer Produkte und tatsächliche Absatzerfolge konnten zusätzliches ergeben überholen und überschüssiger Warenbestand an Hand. Dieses konnte eine bedeutende Auswirkung auf den Wert unseres Warenbestands und unseres berichteten Betriebsergebnisses haben. Einbuchung der Umsatzerlöse. Wir erzeugen Einkommen von den Bewilligungen und von den Forschungsvereinbarungen, von den gemeinschaftlichen Vereinbarungen und von den Produktverkäufen. Einkommen von den Bewilligungen und von den Forschungsvereinbarungen wird auf einer Kostenvergütunggrundlage erkannt, die mit den Leistungsanforderungen der in Verbindung stehenden Vereinbarungen gleichbleibend ist. Einkommen von den gemeinschaftlichen Vereinbarungen wird erkannt, wenn die wissenschaftlichen oder klinischen Resultate, die in der Vereinbarung vereinbart werden, getroffen worden sind und es keine anderen fortwährenden Verpflichtungen auf unserem Teil gibt. Einkommen von den Produktverkäufen wird erkannt, wenn Titel zu den Produktübertragungen und dort keine restlichen Verpflichtungen sind, die die Endabnahme der customer?s des Verkaufes, im Allgemeinen nach Installation und Training beeinflussen. Wenn es restliche Verpflichtungen, einschließlich des Trainings gibt, oder Installation, Einkommen nach Beendigung dieser Verpflichtungen erkannt wird. Einkommen von Lizenzgebühren unter Lizenzvereinbarungen wird als Einkommen erkannt, wenn es keine zukünftigen Leistungsverpflichtungen gibt, die in Bezug auf solche Gebühren restlich sind. Die Zahlungen, die vor allen Verpflichtungen empfangen werden, werden werden eingestuft als Ertragsabgrenzungen erfüllt. Außenstände. Wir bilden Schätzungen Einloesbarkeit von Außenständen auswertend. Wir ununterbrochen überwachen Ansammlungen und Zahlungen von unseren Kunden und behalten eine Genehmigung für die geschätzten Kreditausfälle bei, die auf allen spezifischen Kundenansammlungsausgaben basieren, die wir gekennzeichnet haben. Während solche Gutschriftausgaben nicht bedeutend gewesen sind, gibt es keine Versicherung, daß wir fortfahren, die gleichen Kreditausfälle zukünftig zu erfahren. Inhaltsverzeichnis die Zusammenfassung der bedeutenden Methoden der Buchführung sollte in Verbindung mit unseren Konzernabschluss und bezogenen Anmerkungen und dieser Diskussion über unsere Resultate der Betriebe gelesen werden. Resultate der Betriebseinkommen für das beendete worden Viertel September 30, 2002 waren $93.000, die aus Bewilligungseinkommen und Produktverkäufen und -mieten bestanden, verglichen mit Einkommen von $151.000 während der gleichen Periode 2001. Granteinkommen haben sich vom vorherigen Jahr resultierend aus verringerter Bewilligungsprogrammtätigkeit verringert. Mit dem Preis einer gemeinschaftlichen Bewilligung durch das Defense Advanced Research Projects Agency, für Over $886.000 ein Achtzehnmonats-Periode, die September 2002 anfing, nehmen wir vorweg, daß Bewilligungseinkommen während des steuerlichen Jahres sich erhöhen. Wir fahren fort, bewilligen-finanzierte Programme sowie europäische Verkäufe und Marketing-Gelegenheiten auszuüben. Kosten und Unkosten für das Viertel beendeten September 30, 2002 erhöht bis $2.586.000, verglichen bis $2.166.000 während der gleichen Periode 2001. Zunahmen der Kosten und der Unkosten umfassen eine Zunahme der Forschungs- und Entwicklungsunkosten bis $1.385.000 für das beendete Viertel September 30, 2002, von $1.207.000 für die gleiche Periode 2001 und eine Zunahme der verkaufenden, allgemeinen und Verwaltungskosten bis $1.113.000 von $919.000. Diese erhöhten Kosten und Unkosten sind das Resultat der Erweiterung unserer Programmentwicklungtätigkeiten und erhöhte Marketing-Gelegenheiten in den Bereichen der dendritic auf Zellenbasisimpfstoffe im europäischen Markt und in der Vorbereitung unserer schwebenden Verwaltungskosten Knochenverpflanzens trials.Selling, allgemeines und für das Viertel, das September 30 beendet wird, 2002 umfaßt einen nicht liquiditätswirksamen Aufwand von $159.000 in bezug auf bestimmte Ermächtigungen, die im August 2002 geherausgeben werden. Diese Ermächtigungen wurden in einer privaten Verhandlung zu einem beglaubigten Investor für Investitionbankdienstleistungen herausgegeben und dem Halter erlauben, 2.000.000 Anteile unserer Stammaktien zu kaufen. Kosten Produktverkäufe und -mieten für das beendete Viertel September 30, 2002 und 2001 umfassen Aufladungen von $88.000 und von $40.000 beziehungsweise in bezug auf die Bestimmung für überholten und überschüssigen Warenbestand AastromReplicellTM. Interesseneinkommen war $41.000 für das Viertel, das September 30 beendet wurde, 2002 verglichen bis $122.000 während der gleichen Periode 2001. Die Fluktuationen im Interesseneinkommen sind hauptsächlich zu entsprechenden Änderungen im Niveau des Bargeldes passend, kassieren Äquivalente und kurzfristige Investitionen während der Perioden und der Abnahmen an den Ergebnissen von unseren Investitionen. Reinverlust Aastrom?s war $2.452.000, oder $,05 pro allgemeinen Anteil für das Viertel beendeten September 30, 2002 verglichen bis $1.893.000 oder $,05 pro allgemeinen Anteil während der gleichen Periode 2001. Dies Zunahme in net Reinverlust sein Primär- d Resultat von erhöhen Kosten und Unkosten versetzen auf a pro Anteil Grundlage durch ein Zunahme in d belasten durchschnittlich Zahl von allgemein Aktie outstanding resultieren von zusätzlich Billigkeit Finanzierung. Inhaltsverzeichnisliquidität und Kapitalausstattungen haben wir unsere Betriebe seit Gründung hauptsächlich durch allgemeines finanziert und private Verkäufe der Dividendenpapiere, denen, von der Gründung durch September 30, 2002, ungefähr $106 Million und, auf einen wenigen Grad belaufen haben, durch die finanzierende Bewilligung, die Zahlungen empfangen unter Forschungsvereinbarungen und collaborations und das Interesse erworben auf Bargeld, Bargeldäquivalenten und kurzfristigen Investitionen. Diese Finanzierungsquellen haben uns historisch erlaubt, ausreichende Niveaus des Bargeldes und anderer flüssiger Investitionen beizubehalten. Unser kombiniertes Bargeld, Bargeldäquivalente und kurzfristigen Investitionen zählten $7.930.000 bei September 30, 2002, eine Abnahme von $1.675.000 von einem Juni 30, 2002 zusammen. Die Primärgebräuche von Bargeld, Bargeldäquivalenten und kurzfristigen Investitionen während des Viertels beendeten September 30, schlossen 2002 $2.544.000 mit ein, um unsere Betriebe und Arbeitskapitalanforderungen zu finanzieren. Die Primärquelle des Bargeldes, der Bargeldäquivalente und der kurzfristigen Investitionen war von den Billigkeitsfinanzierungsverhandlungen, von denen $869.000 während des Viertels angehoben wurden. Diese Billigkeitsfinanzierung transacted unter unserem November 16, 2001 Regalausrichtung und der Plan des auf lagererwerbes des Angestellten. Unsere zukünftigen Baranforderungen hängen von vielen Faktoren, einschließlich des anhaltenden wissenschaftlichen Fortschritts in unseren Forschungs- und Entwicklungsprogrammen, im Bereich und in den Resultaten der klinischen Versuche, in der Zeit und in den Kosten, die wenn sie erreichen Genehmigungen durch die zuständige Aufsichtsbehörde, die Kosten mit einbezogen werden ab, die, in die Archivierung mit einbezogen werden und Patente, Konkurrieren technologische und Markterschließungen und die Kosten von Produktkommerzialisierung verfolgen und erzwingen. Wir erwarten nicht, einen positiven Bargeldumlauf von den Betrieben für mindestens die folgenden einige Jahre zu erzeugen wegen der erwarteten Ausgabe für Forschungs- und Entwicklungsprogramme und die Kosten der Kommerzialisierung unserer Produktanwärter. Wir beabsichtigen, die zusätzliche Finanzierung durch Forschung und Entwicklung oder Verteilung und Marketing, Vereinbarungen mit verwendbaren korporativen Mitarbeitern, Bewilligungen und durch die allgemeinen oder privaten Finanzierungsverhandlungen zu suchen. Erfolgreiche zukünftige Betriebe sind abhängig von einigen technischen und Geschäftsgefahren, einschließlich unserer anhaltenden Fähigkeit, zukünftige finanzieren, zufriedenstellende Produktentwicklung zu erreichen und holen Genehmigung durch die zuständige Aufsichtsbehörde und Marktakzept für unsere Produkte ein. Wir erwarten, daß unser vorhandenes Bargeld genügend ist, z.Z. geplante Tätigkeiten in das erste Viertel steuerlichen Jahres 2004 zu finanzieren. Wir üben z.Z. zusätzliche Quellen der Finanzierung aus. Wenn wir nicht die zusätzliche Finanzierung vor dem Ende des dritten Trimesters steuerlichen Jahres 2003 erreichen können, bilden wir erhebliche Verringerungen des Bereichs und der Größe unserer Betriebe und können die Tätigkeiten beschränken, die z.Z. geplant werden wieder aufgenommen zu werden, um Bargeld, bis solche Finanzierung zu konservieren erreicht ist. Diese Schätzungen Vorwärts-schauen die Aussagen, die auf bestimmten Annahmen basieren, die durch die Sachen negativ ausgewirkt werden konnten, die unter dieser Überschrift und unter den Untertitel-?Busineßgefahren beraten über wurden? in unserem jährlichen Bericht 2002 über Form 10-K. um zu wachsen und unser Geschäft zu erweitern, und unsere Produktanwärter in den Markt vorzustellen, müssen wir zusätzliches Kapital aufbringen. Wir benötigen auch zusätzliche Kapital oder ein gemeinschaftlicher Partner oder beide, um die Forschungs- und Entwicklungstätigkeiten unserer Produktanwärter für die Expansion der zusätzlichen Zellenarten zu finanzieren. Wir erwarten, daß unsere Primärquellen des Kapitals während der vorhersehbaren Zukunft durch gemeinschaftliche Vorbereitungen und durch den allgemeinen oder privaten Verkauf unserer Schuld oder Dividendenpapiere sind. Es kann keine Versicherung geben, daß solche gemeinschaftliche Vorbereitungen oder jede allgemeine oder private Finanzierung, auf annehmbaren Bezeichnungen vorhanden sind, wenn an allen oder unterstützt werden kann. Inhaltsverzeichnis einige Faktoren beeinflußt unsere Fähigkeit, zusätzliche Finanzierungs-, einschließlich, aber begrenzt nicht auf, Marktflüchtigkeit unserer Stammaktien und die Wirtschaftslage aufzuwerfen, welche im Allgemeinen die allgemeinen Märkte oder irgendeinen Teil oder die ganze Technologiesektor beeinflußt. Wenn ausreichende Kapital nicht vorhanden sind, können wir zu angefordert werden verzögern, verringern den Bereich von oder beseitigen eins oder mehr unserer Forschungs- und Entwicklungsprogramme, die ein materielles nachteiliges auf unserem Geschäft beeinflussen lassen können. Sehen Sie?BusineßcGefahren? und?Notes zu Konzernabschluss? in unserem jährlichen Bericht 2002 über Form 10-K und?Notes zu Konzernabschluss? hierin umfaßt. Bestimmte Geschäftsbetrachtungen des Inhaltsverzeichnisses unsere letzten Verluste und erwartete zukünftige Verluste Zweifel auf unserer Fähigkeit werfen, rentabel zu funktionieren. Wir wurden 1989 enthalten und haben erhebliche Betriebsverluste seit Gründung erfahren. Ab September 30, 2002, haben wir auf uns die Reinverluste genommen, die ungefähr $95 Million zusammenzählen. Diese Verluste sind hauptsächlich aus den Kosten resultiert, die in der Forschung und in der Entwicklung unserer Zellkulturtechnologien und des AastromReplicell genommen werden? System, allgemeine und Verwaltungskosten und die Verfolgung der Patentanfragen. Wir erwarten, uns bedeutende Betriebsverluste, bis Produktverkäufe, hauptsächlich infolge von unseren Forschungs- und Entwicklungsprogrammen, einschließlich der vor-klinischen Studien und der klinischen Versuche sich erhöhen, und auf die Einrichtung der Marketing- und Verteilungsfähigkeiten zu nehmen, die notwendig sind, Kommerzialisierungbemühungen für unsere Produkte zu stützen. Wir können nicht mit irgendeiner Sicherheit die Menge der zukünftigen Verluste voraussagen. Unsere Fähigkeit, Rentabilität zu erzielen hängt unter anderem von die Entwicklung unserer Produktanwärter erfolgreich durchführen ab und erreicht die Genehmigungen durch die zuständige Aufsichtsbehörde, stellt Herstellung, Verkäufe und Marketing-Vorbereitungen mit dritten Beteiligten her, und bringt genügendes Kapital, um unsere Tätigkeiten zu finanzieren auf. Wir können möglicherweise nicht in der LageSEIN, Rentabilität zu erzielen oder zu unterstützen. Unsere Unfähigkeit, unsere Produktentwicklungstätigkeiten durchzuführen erfolgreich würde streng unsere Fähigkeit begrenzen, Betriebe laufen zu lassen oder zu finanzieren. Kommerzialisierung in den Vereinigten Staaten unseres Leitungproduktanwärters, das AastromReplicell? Zellenproduktionssystem, erfordert zusätzliche Forschung und Entwicklung sowie erhebliche klinische Versuche. Während wir Ausgangsmarketing auf einer begrenzten Grundlage des AastromReplicell begonnen haben? System in Europa, glauben wir, daß die Vereinigten Staaten der Hauptmarkt für unsere Produkte sind. Wir können möglicherweise nicht in der LageSEIN, Entwicklung des AastromReplicell erfolgreich durchzuführen? System oder unsere anderen Produktanwärter oder vermarkten erfolgreich unsere Technologien oder Produktanwärter. Wir und irgendwelche unserer möglichen Mitarbeiter, können Probleme antreffen und verzögern in bezug auf Forschung und Entwicklung, Genehmigung durch die zuständige Aufsichtsbehörde und Rechte am geistigen Eigentum unserer Technologien und Produktanwärter. Unsere Forschungs- und Entwicklungsprogramme können möglicherweise nicht erfolgreich sein, und unsere Zellkulturtechnologien und Produktanwärter können möglicherweise nicht die Produktion der Zellen außerhalb des menschlichen Körpers mit dem erwarteten Resultat erleichtern. Unsere Technologien und Produktanwärter können möglicherweise nicht sein sicher und wirkungsvoll in den klinischen Versuchen, und wir können möglicherweise nicht die beabsichtigten Genehmigungen durch die zuständige Aufsichtsbehörde für unsere Technologien oder Produktanwärter und die Zellen erreichen, die in solchen Produkten produziert werden. Wenn irgendwelche dieser Fälle auftreten, können wir möglicherweise nicht die ausreichenden Betriebsmittel zum Fortsetzen der Betriebe während der Periode haben, die angefordert wird, um die delaying Kommerzialisierung der Ausgabe zu beheben und wir können möglicherweise nicht in der LageSEIN, Kapital anzuheben, um unseren anhaltenden Betrieb während der Periode zu finanzieren, die für Auflösung dieser Ausgabe angefordert wird. Inhaltsverzeichnis können wir möglicherweise nicht in der LageSEIN, das angeforderte Kapital anzuheben, um unsere Betriebe zu leiten und unsere Produkte zu entwickeln. Wir benötigen erhebliche Kapitalausstattungen, um unsere Betriebe zu leiten und unsere Produkte zu entwickeln. Im Oktober 1999, wurden wir gezwungen, die Betriebe zu verringern, die auf unserem abfallenden Niveau der Kapitalausstattungen und unserer begrenzten der Finanzierungsalternativen vorhanden sind zu dieser Zeit basierten. Die vorhergehende Verringerung unserer funktionierenden Tätigkeiten hat unsere Produktentwicklungsprogramme verzögert. Wir erwarten, daß unser vorhandenes Bargeld und erwartetes Interesseneinkommen genügend sind, z.Z. geplante Tätigkeiten durch das erste Viertel steuerlichen Jahres 2004 zu finanzieren. Wir üben z.Z. zusätzliche Quellen der Finanzierung aus. Wenn wir nicht die zusätzliche Finanzierung vor dem Ende des dritten Trimesters steuerlichen Jahres 2003 erreichen können, bilden wir erhebliche Verringerungen des Bereichs und der Größe unserer Betriebe und können die Tätigkeiten beschränken, die z.Z. geplant werden wieder aufgenommen zu werden, um Bargeld, bis solche Finanzierung zu konservieren erreicht ist. um zu wachsen und unser Geschäft zu erweitern, und unsere Anwärter des neuen Produktes zum Markt innen vorzustellen, müssen wir zusätzliches Kapital aufbringen. Wir benötigen auch zusätzliche Kapital oder ein gemeinschaftlicher Partner oder beide, um die Forschungs- und Entwicklungstätigkeiten unserer Produktanwärter für die Expansion der zusätzlichen Zellenarten zu finanzieren. Unser zukünftiger Kapitalbedarf hängt nach vielen Faktoren ab und umfaßt: anhaltender wissenschaftlicher Fortschritt in unseren Forschungs- und Entwicklungsprogrammen; Kosten und TIMING des Leitens der klinischen Versuche und Suchen von Genehmigungen durch die zuständige Aufsichtsbehörde und von Patentverfolgungen; Konkurrieren technologisch und Markterschließungen; unsere Fähigkeit, zusätzliche gemeinschaftliche Verhältnisse aufzubauen; und? der Effekt der Kommerzialisierungtätigkeiten und der Service-Expansionen wenn und wie angefordert. Wegen unserer langfristigen Finanzierungsanforderungen sind wir wahrscheinlich, die Öffentlichkeit oder privaten die Billigkeitsmärkte zugänglich zu machen wenn und wann immer Bedingungen vorteilhaft sind, selbst wenn wir haben eine sofortige Notwendigkeit am zusätzlichen Kapital nicht zu dieser Zeit. Weiter können wir an den Finanzierungsverhandlungen mit Rate teilnehmen, die an einem erheblichen zu vermarktenden Diskont sind. Diese zusätzliche Finanzierung kann möglicherweise nicht für uns auf angemessenen Bezeichnungen oder an allen vorhanden sein. Wenn ausreichende Kapital nicht vorhanden sind, können wir zu weiterem angefordert werden verzögern oder beenden Forschungs- und Entwicklungsprogramme, beschränken Kapitalaufwand und verringern geschäftliche Entwicklung und andere funktionierende Tätigkeiten. Die Austeilung der zusätzlichen Stammaktien für die Finanzierung hat das Potential für erhebliche Verdünnung. Wie oben gemerkt, benötigen wir zusätzliche Billigkeit finanzierend, um uns mit dem Kapital zu versehen, um unsere Zielsetzungen zu erreichen. Zu gängigen Marktpreisen würde solch eine Billigkeitsausteilung eine im wesentlichen größere Anzahl von Anteilen veranlassen, hervorragend zu sein und würde den Eigentumsanteil der vorhandenen Aktionäre verdünnen. Gemäß vorher anerkannten Aktionärauflösungen hat die Direktion die Berechtigung zum Erhöhen der Höchstzahl der autorisierten Anteile von 100 Million bis 150 Million. Inhaltsverzeichnis die Ermächtigungen haben das Potential für erhebliche Verdünnung. Ab September 30, 2002 hatten wir die Ermächtigungen, die, 2.614.386 Anteile von Stammaktien bei $1,44 pro Anteil und 2.000.000 Anteile von Stammaktien bei $0,75 pro Anteil zu kaufen hervorragend sind. Ab diesem Datum hatten wir auch hervorragende Kaufoptionen 3.997.072 Anteile zu einem belasteten durchschnittlichen Preis von $1,43 pro Anteil. Halter von Stammaktien konnten Verdünnung ihrer Investition nach Übung dieser Ermächtigungen und Wahlen folglich erfahren. Unser Aktienpreis ist löschbar gewesen und zukünftige Verkäufe der erheblichen Anzahlen von unseren Anteilen konnten ein nachteiliges auf dem Marktpreise unserer Anteile beeinflussen lassen. Der Marktpreis von Anteilen unserer Stammaktien ist löschbare Erstreckung in scharfkalkuliertem Preis zwischen $0,36 und $2,40, für steuerliches Jahr 2002 gewesen. Der Preis unserer Stammaktien kann fortfahren, in Erwiderung auf eine Anzahl von Fällen und Faktoren, wie zu schwanken: klinische Proberesultate; die Menge unserer Barmittel und unserer Fähigkeit, die zusätzliche Finanzierung zu erreichen; Ansagen der Forschungstätigkeiten, der geschäftliche Entwicklungen, der technologischen Innovationen oder der neuen Produkte durch uns oder unsere Konkurrenten; Änderungen in der Regierungsregelung; Debatten hinsichtlich sind der Patente oder der eigenen Rechte; Änderungen in unseren Einkommen oder in Unkostenniveaus; allgemeines Interesse betreffend ist die Sicherheit, Wirksamkeit oder andere Aspekte der Produkte oder der Methodenlehren, die wir uns entwickeln; und? Änderungen in den möglichen Empfehlungen durch Sicherheitsanalytiker. Irgendwelche dieser Fälle können den Preis unserer Anteile veranlassen zu fallen, die unsere Geschäfts- und Finanzierungsgelegenheiten nachteilig beeinflussen können. Zusätzlich haben die Börse im allgemeinen und die Marktpreise für Biotechnologiefirmen insbesondere bedeutende Flüchtigkeit erfahren, die häufig zum Betriebsverhalten oder zu den finanziellen Zuständen solcher Firmen ohne Bezug gewesen ist. Dieses können ausgedehnte Markt- und Industriefluktuationen den handelnden Preis unseres Vorrates, unabhängig davon unser Betriebsverhalten oder Aussichten nachteilig beeinflussen. Z.B. innerhalb des letzten steuerlichen Jahres, hat unser Aktienpreis einen Tag erfahren, in dem er am Over ungefähr 26% den scharfkalkulierten Preis der vorhergehenden day?s und einen anderen Tag schloß, als er vorbei über 19% vom scharfkalkulierten Preis der vorhergehenden day?s fiel. Unser Vorrat kann sein delisted von Nasdaq, das seinen Marktpreis und Liquidität beeinflussen könnte. Wir werden angefordert, bestimmte finanzielle Tests zu treffen (einschließlich, aber begrenzt nicht auf, ein minimales Gebot unserer Stammaktien von $1,00) um die Auflistung unserer Stammaktien auf der Börse Nasdaq beizubehalten. Resultierend aus neuen Preisschwankungen hat unser Stammaktienpreis unterhalb des Niveaus mit $1,00 Minimums gehandelt und wir wurden mitgeteilt, daß unsere Stammaktien delisted sein würden, wenn wir nicht Befolgung dieser Börsenzulassungsbestimmung vor Februar 24, 2003 wiedergewannen. Wenn wir nicht auf Nasdaq aufgeführt bleiben, konnten der Marktpreis und die Liquidität unseres allgemeinen Inhaltsverzeichnisvorrates gehindert werden. Weiter hat die nationale Verbindung der Wertpapierhändler vor kurzem eine Änderung in den minimalen Börsenzulassungsbestimmungen, neues $2,5 Million der minimalen Nettobilligkeitsanforderung für den Markt SmallCap mit einzuschließen angenommen, den wir z.Z. treffen. Dieser neue Standard ersetzt minimale fühlbare Nettowert Anforderung und wird für uns im November 2002 wirkungsvoll. Das Resultat solch einer Änderung oder weiter die Änderungen, können sein, daß es für uns schwieriger sein könnte, Befolgung der Auflistungsstandards beizubehalten, dessen Resultat sein würde, daß unser Vorrat sein kann delisted. Wir müssen unsere klinischen Versuche erfolgreich durchführen, um in der Lage zuSEIN, unsere Produkte zu vermarkten. um in der Lage zuSEIN, Produkte in den Vereinigten Staaten zu vermarkten, müssen wir, durch umfangreiche preclinical Studien und klinische Versuche, die Sicherheit und Wirksamkeit unserer Prozesse und Produktanwärter, zusammen mit den Zellen demonstrieren, die durch solche Prozesse in solchen Produkten, für Anwendung in der Behandlung der Menschen produziert werden. Wir leiten z.Z. klinische Versuche, um die Sicherheit und die biologische Tätigkeit der Patient-abgeleiteten Zellen zu demonstrieren, die im AastromReplicell produziert werden? System. Abhängig von der Verwendbarkeit der Betriebsmittel, beabsichtigen wir, mindestens einen zusätzlichen klinischen Versuch zu beginnen, um die Sicherheit und die biologische Tätigkeit der Nabelnetzkabel-Blutzellen zu demonstrieren, die im AastromReplicell produziert werden? System. Wenn unsere klinischen Versuche nicht erfolgreich sind, können unsere Produkte möglicherweise nicht vermarktungsfähig sein. Unsere Fähigkeit, unsere klinischen Versuche in einer fristgerechten Weise durchzuführen hängt von vielen Faktoren, einschließlich der Rate der geduldigen Einschreibung ab. Geduldige Einschreibung kann mit der Größe der geduldigen Bevölkerung, der Nähe der verwendbaren Patienten zu den klinischen Aufstellungsorten, der Vorstellungen des Dienstprogrammes der Stammzelletherapie für die Behandlung bestimmter Krankheiten und der Eignungkriterien für die Studie schwanken. Wir haben verzögern Anstaltspatientzuwachs in unseren vorhergehenden und gegenwärtigen klinischen Versuchen erfahren. Wenn wir Zukunft verzögern Anstaltspatientzuwachs erfahren, könnten wir erhöhte Kosten erfahren und verzögert dazugehöriges mit klinischen Versuchen, die unsere Produktentwicklungsprogramme und unsere Fähigkeit hindern würden, unsere Produkte zu vermarkten. Ausserdem überwacht die FDA den Fortschritt der klinischen Versuche und sie kann die klinischen Versuche jederzeit wegen der geduldigen Sicherheit oder anderer Betrachtungen verschieben oder beenden. Störung zu erreichen und beizubehalten erforderte Genehmigungen durch die zuständige Aufsichtsbehörde würde begrenzen streng unsere Fähigkeit, unsere Produkte zu verkaufen. Wir müssen die Zustimmung der FDA erreichen, bevor kommerzielle Verkäufe unserer Produktanwärter in den Vereinigten Staaten beginnen können, denen wir sind der Hauptmarkt für unsere Produkte glauben. Wir können auch angefordert werden, zusätzliche Zustimmungen von den fremden Aufsichtsbehörden zu erreichen, um unsere Verkaufstätigkeiten in jenen Jurisdiktionen fortzusetzen oder zu erhöhen. Wenn wir nicht die Sicherheit, die Zuverlässigkeit und die Wirksamkeit unserer Produktanwärter oder der Zellen demonstrieren können in solchen Produkten produzierte, können wir möglicherweise nicht in der LageSEIN, angeforderte Genehmigungen durch die zuständige Aufsichtsbehörde zu erreichen. Viele der Patienten schrieben in den klinischen Versuchen haben unterzogen vorher umfangreicher Behandlung ein, die im wesentlichen die Patienten geschwächt und die Fähigkeit ihres Bluts und immunen Systems nicht wiedergutzumachend hat beschädigt haben kann zurückzugewinnen. Einige Patienten, die den Transplantwiederaufnahmenprozeß durchmachen, sind, aus Ursachen gestorben, die, nach Ansicht der Ärzte waren, die betroffen sind, ohne Bezug zum AastromReplicell? Systemverfahren und es sind möglich, daß anderes Patienteninhaltsverzeichnis strenge Komplikationen entweder während der gegenwärtigen oder zukünftigen klinischen Versuche sterben oder erleiden kann. Zusätzlich produzierten die Patienten, die Zellen empfangen, mit unseren Technologien und Produktanwärter können möglicherweise nicht das langfristige engraftment demonstrieren, das mit den Zellen in gewissem Sinne vergleichbar ist, die von den gegenwärtigen Verfahren der Stammzelle-Therapie erhalten werden. Wenn wir nicht die Sicherheit oder die Wirksamkeit unserer Technologien und Produktanwärter, einschließlich des langfristigen unterstützten engraftment demonstrieren können oder wenn ein oder mehr Patienten strenge Komplikationen sterben oder erleiden, konnten die FDA oder andere Aufsichtsbehörden Genehmigung durch die zuständige Aufsichtsbehörde unserer Produktanwärter verzögern oder zurückhalten. Schließlich selbst wenn wir Genehmigung durch die zuständige Aufsichtsbehörde eines Produktes erreichen, daß Zustimmung abhängig von Beschränkungen auf dem angezeigten Gebrauch sein kann, für die sie vermarktet werden kann. Sogar nach dem Bewilligen von Genehmigung durch die zuständige Aufsichtsbehörde, fahren die FDA, andere Aufsichtsbehörden und Regierungen in anderen Ländern fort, vermarktete Produkte, Hersteller und Produktionsanlagen zu wiederholen und zu kontrollieren. Neuere Entdeckung der vorher unbekannten Probleme mit einem Produkt, einem Hersteller oder einem Service kann Beschränkungen auf dem Produkt oder dem Hersteller, einschließlich einer Zurücknahme des Produktes aus dem Markt ergeben. Weiter können die Regierung betreffendaufsichtsbehörden zusätzliche Regelungen herstellen, die verhindern konnten oder verzögern Genehmigung durch die zuständige Aufsichtsbehörde unserer Produkte. Selbst wenn wir Genehmigungen durch die zuständige Aufsichtsbehörde erreichen, um unsere Produkte zu verkaufen, würde Mangel an kommerzieller Annahme unser Geschäft hindern. Wir suchen, Genehmigung durch die zuständige Aufsichtsbehörde zu erreichen, um das AastromReplicell zu vermarkten? System als Alternative oder als zu Verbesserung für, zu die Knochenmarkernte und Zusatzzu die blutprogenitorzellen-Stammzelleansammlungsmethoden. Diese Stammzelle-Ansammlungsmethoden sind weit für eine Anzahl von Jahren geübt worden, und unsere Technologien oder Produktanwärter können möglicherweise nicht durch den Markt wie diese oder andere konkurrierende Prozesse und Methodenlehren so bereitwillig angenommen werden. Zusätzlich können unsere Technologien oder Produktanwärter möglicherweise nicht in allen möglichen Anwendungen beschäftigt werden, die nachgeforscht werden, und jede mögliche Verringerung der Anwendungen würde die Marktannahme unserer Technologien und Produktanwärter und unserer möglichen Einkommen begrenzen. Infolgedessen selbst wenn wir alle angeforderten Genehmigungen durch die zuständige Aufsichtsbehörde erreichen, können wir nicht sicher sein, daß unsere Produkte und Prozesse auf einem Niveau angenommen werden, das uns erlauben würde, rentabel zu funktionieren. Störung der dritten Beteiligter, Bestandteile herzustellen oder begrenzte Quell-Versorgungsmaterialien zur Verfügung zu stellen würde unsere Entwicklung neuer Produkte und unsere Verkaufstätigkeiten hindern. Wir bauen nur auf dritte Beteiligte wie Plexus, Moll, Biowhittaker und Amgen, um unsere Produktanwärter, ihre Bestandteile und Wachstumfaktoren und andere Materialien herzustellen, die im Zellenexpansionsprozeß benutzt werden. Wir würden nicht in der LageSEIN, wechselnde Quellen des Versorgungsmaterials für viele dieser Einzelteile auf einer kurzfristigen Grundlage zu erhalten. Plexus hat gewählt, um sein Recht auszuüben, unser Herstellungsversorgungsabkommen zu beenden, das im Februar 2004 wirkungsvoll ist. Infolgedessen vermitteln wir mit einem anderen Lieferanten für anhaltendes Versorgungsmaterial auf kommerziell angemessenen Bezeichnungen. Jedoch können wir möglicherweise nicht Vereinbarung mit diesem neuen Lieferanten erreichen und die neue Vereinbarung kann auf weniger vorteilhaften Bezeichnungen sein. Wenn irgendwelche unserer Schlüsselhersteller oder Lieferanten ihre jeweiligen Verpflichtungen durchführen nicht können, oder wenn unser Versorgungsmaterial Wachstumfaktoren, ist Bestandteile oder andere Materialien begrenzt, oder unterbrochen, würden wir nicht in der LageSEIN, klinische Versuche zu leiten oder unsere Produktanwärter auf einer fristgerechten und Kosten-konkurrierenden Grundlage zu vermarkten, wenn an allen. Inhaltsverzeichnis an September 10, 2002 ein Hauptgläubiger von Moll ordnete eine unfreiwillige Petition für Bankrott gegen Moll ein. An September 19, 2002 verkündete Moll, daß es den Fall in einen freiwilligen Reorganisierungfall des Kapitels 11 umgewandelt hatte und hatte einleitende Zustimmung für eine Finanzierung des Schuldner-in-Besitzes $50 Million empfangen. Diese Faktoren können unser Versorgungsmaterial Bestandteile beeinflussen. Jedoch bis jetzt hat es keine Auswirkung auf unser Versorgungsmaterial Bestandteile von Moll gegeben. Ausserdem beziehen einige der Mittel, die von uns in unseren gegenwärtigen Knochenmark- oder Netzkabelblutzellen-Expansionsprozessen benutzt werden, den Gebrauch der Tier-abgeleiteten Produkte mit ein. Lieferanten oder Aufsichtsbehörden können die Verwendbarkeit solcher Mittel für klinischen und kommerziellen Gebrauch begrenzen oder einschränken. Alle mögliche Beschränkungen auf diesen Mitteln würden einen möglichen konkurrierenden Nachteil für unsere Produkte auferlegen. Unsere Unfähigkeit, alternative Mittel zu entwickeln oder zu erreichen würde unsere Produktentwicklungs- und -kommerzialisierungbemühungen schädigen. Schließlich können wir möglicherweise nicht sein, unsere anwesenden Vorbereitungen mit unseren Lieferanten fortzusetzen, vorhandene Verhältnisse zu ergänzen, neue Verhältnisse aufzubauen oder zu sein, die untergeordneten Materialien zu kennzeichnen und zu erhalten, die notwendig sind, um unsere Produktanwärter zukünftig zu entwickeln. Unsere Abhängigkeit nach dritten Beteiligten für das Versorgungsmaterial und die Herstellung dieser Einzelteile konnte unsere Fähigkeit nachteilig beeinflussen, kommerziell durchführbare Produkte auf einer fristgerechten und konkurrierenden Grundlage zu entwickeln und zu liefern. Unsere begrenzten internen Verkäufe und Marketing-Fähigkeiten gegeben, müssen wir gemeinschaftliche Verhältnisse zum Verkauf entwickeln, vermarkten und verteilen unsere Produkte. Während wir Ausgangsmarketing auf einer begrenzten Grundlage des AastromReplicell begonnen haben? System- und Sc--ich, Columbium--ich, DC--ich und Dcv-itherapieinstallationssätze in Europa, haben wir nur interne Verkäufe, Marketing und Verteilungsfähigkeiten begrenzt. Wir beabsichtigen, unsere Produkte durch gemeinschaftliche Verhältnisse zu den Firmen mit hergestellten Verkäufen, Marketing und Verteilungsfähigkeiten zu vermarkten. Unsere Unfähigkeit, jene Verhältnisse zu entwickeln und beizubehalten würde unsere Fähigkeit begrenzen, unsere Produkte zu vermarkten, zu verkaufen und zu verteilen. Unsere Unfähigkeit, an den erfolgreichen, langfristigen Verhältnissen teilzunehmen könnte uns erfordern, wechselnde Vorbereitungen zu entwickeln, zu einer Zeit als wir Verkäufe, Marketing oder Verteilungsfähigkeiten benötigen, vorhandene Nachfrage zu befriedigen. Alle mögliche Änderungen in den regelnden die Regierung betreffendklassifikationen unserer Produkte konnten verhindern, begrenzen oder verzögern unsere Fähigkeit, unsere Produkte zu vermarkten oder zu entwickeln. Die FDA stellt die regelnden Anforderungen her, die auf der Klassifikation eines Produktes basieren. Das AastromReplicell? System kann als medizinische Vorrichtung der Kategorie III reguliert werden, oder die FDA kann schließlich beschließen, das AastromReplicell zu regulieren? System unter einer anderen Kategorie. Weil unsere Produktentwicklungsprogramme entworfen werden, um die Standards zu erfüllen, die auf medizinische Vorrichtungen der Kategorie III anwendbar sind, würde eine Änderung in der regelnden Klassifikation unsere Fähigkeit beeinflussen, FDA-Zustimmung unserer Produkte zu erreichen. Das AastromReplicell? System ist zum Produzieren der unterschiedlichen Zellenmischungen fähig, und mindestens einige dieser Zellenmischungen willen, unter gegenwärtigen Regelungen werden reguliert als biologische Produkte, die eine vollständig andere Strategie erfordern. Inhaltsverzeichnis, wenn wir nicht Schritt mit unseren Konkurrenten und mit den technologischen und Marktänderungen halten, unsere Produkte kann überholt werden und unser Geschäft kann leiden. Der Markt für unsere Produkte ist sehr konkurrierend, ist abhängig von schnellen technologischen Änderungen und schwankt für unterschiedliche einzelne Produkte. Für jedes unserer möglichen Produkte, glauben wir, daß es möglicherweise viele konkurrierende Annäherungen gibt, die ausgeübt werden, einschließlich einiges durch Privatunternehmen, für die Informationen schwierig zu erreichen sind. Viele unserer Konkurrenten haben erheblich grössere Betriebsmittel, mehr Produktanwärter und haben Produktanwärter und -prozesse entwickelt, die direkt mit unseren Produkten konkurrieren. Unsere Konkurrenten können sich entwickelt haben oder konnten zukünftig sich entwickeln, neue Technologien, die mit unseren Produkten konkurrieren oder sogar unsere Produkte überholt machen. Als Beispiel, in der Vergangenheit, erschienene Studien vorgeschlagen haben, daß Stammzelletherapie klinischen Nutzen in der Behandlung des Brustkrebses begrenzt haben kann, der ein bedeutender Teil des gesamten Stammzelletransplantmarktes war. Dieses hat eine erhebliche Abnahme im Markt für das AastromReplicell ergeben? System mit unserem Installationssatz Sc-ich. Unsere Produkte werden entworfen, um die Prozesse für das Produzieren der Zellen zu verbessern und zu automatisieren, die in den therapeutischen Verfahren benutzt werden. Selbst wenn wir in der LageSIND, die verbesserten oder gleichwertigen Resultate zu demonstrieren, können Forscher und Praktiker möglicherweise nicht unsere Produkte benutzen und wir erleiden einen konkurrierenden Nachteil. Infolgedessen können wir nicht imstande sein, den Nettobuchwert unseres Warenbestands zurückzugewinnen. Schließlich soweit daß andere neue Technologien entwickeln, die die gerichtete Anwendung für unsere Produkte adressieren, leidet unser Geschäft. Wenn wir nicht Schlüsselpersonal anziehen und behalten können, dann leidet unser Geschäft. Unser Erfolg hängt im großen Teil nach unserer Fähigkeit, in hohem Grade qualifiziertes wissenschaftliches und Managementpersonal anzuziehen und zu behalten ab. Wir stellen Konkurrenz für solches Personal von anderen Firmen, von Forschung und von akademischen Anstalten und von anderen Wesen gegenüber. Weiter in einer Bemühung, finanzielle Betriebsmittel zu konservieren, haben wir Verringerungen unserer Arbeitskraft bei zwei verschiedenen Gelegenheiten eingeführt. Resultierend aus diesen und anderen Faktoren können wir möglicherweise nicht in anstellenoder Halteschlüsselpersonal erfolgreich sein. Die Firma hat eine Schlüsselfigurlebensversicherungspolice für R. Douglas Armstrong, der Vorsitzende, Generaldirektor und Präsident von Aastrom. Unsere Unfähigkeit, jeden anderen verlorenen Schlüsselangestellten zu ersetzen konnte unsere Betriebe schädigen. Wenn unsere Patente und eigenen Rechte nicht erheblichen Schutz liefern, dann leiden unser Geschäft und Wettbewerbsposition. Unser Erfolg hängt im großen Teil von unserer Fähigkeit, eigene Produkte und Technologien zu entwickeln oder zu genehmigen und zu schützen ab. Jedoch können Patente möglicherweise nicht auf irgendwelchen unserer schwebenden oder zukünftigen Patentanfragen bewilligt werden. Auch der Bereich von irgendwelchen unserer herausgegebenen Patente kann möglicherweise nicht genug ausgedehnt sein, sinnvollen Schutz anzubieten. Zusätzlich konnten unsere herausgegebenen Patente oder die Patente, die zu uns genehmigt wurden, erfolgreich herausgefordert werden, ungültig erklärt werden oder verhindert werden, damit unsere Patentrechte nicht eine wirkungsvolle konkurrierende Sperre verursachen würden. Ausserdem bauen wir auf drei exklusiv, die weltweiten Lizenzen in bezug auf sind die Produktion der menschlichen Zellen, die uns durch die Universität von Michigan für sicheres unserer Patentrechte bewilligt werden. Wenn wir materiell solches Vereinbarungsinhaltsverzeichnis oder Ausfallen, um durchbrechen mit solchen Vereinbarungen anders materiell einzuwilligen oder wenn solche Vereinbarungen ablaufen oder anders von uns beendet werden, können wir unsere Rechte unter den Patenten verlieren, die durch die Universität von Michigan gehalten werden. Spätestens enden diese Lizenzen, wenn das zugrundeliegende Patent die Lizenz abläuft. Das erste dieser zugrundeliegenden Patente läuft an März 21, 2012 ab. Wir bauen auch auf Geschäftsgeheimnisse und unpatentable Know-how, denen wir suchen, im Teil, durch Vertrauensabkommen mit unseren Angestellten, in den Beratern, in den Lieferanten und in den Lizenznehmern zu schützen. Diese Vereinbarungen können durchgebrochen werden, und wir konnten nicht ausreichende Hilfsmittel für irgendeinen Bruch haben. Wenn dieses auftreten sollten, würden unser Geschäft und Wettbewerbsposition leiden. Rechtsstreit des geistigen Eigentums konnte unser Geschäft schädigen. Unser Erfolg hängt auch im Teil von unserer Fähigkeit, kommerziell entwicklungsfähige Produkte zu entwickeln ab, ohne die eigenen Rechte von anderen zu verletzen. Obgleich wir nicht abhängig von irgendwelchen eingeordneten Verletzungansprüchen gewesen sind, konnten andere Patente bestehen oder konnten eingeordnet werden, die unsere Fähigkeit verbieten oder begrenzen würden, unsere Produkte zu vermarkten oder unsere Wettbewerbsposition beizubehalten. Im Falle einer Debatte des geistigen Eigentums, können wir gezwungen werden zu streiten. Rechtsstreit des geistigen Eigentums würde management?saufmerksamkeit vom Entwickeln unserer Produkte umleiten und würde uns zwingen, uns auf erhebliche Kosten unabhängig davon zu nehmen, ob wir erfolgreich sind. Ein nachteiliges Resultat konnte uns bedeutenden Verbindlichkeiten dritten Beteiligten unterwerfen und zwingt uns, die Entwicklung und den Verkauf unserer Produkte und Prozesse zu beschränken oder aufzuhören. Die Regierung wahrt bestimmte Rechte in der Technologie, die wir mit Regierungsbewilligungsgeld entwickeln und wir die Einkommen von solcher Technologie verlieren können, wenn wir die Technologie nicht gemäß hergestellten Regierungsrichtlinien in den Handel bringen und verwenden. Sicher unserer und unserer Lizenzgeber?, Forschung ist gewesen oder wird im Teil durch Regierungsbewilligungen finanziert. Resultierend aus solcher Finanzierung hat die STAATREGIERUNG bestimmte Rechte in der Technologie, die mit der Bewilligung entwickelt wird. Diese Rechte schließen eine non-exclusive, eingezahlte, weltweite Lizenz mit ein, die Technologie für jeden Regierungszweck zu verwenden. Zusätzlich hat die Regierung das Recht, uns zu erfordern, eine ausschliessliche Lizenz zu bewilligen, die entwickelte Technologie zu einem dritten Beteiligten zu verwenden, wenn die Regierung die feststellt: wir haben nicht ausreichende Schritte unternommen, um solche Technologie in den Handel zu bringen; solche Tätigkeit ist notwendig, um Bedürfnisse des öffentlichen Gesundheitswesens oder Sicherheit zu erfüllen; oder? solche Tätigkeit ist notwendig, um Anforderungen für allgemeinen Gebrauch unter Bundesverordnungen zu entsprechen. In diesen Fällen würden wir nicht Einkommen auf den Produkten empfangen, die wir uns entwickelten. Zusätzlich ist Technologie, die teilweise durch eine Bundesforschungsbewilligung finanziert wurde, abhängig von den folgenden Regierungsrechten: die Produkte, welche die Technologie verwenden, die in den Vereinigten Staaten verkauft werden, sollen in den Vereinigten Staaten im wesentlichen hergestellt werden, es sei denn ein Waiver erreicht wird; Inhaltsverzeichnis? die Regierung kann das Bewilligen einer Lizenz zu einem dritten Beteiligten zwingen, das das erforderliche Produkt bildet und verkauft, wenn wir nicht angemessene Kommerzialisierung eines erforderlichen Produktes mit der Technologie ausüben; und? die STAATREGIERUNG kann die Technologie für seine eigenen Notwendigkeiten verwenden. Wenn wir diese Richtlinien treffen nicht können, würden wir unsere ausschließlichen Rechte zu diesen Produkten verlieren und wir würden die möglichen Einkünfte verlieren, die aus dem Verkauf dieser Produkte bezogen wurden. Der Markt für unsere Produkte ist schwer Abhängiges auf Vergütungpolitischen Linien des dritten Beteiligten. Unsere Fähigkeit, unsere Produktanwärter erfolgreich in den Handel zu bringen hängt vom Umfang, in dem Regierungshealthcare, wie Medicare programmiert und Medicaid, sowie private Krankenversicherer, Gesundheitswartungsorganisationen ab und andere payors des dritten Beteiligten zahlen für unsere Produkte und in Verbindung stehenden Behandlungen. Vergütung durch payors des dritten Beteiligten hängt von einer Anzahl von Faktoren, einschließlich der payor?sermittlung ab, die Gebrauch des Produktes sicher und wirkungsvoll ist, nicht experimentell oder Untersuchungs, medizinisch notwendig, passend für den spezifischen Patienten und kosteneffektiv. Vergütung in den Vereinigten Staaten oder im Ausland kann möglicherweise nicht vorhanden oder beibehalten für irgendwelche unserer Produktanwärter sein. Wenn wir nicht Zustimmungen für ausreichende Vergütungen des dritten Beteiligten erreichen, können wir möglicherweise nicht in der LageSEIN, die Preisniveaus herzustellen oder beizubehalten, die genügend sind, eine passende Rückkehr auf unserer Investition in der Produktentwicklung zu verwirklichen. Alle mögliche Begrenzungen auf der Vergütung, die von den payors des dritten Beteiligten vorhanden ist, können die Nachfrage nach verringern, oder beeinflussen Sie negativ den Preis von, unsere Produkte. Z.B. in der Vergangenheit, haben erschienene Studien diese Stammzelleversetzung im Brustkrebs vorgeschlagen, die einen bedeutenden Teil des gesamten Stammzelle-Therapiemarktes festsetzen, zu der Zeit als, klinischen Nutzen begrenzt haben kann. Der Mangel an Vergütung für diese Verfahren durch Versicherungspayors würde negativ die Marktfähigkeit unserer Produkte beeinflussen. Mögliche Produkthaftungsansprüche konnten unser Einkommen und finanziellen Zustand beeinflussen. Wir stellen eine zugehörige Geschäftsgefahr der Aussetzung zu den Produkthaftungsansprüchen im Falle daß der Gebrauch des AastromReplicell gegenüber? System während der Forschungs- und Entwicklungsbemühungen, einschließlich der klinischen Versuche oder nach Kommerzialisierungresultaten in nachteiligem beeinflußt. Infolgedessen können wir auf bedeutende Zuverläßlichkeit von Produktenbelichtung uns nehmen, die vorhandene Versicherungsdeckung übersteigen könnte. Wir können möglicherweise nicht in der LageSEIN, ausreichende Niveaus der Versicherung an den angemessenen Kosten und/oder an den angemessenen Bezeichnungen beizubehalten. Übermäßige Versicherungskosten oder nicht versicherte Ansprüche würden unseren Betriebsverlust erhöhen und unseren finanziellen Zustand beeinflussen. Unsere korporativen Dokumente und Michigangesetz enthalten Bestimmungen, die es schwieriger bilden können, damit wir erworben werden können. Unsere Direktion hat die Berechtigung, ohne Aktionärzustimmung, um zusätzliche Anteile der Vorzugsaktie herauszugeben und Regeln der Rechte, der Präferenzen, der Privilegien und der Beschränkungen dieser Anteile ohne irgendeine weitere Stimme oder Tätigkeit durch unsere Aktionäre. Diese Berechtigung, zusammen mit bestimmten Bestimmungen unserer Charterdokumente, kann beeinflussen des Bildens es haben schwieriger, damit ein drittes Beteiligtes erwirbt, oder vom Entmutigen eines dritten Beteiligten vom Versuchen zu erwerben Sie Steuerung des Inhaltsverzeichnisses unsere Firma. Dieses beeinflussen könnte auftreten, selbst wenn unsere Aktionäre die Änderung in der Steuerung betrachten, in ihrem besten Interesse zu sein. Aussagen Vorwärts-schauend, die dieser Report bestimmte Vorwärts-schauende Aussagen innerhalb der Bedeutung des Abschnitts 27A der Aktien enthält, fungieren Sie und unterteilen Sie 21E des Börsengesetzes. Diese Vorwärts-schauenden Aussagen umfassen die betreffend Aussagen: strategische collaborations des Potentials mit anderen; zukünftige Kapitalnotwendigkeiten; Produktentwicklung und Marketing-Plan; klinische Probepläne und vorweggenommene Resultate; Erwartung der zukünftigen Verluste; und? Wiedereinbau der Herstellungsquellen. Diese Aussagen sind abhängig von Gefahren und Ungewißheiten, einschließlich deren, die in diesem Geschäftsgefahrenabschnitt festgelegt wurden, und tatsächliche Resultate konnten von denen materiell sich unterscheiden, die in diesen Aussagen ausgedrückt wurden oder angedeutet waren. Alle Vorwärts-schauenden Aussagen, die in dieser Ausrichtungsaussage umfaßt werden, werden ab dem Datum hiervon abgegeben. Wir nehmen keine Verpflichtung an, irgend solche Vorwärts-schauende Aussage zu aktualisieren oder zu folgern, warum tatsächliche Resultate sich unterscheiden konnten. Diese Geschäftsbetrachtungen und andere, werden ausführlicher besprochen und sollten in Verbindung mit den?Busineßgefahren gelesen werden? besprochen worden in unserem jährlichen Bericht 2002 der Form 10-K.

[Tullie09]

Hi Leute...

Im nächste Letter von Biotech-World.de wird eine detailierte Analyse von AA-Strom mit dabei sein. Der Letter wird jetzt am Sonntag kommen.


AUSSCHNITT DES LETTER

#####################################################

Stichwort des Monats ist :

Omnis Cellula Ex Cellula - Stammzellen

Stammzelle ist ein allgemeiner Ausdruck für eine Zelle, egal welchen Typs, die sich noch nicht differenziert hat. Dies bedeutet, dass die Zelle ihre zukünftige Aufgabe noch nicht „ausführt“, ihr Entwicklungsprogramm ist noch nicht abgelaufen. Sie besitzt somit noch die Fähigkeit, jeden Zelltyp anzunehmen. Stammzellen haben, jedenfalls in der Theorie, das Potential sich unendlich oft zu teilen. Diese Qualität des Nichtsterbens kommt wahrscheinlich von einer Überexpression der Telomerase, einem Enzym, das repetitive (TTAGGG)n-Sequnezen (TTAGGGTTAGGG...n>100) an die Chromosomenenden (=Telomere) anfügt, welche sonst durch sukzessive Zellteilungen verkürzt würden und verloren gingen. Verlust der Telomere verursacht Verkürzung, Degradation und Aggregation der Chromosomen, was schliesslich zum Zelltod führen wird. Im Gegensatz dazu besitzen unsere ausdifferenzierten Körperzellen keine Telomerase mehr, nach maximal 70 Zellteilungen sterben die Körperzellen...

Analyse :

AAStrom und Geron

und noch vieles mehr...

#################################################

ANMELDEN UNTER : www.Biotech-World.de

#################################################

Gruss

[meislo]

Da meldet sich ausser mir ja noch jemand im Board Hurra das Board lebt. Ich habe auch den monatlichen Newsletter von Biotechworld abboniert , meine aber der letzte stammt aus dem August und dachte es gibt Sie nicht mehr . Bin gespannt was die zu unserer Pleitefirma zu berichten haben.

[t.1]

@meislo
pleitefirma ich hoffe nicht!bin mit dir im gleichen kutter,und freue mich auch schon auf deren analyse zu aastrom.
grüße t.1

[meislo]

Nur wird die Analyse den Kursverlauf in keinster Weise beeinflussen und im Grunde genommen ist sowieso schon alles bekannt.Entscheidend in naher Zukunft wird sein ob man in Europa ein paar Käufer für die Produkte findet oder nicht . Angekündigt sind diese Käufer schon seit gut einem Jahr, nur hat sich keiner der Käufer bis heute geoutet.

[Tullie09]

Hi

Der Letter kommt wohl erst morgen...

Gruss

[meislo]

Hallo Tullie09

Woher weisst Du das ein neuer Newsletter erscheinen soll?
Ich habe auf deren Portal nichts entdecken können worauf man schliessen könnte das ein neuer Letter erscheint . Vielleicht bin ich ja auch nur einfach zu blöde.

gruss meislo

[meislo]

Hallo Tullie09

Was ist nun mit der Analyse?
Kommt sie oder kommt sie nicht?

gruss meislo

[Tullie09]

Der neue BioTech-World Letter ist heute raus

folgende Themen:

Inhaltsangabe

Stichwort des Monats : Omnis Cellula Ex Cellula Stammzellen – S. 1-4
Analyse : Geron – S. 5-10
Werbung : Krebs-Report 2002 S. 11
Analysen : Aastrom – S. 12-15
Impressum – S. 16

Gruss Tullie09

[meislo]

Danke Dir, aber woher war dir der Inhalt schon seit einer Woche bekannt? Hast Du Insiderwissen?

gruss meislo

[meislo]

Nicht sehr vielversprechend was über astm geschrieben wird. Neuarragements sollten sich wirklich gut überlegt sein. Vielleicht werde ich auch umsatteln, muss erstmal eine Nacht drüber schlafen Danke nochmals

Ein etwas enttäuchter meislo

[Tullie09]

Hi... also wenn du dein geld in einer firma investieren möchtest so würde ich ganz klar geron nehmen...

[meislo]

Das Problem bei Geron ist das sie auf Jahre kein Umsatz durch Produktverkäufe generieren werden. Es ist absehbar das die Finanzen genau wie bei Stemcells auch, bei weitem nicht reichen werden Hier sind Fragen der Finanzierung zu klären. Sicherlich ist es möglich über Aktienverkäufe und Wandeloptionen Geld zu bekommen. Ersteres ist bei Geron auch geplant ,nur müsste der Kurs auch steigen damit sich die Verwässerung durch neue Aktien in Grenzen hält. Das darf erstmals bezweifelt werden deshalb bin ich in Geron auch nicht investiert und werde es auch so schnell nicht tun, werde aber Geron über die Jahre weiter beobachten und gegebenfalls investieren .

[Tullie09]

wie gesagt "wenn" ?!

ich würde es sein lassen...

mologen scheint auch extrem grosse finanzprobleme zu haben...

gruss

[meislo]

Mologen hatte mich auch mal interessiet.
Habe mir aber überlegt wieso ein Landwirt Geld für Herpesimpfungen ausgeben wird wenn Herpes die Fleischqualität nicht verschlechtert. Folglich wird es für dieses Produkt keinen Markt geben, die letzten Zahlen von Mologen waren fürchterlich.

gruss meislo

[meislo]

IVSIDERKÄUFE BEI AASTROM

SOURCE: Form 4

ISSUER: AASTROM BIOSCIENCES INC
SYMBOL: ASTM

FILER: ARMSTRONG R DOUGLAS
TITLE: Chairman of the Board
TRANSACTION: Purchase 10,000 11/19/02 $.33
OWNERSHIP: N/A

The Form 4 is filed with the Securities and Exchange Commission by any
insider buying or selling their company`s shares. This form must be
filed within two business days of the transaction.

Insider data source: Washington Service ([e-mail] or 202-778-1384)


(END) DOW JONES NEWS 11-22-02

01:26 AM

01:26 112202





10000 Aktien für einen Vorstandsvorsitzenden der jährlich 500000 Dollar verdient eine wahnsinnige Menge Geld die er investiert WOW Haut mich wirklich vom Hocker

[Tullie09]

x

[meislo]

Eine kurze Chartanalyse zu Aastrom findet man unter www.biotech-world.de. Die Analyse wurde heute erstellt.

[meislo]

AASTROM geht ab durch die Decke Nachbörslich gerade bei 0,60 cent

Hier die Nachricht Nachbörslich erschienen

Aastrom Biosciences Enters Into Common Stock Purchase Agreement With Fusion Capital
Wednesday November 27, 4:15 pm ET


ANN ARBOR, Mich., Nov. 27 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM), a leader in cell therapies for tissue repair and the treatment of cancer and disease, announced it has entered into a common stock purchase agreement with Fusion Capital Fund II, LLC, a Chicago-based institutional investor. Under the agreement, Fusion Capital shall buy up to $12 million of Aastrom`s common stock over a period of time up to 24 months, subject to Aastrom`s right to extend the agreement for six months. Aastrom has the right to control the timing and the amount of stock sold to Fusion Capital.
ADVERTISEMENT


Under the common stock purchase agreement, funding of the $12 million shall occur from time to time after the Securities and Exchange Commission has declared effective a registration statement covering the shares of common stock to be purchased by Fusion Capital. The purchase price of the shares to be sold to Fusion Capital shall be based upon the market price of the common stock at the time of each sale. A more detailed description of the transaction is set forth in Aastrom`s report on Form 8-K, recently filed with the SEC.

"This financing program should help provide Aastrom with funding to continue growing its tissue repair programs in important markets such as bone grafting, in addition to expanding its Cell Production Products business in the European market, near-term," said Alan M. Wright, Senior Vice President Administrative and Financial Operations and Chief Financial Officer of Aastrom. "We are pleased to add Fusion Capital to our team as we expect it to be a valuable, long-term financial and business partner."

Jonathan Cope of Fusion Capital stated, "We are extremely impressed by Aastrom`s management team and its ability to rapidly expand its proprietary technologies into large addressable markets such as bone grafting and disease treatments. We believe the Company has a dominant position in cell production for both tissue repair, and cancer and infectious disease therapies, and can anticipate near-term revenue prospects from the Cell Production Products business already underway. We are excited to enter into this long-term relationship with Aastrom."

About Fusion Capital

Fusion Capital Fund II, LLC is a broad-based investment fund, located in Chicago, Illinois. Fusion Capital makes a wide variety of investments ranging from special situation financing to long-term strategic capital. For more information about Fusion Capital, please visit www.fusioncapital.com.

About Aastrom Biosciences, Inc.

Aastrom develops unique cell-based products through proprietary technologies for stem cell tissue repair, and the treatment of cancer and infectious disease. These competencies are based on dual-technology platforms: patented single-pass perfusion (SPP), providing cells with excellent biological function, and patented GMP-compliant system automation facilitating the delivery of cells for therapeutic use in medical practice. These technologies are integrated into the AastromReplicell(TM) System, to uniquely standardize and automate the processes involved in producing high quality Tissue Repair Cells (TRCs) and Therapeutic Cells (TCs). Aastrom`s growing pipeline of TRC products, derived from bone marrow and cord blood, target the reconstruction of normal tissues. These TRCs are intended for use in stem cell transplants, the treatment of severe osteoporosis and in bone grafting procedures. Aastrom also has an expanding line of potential TC products. These TCs are intended to function similarly to drugs in causing a therapeutic action. Aastrom`s TC products under development include the Dendricell(TM) dendritic cell products for the cancer vaccine market. In addition, Aastrom has developed a proprietary cell-manufacturing device, the AastromReplicell(TM) System. These products are not available for sale at this time in the U.S., except for research or investigational use. The SC-I, CB-I, DC-I, DCV-I cell production products and the AastromReplicell(TM) System are CE Mark approved for European marketing and sales, and the System is also available to clinical research programs and companies developing cell therapies.

Please visit our website at www.aastrom.com

This document contains forward-looking statements, including without limitation, statements regarding product development objectives, potential product applications, potential advantages of the AastromReplicell(TM) System and related cell therapy kits, and financing plans which involve certain risks and uncertainties. The forward-looking statements are also identified through use of the words "intend," "expect," "potential," "should," "can," "believe," and other words of similar meaning. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are the results obtained from clinical trial and development activities, regulatory approval requirements, the availability of resources, financial market conditions, and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom`s Annual Report on Form 10-K, and other filings with the Securities and Exchange Commission.

[meislo]

Deutsche Übersetzung

ANN ARBOR, Mich., November 27/PRNewswire-FirstCall/-- Aastrom Biosciences, Inc. (NasdaqSC: ASTM), ein Führer in den Zellentherapien für Gewebereparatur und die Behandlung des Krebses und der Krankheit, verkündet ihm hat an einer Stammaktienkaufvereinbarung mit Kapitalfonds II, LLC, ein Chicago-gegründeter institutioneller Anleger des Schmelzverfahrens teilgenommen. Unter der Vereinbarung kauft Schmelzverfahrenskapital bis $12 Million von Stammaktien Aastrom`s über eine Zeitdauer von Zeit bis 24 Monate, abhängig von Recht Aastrom`s, die Vereinbarung für sechs Monate zu verlängern. Aastrom hat das Recht, das TIMING und die Menge des Vorrates zu steuern verkauft an Schmelzverfahrenskapital. REKLAMEANZEIGE unter der Stammaktienkaufvereinbarung, Finanzierung der $12 Million tritt von Zeit zu Zeit nach den Aktien auf und Austauschkommission hat wirkungsvoll eine Ausrichtungsaussage erklärt, welche die Anteile der von Fusion Capital zu kaufenden Stammaktien umfaßt. Der Kaufpreis der an Schmelzverfahrenskapital zu verkaufenden Anteile basiert nach dem Marktpreise der Stammaktien zu der Zeit jedes Verkaufes. Eine ausführlichere Beschreibung der Verhandlung wird im Bericht Aastrom`s über die Form 8-K festgelegt, vor kurzem eingeordnet mit der sek. "dieses Finanzierungsprogramm sollte helfen, Aastrom mit der Finanzierung zu versehen zum Fortfahren, seine Gewebereparaturprogramme in den wichtigen Märkten wie verpflanzendem Knochen zu wachsen, zusätzlich zur Erweiterung seines Zellenproduktions-Produktgeschäfts im europäischen Markt, kurzfristig,", sagte Alan M. Wright, die administrativen und Finanzgeschäfte des älteren Vizepräsidenten und Finanzleiter von Aastrom. "wir freuen uns, Schmelzverfahrenskapital unserer Mannschaft hinzuzufügen, wie wir sie erwarten, um ein wertvoller, langfristiger finanzieller und Teilhaber zu sein.", Jonathan werden vom angegebenen Schmelzverfahrenskapital fertig, "wir werden extrem durch Aastrom`smanagementmannschaft und seine Fähigkeit, seine eigenen Technologien in große ansprechbare Märkte wie Knochen schnell zu erweitern verpflanzend und Krankheitbehandlungen beeindruckt. Wir glauben, daß die Firma eine dominierende Position in der Zellenproduktion für Gewebereparatur und Krebs und ansteckende Krankheittherapien hat und kurzfristige Einkommensaussichten vom Zellenproduktions-Produktgeschäft bereits unterwegs vorwegnehmen kann. Wir werden aufgeregt, um an diesem langfristigen Verhältnis zu Aastrom teilzunehmen.", Über Kapitalfonds II des Schmelzverfahrenshauptschmelzverfahrens, ist LLC eine broad-based Investitionkapital, gelegen in Chicago, Illinois. Schmelzverfahrenskapital bildet eine breite Vielzahl von den Investitionen, die von der speziellen Situation reichen, die bis zu strategischem Kapital des Long-term finanziert. Zu mehr Information über Schmelzverfahrenskapital, besuchen Sie bitte www.fusioncapital.com.

[meislo]

Ich habe so meine Zweifel ob FusionCapitel
der richtige Partner ist . Irgendwie habe ich Bauchschmerzen. Ich glaube das ist so eine Firma unter der
alle Pleite gehen . Sie verdienen sich am Shortselling und brauchen sich nicht über den Markt zu bedienen wenn der Kurs steigen sollte was natürlich zur Folge hätte das der Kurs weiter steigen würde. Sie haben ja von AASTROM die Aktien und bräuchten dem Kurs nicht hinterherzulaufen. Sollte der Kurs hoch steigen so würden sie am Kursgewinn der von AASTROM gelieferten Aktien verdienen. Ein sicheres Geschäft!! Angeblich betreibt die Firma kein Shortselling wie auf der Homepage zu lesen ist.
Irgendwie glaub ich denen aber nicht

Meinungen dazu Weissjemand was über die Firma

Ich stelle mal einen Auszug von der Homepage der Firma ins Board

Gruss Lothar

• Company Control — company determines how and when to use the facility


• Flexibility — tailored to a company`s unique financial needs, no restrictive covenants


• No Overhang — shares are issued as the company determines, no uncertainty regarding dilution


• Single Investor — Fusion Capital is the only investor


• Certainty — eliminates financing uncertainty so management can focus on its business


• Inexpensive — low cost way to access equity markets on a periodic and frequent basis


• Amount — $5 million to $50 million in the aggregate.


• Use of Proceeds — Cash may be used for general corporate purposes.


• No Short Selling or Hedging by Fusion Capital — Fusion Capital and its affiliates shall covenant not to cause or engage in, in any manner whatsoever, any direct or indirect short selling or hedging of the securities of a partner company. Fusion Capital and its affiliates shall represent and warrant to the partner company that at no time in the past has Fusion Capital or any of its affiliates caused or engaged in, in any manner whatsoever, any direct or indirect short selling or hedging of the securities of a partner company.

[meislo]

Mir geht es wohl nicht alleine so der schlecht über FusionCapitel denkt

BullnBear:

I would take my profits and run for the hills.

Should you read the boards of some of the other companies I previously mentioned, they ALL said the same thing. Fusion was the answer to their problems.

As it currently stands, Fusion is only "liable" for another 11,000,000 shares as 970,000 have already been issued. The key phrase there is shares, not dollars.

I really suggest you spend a significant amount of time investigating Fusion as I did about a 18 months ago. Go visit their offices in Chicago and start asking some tough questions, if you find them occupied.

All but one Fusion deal I know of has blown up in investors faces and I am most certain if I could track down the one where the stock remained relatively unchanged it would be decimated by now also.

As for those insiders in ASTM, the second best way for them to make money is to find someone offshore to short the stock for them.

I would also like you to understand that most public companies, BB or not, are set up to make money for management, with investors being the source of managements income.

Also, there is no way Fusion could have survived this long without holding a large offshore short position.

This is not rocket science. Fusions track record speaks for itself.

As for ASTM, they will never see the $6 Million Dollars as stated in the filing. This is a facade, a smoke and mirrors game to relieve investors of the balance of their funds.

I would also add that if ASTM was a leader in stem cell research, or if they had science that was above and beyond that of competitors, another larger and better financed company would step in and either buy them out or form a partnership that would provide cash advances for meeting certain protocols of development.

Fusion is a death certificate. Count on it.

[meislo]

Gleicher Autor wie in 47 aber er denkt genauso wie ich über die Sache deshalb stelle ich es ins Board

BullnBear:

ASTM just signed their death certificate. Based on what I have observed of Fusion financing in the past, all that is happening is that the financing agreement will allow insiders to cash out more of their own holdings, pay themselves monies owed in back wages, while investors will lose the tiny bit of equity they now have.

If you take the time to do an in depth analysis of some of the stocks I previously mentioned that used Fusion financing you will likely see a pattern.

Fusion, to my knowledge has never provided the full amount of dollars referenced in the filings. The catch to the financing is that the $6 million is not really $6 Million, but the amount of registered shares. In the case of ASTM that is slightly under 12,000,000 shares. Those 12,000,000 shares could provide as little as $1,200,000 if the stock price is at $.10, which assuredly it will be if the pattern holds.

As I have been a biotech investor for many years (that is how ASTM came to my attention as I follow over 200 daily) I understand the ins and outs of deals that are put together to attempt to save companies. Dealing with Fusion is not the way to success, but just the opposite.

Fusion could not remain in business if they had lost the 10`s of millions of dollars that they purportedly would have if they were long all the companies they financed.

The only way they could remain profitable is to have shorted the stock and covered with the shares issued to them.

If ASTMs science was really as good as some would make of it, it would then be possible for ASTM to get financing from other sources such as through a partnership with another biotech company or drug maker such as Schering-Plough, Roche, Abbott, or many others.

As it is it appears that the only people who are going to benefit from the financing are Fusion and insiders. Investors as usual will get the shaft.








- - - - -

[meislo]

Ein Paar Beispiele wie sich Aktienkurse entwickelt haben wo FusionCapitel die Finger im Spiel hatte Es können auch positive Entwicklungen stattgefunden haben, nur sind mir keine bekannt.

A few more for your entertainment:

Fusion Deals:

4/6/200--MACE
Closed that day at--$4.00
Todays Close--$.94

The very next day Fusion financed FAVE on 4/7/2000
Fave Closed on 4/7/200 at--4.88
Today, FAVE closed at--$.01

and...........drum roll please.........The Grand Daddy of them ALL:

PPRO

Financed by Fusion less than one year ago on December 31, 2001.

Closing Price 12/31/2002--$30.09
Todays Close on the Pinkies--$.033

Is that enough sand for you this evening?




- - - - -
June 3, 2002

Fusion Capital Provides ADAM Financing

Close on June 3, 2002: $1.68
Close on November 27, 2002: $.46

June 25, 2002

Fusion Capital Provides OILS Financing:

Closed on June 25, 2002: $.42
Colsed today: $.02

Fusion Capital Provides TSET Financing:

Date of Financing About May 2001:

TSET/KNOS Closed at $.80
Todays Close: $.16

October 23, 2002

Fusion Provides INSG Financing:

Closed October 23, 2002: $.48
Todays Close: $.44

Just FYI, Fusion usually gets an upfront amount of shares to put financing together. If you look at the trading volume charts you will see huge Volumes right after the deal is announced.

Fusion usually provides $6 Million Dollars in Financing, sometimes $10 Million as in the case of UAX.

No company with half a brain would finance stock scams like Fusion does giving them the right to Put stock to their company at any time.

In all but 1 of the dozen or so cases where Fusion has provided financing that I have examined the stock has later tanked massively.

If Fusion were not shorting the stock, they would have lost 10`s of Millions by now.

Don`t take my word for it though, as I have only been investing for 45 years and have also visited the offices of said organization in Chicago. Try it sometime, and don`t forget to bring your BS detector along.

[meislo]

TheSUBWAY.com Announces Investment Opinion: Today`s Watch List!

WESTON, Fla., Dec 2, 2002 (BUSINESS WIRE) -- Keep an Eye on Creative Holdings & Marketing Corporation (OTCBB:CRHM). CRHM just announced major news about another site acquisition that upon completion could yield revenues for the Company of approximately $19,000,000! Watch for the stock to move! Other stock market standouts include: Go Online Networks Corp. (OTCBB:GONT): Market Perform, Aastrom Biosciences Inc. (Nasdaq:ASTM): Market Outperform, Genuity Inc. (Nasdaq:GENU): Market Underperform, Internet Capital Group Inc. (Nasdaq:ICGE): Market Perform.

[meislo]

Aastrom Biosciences Signs Sublicensing Agreement With Corning
Thursday December 12, 8:31 am ET
-- Aastrom`s Proprietary Technology to Support Corning Life Sciences` Applications --


ANN ARBOR, Mich., Dec. 12 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced that it has granted an exclusive sublicense to Corning Incorporated (NYSE: GLW - News) relating to Aastrom`s cell transfection technology for increased efficiency in loading genetic material into cells.
ADVERTISEMENT


Aastrom owns the intellectual property rights to methods, compositions and devices that increase the frequency and efficiency of depositing particles into cells to modify their genetic code. Under terms of the agreement, Corning`s Life Sciences business will utilize Aastrom`s unique technology to enhance the development of their molecular and cell culture applications in areas that are not competitive to Aastrom`s core business interests. Aastrom retains exclusive rights to the applications of the technology involving cells for therapeutic applications, and will receive up-front payments and future royalties from Corning.

"Aastrom continuously pursues new opportunities that could utilize our technology to build value for our shareholders," said R. Douglas Armstrong, Ph.D., President and Chief Executive Officer of Aastrom. "Corning Life Sciences is highly regarded as a manufacturer of cell culture systems for new drug discovery. We consider this agreement an important step that will further broaden the potential benefits of Aastrom`s technologies in the development of cell-based products."

"We are very pleased to have sublicensed this important piece of intellectual property from Aastrom Biosciences," said Jeff Mooney, Ph.D., Program Director, Corning Advanced Life Sciences. "This technology will enable Corning Life Sciences to both bolster and advance its product lines in the areas of advanced molecular and cellular biology."

About Corning Incorporated

Established in 1851, Corning Incorporated (www.corning.com) creates leading-edge technologies for the fastest-growing markets of the world`s economy. Corning manufactures optical fiber, cable and photonic products for the telecommunications industry; and high-performance displays and components for television, information technology and other communications-related industries. The company also uses advanced materials to manufacture products for scientific, semiconductor and environmental markets. Corning revenues for 2001 were $6.3 billion. Corning Life Sciences manufactures and supplies leading high throughput products for drug discovery, with an emphasis on cell culture systems, including vessels for cell growth and microplates for cell analysis.

[meislo]

Leute Kauft!! Die Post Geht ab!!!

gruss meislo

[MSolver]

wow, in USA schon vorbörslich 70 % des normalen Volumens gehandelt.

RTQ 0.67 oder +34 %

[meislo]

07:57 0,80 cent Wow

[t.1]

@meislo
das haben wir uns aber nach der langen leidenszeit verdient
t.1

[meislo]

Wurde auch Zeit .Es hat mich viele Nerven gekostet Ich war oft versucht meine Bestände in AASTROM zu reduzieren . Das nächste Etappenziel muss heissen einen Kurs von 1 Dollar bis zum 10 Februar zu erreichen damit uns ein Reverse Splitt erspart bleibt.

Alles Gute
Lothar

[meislo]

So ein Mist Es geht schon wieder Runter 0,61 Dollar zur Zeit, Mal sehen was uns der Tag bringt.

[meislo]

Zur Erinnerrung ist garnicht solange her Ich glaube da stand der kurs um die 40 cent

22.11.2002
Aastrom Biosciences reduzieren
BioTech-World

Die Analysten von "BioTech-World" empfehlen derzeit die Aktien von Aastrom Biosciences (WKN 905286) zu reduzieren.

Aastrom sei eine sehr kleine, hochspekulative Firma, die sich nicht direkt mit Medikamenten beschäftige, sondern ausschließlich mit Therapien, welche den Einsatz ganzer Zellen beinhalten würden. Diese so genannten "therapeutischen Zellen“ würden im wesentlichen drei verschiedene Einsatzgebiete besitzen, die aber alle zusammenhängen würden: Gewebereparatur und Gewebeersatz durch Stammzellen, z.B. bei degenerativen Gewebeerkrankungen wie Osteoporose, einen Krebs-Impfstoff in Form einer Immuntherapie mit "programmierbaren“ Zellen des Immunsystems und eine automatisierte Anlage für klinische Anwendungen und Forschungszwecke, um jegliche Art lebender Zellen in großem Maßstab zu züchten und herzustellen. In Europa seien vier Produkte auf dem Markt, in den USA würden sich drei davon in Phase III befinden.

Am 30. Oktober habe Aastrom die Zahlen für das erste Geschäftsquartal 2003 veröffentlicht. Der Verlust habe 2,5 Millionen US-Dollar bzw. 0,05 US-Dollar je Aktie (vergleichbarer Vorjahreszeitraum: 1,9 Millionen US-Dollar bzw. 0,05 US-Dollar je Aktie) betragen. Dies liege genau im Jahresschnitt von 2002, getan habe sich also trotz der Produktzulassungen in Europa nichts. Im Gesamtjahr 2002 habe der Verlust bei 0,19 US-Dollar je Aktie und damit 2 US-Cent über dem von 2001 gelegen. Zwar seien in den Jahren 1998 bis 2001 die Verluste stark reduziert worden, doch momentan scheine hier eine Stagnation einzusetzen. Die "Einnahmen“ von 877.000 US-Dollar für das Jahr 2002 seien bei diesem Verlust kaum erwähnenswert, denn sie würden vorwiegend aus Forschungsgeldern der Regierung und eben nicht aus Produktverkäufen stammen.

Die Ausgaben in diesem Zeitraum im Bereich Forschung seien von 4,9 Millionen US-Dollar auf 5,48 Millionen US-Dollar gestiegen, was auch nicht gerade für einen Abbau der Verluste spreche. Das Cashpolster von 8,6 Millionen US-Dollar sei nicht sehr beruhigend, denn bei einem Quartalsverlust von rund 2 Millionen US-Dollar könne man sich leicht ausrechnen wie weit dies noch reichen werde, falls der Verlust nicht mehr nach unten geschraubt werden könne. Aastrom bleibe aus dieser Sicht ein sehr spekulatives Investment. In den nächsten ein bis zwei Jahren müssten viel mehr Einnahmen durch Produktverkäufe erzielt werden, sonst werde das Geld und vor allem auch neue Investoren sehr knapp.

Aastrom sei im negativen Sinne berechenbar, im Vergleich zu anderen Unternehmen dieser Spekulationsklasse sogar relativ phantasielos. Aastrom sei eine Firma, die sich fast ausschließlich mit Zellkultur beschäftige und zu diesem Zwecke Zellen sowie fertige Mischungen an Zellmedien und Reagenzien verkaufe. Außerdem werde eine automatisierbare Anlage zur Zellproduktion angeboten mit dem Ziel einen klinischen Standard für die Anlagen zukünftig formen zu können. Dieser "Wunsch“ brauche nicht ernsthaft kommentiert zu werden. Warum dieses System gegenüber Konkurrenzprodukten im Vorteil sein solle, sei nicht ganz einleuchtend. Eine weitere Unbekannte sei das Know-how, die Strategie und Erfahrung im Bereich des Geldverdienens per se: Marketing, Verkauf, Vertrieb. "BioTech-World" sehe hier relative Unsicherheiten und eine gute Positionierung des Unternehmens, auch im Vergleich zu den zahlreichen Konkurrenten, könne in diesem Zusammenhang durchaus bezweifelt werden.

Aastrom habe es nach elf Jahren gerade einmal zu 15 Millionen US-Dollar Marktkapitalisierung geschafft, das schmecke nicht nach Erfolg. Einen drastischen Ausweg auf Besserung sehe "BioTech-World" nicht, denn Aastrom sollte sich nach Meinung von "BioTech-World" schlechter entwickeln als ein vergleichbarer Bio-Index. Zwar würden sogenannte "Milliardenmärkte“ fokussiert, aber die Gewinnmarge für Aastrom schätze "BioTech-World" als zu gering ein. Im Bereich Stammzellen wären z.B. Geron und Stemmcells auf jeden Fall die bessere Alternative, wenn auch nicht kurzfristig. Immerhin, und das wolle "BioTech-World" nicht unterschlagen, habe Aastrom Produkte am Markt, sowie ein paar weitere relativ kurz vor der Zulassung: in Europa und in den Vereinigten Staaten. Es sollte Aastrom deshalb möglich sein, die Umsätze bald etwas steigern zu können. Zusätzlich sei die Bewertung momentan nicht zu hoch. Aus diesem Grund schramme das Unternehmen haarscharf an einer "sell“-Einschätzung vorbei. Bei Aastrom übersteige das Risiko die Chance.

Das Rating der Analysten von "BioTech-World" für Aastrom lautet auf "reduzieren".

[biologist]

Ja,ja! Hochspekulativ, vielleicht! Aber mit dem neuen Sublicensing dürfte sich der Kurs schnell auf neue Höhen zubewegen. Immerhin sind gestern gute 12,5% des gesamten floatenden Aktienvolumens gehandelt worden! Das gab es bei dieser Firma noch nie. Nachbörlich stieg der Kurs dann noch einmal stark an und konnte auf Tageshoch schließen.
Die Vereinbarung mit Corning, die jedes Quartal fast 1 Milliarde USD Umsatz machen, dürften erhebliche Finanzmittel in aastroms Kassen spülen. Durch das Sublicensing gibt Aastrom außerdem nur begrenzt die Rechte aus eigener Hand. Dies könnte ein Indiez für die Dringlichkeit sein, mit der Corning die auswertige Technologie einkauft.

[puhvogel]

Als corning Aktionär kann ich nur dazu sagen, dass Corning selber notleidend ist. so viel Geld haben die nicht zu verschenken.
Sie sind auch keine Experten der Biotech-Branche. Dafür stellen sie geile Spiegelgläser her.

[meislo]

Interview mit Dr. Douglas CEO von AASTROM auf ceocast.com
erschienen, ca. 30 Sekunden lang .
Unbedingt anhören,darin gibt er Auskunft über AASTROMS Zukunft Die Anmeldung ist kostenlos und verpfichtet zu nichts.Leider ist meine Soundkarte defekt und kann es selbst nicht verfolgen aber alles was ich in den Boards darüber gelesen hab ist äusserst positiv Also viel Spass beim hören

[meislo]

J.M.Dutton raises target to 1.00
by: trygirl2002 12/14/02 09:24 am
Msg: 52814 of 52832

12/13/2002

Corning Executes Sublicense With Aastrom - Raising ASTM 12-month Target Price

Aastrom Biosciences has announced the granting of an exclusive sublicense related to the Company`s proprietary cell transfection technology to the Corning Life Sciences division of Corning Incorporated (NYSE: GLW).. Corning Incorporated generated revenue of $6.3 billion in 2001. Corning Life Sciences manufactures and sells high throughput cell culture systems and associated equipment for the drug discovery and research marketplaces. The exclusive sublicense enables Corning to advance their molecular and cell culturing applications by incorporating Aastrom`s proprietary cell transfection technology. Aastrom will receive up-front payments and royalties on sales from Corning, but will retain exclusive rights to the technology in applications involving cells for therapeutic applications.

We believe signing this agreement is an important step in Aastrom`s transition to a commercial therapeutics products company. This announcement will be one of a series expected over the next 12-18 months which demonstrate the goal of management to broaden the Company`s potential revenue base and `monetize` aspects of the Company`s technology that are not directly related to the Company`s focus on cell-based therapeutic products. Further, establishing a relationship with a leading company such as Corning adds credibility to the Company`s leading edge technology and should facilitate the formation of other corporate collaborations in the future.

Aastrom shares have responded most positively to this announcement and the recent announcement of the Fusion Capital share purchase. The stock has risen sharply from our initial report price of $0.23 to achieving our 12-month target price, $0.65, yesterday. While this move has been dramatic on a percentage basis and the shares have outperformed the market, we believe that a good portion of the share appreciation was due to `normalization` of the share price from extremely depressed levels. Considering the Company`s progress during the last several weeks, we are now raising our 12-month target to $1.00. We continue to rate the shares a Speculative Buy.



--------------------------------------------------------------------------------

J.M.Dutton & Associates, LLC. John M. Dutton, President and Supervisory Analyst, 1129 Manning Drive,

[meislo]

Positiver Bericht über Stammzellen


Friday, 20 December, 2002, 09:00 GMT
Stem cells `target disease`


Stem cell research has yet to deliver treatments

Researchers in the United States say they could be ready to start clinical trials of a stem cell therapy on stroke victims or brain tumour patients within a year.
Their latest work suggests that stem cells are naturally attracted to diseased areas of the brain - a trait they want to exploit.

[Stem cells] can be used like heat-seeking missiles



Dr John Yu

The team has shown for the first time that adult bone marrow stem cells can be differentiated into several cell types in the central nervous system.

Their work has been done so far only in rats and they now want to extend it to human patients.

Stem cells are the "master cells" that give rise to the various specific cells of the body. Scientists envision using these "starter" cells to treat a wide range of conditions, replenishing tissues that have been damaged by disease.

Chemical attraction

Tumour cells that spread throughout the brain are very difficult to treat with surgery and conventional techniques like radiotherapy.

But the latest work from Dr John Yu, from the Comprehensive Brain Tumor Program, at the Cedars-Sinai Maxine Dunitz Neurosurgical Institute in Los Angeles, and colleagues offers a potential solution to this difficulty.

The scientists found that stem cells are naturally drawn to damaged areas of the brain - quite why, they do not know.

Dr Yu said: "Areas of disease in the brain may be making some chemicals that attract these stem cells there.

"If you manipulate the stem cells and make them secrete proteins from genes of interest into these areas of disease, they can be used like heat-seeking missiles."

So stem cells could eventually be developed to deliver chemicals to repair brain damage.

Adult stem cell breakthrough

The scientists` work also adds to the body of evidence that shows adult stem cells are more versatile than previously thought.

The researchers found that adult stem cells from bone marrow can differentiate into several cell types of the central nervous system.

Many scientists maintain that the most versatile types of stem cells come from embryos or foetuses.

These can develop into all the different cell types in the body - but they represent a minefield of ethical dilemmas.

Adult stem cells not only avoid these moral issues, it is possible they will be more effective as well.

Scientists hope to replace the damaged areas of the brains in patients with diseases like Alzheimer`s, Parkinson`s and multiple sclerosis.

If they use embryonic of foetal cells to do this, there is a danger that patients` bodies may reject the new cells.

But if the stem cells used come from the patients` own adult tissues then there is no danger of them being rejected and the treatment is much more likely to work.

Dr Yu told the BBC he hopes to start clinical trials with stroke patients using their own stem cells in a year`s time.

Dr Yu and colleagues have published details of their work in the Journal of Experimental Neurology.

[meislo]

Sieht gut aus an der Nasdag

Steigender Kurs bei gutem Volumen 205000 Aktien in der ersten halben Stunde
Auch die 200-Tagelinie die bei 49 cent als Unterstützungslinie fungiert hat gehalten und der Kurs bewegt sich nach oben in Richtung 55 cent.Sieht alles gut aus.

[meislo]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[thebull 2]

so langsam sollte mal wieder interesse für astm aufkommen

[thebull 2]

achtet drauf,was heute passiert

[thebull 2]

ASTM
GET STOCK

Symbol Search
LAST MATCH
Price 0.4500
Time 8:38:30.300

[thebull 2]

Press Release Source: Aastrom Biosciences, Inc.

Aastrom Biosciences Announces Publication of Clinical Results Supporting the Use of its TRC Stem Cells for Bone Disease
Wednesday April 2, 8:30 am ET
-- Important Advancement for Major Bone Generation Markets --

ANN ARBOR, Mich., April 2 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today announced that the results of a study in which the Company`s Tissue Repair Cells (TRCs) were used to safely generate bone in a girl with the genetic bone disease hypophosphatasia, have been published in the April 2003 edition of the Journal of Bone and Mineral Research.

The eight-month-old female patient was born with the infantile form of hypophosphatasia, a genetic skeletal disease, indicating a prognosis of certain death. She underwent an initial trial of bone marrow cell transplantation, donated by a matched donor, which had a transient clinical effect. The child was then given a single infusion of Aastrom`s TRCs, which resulted in significant, prolonged, clinical and radiographic improvement of skeletal bone within a very short time. The authors of the paper describing the study and its results concluded that the most plausible hypothesis was that a transient and then long-term engraftment of the bone-forming cells from the Aastrom TRCs resulted in the amelioration of the child`s skeletal disease.

Aastrom`s TRCs are produced from small samples of bone marrow (which contain adult stem cells), using the AastromReplicell(TM) System, the Company`s pioneering automated platform. TRCs are enriched for early-stage stem and progenitor cells that can form bone and other tissues. A typical TRC product contains more than an 80-fold increase in the bone-forming cell types. To date, TRCs have been safely used in more than 150 patients to generate normal bone marrow, blood and immune system cells. The results of this new report expand the use of TRCs to include the ability to generate bone in humans.

The lead author of the report was Dr. Michael P. Whyte, M.D. from Shriners Hospitals for Children, located in St. Louis, Missouri. The patient was treated with the TRCs by Joanne Kurtzberg, M.D. at Duke University Medical Center, under a compassionate-use request. Other participating researchers were with Barnes-Jewish Hospital at Washington University School of Medicine, St. Louis Children`s Hospital at Washington University School of Medicine, Fort Wayne State Developmental Center, and the Medical College of Wisconsin.

"This exciting clinical data validates our expectation that the potential clinical use of TRCs may be expanded to include bone-regeneration markets such as bone grafting and osteoporosis," said R. Douglas Armstrong, Ph.D., President, Chief Executive Officer and Chairman of Aastrom. "We will continue to broaden the use and evaluation of our stem cell technology through other clinical collaborations."

This study was funded in part by grants from Shriners Hospitals for Children, the Clark and Mildred Cox Inherited Metabolic Bone Disease Research Fund, and the Hypophosphatasia Research Fund. It is published in the April 2003 edition of the Journal of Bone and Mineral Research, Vol.18, page 624.

About Aastrom Biosciences, Inc.

Aastrom Biosciences, Inc. (NasdaqSC: ASTM) is a late-stage development company focused on human cell-based therapies. The AastromReplicell(TM) System -- a patented, integrated system of instrumentation and single-use consumable kits for the production of patient-specific cells -- is the Company`s core technology for its Prescription Cell Products (PCP) business and the Cell Production Products (CPP) business. These two businesses will enable Aastrom to generate multiple paths to revenue. The principal focus of the PCP business is the repair or regeneration of tissue intended for large markets such as bone grafting and severe osteoporosis. The CPP business markets the AastromReplicell(TM) System to researchers and companies for their production of cells for clinical trials. The initial commercial phase of the CPP business is underway in Europe and the U.S. for the dendritic cell production products. For more information, visit Aastrom`s website at www.aastrom.com.

This document contains forward-looking statements, including without limitation, statements concerning product development objectives, potential product applications, and potential advantages of the AastromReplicell(TM) System, which involve certain risks and uncertainties. The forward-looking statements are also identified through use of the words "potential," "intended," "expectation," "may," "can," and other words of similar meaning. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are future clinical trial results, the results of product marketing activities conducted by third parties, actions taken by marketing partners and competitors, the availability of resources and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom`s Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.

CONTACTS:
Kris M. Maly or
Becky Anderson
Investor Relations Department
Aastrom Biosciences, Inc.
Phone: [phone]


Source: Aastrom Biosciences, Inc.

[Jonny2]

Hi,
was soll denn heute passieren ???

[Jonny2]

SUPERKURSCHANCE NOCH HEUTE UND MORGEN BEI AASTROM !!!

Waaaahhhhhhnsinn !!!

[thebull 2]

würd mich nicht wundern wenn wir diese woche noch die 0,50 sehn

[meislo]

Mit Sicherheit werden die 0,50 cent diese Woche fallen da durch Geron neues Innteresse an Stammzellen geweckt wurde

gruss meislo

[meislo]

In USA 0,48 Dollar +60%

[thebull 2]

in amiland 0,52 schon bezahlt

[thebull 2]

0,55$

[meislo]

0,57 +90%!!!!

[thebull 2]

taxe in dt
0,50 zu 0,54
tradingziel damit eigendlich erreicht
bleib aber mit kk 0,28 dabei

[Jonny2]

Wieder suuper NEWS !!

ICH HALTS NICHT AUS !!!!

[thebull 2]

Press Release Source: Aastrom Biosciences, Inc.

Aastrom Biosciences Signs Collaboration Agreement for German Bone Graft Clinical Trial
Wednesday April 16, 8:30 am ET
-- Mathys Medical and Bergmannsheil University Join Aastrom in Implementing New Bone Grafting Approach --

ANN ARBOR, Mich., April 16 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today announced that, through its wholly owned subsidiary, Zellera AG, it has signed an agreement with Mathys Medical, Ltd. (Mathys), located in Bettlach, Switzerland, and Bergmannsheil University Clinic (University), located in Bochum, Germany, to begin the first collaborative clinical trial using the Company`s Tissue Repair Cells (TRCs) for bone graft applications. If successful, the study may lead to an alternative to the current, highly invasive standard of treatment in the multi-billion dollar bone graft market.

ADVERTISEMENT
The bone graft clinical study will use Aastrom`s proprietary bone-forming TRCs in combination with Mathys` commercial synthetic bone graft matrix to treat patients with serious leg (tibia) fractures that require a bone graft for recovery. Mathys is a leading supplier of synthetic bone graft matrix for the orthopedic market. The trial, which expects to accrue five to ten patients, will be conducted at the University, a leading orthopedic treatment center in Germany. The lead investigator for the trial is Thomas A. Schildhauer, M.D., Senior Physician of the Traumatology-Surgery Department.

Aastrom`s TRCs are produced from small samples of bone marrow (which contain adult stem cells), using the AastromReplicell(TM) System, the Company`s pioneering automated platform. TRCs are enriched for early-stage stem and progenitor cells that can form bone and other tissues. A typical TRC product contains more than an 80-fold increase in the bone-forming cell types. To date, TRCs have been safely used in more than 150 patients to generate normal bone marrow, blood and immune system cells. The Company recently announced that in the April 2003 issue of The Journal of Bone and Mineral Research, results of a compassionate-use study were published that demonstrated the ability of TRCs to form skeletal bone in a patient with a genetic skeletal disease.

"This collaboration follows a very successful two years of progress in our research program and is an excellent example of the expanding product and collaboration opportunities that Aastrom is pursuing for our proprietary technology," said R. Douglas Armstrong, Ph.D., President, Chief Executive Officer and Chairman of Aastrom. "Success in this clinical approach may provide the more than one million patients in the U.S. and Europe who require bone grafting procedures with an efficacious but less invasive, and therefore less morbid, alternative to the current standard procedure. If this approach is successful, it should result in an important product opportunity for the clinical use of TRCs in a major, multi-billion dollar market."

Typical bone grafting procedures include various types of spinal fusions and repair of major fractures such as non-union fractures of legs and arms. The long-time standard procedure involves surgically chiseling out bone chips and marrow from the patient`s hip to obtain the necessary quantities of bone graft material. This process generally results in substantial acute and chronic pain and complications at the hip collection site. In an attempt to eliminate this clinical problem, various bone matrix substitutes have been developed and are sometimes used as an alternative to the standard procedure. They are not as effective, however, because they lack the cellular components needed to generate bone. In this clinical study, Aastrom`s bone-forming TRCs will be combined with Mathys` synthetic bone matrix product, and used by Dr. Schildhauer to augment the repair of serious non-union leg fractures.

In addition to this German bone grafting trial, Aastrom is planning other bone graft trials. The Company has submitted its lead bone graft trial plan to the U.S. Food and Drug Administration (FDA), and is currently in discussion with the FDA to move forward with this clinical track.

Aastrom has demonstrated success with its TRCs in clinical trials for bone marrow transplantation and, on a compassionate-use basis, in a young patient requiring bone generation. This progress has stimulated the Company to move toward larger market opportunities, such as bone grafting. With Aastrom`s focus shifting to products for these multi-billion dollar markets, efforts previously directed to the now-declining bone marrow transplantation market are being decreased. Consequently, Aastrom`s U.S. SC-I clinical trials are being closed out and there are no current plans to continue this product development activity.

About Mathys Medical, Ltd.

Mathys Medical, Ltd. is a private company focused on the development of state-of-the-art medical products for the treatment of the skeleton. Mathys offers products and services worldwide in the trauma, joint replacement and biomaterials business sectors. For more information, visit Mathys` website at www.mathysmedical.com.

About Zellera AG

Zellera AG is a wholly owned subsidiary of Aastrom Biosciences, Inc., located in Berlin, Germany. Zellera serves as the sales and marketing operational base for Aastrom`s products throughout Europe. For more information, visit Zellera`s website at www.zellera.de.

About Aastrom Biosciences, Inc.

Aastrom Biosciences, Inc. (NasdaqSC: ASTM) is a late-stage development company focused on human cell-based therapies. The AastromReplicell(TM) System -- a patented, integrated system of instrumentation and single-use consumable kits for the production of patient-specific cells -- is the Company`s core technology for its Prescription Cell Products (PCP) business and the Cell Production Products (CPP) business. These two businesses will enable Aastrom to generate multiple paths to revenue. The principal focus of the PCP business is the repair or regeneration of tissue intended for large markets such as bone grafting and severe osteoporosis. The CPP business markets the AastromReplicell(TM) System to researchers and companies for their production of cells for clinical trials. The initial commercial phase of the CPP business is underway in Europe and the U.S. for the dendritic cell production products. For more information, visit Aastrom`s website at www.aastrom.com.

This document contains forward-looking statements, including without limitation, statements concerning planned clinical trials, product development objectives, potential product applications, and potential advantages of the AastromReplicell(TM) System, which involve certain risks and uncertainties. The forward-looking statements are also identified through use of the words "expect," "intended," "planning," "may," "plan," "should," "can," and other words of similar meaning. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are clinical trial results, potential product development difficulties, the availability of financial and other resources and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom`s Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.

CONTACTS:
Kris M. Maly or Holger Beckmann
Becky Anderson Managing Director
Investor Relations Department Zellera AG
Aastrom Biosciences, Inc. Berlin, Germany
Phone: [phone] Phone: [phone]


Source: Aastrom Biosciences, Inc.

[steigenderengel]

Wie weit werden sie steigen ?????

[steigenderengel]

Jetzt geht es nach oben und immer noch keiner Investiert.

[diegutefee]

Ich bin auch investiert und auch bei Stemcells!

Weiterhin viel Glück!

diegutefee

[meislo]

Independent Analyst Rating of ASTM
by: brooklynct2003 05/03/03 06:07 pm
Msg: 66944 of 66970

J.M. Dutton & Associates Announces Investment Opinion: Aastrom Biosciences Rating Raised to Strong Speculative Buy

Business Editors
NOTE TO EDITORS: The following is an investment opinion issued by
J.M. Dutton & Associates

EL DORADO HILLS, Calif.--(BUSINESS WIRE)--April 10, 2003--J.M. Dutton & Associates continues coverage of Aastrom Biosciences (Nasdaq:ASTM) with its update report raising its rating to Strong Speculative Buy. The 6-page report by J.M. Dutton senior analyst Sherry Grisewood, CFA, is available at www.jmdutton.com, as well as from Bloomberg, First Call, Zacks, First Call, Multex, and other leading financial portals.
Aastrom is experiencing increasing commercial sales of its cell production products. Installations of the Company`s AastromReplicell(TM) System for cell replication; the DC-I dendritic cell product for fusion and transfection cell-based therapeutics; the DCV-I antigen-loaded dendritic cell complex; and DCV-II, peptide- loaded dendritic cells at academic research and commercial cancer vaccine development organizations in Europe increased by 20% in the December quarter with its 15 installations of the AastromReplicell(TM) System in Europe and the U.S. On April 1, Aastrom announced the results of a study in which the Company`s Tissue Repair Cells (TRCs) were used to safely generate bone in a girl with the genetic bone disease hypophosphatasia. Our rationale for the rating upgrade is underpinned by the Company`s progress, the recent infusion of capital and, in our view, the misguided selling pressure in the Company`s shares as a result of investor confusion and concern over the Company`s listing status.

About Dutton & Associates

Dutton & Associates is one of the largest independent investment research firms in the U.S. Its 19 senior analysts, primarily CFAs, have expertise in many industries, including healthcare, technology, finance, banking, mining, gaming, and energy. Dutton & Associates provides economically bias-free, continuing analyst coverage of enrolled companies, and its research, estimates, and recommendations are carried in all the major databases serving institutions and online investors.
The cost of enrollment in the Dutton & Associates one-year continuing research program is presently US$25,000, prepaid before commencement of its research activities. Dutton & Associates received $22,000 from the Company for coverage for the year. Dutton & Associates does not accept payment of any of its fees in company stock. Its principals and analysts are prohibited from owning or trading in securities of covered companies. Please review full disclosures, analyst background, and company rating history at www.jmdutton.com before investing

[meislo]

http://www.jmdutton.com/Research/ASTM/Notes/ASTM_Note_041703…

[meislo]

Ohne News aber trotzdem bis jetzt +14%

Aktie hat nach den Hypes von Curis, Dendreon, Stemcells und Geron noch einiges aufzuholen!! Stammzellen-aktien werden zur Zeit gesucht in Amerika, nicht zuletzt auch wegen der vorangegangenen Verluste! Stammzellen könnten sich aber auch zur neuen Säule des Biotechbereichs in diesem Jahrzehnt entwickeln!! In meinen Augen haben diese Aktien enormes Potenzial.

gruss meislo

[DOXA DRAMA]

up!

[diegutefee]

Stammzellen-Aktien - die nächsten Outperformer!

Wer heute in Stammzellen-Aktien investiert, hat in
einigen Jahren ausgesorgt!

Die Chancen sind wesentlich größer als 6 Richtige im Lotto!

diegutefee

[Bocknase]

Hoffen wir, daß es weiterhin aufwärts geht. ASTM ist ja in
der Vergangenheit sehr geprügelt worden, ich denke, zu
unrecht.
Da gibt es im Kurs viel aufzuholen.



Ob wir wohl jemals wieder die 4$ sehen ???

Gruß BOCKNASE

[meislo]

Ich weiss zwar nicht wo der Chart her ist aber das soll keinen interessieren!! ER führt in die IRRE!!AASTROM Stand nie im letzten jahr bei 4 Dollar!!!!!!!!!
Ich weiss nicht was das sollll????????

Hier der richtige Chart

http://stockcharts.com/gallery?ASTM


gruss meislo

[meislo]

Ich korrigiere mich der Chart stimmt doch er geht ja bis ins Jahr 2000 zurück

Tut mir Leid

gruss meislo

[meislo]

AASTROM Brennt gerade ein Feuerwerk ab 1,17 Dollar!!!!!!!!!!!

[meislo]

Damit dürfte ein möglicher reverse splitt der Vergangenheit angehören um ein delisting an der Nasdaq zu entgehen

gruss meislo

[meislo]

Nachbörslich geht die Party munter weiter bis jetzt 1,35 Dollar +12 %

gruss meislo

[meislo]

1,43 ein tagesplus von 57% und es ist kein Ende abzusehen

gruss meislo

[meislo]

Oh man und ich hab mich im Januar von 20000 Aktien zu 0,45 cent getrennt und das obwohl ich über 2 Jahre investiert war !!Ich könnte mir den Arsch aufreissen Habe jetzt nur noch einen kleinen Rest von 2000 Stück


Penny-stock Aastrom Bioscience (ASTM:Nasdaq - news - commentary - research - analysis) shot up in Tuesday`s premarket session as traders decided a partnership involving bone-grafts was potentially big news.

The Ann Arbor, Mich., biotech will collaborate with the Musculoskeletal Transplant Foundation to develop treatments for regeneration of tissue like bone and cartilage. It described the foundation as the "leading provider of allograft, or donor-derived tissue, matrices."

Aastrom`s shares rose 49 cents, or 41%, to $1.69 on the Instinet premarket session



meislo

[meislo]

Aastrom Biosciences, Musculoskeletal Transplant Foundation Partner to Develop Novel Treatments for Tissue Regeneration
Tuesday June 10, 7:01 am ET
-- Alliance Brings Together Industry Leaders in Stem Cells and Orthopedic Medicine --


ANN ARBOR, Mich., and EDISON, N.J., June 10 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) and Musculoskeletal Transplant Foundation (MTF) today announced a strategic alliance to jointly develop and commercialize innovative treatments for the regeneration of tissues such as bone and cartilage. The companies will initially focus on combining their respective technologies to establish a novel treatment approach for bone graft applications. This market is estimated at over 1.4 million procedures annually, including spinal fusions, non-union fractures, dental defects and facial bone repair, and is expected to exhibit progressive growth in the future.
The partnership aligns an industry leader in stem cell therapies (Aastrom) with the leading provider of allograft, or donor-derived tissue, matrices (MTF) to form a coordinated business and clinical approach for new products and treatments needed in orthopedic medicine. Under the terms of the alliance, the companies will provide each other with rights to their respective technologies for treatments and products that are based on combinations of MTF`s matrices and Aastrom`s Tissue Repair Cells (TRCs). The companies will share in the development and clinical trial expense of these treatment approaches and products, and will adopt a coordinated promotion and marketing strategy for future products. In addition to allograft-based bone graft treatments, the companies will explore new approaches for the regeneration of joint cartilage, as well as effective combinations of TRCs with MTF`s new ceramic matrix technology.

"This strategic alliance gives Aastrom the partner we have been seeking in the orthopedic field, and will allow us to combine our capabilities and resources to jointly develop and then market an effective alternative to the current standard bone graft procedures," said R. Douglas Armstrong, Ph.D., President and Chief Executive Officer of Aastrom. "MTF is the world`s largest and most respected allograft matrix provider, and its decision to partner with Aastrom validates our strategic position and focus on the commercial development of our bone and cartilage regeneration programs. This alliance, supported by MTF`s technology, expertise and funding, should enable us to bring our technology through the regulatory and logistics pipeline and into the marketplace in the near term."

"We are very excited to be working with Aastrom in the area of stem cell technology. We believe that the combination of bone progenitor cells with the native architecture and compatibility provided by allograft tissues will produce a superior graft equal to the `gold standard` of the patient`s own tissues," said Bruce W. Stroever, President and Chief Executive Officer of MTF. "We believe this alliance brings together the business and technology components needed to pioneer the next era in orthopedic medicine, and maximize the beneficial use of the precious resource of donated tissue."

Aastrom has developed a powerful technology capable of producing a stem cell-based cell mixture from a small sample of the patient`s own cells. These cells -- called Tissue Repair Cells -- have been shown in clinical trials to generate normal human tissues safely and reliably in patients. The Company has demonstrated in laboratory research that its TRCs contain more than a 70- fold increase in the number of bone-forming cell types, compared with the patient`s own bone marrow.

Traditional bone grafting procedures, which use autograft, require the collection of bone and marrow by removing bone chips from a patient`s own hip, an invasive surgical process resulting in acute and chronic pain, as well as long-term complications. In an attempt to eliminate this undesirable procedure, MTF has developed various forms of bone matrices from donated tissues. The companies believe that combining these matrices with Aastrom`s TRCs will bring together all the components needed to regenerate bone similarly to autograft, and will eliminate the undesirable and painful surgical procedure currently needed to provide the autograft.

About Aastrom Biosciences, Inc.

Aastrom Biosciences, Inc. (NasdaqSC: ASTM) is a late-stage development company focused on human cell-based therapies. The AastromReplicell(TM) System - a patented, integrated system of instrumentation and single-use consumable kits for the production of patient-specific cells - is the Company`s core technology for its Prescription Cell Products (PCP) business and its Cell Production Products (CPP) business. The principal focus of the PCP business is the repair or regeneration of tissue intended for large markets such as bone grafting and severe osteoporosis. The CPP business markets the AastromReplicell(TM) System to researchers and companies for their production of cells for clinical trials. These two businesses are intended to enable Aastrom to generate multiple paths to revenue. The initial commercial phase of the CPP business for dendritic cell production products is underway in Europe and the United States. For more information, visit Aastrom`s website at www.aastrom.com.

About Musculoskeletal Transplant Foundation

The Musculoskeletal Transplant Foundation is the country`s largest tissue organization dedicated to providing quality tissue through a commitment to excellence in education, research, recovery and care for recipients, donors and their families. A not-for-profit 501(c)3 organization, MTF is a consortium of academic medical institutions and organ procurement and tissue recovery organizations across the country. In 2002, over 275,000 tissue grafts were distributed by MTF, helping over 200,000 patients. For more information, visit MTF`s website at www.mtf.org.

This document contains forward-looking statements, including without limitation, statements concerning product development objectives and anticipated results, potential product applications, anticipated market growth and potential advantages of the AastromReplicell(TM) System, which involve certain risks and uncertainties. The forward-looking statements are also identified through use of the words "expected," "intended," "should," "believe," and other words of similar meaning. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are clinical trial results, potential product development difficulties, regulatory approval uncertainties, the availability of financial and other resources and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom`s Annual Report on Form 10-K and other filings with the Securities and Exchange Commission

[Sugar2000]

@Meislo:
ging mir genau so.. habe mich beim kurs von 0,33 getrennt...
Naja, was solls...

[Boersi]

Hallo Leute,

habe Aastrom schon seit mehr als einem halben Jahr auf meiner Watchlist. Ich musste heute einfach zugreifen. Die News in letzter Zeit sind doch recht interessant und der Chart spricht Bände. Bin heute zu 1,21 € rein.

[Boersi]

Umsatzvolumen in den USA lag heute bei sage und schreibe 24,6 Mio Stück! Das ist echt der Hammer.

[Boersi]

Shit war wohl ein bisserl voreilig mit meinem Kauf. Bleibe voerst drin und setze nen Stop. Chart sieht nachwievor super aus: Kurzfristiger steiler Aufwärtstrend nach wie vor voll in Takt:



Mal sehen ob die klitze kleine Unterstützung bei 1,20 $ hält unter 1 $ sollte es nicht mehr gehen...

[Boersi]

Habe heute noch einmal nachgelegt!

[meislo]

Aastrom Biosciences Announces Publication of Cord Blood Clinical Study Results in Blood Medical Journal
Thursday June 12, 8:01 am ET


ANN ARBOR, Mich., June 12 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that the results of its collaborative study with Duke University Medical Center (Duke) will be published in the June 15, 2003 issue of Blood, the journal of the American Society of Hematology, Volume 101, Issue 12.
The study covered the Phase I clinical trial that investigated the safety and feasibility of Aastrom`s ex vivo-expanded CB-I cell product in the augmentation of umbilical cord blood (UCB) transplants. Banked, unrelated UCB is being investigated as an alternative for patients who lack traditional matched bone marrow donors. The CB-I cells were produced from a small starting sample of banked UCB cells utilizing the unique, patented technology of the AastromReplicell(TM) System. Joanne Kurtzberg, MD, Professor of Pediatrics and Pathology, and Director of the Pediatric Bone Marrow and Stem Cell Transplant Program at Duke, was the lead investigator in the trial, which involved 28 leukemia and genetic disease patients and was conducted between October 1997 and September 1998. Results were based on a median follow-up of 47 months.

The authors of the report, titled "Augmentation of Umbilical Cord Blood (UCB) Transplantation with Ex-Vivo Expanded UCB Cells: Results of a Phase I Trial Using the AastromReplicell System," stated, "Clinical scale ex-vivo expansion of UCB is feasible, and the administration of ex-vivo expanded cells is well tolerated."

While Aastrom has halted its CB-I trials due a current diminished market opportunity, the Company believes these results, along with the recent announcements of an NIH grant award and the strategic alliance with the Musculoskeletal Transplant Foundation for bone grafting treatments, underscore the value of its proprietary technology in the clinical-scale production of cells for broad use in medical/therapeutic applications.

About Aastrom Biosciences, Inc.

Aastrom Biosciences, Inc. (NasdaqSC: ASTM) is a late-stage development company focused on human cell-based therapies. The AastromReplicell(TM) System - a patented, integrated system of instrumentation and single-use consumable kits for the production of patient-specific cells - is the Company`s core technology for its Prescription Cell Products (PCP) business and its Cell Production Products (CPP) business. The principal focus of the PCP business is the repair or regeneration of tissue intended for large markets such as bone grafting and severe osteoporosis. The CPP business markets the AastromReplicell(TM) System to researchers and companies for their production of cells for clinical trials. These two businesses are intended to enable Aastrom to generate multiple paths to revenue. The initial commercial phase of the CPP business for dendritic cell production products is underway in Europe and the United States. For more information, visit Aastrom`s website at www.aastrom.com.

This document contains forward-looking statements, including without limitation, statements concerning product development objectives, potential product applications, and potential advantages of the AastromReplicell(TM) System, which involve certain risks and uncertainties. The forward-looking statements are also identified through use of the words "intends," "believes" and other words of similar meaning. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are uncertainties inherent in clinical development programs, changes in anticipated demand for products being developed, the availability of resources and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom`s Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.

[Boersi]

Hab wohl grad noch welche günstig erwischt. Kurs in Frankfurt zieht schon wieder mächtig an: derzeit 1,27€ +20%

[meislo]

Korrektur setzt ein bei Biotechs

Aastrom schon nur noch bei 1,33 Dollar

[Boersi]

Lass sie doch ein bisschen korrigieren, sonst krieg ich noch nen Herzinfarkt

Meine Curis hatten heute auch schon + 50 %

[meislo]

Sind schon wieder bei 1,47

[meislo]

Biotechs haben noch Luft nach oben
Der Biotechsektor wird weiterhin gut performen



Schon fast glaubte man in den letzten Tagen, die Biotech-Rallye müsse nun einmal ein Ende haben. Doch weit gefehlt nach einigen Tagen Abkühlung, ausgelöst durch eher moderate Gewinnmitnahmen, folgte bereits die nächste Flut positiver Nachrichten und ließ den Sektor erneut in ungeahnte Höhen schweben.

Auch wenn der Biotechsektor überhitzt erscheint, so spricht doch der noch anstehende Newsflow für eine weiterhin gute Performance der Branche. Allerdings lohnt es sich nicht bei allen Unternehmen einzusteigen, entscheidend ist es sich auf solche Kandidaten zu konzentrieren die entweder fundamentale Stärke besitzen oder aber mit positivem Newsflow locken. Fundamental stark sind, trotz des bereits gigantischen Kurssprungs, Genentech, Genzyme und vor allem Gilead. Bei Gilead werden die besten Umsätze wohl erst im Jahr 2005 erwartet, das Unternehmen besitzt also zudem noch Wachstumspotenzial.



Bei den kleineren mit positivem Newsflow sind vor allem Dendreon, das in diesem Jahr noch eine Vermarktungspartnerschaft für seine Prostatakrebsvakzine Provenge bekannt geben will, und Cubist, das demnächst einen Zulassungsbescheid der FDA für sein innovatives Antibiotikum Cidecin erwartet, interessant. Doch auch im Stammzellensektor tut sich einiges, positive News könnten diesbezüglich noch von Geron, aber auch StemCells und Aastrom kommen. Ein entscheidender Faktor ist auch, dass der Kapitalfluss in die Healthcare- und Biotechfonds wieder stark zugenommen hat.



Ein anderer Faktor der für eine weiterhin gute Performance ist das sogenannte „Window Dressing“, das stets zum Ende des Quartals einsetzt und dieses Mal die Biotechbranche profitieren lassen dürfte. Weitere Kandidaten, die in diesem Jahr mit einer guten Performance glänzen könnten sind ICOS, das noch in diesem Jahr den Zulassungsentscheid für seinen potenziellen Blockbuster Cialis gegen erektile Dysfunktion erwartet, und Medimmune, das noch noch auf die Zulassung von FluMist wartet. Auch Human Genome Sciences, das noch in diesem Jahr einige Zulassungsanträge an die FDA überstellen will, und Millennium, dass das erst kürzlich zugelassene Velcade auch noch bei anderen Tumoren testet, sind interessante Kandidaten für dieses Jahr.



Am gestrigen Tag gehörten zwei meiner Favoriten, nämlich Dendreon und ICOS zu den Spitzenreiter. Während Dendreon bereits im vorbörslichen Handel deutlich zulegen konnte, kam der große Kurssprung für ICOS erst am späten Nachmittag. Zum Börsenschluss notierte Dendreon mit 20% im Plus, ICOS zog um 10,9% an. Gute Nachrichten bezüglich des Fortschreitens der Entwicklung mit der Krebsvakzine Provenge, die FDA hatte schriftlich bestätigt bestimmte Phase III Daten als die Grundlage für einen Zulassungsantrag zu akzeptieren, sorgte für den Kurssprung bei Dendreon. Bei ICOS war es eine Aufstufung von Lehman Brothers sowie eine Präsentation von Eli Lilly, bei der das Pharmaunternehmen die Zulassung des Gemeinschaftsproduktes Cialis noch für dieses Jahr prognostizierte, welche den Aktienkurs kurz vor Börsenschluss nochmals nach oben schnellen ließen.



Simone Hörrlein
Staatl. gepr. LebChem (TUM)
Live Scient

[Boersi]

Ist zwar schon ein bisschen verstaubt, aber...


http://www.aastrom.com/pdf/ASTMFactSheet.pdf

[meislo]

Welcome [Sign In] To track stocks & more, Register
Financial News
Enter symbol(s) BasicDayWatchPerformanceReal-time MktDetailedChartResearchOptionsOrder Book Symbol Lookup







Press Release Source: Aastrom Biosciences, Inc.


Aastrom Biosciences Receives NIH Grant to Optimize its Stem Cell Products for the Generation of Normal Human Tissue
Wednesday June 18, 8:01 am ET


ANN ARBOR, Mich., June 18 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that the Company has received a grant from the National Institute of Diabetes and Digestive and Kidney Diseases, providing research funding of up to $443,000 over a two-year period. This Small Business Innovation Research Phase I grant from the National Institutes of Health (NIH) will support studies to further optimize the production of Aastrom`s Tissue Repair Cells (TRCs) for the clinical generation of normal human tissue.
ADVERTISEMENT


"This grant validates our strategic industry position and our capability to develop cell products that are able to generate normal human tissues in patients," said R. Douglas Armstrong, Ph.D., President, Chief Executive Officer and Chairman of Aastrom. "In addition to other cell types, Aastrom`s TRCs contain high numbers of mesenchymal cells that we believe are capable of maturing to form tissues such as bone, cartilage and vascular tissue. TRCs are the basis for our focus on the bone and vascular segments of the cell therapy marketplace. Through our unique, patented technology, we can enable an effective approach that provides for the use of TRCs in the clinic. This NIH grant supports the expansion of Aastrom`s development program that should enhance our TRC process to address growing medical needs."

Stem cells and other types of cells found in bone marrow are capable of generating many types of human tissues and are therefore useful in a variety of potential medical treatments. Aastrom has patented technology for the production of these different types of cells. This grant will fund studies to further develop and refine Aastrom`s cell production devices, as well as the process used to produce these important cells.

Aastrom`s technology provides a novel approach for the production of clinical quantities of mesenchymal cells including a fixed short-term (12-day) production cycle utilizing the AastromReplicell(TM) System (ARS), the only automated, Good Manufacturing Practices (GMP) compliant cell production system. In addition, Aastrom`s approach allows the inclusion of other non- mesenchymal cell types that may aid normal tissue repair, as well as the inclusion of mesenchymal cells at multiple stages of maturation or development, as opposed to the use of a single stage of cell, that may be less effective.

TRCs are Aastrom`s proprietary mixture of stem and progenitor cells, including mesenchymal cells, which can form bone, cartilage and other tissues, produced from a small amount of bone marrow using the ARS. A typical TRC product contains more than a 70-fold increase in bone-forming cell types. TRCs have been safely used in over 150 patients to generate normal bone marrow, as well as bone, blood and immune system cells. While there are many research approaches to growing mesenchymal cells, Aastrom believes that its technology is unique for a growing number of clinical applications.

[Boersi]

....soll soviel heissen, wie

AASTROM erhält eine Spende (Stipendium) von ca. 450000 $ zur Weiterentwicklung ihrer Stammzellenprodukte vom National Institutes of Health (NIH)!

Offensichtlich ist die Öffentlichkeit an Aastroms Produkten stark interessiert.

[meislo]

Das ist kein besonderer Vorgang und in den letzten Jahren immer wieder mal vorgekommen Auch die Summe ist im Vergleich zu früheren grants eher niedrig

gruss meislo

[Boersi]

Die Pipline von ist prall gefüllt. AAstrom besitzt eine Menge Phase III - Produkte, d. h. diese sind kurz vor der Vermarktung:

http://www.zellera.de/overview.html

Zellera ist, soweit ich das weiss, ein 100 % Tochter von Aastrom und kümmert sich um die Vermarktung der Aastrom-Produkte in Europa. Sitz ist in Berlin.

Eigenartigerweise ist die Seite von Zelera wesentlich informativer, als die von Aastrom selbst.

[ab@h]

Hi

Aastrom hat 10 Börsentage hintereinander über 1$ geschlossen. Die Gefahr des Delistings in den USA ist somit (vorerst) gebannt. Siehe auch hier: http://ragingbull.lycos.com/mboard/boards.cgi?board=ASTM&rea…

ab
*mit einer kleinen Position seit 0,49 EUR dabei

[meislo]

Aastrom Biosciences Receives European Patent Covering Culture Chamber For Producing Human Cells
Monday June 23, 8:01 am ET
-- Patent Provides European Coverage of Technologies Crucial to Ex Vivo Cell Therapies --


ANN ARBOR, Mich., June 23 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that it has received from the European Patent Office patent 0871701, entitled "Bioreactor for Mammalian Cell Growth and Maintenance", covering the key culture device components of the AastromReplicell(TM) System (ARS). This patent provides coverage for the key features of the ARS, including the entire closed-loop system for the production of cells for human use and the ability to implement Aastrom`s single-pass perfusion technology. These features enable Aastrom to produce novel cell-based mixtures for clinical use.
ADVERTISEMENT


These proprietary technologies are integrated into a growing line of devices, Aastrom`s Cell Production Products (CPP), that currently include the ARS instrumentation platform and single-use consumable kits for the automated production of dendritic cells intended for a variety of cancer vaccine approaches. Aastrom`s GMP-compliant CPP products combine to provide nutrients to cells by mimicking the natural cell-growth environment, enabling the ex vivo production of clinical-scale quantities of human cells while retaining high biological function.

In addition to the CPP line, Aastrom has an expanding pipeline of Tissue Repair Cells that make up the lead products of the Company`s Prescription Cell Products business. The ARS and patient-specific, single-use kits utilize Aastrom`s proprietary technologies to enable the clinical-scale production of a broad array of Tissue Repair Cells intended for the bone and vascular regeneration markets, including bone grafting. In response to the emerging development of cell therapeutics in Europe, Aastrom has been marketing its CPP products through its wholly-owned subsidiary, Zellera, AG, and is currently generating revenues from European sales.

"Europe constitutes a significant market for our technology and products which we have successfully begun to penetrate," said R. Douglas Armstrong, Ph.D., President, Chief Executive Officer and Chairman of Aastrom.

The new European patent extends the Company`s intellectual property, which is protected under several U.S. patents as well. Aastrom believes that by aggressively covering its technology and products by patents both in the United States and Europe, it will maintain its proprietary status in the rapidly-growing cell therapeutics industry.

About Zellera AG

Zellera AG is a wholly-owned subsidiary of Aastrom Biosciences, Inc., located in Berlin, Germany. Zellera serves as the sales and marketing operational base for Aastrom`s products throughout Europe. For more information, visit Zellera`s web site at www.zellera.de.

About Aastrom Biosciences, Inc.

[Boersi]

Jetzt ist´s amtlich:

Dow Jones Business News
Aastrom Bio Retains Listing On Nasdaq SmallCap
Friday June 27, 12:19 pm ET


ANN ARBOR, Mich. (Dow Jones)--Aastrom Biosciences Inc. was notified by Nasdaq that the company is in compliance with all Nasdaq SmallCap listing requirements, including the $1 minimum bid closing price requirement.
As a result of the notice, the hearing requested by Aastrom due to prior noncompliance has been canceled, and the company will continue to trade on the Nasdaq SmallCap Market.

Shares of the biomedical development company closed below $1 between Jan. 2002 and June 6 of this year. But shares closed at $1.20, up more than 25%, on June 9, the day before the company announced a new partnership with the Musculoskeletal Transplant Foundation to develop tissue regeneration treatments.

[diegutefee]

Aastrom - strong buy!

Kein Stück aus den Händen geben!
1000 % und mehr in den nächsten Monaten/Jahren!
Kaufen und liegen lassen.

diegutefee

[meislo]

Aastrom Biosciences Receives Third NIH Grant During Fiscal Quarter for Stem Cell Research
Wednesday July 2, 8:02 am ET
-- Study to Expand Approaches for Aastrom`s Stem Cell-Based Products for Tissue Repair --


ANN ARBOR, Mich., July 2 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today announced that it has received a Small Business Innovation Research Phase I grant from the National Institutes of Health (NIH) entitled "Clinical-Scale Production of Osteoprogenitor Cells". The grant will support investigations to expand the Company`s development of effective stem cell-based approaches for the regeneration of bone in patients requiring a bone graft treatment. Bone grafting is required annually in over one million people in the United States and Europe, for orthopedic procedures such as fusion of spine vertebrae, repair of major leg fractures, and other bone repair applications.
ADVERTISEMENT


The six-month study, funded at $110,062 by the NIH`s National Institute of Arthritis and Musculoskeletal and Skin Diseases, seeks to further optimize Aastrom`s proprietary technology for producing its line of Tissue Repair Cells (TRCs), which are mixtures of stem and other cells produced from a small starting sample of the patient`s own bone marrow. The Company has previously demonstrated that its TRCs contain a large number of bone-forming stem cells, at levels equivalent to that found in approximately a liter or more of bone marrow. The new studies will explore ways to further increase the types of cells that may provide a more potent treatment, and ways to simplify the production process towards a more cost-effective endpoint.

Aastrom is seeking to replace the current standard approach for bone grafting that involves an invasive collection of bone and tissue from the patient`s hip, which is then used for the graft application (called "autograft"). The associated acute and chronic pain, as well as limited amounts of source material from this autologous graft collection procedure, has created a need for an alternative approach for bone repair. The Company believes that the large number of bone-forming cells in its TRC product, when combined with a carrier matrix may provide an effective alternative to the traditional autograft procedure, offering more flexible options for orthopedic surgeons and their patients. This same technology approach may also be extended in the future to the generation of cartilage and vascular tissue.

This is the third NIH grant awarded to the Company in the last quarter providing support for its TRCs and its industry-unique cell production platform, the AastromReplicell(TM) System. The announcement of these grants provides important recognition of Aastrom`s strategic position in the bone regeneration field. These third party validations were enhanced when the Company announced a strategic alliance with one of the largest participants in the bone graft field, the Musculoskeletal Transplant Foundation (MTF) in early June 2003. This alliance combines Aastrom`s TRCs with MTF`s allograft matrices to coordinate a development path to bring these products through U.S. clinical trials and into the marketplace.

Aastrom also previously announced an additional collaboration with Mathys Medical, Ltd., a leader in the development of synthetic bone matrix products located in Switzerland, and Bergmannsheil University Clinic, a leading orthopedic treatment center in Germany, to begin an European clinical trial using the Company`s TRCs for bone grafting in the repair of tibial non-union fractures. The Company has also submitted its lead bone graft trial plan to the U.S. Food and Drug Administration (FDA), and is currently in discussion with the FDA to move forward with this clinical track.

The studies supported by this grant will be completed at Aastrom and at Case Western Reserve University, one of the Company`s collaborators in the analysis of its bone-forming technology. Following completion of the specific objectives in this Phase I study, the Company intends to submit a follow-on Phase II proposal for additional grant funding.

About Aastrom Biosciences, Inc

[Boersi]

Hier die selben News, m. E. nur ein bischen verständlicher:




Dow Jones Business News
Aastrom Biosciences Gets Grant for Stem Cell Research
Wednesday July 2, 10:29 am ET


ANN ARBOR, Mich. (Dow Jones)--Aastrom Biosciences Inc. received a 6- month grant from the National Institutes of Health for its stem cell research.
In a press release Wednesday, the biodevelopment company said the Small Business Innovation Research Phase I grant, for $110,100, will support investigations of stem cell-based approaches for bone regeneration for patients needing a bone graft treatment.

ADVERTISEMENT


Bone grafting is used in orthopedic procedures such as fusion of spine vertebrae, repair of major leg fractures, and other bone repair applications.

The study will use Aastrom`s technology for producing its line of tissue repair cells, which are mixtures of stem and other cells produced from a small starting sample of the patient`s own bone marrow.

The studies supported by the grant will be completed at Aastrom and at Case Western Reserve University, one of the company`s collaborators in the analysis of its bone-forming technology.

Following completion of the specific objectives in this phase I study, the company intends to submit a follow-on phase II proposal for additional grant funding.

This is the third NIH grant awarded to the company in the last quarter providing support for its tissue repair cells and its cell production platform, the AastromReplicell System.

Aastrom has also submitted its lead bone graft trial plan to the Food and Drug Administration (News - Websites), and is currently in talks with the FDA to move forward with this clinical track, it said.

Aastrom`s Nasdaq-traded shares recently changed hands up 8 cents, or 8.3%, to $1.04, on volume of 1.5 million shares, compared to daily average volume of 2.9 million shares.

-Thomas Gryta; Dow Jones Newswires; 201-938-5400

[Boersi]

Aastrom Biosciences Announces Completion of Financings - Aastrom`s 2004 Fiscal Year Starts Strong with New Investors, New Funding and New Partner -


ANN ARBOR, Mich., Jul 10, 2003 /PRNewswire-FirstCall via COMTEX/ -- Aastrom
Biosciences, Inc. (Nasdaq: ASTM) announced today that it has raised a total of
$9.5 million at an average price to the Company of $0.96 per share since June 1,
2003 through multiple sales transactions of the Company`s common stock. This
series of financings culminated in a final private placement of 5.06 million
shares of the Company`s common stock for gross proceeds of $4.3 million.

Rodman & Renshaw, Inc. served as the exclusive placement agent in the latest
financing that introduced several new institutional investors to Aastrom. As
part of this transaction, the Company will also issue warrants exercisable for 4
years to purchase up to 1.26 million shares of common stock at a price of $1.23,
as well as warrants to purchase up to approximately one million shares of common
stock at $1.50 per share prior to October 31, 2003.

"These financings, along with recent NIH grant awards, provide financial
resources to support the further development of Aastrom`s bone regeneration,
cancer vaccine and vascular system programs and to increase the general working
capital already in place, bringing total cash-on-hand to approximately $16
million," said Alan M. Wright, Senior Vice President Administration & Financial
Operations and Chief Financial Officer of Aastrom. "With this funding secured,
Aastrom will be able to aggressively pursue its operating plan for the entire
2004 fiscal year, and continue to meet the Nasdaq core listing requirements."

Aastrom`s funding progress follows its recently announced strategic alliance
with the Musculoskeletal Transplant Foundation (MTF), the leading provider of
allograft matrices (donor-derived tissues) to the orthopedic market. This new
partnership and increased investor interest have been stimulated by Aastrom`s
advancements with its Tissue Repair Cell program. With MTF sharing the
development and clinical trial expenses of the new bone grafting treatment
approaches and products, these financings have greatly enhanced Aastrom`s
ability to move its new major market products forward. The 5.06 million private
placement shares and the associated warrants were offered to several accredited
investors in reliance on an exemption from the registration requirements of the
Securities Act of 1933, as amended (the "Securities Act"). The offering has not
been registered under the Securities Act or any state securities laws and the
securities may not be offered or sold absent registration or an applicable
exemption from the registration requirements of the Securities Act and
applicable state securities laws. In connection with the offering, Aastrom
Biosciences, Inc. has agreed, subject to certain terms and conditions, to file a
registration statement under the Securities Act covering the resale of the
shares purchased and shares issuable upon exercise of the warrants. This press
release does not and will not constitute an offer to sell or the solicitation of
an offer to buy shares or warrants.

About Aastrom Biosciences, Inc.

Aastrom Biosciences, Inc. (Nasdaq: ASTM) is a late-stage development company
focused on human cell-based therapies. The AastromReplicell(TM) System -- a
patented, integrated system of instrumentation and single-use consumable kits
for the production of patient-specific cells -- is the Company`s core technology
for its Prescription Cell Products (PCP) business and its Cell Production
Products (CPP) business. The principal focus of the PCP business is the repair
or regeneration of tissue intended for large markets such as bone grafting and
severe osteoporosis. The CPP business markets the AastromReplicell(TM) System to
researchers and companies for their production of cells for clinical trials.
These two businesses are intended to enable Aastrom to generate multiple paths
to revenue. The initial commercial phase of the CPP business for dendritic cell
production products is underway in Europe and the United States. For more
information, visit Aastrom`s website at www.aastrom.com.

This document contains forward-looking statements, including without limitation,
statements concerning capital availability, product development objectives,
potential product applications, and potential paths to revenue, which involve
certain risks and uncertainties. The forward-looking statements are also
identified through use of the words "expected," "intended," and other words of
similar meaning. Actual results may differ significantly from the expectations
contained in the forward-looking statements. Among the factors that may result
in differences are uncertainties inherent in product development activities,
actions taken by marketing alliance partners, the availability of resources and
the allocation of resources among different potential uses. These and other
significant factors are discussed in greater detail in Aastrom`s Annual Report
on Form 10-K and other filings with the Securities and Exchange Commission.

SOURCE Aastrom Biosciences, Inc.

[Boersi]

Wichtigste Kernaussage aus der News von heute:

"With this funding secured, Aastrom will be able to aggressively pursue its operating plan for the entire 2004 fiscal year, and continue to meet the Nasdaq core listing requirements."

... Kapital reicht bis Anfang 2005!

[analle]

heute ein

[Boersi]

Upss

Ganz schön dynamisch, der Anstieg von Heute und das ganze ohne News. Könnte auch bedeuten das bald News kommen.

Schlusskurs = Höchstkurs

[Boersi]

Aastrom spekulative Kaufempfehlung Strong Buy

J.M. Dutton & Associates Announces Investment Opinion: Aastrom Biosciences Rating Maintained at Strong Speculative Buy by Dutton & Associates


EL DORADO HILLS, Calif., Aug 13, 2003 (BUSINESS WIRE) -- J.M. Dutton &
Associates continues coverage of Aastrom Biosciences (Nasdaq: ASTM) with its
update report maintaining its rating at Strong Speculative Buy. The 6-page
report by J.M. Dutton senior analyst Sherry Grisewood, CFA, is available at
www.jmdutton.com as well as from Bloomberg, First Call, Zacks, Multex, and other
leading financial portals.

Aastrom`s financial condition has been materially strengthened as it begins a
new fiscal year, successfully raising $9.5 million in its fiscal Q4 ended June
30th. The Company is moving towards the initiation of clinical trials later this
fall for its Tissue Repair Cells (TRC) in orthopedic applications. TRCs are a
proprietary mixture of stem, mesenchymal and other progenitor cells capable of
forming bone, cartilage, and other tissues in its proprietary
AastromReplicell(TM) System. Aastrom increased its intellectual property estate
with a new European patent covering the key components of its closed loop
AastromReplicell(TM) cell replication system and single-use consumables. ASTM
announced a strategic alliance with the Musculoskeletal Transplant Foundation
(world`s largest tissue bank) for the joint development of novel treatments and
products for the regeneration of tissues such as bone and cartilage. Our new FY
2004 forecast calls for revenue of $3.9 million and a loss per share of $0.12,
versus minimal revenues estimated for 2003 and a per share loss of $0.18.

About Dutton & Associates

Dutton & Associates is one of the largest independent investment research firms
in the U.S. Its 21 senior analysts, primarily CFAs, have expertise in many
industries including healthcare, technology, finance, banking, mining, gaming,
and energy. Dutton & Associates provides continuing analyst coverage on over 60
enrolled companies, and its research, estimates, and recommendations are carried
in all the major databases serving institutions and online investors.

The cost of enrollment in the Dutton & Associates one-year continuing research
program is presently US $28,000 prepaid before commencement of its research
activities. Dutton & Associates received $22,000 from the Company for coverage
for the year. Dutton & Associates does not accept payment of any of its fees in
company stock. Its principals and analysts are prohibited from owning or trading
in securities of covered companies. Please review full disclosures, analyst
background, and company rating history at www.jmdutton.com before investing.

SOURCE: J.M. Dutton & Associates, LLC



CONTACT: J.M. Dutton & Associates, LLC

John M. Dutton, 916-941-4985

TICKERS: NASDAQ:ASTM



URL: http://www.businesswire.com

Today`s News On The Net - Business Wire`s full file on the Internet

with Hyperlinks to your home page.


Copyright (C) 2003 Business Wire. All rights reserved.





KEYWORD: CALIFORNIA

INDUSTRY KEYWORD: INVESTMENT

OPINION



---------------------------------------------------
... und hier noch der komplette Research-Bericht:



http://www.jmdutton.com/Research/ASTM/Reports/ASTM_Report_08…

[ChristianeSabinsen]

Jetzt geht´s los...

Aastrom Biosciences Completes CE Mark Requirements for Third DendriticCell Therapy Product

ANN ARBOR, Mich., Aug 21, 2003 /PRNewswire-FirstCall via COMTEX/ -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today announced that it has completed all requirements to affix the CE Mark on its DCV-II kit in the European Union. This is the third of the Company`s dendritic cell production kits to use the CE Mark. The DCV-II kit operates on the AastromReplicell(TM) System instrument platform, and produces peptide-loaded dendritic cells that are being investigated in clinical trials as therapeutic cancer vaccines. The CE Mark allows Aastrom to market and sell DCV-II kits in Europe; the kits are available as well in the United States for clinical research use.

Dendritic cells loaded with specific tumor-associated fragments called peptides are one of the new approaches currently being clinically investigated to induce a therapeutic immune response to different forms of cancer. These tumor-associated peptides include melanoma, colon, breast and prostate cancer- associated peptides. The AastromReplicell(TM) System and the DCV-II vaccine production kits facilitate such studies by allowing researchers and investigators to produce sufficient clinical quantities of dendritic cells in an automated, closed-system, Good Manufacturing Practices (GMP)-compliant process. In addition, like the previously released DC-I and DCV-I kits, the DCV-II kit offers clinical investigators the ability to produce dendritic cells loaded with a broad array of tumor antigens, and are intended to bring forward a variety of vaccines based on Aastrom`s technology.

"Dendritic cell-based cancer vaccine therapies are being evaluated in a large number of studies in both Europe and the United States. The DCV-II kit meets the need for GMP-compliant production of peptide-loaded dendritic cells, which is one of the newest approaches being evaluated for widespread use of these vaccines," said R. Douglas Armstrong, Ph.D., President, Chief Executive Officer and Chairman of Aastrom.

"This market offers a new potential path to near-term revenue for the Company. We believe that the new DCV-II kit, along with the DC-I and DCV-I kits, can support the growth of this market, as well as improve the clinical success of these innovative cancer vaccine approaches," concluded Armstrong.

Other CE Marked Aastrom products include: the AastromReplicell(TM) System ("System"), the DC-I kit, intended for the production of dendritic cells for use in fusion or transfection cell-based cancer vaccines and the DCV-I kit, intended for the production of complete antigen-loaded dendritic cell vaccines. Aastrom has installed the System for several of its products in fifteen sites in Europe and the United States; sites evaluating the Company`s dendritic cell production products include: Stanford University and Duke University in the United States, and University of Mannheim and University of Erlangen in Germany.

The Company markets and sells its Cell Production Products in Europe through its wholly owned subsidiary, Zellera AG. In the United States, for more information about Aastrom`s Cell Production Products, contact Ron Dudek, Director Sales and Marketing, at 734-930-5768.

About Zellera AG

Zellera AG is a wholly owned subsidiary of Aastrom Biosciences, Inc., located in Berlin, Germany. Zellera serves as the sales and marketing operational base for Aastrom`s products in Europe. For more information, visit Zellera`s website at www.zellera.de, or contact Holger Beckmann, Managing Director, at 011-49-30-2065-9165.

About Aastrom Biosciences, Inc.

Aastrom Biosciences, Inc. (NasdaqSC: ASTM) is a late-stage development company focused on human cell-based therapies. The AastromReplicell(TM) System - a patented, integrated system of instrumentation and single-use consumable kits for the production of patient-specific cells - is the Company`s core technology for its Prescription Cell Products (PCP) business and its Cell Production Products (CPP) business. The principal focus of the PCP business is the repair or regeneration of tissue intended for large markets such as bone grafting, vascular systems and severe osteoporosis. The CPP business markets the AastromReplicell(TM) System to researchers and companies for their production of cells for clinical trials. These two businesses are intended to enable Aastrom to generate multiple paths to revenue. The initial commercial phase of the CPP business for dendritic cell production products is underway in Europe and the United States. For more information, visit Aastrom`s website at www.aastrom.com.

This document contains forward-looking statements, including without limitation, statements concerning product development objectives, potential product applications, product results, product revenue generation and potential advantages of the AastromReplicell(TM) System, which involve certain risks and uncertainties. The forward-looking statements are also identified through use of the words "intended," "believe," "can," "potential," and other words of similar meaning. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are future clinical trial results, the results of product marketing activities conducted by third parties, actions taken by marketing partners and competitors, the availability of resources and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom`s Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.



CONTACTS:
Kris M. Maly or Holger Beckmann
Becky Anderson Managing Director
Investor Relations Department Zellera AG
Aastrom Biosciences, Inc. Phone: [phone]
Phone: [phone]

SOURCE Aastrom Biosciences, Inc.


CONTACT: Kris M. Maly or Becky Anderson, Investor Relations Department of
Aastrom Biosciences, Inc., [phone]; or Holger Beckmann, Managing
Director of Zellera AG, 011-49-30-2065-9165

URL: www.aastrom.com

[Forum]

Riesenumsätze nach 30 Minuten USA-Handel!!!!

[analle]

heute knallen meine Werte durch die Decke. Geduld und die richtigen Werte zahlen sich aus.

[meislo]

CE Gütesiegel ist nichts besonderes

AASTROM hat schon mehrere davon.
Jedes Produkt aus China hat so ein Siegel

Also nicht abheben. Als langjähriger AASTROM-Aktionär weiss ich wovon ich Rede Was AASTROM braucht ist eine FDA-Zulassung dann geht der Kurs durch die Decke

gruss meislo

[meislo]

Im moment explodiert AASTROM förmlich 1,19 US Dollar +32 %

Aastrom Biosciences Gets EU OK for Cancer Vaccine Kits
Thursday August 21, 11:24 am ET


ANN ARBOR, Mich. (Dow Jones)--Aastrom Biosciences Inc. received approval to market and sell its DCV-II cancer vaccine production kits in the European Union (News - Websites).
In a press release Thursday, the biopharmaceutical company said the cancer- vaccine production market offers a new potential path to near-term revenue.

ADVERTISEMENT


The company reported revenue of $877,000 for the fiscal year ended June 30, 2002 and $669,000 for the nine months ended March 31.

Aastrom completed all requirements to affix the CE Mark on the DCV-II kit, the third of the company`s dendritic cell-production kits to use the CE Mark, along with the DC-I and DCV-I kits. In the U.S., the DCV-II kits are available for clinical research use.

The DCV-II kit produces dendritic cells that can be loaded with specific tumor-associated fragments called peptides. Such antigen-loaded cells are being investigated in clinical trials as cancer vaccines to induce immune responses to melanoma and cancers of the colon, breast and prostate.

At about 10:30 a.m. EDT Thursday, Aastrom`s shares traded at $1.02, up 12 cents, or 13.3% on composite volume of 5.8 million shares, more than one-and-a- half times the average daily trading volume



gruss meislo

[diegutefee]

Aastrom ist ein lupenreiner Diamant zum Schnäppchenpreis!

Wer auf meine Kaufempfehlung zu 0,80 $ gehört hatte, kann
sich nun freuen!

Aastrom wird weiterhin explodieren!

Herzliche Grüße

diegutefee

[Boersi]

Aastrom Biosciences Receives FDA Approval to Initiate Multi-Center Clinical Trial for Bone Graft Product
Tuesday September 2, 8:00 am ET
-- IND Approval Key Milestone for Aastrom`s Stem Cell Product Program for Tissue Generation --


ANN ARBOR, Mich., Sept. 2 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for a multi-center Phase I/II clinical trial for the Company`s bone generation Tissue Repair Cell (TRC) stem cell product. The study allows Aastrom`s TRCs to be used at up to three centers for the treatment of tibial non-union fractures, and could lead to a viable alternative to the current, highly morbid standard of treatment for use in the multi-million dollar bone graft market. The approval of the IND represents a key milestone that supports Aastrom`s focus on the use of its stem cell-based TRCs for tissue generation.
The FDA`s approval was based on its review of Aastrom`s TRC product and data supporting the safety and bone forming capability of these cells. Although a start date for the trials has yet to be determined, Aastrom is currently finalizing documents, and participation agreements with leading orthopedic centers. Up to three such centers will be included in the trials, and as many as 20 patients will be recruited who have either long-term (a minimum of 8 months) non-healing tibial leg fractures, or non-union fractures that are severe enough to require a bone graft to aid repair.

The bone graft trial protocol combines Aastrom`s TRCs with a standard orthopedic matrix, to be provided by the Musculoskeletal Transplant Foundation (MTF). This trial is the first conducted by Aastrom in affiliation with its new strategic partner, MTF, an industry leader in providing bone graft matrices for orthopedic surgery. The Company anticipates that this trial will be conducted concurrently with other planned trials in Europe that are intended to demonstrate the safety and efficacy of TRCs for bone graft indications.

"We are in the final stages of preparation for this trial of our stem cell product for the repair of major leg fractures, which represents a significant achievement in bringing our novel, cell-based procedure to the multi-million dollar bone graft market," said R. Douglas Armstrong, Ph.D., President, Chief Executive Officer and Chairman of Aastrom. "FDA approval of our IND is an important benchmark that supports the research and development resources we have devoted to our TRC products, and allows the Company to move forward with this initial U.S. bone generation clinical trial."

TRCs are Aastrom`s proprietary stem and progenitor cells, produced from small samples of a patient`s own bone marrow (autologous cells). TRCs are enriched for early stage stem and progenitor cells that can form bone and other tissues, and have been safely used in over 150 patients to generate normal bone marrow, as well as immune system cells. In addition, TRCs were successfully used in a compassionate use case to generate systemic bone in a patient with the genetic bone disease, infantile hypophosphatasia.

About Bone Grafting

Bone grafting is used in over 1 million patients annually in the U.S. and Europe, including repair of major fractures such as tibial non-union fractures, and various types of vertebral fusion. A standard approach to obtain bone graft material involves chiseling out bone and marrow

[Boersi]

Jetzt nocheinmal, aber komplett

Aastrom Biosciences Receives FDA Approval to Initiate Multi-Center Clinical Trial for Bone Graft Product -- IND Approval Key Milestone for Aastrom`s Stem Cell Product Program for Tissue Generation --


ANN ARBOR, Mich., Sep 2, 2003 /PRNewswire-FirstCall via COMTEX/ -- Aastrom
Biosciences, Inc. (NasdaqSC: ASTM) today announced that the U.S. Food and Drug
Administration (FDA) has approved its Investigational New Drug (IND) application
for a multi-center Phase I/II clinical trial for the Company`s bone generation
Tissue Repair Cell (TRC) stem cell product. The study allows Aastrom`s TRCs to
be used at up to three centers for the treatment of tibial non-union fractures,
and could lead to a viable alternative to the current, highly morbid standard of
treatment for use in the multi-million dollar bone graft market. The approval of
the IND represents a key milestone that supports Aastrom`s focus on the use of
its stem cell-based TRCs for tissue generation.

The FDA`s approval was based on its review of Aastrom`s TRC product and data
supporting the safety and bone forming capability of these cells. Although a
start date for the trials has yet to be determined, Aastrom is currently
finalizing documents, and participation agreements with leading orthopedic
centers. Up to three such centers will be included in the trials, and as many as
20 patients will be recruited who have either long-term (a minimum of 8 months)
non-healing tibial leg fractures, or non-union fractures that are severe enough
to require a bone graft to aid repair.

The bone graft trial protocol combines Aastrom`s TRCs with a standard orthopedic
matrix, to be provided by the Musculoskeletal Transplant Foundation (MTF). This
trial is the first conducted by Aastrom in affiliation with its new strategic
partner, MTF, an industry leader in providing bone graft matrices for orthopedic
surgery. The Company anticipates that this trial will be conducted concurrently
with other planned trials in Europe that are intended to demonstrate the safety
and efficacy of TRCs for bone graft indications.

"We are in the final stages of preparation for this trial of our stem cell
product for the repair of major leg fractures, which represents a significant
achievement in bringing our novel, cell-based procedure to the multi-million
dollar bone graft market," said R. Douglas Armstrong, Ph.D., President, Chief
Executive Officer and Chairman of Aastrom. "FDA approval of our IND is an
important benchmark that supports the research and development resources we have
devoted to our TRC products, and allows the Company to move forward with this
initial U.S. bone generation clinical trial."

TRCs are Aastrom`s proprietary stem and progenitor cells, produced from small
samples of a patient`s own bone marrow (autologous cells). TRCs are enriched for
early stage stem and progenitor cells that can form bone and other tissues, and
have been safely used in over 150 patients to generate normal bone marrow, as
well as immune system cells. In addition, TRCs were successfully used in a
compassionate use case to generate systemic bone in a patient with the genetic
bone disease, infantile hypophosphatasia.

About Bone Grafting

Bone grafting is used in over 1 million patients annually in the U.S. and
Europe, including repair of major fractures such as tibial non-union fractures,
and various types of vertebral fusion. A standard approach to obtain bone graft
material involves chiseling out bone and marrow from a patient`s hip. This
invasive "autograft" process can result in substantial acute and chronic pain,
discomfort, and mobility problems.

Current bone graft substitute products lack the cells needed to promote
effective bone growth, and are therefore a less effective alternative. TRCs have
substantially more bone forming cells compared to native bone marrow, as has
been demonstrated by lab and animal models testing bone. TRCs mixed with a
matrix (allograft) should provide the components to form bone, and may provide
an effective alternative to autograft.

About the Aastrom/MTF Strategic Alliance

Aastrom and the Musculoskeletal Transplant Foundation (MTF) have formed a
strategic alliance to jointly develop and commercialize innovative treatments
for the regeneration of tissues such as bone and cartilage. Aastrom`s
collaboration with MTF, the leading provider (annual revenue over $200 million)
of allograft matrices, or donor-derived tissue, will focus on forming a
coordinated business and clinical approach for new products and treatments
needed in orthopedic medicine. Under the terms of the alliance, Aastrom and MTF
will coordinate and fund the development of products that are based on
combinations of MTF`s matrices and Aastrom`s Tissue Repair Cells (TRCs). The
companies will share in the development and clinical trial expense of these
treatment approaches and products, and will adopt a coordinated promotion and
marketing strategy for future products. In addition to the initial focus on
jointly developed bone graft treatments, the companies will explore new
approaches for the regeneration of joint cartilage, as well as effective
combinations of TRCs with MTF`s new ceramic technology.

About Aastrom Biosciences, Inc.

Aastrom Biosciences, Inc. (NasdaqSC: ASTM) is a late-stage development company
focused on human cell-based therapies. The AastromReplicell(TM) System - a
patented, integrated system of instrumentation and single-use consumable kits
for the production of patient-specific cells - is the Company`s core technology
for its Prescription Cell Products (PCP) business and its Cell Production
Products (CPP) business. The principal focus of the PCP business is the repair
or regeneration of tissue intended for large markets such as bone grafting,
vascular systems and severe osteoporosis. The CPP business markets the
AastromReplicell(TM) System to researchers and companies for their production of
cells for clinical trials. These two businesses are intended to enable Aastrom
to generate multiple paths to revenue. The initial commercial phase of the CPP
business for dendritic cell production products is underway in Europe and the
United States. For more information, visit Aastrom`s website at www.aastrom.com.

This document contains forward-looking statements, including without limitation,
statements concerning planned clinical trials, product development objectives,
potential product applications, and potential advantages of the
AastromReplicell(TM) System and related cells, which involve certain risks and
uncertainties. The forward-looking statements are also identified through use of
the words "intended," "may," "should," "could," "can," "anticipates," and other
words of similar meaning. Actual results may differ significantly from the
expectations contained in the forward-looking statements. Among the factors that
may result in differences are future clinical trial results, actions taken by
collaborators and competitors, the availability of resources and the allocation
of resources among different potential uses. These and other significant factors
are discussed in greater detail in Aastrom`s Annual Report on Form 10-K and
other filings with the Securities and Exchange Commission.





CONTACTS: Kris M. Maly or

Becky Anderson

Investor Relations Department

Aastrom Biosciences, Inc.

Phone: [phone]

SOURCE Aastrom Biosciences, Inc.



CONTACT: Kris M. Maly or Becky Anderson, Investor Relations Department

both of Aastrom Biosciences, Inc., [phone]



URL: http://www.aastrom.com

http://www.prnewswire.com


Copyright (C) 2003 PR Newswire. All rights reserved.





KEYWORD: Michigan

INDUSTRY KEYWORD: MTC

BIO

[Boersi]

...und ich wollte schon bei 80 cent verkaufen...

[meislo]

Endlich

gruss meislo

[109]

Riesige Umsätze in USA.

[meislo]

Jemand an Stammzellenreport interessiert?

Wenn ja, bitte per Boardmail melden

gruss meislo

[meislo]

The Wall Street Analyst Forum -- Drugs & Biotechnology Conference
Thursday September 11, 3:30 pm ET


ANN ARBOR, Mich., Sept. 11 /PRNewswire-FirstCall/ -- Aastrom Biosciences (NasdaqSC: ASTM) to present at Wall Street Analyst Forum.
R. Douglas Armstrong, Ph.D., President and CEO
Aastrom Biosciences, Inc.
The Cell Therapy Company
Website: www.aastrom.com

-- Aastrom -- capturing the therapeutic potential of bone marrow stem
cells

-- FDA approval of IND application to initiate multi-center trials for
bone grafting product

-- Strategic alliance with MTF -- the leading provider of orthopedic
matrices

-- Multiple grants from the NIH to optimize proprietary technology and
products related to tissue generation

-- Proven clinical success in regenerating skeletal bone tissue in patient
with potentially fatal, genetic skeletal disease

-- Significant collaborations signed with prestigious organizations and
universities

LIVE PRESENTATION & WEBCAST

DATE: Monday, September 15, 2003 at 9:00 am (EDT)
[Recorded webcast available for 30 days after conference]

Choose Aastrom Biosciences` Presentation by linking to:

http://www.firstcallevents.com/service/5580_Agenda1.html

[meislo]

1,57 Dollar bei hohen Umsätzen

gruss meislo

[meislo]

Aastrom Biosciences Receives NIH Grant to Develop Stem Cell Treatment for Diabetic Circulation Disorders
Monday October 6, 8:00 am ET
-- Study Marks Aastrom`s Entry into Vascular Regeneration Marketplace --


ANN ARBOR, Mich., Oct. 6 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that it has received a $100,000 Phase I Small Business Innovation Research grant from the National Institutes of Health (NIH) to develop a bone marrow stem cell-based treatment of circulation ischemia caused by vascular diseases and diabetes.
ADVERTISEMENT


In this six-month study, undertaken in collaboration with Case Western Reserve University, Aastrom`s patented single-pass perfusion stem cell technology will be utilized to create a clinically suitable cell therapy for regeneration of vascular tissue (veins and arteries). The Company`s proprietary AastromReplicell(TM) System ("System") will be used to produce the expanded bone marrow stem and endothelial progenitor cell (EPC) product that will be tested in an in vivo animal model for hind limb ischemia. The Company anticipates that successful completion of this study will lead to further grant applications as well as clinical trials for the treatment of vascular diseases. Kristin Goltry, Ph.D., Stem Cell Program Leader at Aastrom Biosciences, is lead investigator on the study.

"The expansion of our tissue engineering program is extremely exciting for the Company. Our movement into the major market of vascular tissue regeneration is a natural `next step` in broadening the potential applications of our technology," said R. Douglas Armstrong, Ph.D., Chairman, President and Chief Executive Officer of Aastrom. "Our vascular tissue program is based on the same internal infrastructure as our bone regeneration program, which has shown ongoing positive achievements such as the recent FDA approval to initiate a multi-center trial for our bone grafting product. We are now building upon that strong foundation to further develop the therapeutic potential of our bone marrow stem cell products."

Ischemia is a blood circulation deficiency in an organ or tissue caused by constriction or obstruction of its blood vessels, and is commonly associated with arteriosclerosis and diabetes. Small artery obstruction is a major contributor to stroke, heart disease, and limb loss. For certain severe peripheral vascular diseases, current surgical treatment methodologies have been proven ineffective in the long-term management of the disease. As a result, the medical and research communities have recently turned to the development of cell-based therapies as alternative treatments.

"In clinical terms, this new study offers tremendous potential for revolutionizing the treatment of diabetic vascular disorders and certain cardiovascular diseases that may bring greatly improved results for many patients worldwide," Dr. Goltry commented. "Clinical results published in various medical publications indicate that large volumes of bone marrow stem cells, when injected into the surrounding tissue area, are capable of regenerating vascular tissues. Current procedures for obtaining large volumes of bone marrow stem cells are very invasive and often yield insufficient quantities. Aastrom`s solution to address this limitation is based on our proprietary technology for the production of clinical quantities of therapeutic cells. The information collected through this study should pave the way for the continued development and additional clinical trials of this technology."

gruss meislo

[wintermaerchen]

Was ist derzeit los mit aastrom ?

[meislo]

Biokonferenz mit AASTROM

Healthcare & Biotechnology Investment Conference

Please mark on your calendar and attend on January 22nd at the San Francisco Omni Hotel our next Healthcare & Biotechnology conference of companies covered by JM Dutton & Associates. This conference follows our very successful September 24th New York City Healthcare and Biotechnology conference with over 220 in attendance.

We expect approximately 12 companies to present from the list of our covered Healthcare and Biotechnology companies. These leading small cap biotechnology companies include:

Neurobiological Technologies – Nasdaq: NTII
Aastrom Biosciences – Nasdaq: ASTM
Isolagen – AMEX: ILE
GlycoGenesys – Nasdaq: GLGS
Calypte Biomedical Corp - OTCBB: CYPT
AP Pharma – Nasdaq: APPA
BioSante – AMEX: BPA
Draxis Health Inc – Nasdaq: DRAX
Pharmos – Nasdaq: PARS
Physiometrix – Nasdaq: PHYX

Our research on most all of the above companies can be found on our site at www.jmdutton.com, while our initiating coverage on a few attending companies should be available shortly.

Tickets for the event at no cost for qualified institutional and other investors can be obtained by clicking here: www.friedlandcapital.com/Dutton.htm. The conference is administered for us by Friedland Capital.

The January 2004 edition of Buyside Magazine points out, JM Dutton & Associates was ranked the top independent research provider in the US among a list of the the top 18 independent providers. This was a ranking based on research performance and other factors, including analyst quality and experience. Based on the Investars results, a third party statistical monitoring firm covering the 120 major Wall Street research firms, we were ranked in the top quartile of the 10 industries tracked by Investars, including healthcare and biotechnology. Based on Investars` evaluation, JM Dutton & Associates ranked in the top 10% of the 111 Wall Street firms monitored during the past two years. The article can be read by clicking here.
We look forward to seeing you at our conference.

John M. Dutton
JM Dutton & Associates, LLC
Independent Investment Research
San Francisco Los Angeles New York London
t. [phone] f. [phone]
c. [phone]
[e-mail] www.jmdutton.com

[meislo]

Aastrom Biosciences Initiates Bone Graft Clinical Trial at Lead U.S. Site
Wednesday January 14, 8:00 am ET
Evaluation of Stem Cell Product for Leg Fracture Healing Begins in Chicago


ANN ARBOR, Mich., Jan. 14 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today announced that its U.S. clinical trial of the Company`s bone generation Tissue Repair Cell (TRC) stem cell product has been initiated at its lead clinical trial site in Chicago, IL. This study follows the previously announced FDA approval of the Company`s Investigational New Drug (IND) application which allows Aastrom`s TRCs to be used at up to three centers for the treatment of tibial non-union fractures. The Principal Investigator in the trial is Matthew L. Jimenez, M.D., of the Illinois Bone & Joint Institute. The clinical trial will be conducted at Lutheran General Hospital in Park Ridge, IL.
ADVERTISEMENT


This bone graft trial represents a key milestone that supports Aastrom`s focus on the use of its stem cell-based TRCs for tissue generation. Laboratory evaluations of Aastrom`s TRCs indicate that they contain a large number of bone-forming cells. In addition, these cells have been proven safe when administered to patients in previous clinical trials. Aastrom`s new clinical trial will evaluate the use of these cells when applied at the fracture site to generate bone in patients with severe types of leg fractures. Pending the successful completion of the trial, TRCs could lead to a viable alternative to the current, highly invasive standard of treatment, for use in the multi-million dollar bone graft market.

"The launch of this bone generation trial brings Aastrom into the active clinical trial stage for our TRC stem cell product -- clearly an important accomplishment for the Company that points to the leading strategic position we have attained in the cell therapeutics industry," said R. Douglas Armstrong, Ph.D., President, Chief Executive Officer and Chairman of Aastrom. "Progress is achieved one step at a time, and we intend to pursue additional clinical studies both here and in Europe, to determine the ability of TRCs to safely generate bone in patients and thus provide a valuable new tool in orthopedic medicine."

Up to three centers will be included in the current trial, and as many as 20 patients will be recruited who have either long-term (a minimum of 8 months) non-healing tibial leg fractures, or tibial non-union fractures that are severe enough to require a bone graft to aid repair. Aastrom expects to initiate the further evaluation of its TRCs at other centers in both the U.S. and Europe.

About Aastrom`s TRCs

TRCs are Aastrom`s proprietary stem and progenitor cells, produced from small samples of a patient`s own bone marrow (autologous cells). TRCs are enriched for early stage stem and progenitor cells that can form bone and other tissues, and have been safely used in over 150 patients to generate normal bone marrow, as well as immune system cells. In addition, TRCs were successfully used in a compassionate use case to generate systemic bone in a patient with the genetic bone disease, infantile hypophosphatasia.

About Bone Grafting

Bone grafting is used to treat over 1 million patients annually in the U.S. and Europe, in procedures including the repair of major fractures such as tibial non-union fractures, and various types of vertebral fusion. The current standard approach to obtain bone graft material involves chiseling out bone and marrow from a patient`s hip. This invasive "autograft" process can result in substantial acute and chronic pain, discomfort, and mobility problems.

Current bone graft substitute products lack the cells needed to promote effective bone growth, and are therefore a less effective alternative. TRCs have substantially more bone-forming cells compared to native bone marrow, as has been demonstrated by lab and animal models testing bone generation. TRCs mixed with a matrix (allograft) should provide the components to form bone, and may provide an effective alternative to autograft. In the U.S. trial for tibial non-union fractures, Aastrom`s TRCs will be mixed with commercial allograft matrix provided by the Musculoskeletal Transplant Foundation (MTF), Aastrom`s collaboration partner for this trial.

About Aastrom Biosciences, Inc.

[meislo]

Aastrom Biosciences Announces Initiation of Bone Graft Clinical Study in Germany
Thursday January 22, 8:00 am ET
Bergmannsheil University Begins Patient Enrollment for New Stem Cell Treatment of Severe Leg Fractures


ANN ARBOR, Mich., Jan. 22 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) and its wholly owned subsidiary, Zellera AG (Berlin, Germany), announced today that its clinical study in collaboration with BG- Kliniken `Bergmannsheil` Ruhr-University, located in Bochum, Germany, has been initiated. This bone graft clinical study will use Aastrom`s proprietary bone-forming TRCs in combination with a commercial synthetic bone graft matrix (provided through collaboration with Mathys Medical, a division of Synthes located in Bettlach, Switzerland) to treat patients with serious leg (tibia) fractures that require a bone graft for recovery. The study, which expects to accrue up to ten patients, will be conducted at Bergmannsheil, a leading orthopedic trauma treatment center in Germany. The lead investigator for the trial is Thomas A. Schildhauer, M.D., Ph.D., Attending Physician of the Traumatology-Surgery Department.
ADVERTISEMENT


The trial initiation follows a series of successful preclinical and clinical studies that have demonstrated the bone-forming potential of Aastrom`s TRCs and their safety in patients, as well as FDA approval of the Company`s Investigational New Drug (IND) application for a bone grafting trial in the U.S., and finally, successful validation experiments at the Bergmannsheil University Clinic. Aastrom`s TRCs are produced from small samples of bone marrow (which contain adult stem cells) using the AastromReplicell(TM) System, the Company`s pioneering automated cell production platform. The AastromReplicell(TM) System has already received approval to affix the CE Mark, a regulatory requirement for commercial use in Europe.

"The initiation of this trial in Bochum is a material step towards commercial use of Aastrom`s TRCs in patients for bone regeneration. The clinical evaluation of TRCs is now active in both the U.S. and Europe, and we are gratified by the enthusiasm these studies are generating," said R. Douglas Armstrong, Ph.D., President, Chief Executive Officer and Chairman of Aastrom. "We are very impressed with our partners in this collaborative study, and believe that the data generated will provide a strong indication of the usefulness of TRCs in bone regeneration, a major medical market."

Typical bone grafting procedures include various types of spinal fusions and repair of major fractures such as non-union fractures of legs and arms. The long-time standard treatment procedure involves surgically chiseling out bone chips and marrow from the patient`s hip to obtain the necessary quantities of bone graft material. This process generally results in substantial acute and chronic pain and complications at the hip collection site. In an attempt to eliminate this clinical problem, various bone matrix substitutes have been developed and are sometimes used as an alternative to the standard procedure. These alternatives are typically not as effective, however, because they lack the cellular components needed to generate bone. In this clinical study, Aastrom`s bone-forming TRCs will be combined with Synthes` synthetic bone matrix product, and used by Dr. Schildhauer and his colleagues to augment the repair of serious non-union leg fractures.

[meislo]

Researchbericht vom 18.11.2003


AASTROM strong speculativ buy




http://www.jmdutton.com/Research/ASTM/Reports/ASTM_Report_11…

gruss meislo

[meislo]

Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that it will hold an investor conference call on Wednesday, February 4, 2004 at 11:00 a.m. EST. The call is intended to bring shareholders and other interested parties up-to-date on the Company`s recent progress and future goals.
The call will begin with brief presentations by R. Douglas Armstrong, Ph.D., Chairman, President and Chief Executive Officer, and Alan M. Wright, Senior Vice President Administrative & Financial Operations and Chief Financial Officer. The balance of the call will be devoted to questions from registered callers.

Interested parties should call 785-832-2422, or toll-free 800-540-0559, fifteen minutes before the start of the call to register and to identify themselves as registrants of the `Aastrom Conference Call`. The call will also be simulcast on the web at http://www.firstcallevents.com/service/ajwz398543957gf12.htm… and will be available for replay at the same site for 90 days.

[meislo]

Aastrom Biosciences, Inc. to Present at the Roth Capital Partners 16th Annual Growth Stock Conference
Wednesday February 18, 8:30 am ET


DANA POINT, Calif.--(BUSINESS WIRE)--Feb. 18, 2004--Aastrom Biosciences, Inc. will be presenting on Thursday, February 19, 2004 at 11:30 a.m. at the Roth Capital Partners 16th Annual Growth Stock Conference taking place at the St. Regis Monarch Beach Resort and Spa in Dana Point, CA.
Aastrom Biosciences, Inc. (Nasdaq:ASTM - News) is developing its proprietary Tissue Repair Cell (TRC) product for the regenerative repair of damaged human tissues and other medical disorders. TRCs are a unique mixture of bone marrow-derived stem and progenitor cells that are produced ex vivo with the Company`s pioneering manufacturing platform, the AastromReplicell System. TRCs have been proven, in completed clinical trials, to be safe in patients and to effectively generate normal human tissues such as bone, blood and immune system cells.

Aastrom has recently announced the initiation of clinical trials in the U.S. and Europe, for the use of TRCs to regenerate bone in bone graft indications. The bone graft market includes major indications such as long bone fractures, spine fusion, and various bone building procedures in the dental field. In these markets the current leading procedure is the collection of bone and marrow from the patient`s hip to be used as the bone graft material. This process often leaves undesirable long-term pain and mobility issues for the patient. Bone graft substitutes such as matrix and BMPs lack the cells needed for optimal tissue growth. Aastrom`s TRCs have been shown to have very high volumes of bone-forming cells and are being evaluated to enable a new standard for bone grafting.

The Company has additional preclinical stage activities for the use of TRCs to regenerate peripheral vascular tissue and cartilage.

Aastrom has emerged with a strong strategic position in the stem cell field with a proprietary stem cell product that is in the clinic, and with an industry-unique cell manufacturing system that has overcome limitations that have prevented others from bringing cells into standard medical practice.

About the Roth Capital Partners 16th Annual Growth Stock Conference

This annual event is the largest in the nation for emerging growth companies. It provides a concentrated forum where Institutional Investors can meet the executives of growth companies hand picked by Roth Capital`s research team. The conference will highlight approximately 225 companies from industry groups including Health Care, Consumer Products, Technology and Financial Services. This year, as a result of numerous client requests, Roth has extended the conference to three working days, including a Discovery Day, which will highlight companies "undiscovered" by Wall Street. For more information about the conference visit http://www.apgweb.com/roth/danapoint/.

[wintermaerchen]

Hollo Aastromfreunde,

any news ????? Weiss wer was ?

[heideperle]

Aastrom Biosciences Receives Patent for Transplantation Use of Its Stem Cell Products
Wednesday March 3, 8:01 am ET
-- Patent Covers Bone Marrow, Blood and Cord Blood-Sourced Products --


ANN ARBOR, Mich., March 3 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that it has received patent number 6,667,034 B2 from the United States Patent and Trademark Office. The patent covers a method of bone marrow transplantation, often referred to as stem cell transplants, using cells produced with Aastrom`s proprietary single-pass perfusion technology that enables the growth of normal human cells outside the body.
Bone marrow stem cell transplants are used to regenerate healthy tissues in patients following traumatic injury, or to repair damage caused by chemotherapy or radiation. A bone marrow stem cell transplant typically requires large volumes of cells to treat major tissue damage. Such procedures necessitate the invasive collection of a quart or more of bone marrow. With some patients this is not practical, and with others even more cells are needed for transplantation. Therefore, the ability to produce clinical quantities of these cells from a much smaller starting sample, the basis of Aastrom`s proprietary technology, is intended to provide a therapeutic substitute for medical applications that are treatable with large volumes of bone marrow cells.

Bone marrow has stem and progenitor cells that can lead to the regeneration of many tissues in the human body, including blood, immune system and solid tissues such as bone, cartilage and vasculature (veins and arteries). Aastrom`s new patent covers the medical use of bone marrow cell products cultured outside the body under specific conditions, and comprises a mass of stromal cells, often called mesenchymal cells. Stromal cells generate biological signals that can support the growth of stem cells, and certain types of stromal cells can also generate certain solid tissues. Additionally, this patent covers cells produced from blood or umbilical and placental cord blood.

"This patent is an important addition to our expanding portfolio of proprietary stem cell technologies," said R. Douglas Armstrong, Ph.D., Chairman, President and Chief Executive Officer of Aastrom. "The value of our technology is becoming increasingly evident, as industry research and clinical publications continue to demonstrate that bone marrow cells help patients with major fractures of limbs and spine, and can aid in the regeneration of vascular tissue in diabetic and heart disease patients."

About Aastrom Biosciences, Inc.

[Flashpompa]

@ alle

http://www.stockpickreport.com/rating.php

wenn die verkaufen sagen dann steigt meistens der kurs.

astm long

[xwin]

nach einer einigermassen schmerzhaften Konsolidierung ist die Aktie ja nun wieder offenbar vollkommen unbemerkt gestiegen in den letzten Tagen. Ist hier irgendjemand ausser mir noch investiert?

letzte Nachrichten zu dieser Aktie:

http://ragingbull.lycos.com/mboard/boards.cgi?board=NASDAQ:A…

[xwin]

hmmm....so 20% Plus in den letzten Tagen scheinen ja keinen zu interessieren...naja....

[ollihat]

Wurde heute auf die Kaufliste von BUYHIGH.NET gesetzt:

Kursziel + 100%

[xwin]

aber das interessiert hier wohl niemanden. Heute hätte man locker +25% Plus machen können und es sieht so aus als wenn die mal eben weiter steigen....

[sclabbo]

mich interessiert es auf jeden Fall
Bin seid etwa 2 Jahren dabei

[xwin]

Ich hoffe die bleibt mal oben Bin auch investiert, habe vor 3 Monaten gekauft.

[meislo]

Das interesse an stammzellenfirmen könnte in den nächsten monaten zunehmen.

sollte bush die wahl nicht gewinnen, werden stem, astm, und gern zu den outperformern der kommenden wahl werden. kein grosses pharmaunternehmen ist bisher ernstzunehmend in der stammzellenforschung aktiv und muss sich in diesem bereich verstärken. entweder durch übernahme,kooperation oder durch den ausbau einer eigenen stammzellenforschung. letzteres könnte teuer werden und man wird knowhow einkaufen müssen.

gruss meislo

Reagans Tod soll Forschung an Embryos befeuern

58 amerikanische Senatoren haben US-Präsident Bush aufgefordert, Restriktionen für die umstrittene Forschung an embryonalen Stammzellen zu lockern. Ihr neuestes Argument: der Tod des Alzheimer-Patienten Ronald Reagan.



Sarg von Ex-Präsident Reagan: Tod nach zehnjährigem Kampf gegen Alzheimer
Am Freitag vergangener Woche ging das Schreiben bei Präsident George W. Bush ein. Die 58 Unterzeichner, allesamt Mitglieder des amerikanischen Senats, ahnten nicht, dass der ehemalige US-Präsident Ronald Reagan schon wenige Stunden später sterben würde. Am Samstag, im Alter von 93 Jahren, verlor er den Kampf gegen die Alzheimersche Krankheit, an der er seit über zehn Jahren gelitten hatte.

Es wirkte beinahe so, als sollte Reagans Tod das Anliegen der Abgeordneten untermauern. 43 Demokraten, 14 Republikaner und ein Parteiloser verlangen in dem Schreiben an Bush Erleichterungen in der Forschung an embryonalen Stammzellen, deren Ergebnisse eines Tages auch bei Krankheiten wie Alzheimer oder Parkinson Hilfe versprechen könnte.

Die Angelegenheit sei angesichts des Todes von Ronald Reagan besonders schmerzlich, sagte eine kalifornische Abgeordnete. Die Witwe des Ex-Präsidenten, Nancy Reagan, hatte wenige Wochen vor dem Tod ihres Mannes ein klares Statement für die Stammzellforschung abgegeben. " Die Wissenschaft hat uns mit der Stammzellforschung Hoffnung gegeben" , sagte sie auf einem Treffen einer Diabetikervereinigung. " Ich verstehe nicht, wie wir davor die Augen verschließen können."



REUTERS
Stammzellen-Bank: Ethische Konflikte um menschliche Embryos
Präsident Bush hatte im Jahr 2001 strenge Restriktionen für die Stammzellforschung verfügt. Amerikanische Wissenschaftler dürfen demnach nur noch mit 78 existierenden Stammzelllinien arbeiten. Neue Stammzellen aus Embryos zu gewinnen, untersagte Bush aus ethischen Gründen. Konservative Politiker in den USA bekämpfen die Nutzung von Stammzellen genauso wie die Abtreibung.

Angesichts des Todes von Reagan hoffen die Senatoren nun auf einen Sinneswandel beim Präsidenten. Ein Sprecher des Weißen Hauses unterstrich jedoch, dass sich Bushs Position nicht geändert habe. Der Präsident fühle sich der Stammzellforschung verpflichtet, lehne die Tötung menschlicher Embryos jedoch weiterhin ab.

Wissenschaftler hoffen, eines Tages aus Stammzellen beliebige Arten menschlichen Gewebes züchten zu können und damit Krankheiten wie Diabetes, Krebs oder Parkinson zu heilen. Gegenüber adulten Stammzellen, deren Einsatz ethisch unbedenklich ist, haben embryonale Stammzellen deutliche medizinische Vorteile. Allerdings können sie bisher nur durch die Tötung menschlicher Embryos gewonnen werden - weshalb seit Jahren ein heftiger Streit unter Wissenschaftlern, Politikern, Ethikern und Geistlichen tobt.

Deutsche Forscher glauben, eine Alternative zu den umstrittenen Stammzellen entdeckt zu haben. Sie halten die Bauchspeicheldrüse von Menschen und Ratten für eine ergiebige Quelle für Zellen, die sich ähnlich wie embryonale Stammzellen verhalten - und diese künftig ersetzen könnten

[xwin]

das ich Bush und Reagan noch mal toll finden könnte.... hätte ich nicht geglaubt.

[xwin]

1 EUR in Frankfurt!!! Ich hoffe die NASDAQ hält da nachher mit.

[xwin]

Geht stetig bergab. Und von ASTM kommen seit einiger Zeit keine Nachrichten. Weiss jemand wann mit neuen Nachrichten zu rechnen ist? Das einzige Datum das mir bekannt ist ist ein Zwischenbericht zur Studie in Deutschland mit der im Oktober zu rechnen ist. Die Wahl in den USA könnte auch noch einmal Einfluss auf ASTM haben wenn ich mir den steilen Anstieg anschaue als durch Reagans Tod die Stammzellenforschung beflügelt wurde.

Wäre schön wenn in diese Board mal wieder ein wenig Leben kommt

[meislo]

imyahoo-board ist mehr los

http://finance.yahoo.com/q/mb?s=ASTM

gruss meislo

[xwin]

danke - das kannte ich schon. Ist ein bischen unter der Gürtellinie diese Board Die sexuelle Orientierung der Boardteilnehmer interessiert mich ja dann doch eher weniger

[xwin]

Guten Morgen!

die Kursentwicklung von ASTM im Moment ist nicht übermässig erfreulich. Was meint ihr wie weit die Aktie noch fallen wird?

Unterstellt man das Bush im Herbst die Wahlen verliert, was meint ihr wird vom Förderprogramm für Stammzellenforschung für ASMT abfallen?

Danke!

[meislo]

Harnessing stem cells to battle Alzheimer`s worth a try - WSJ

The Wall Street Journal`s Science Journal section discusses diseases that damage the brain, and saying stem cells may be a cure for these diseases. So far, human studies have been disappointing. But now, in one tantalizing study, neuroscientist Kiminobu Sugaya of the University of Central Florida transplanted about 10K human neural stem cells from fetuses into the brains of memory-impaired rats, whose age of 24 months corresponds to a human age of about 80. After the transplant, most of the once-forgetful rats could navigate a water maze, a test of memory, as adeptly as rats one-fourth their age. Even more strikingly, microscopic examination showed that the stem cells had not only differentiated into neurons, but had also "become incorporated into brain areas related to spatial memory," says Sugaya. "It is now feasible to think about incorporating new neurons into the adult brain," says Dr. Jeffrey Macklis of Harvard Medical School. "Though it will be difficult, I think we as a field will be able to rebuild neural circuits." For simple circuits, such as those severed in spinal-cord injury, that may happen within 10 years. Repairing the complex circuits of Alzheimer`s may take 30. "In the meantime, we should use anything we have, including embryonic stem cells." (Briefing.com note: The article could spark interest in stem cell stocks such as ASTM and STEM.)
briefing dot com and wsj today

[xwin]

mal wieder eine neue Studie...naja immerhin. Bin gespannt auf die Ergebnisse aus Spanien in ca. 5 Wochen.

AASTROM BIOSCIENCES AWARDED NIH GRANT FOR STUDY TO ENHANCE DENDRITIC CELL-BASED CANCER VACCINES UTILIZING THE AASTROMREPLICELL® SYSTEM

-- Aastrom`s Proprietary Technology Provides Method of Cell Production and Antigen Loading Needed to Improve Vaccines --

Ann Arbor, Michigan, September 30, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today announced that it has received a $109,586 Phase I Small Business Innovation Research (SBIR) grant entitled Dendritic Cell Subset for Enhanced Cancer Vaccine (Grant Number: 1 R43 CA105686-01A1) from the National Institutes of Health (NIH) National Cancer Institute. The eight-month study will determine the efficacy and ability of the Company`s proprietary AastromReplicell® System to enhance the immunostimulatory potency of dendritic cell-based cancer vaccines through its patented Single-Pass Perfusion technology. The Principal Investigator in the study is Douglas M. Smith, Ph.D., Immunology Program Leader at Aastrom.

This Phase I SBIR study will utilize the AastromReplicell System for the production, cancer antigen-loading, maturation and harvesting of human dendritic cells (DCs). The primary goal of this study is to enhance the immunostimulatory potency of dendritic cell-based cancer vaccines by removing immunosuppressive DC subsets while enriching highly activating DC subsets. This new capability for selective collection of only activating DC subsets differentiates this grant from previous NIH grants received by the Company for other immunotherapy studies, and may increase the potency of a broad array of DC-based cancer vaccines.

"This NIH grant further supports the unique advantages of the AastromReplicell System that are intended to provide the medical and research communities with the technology needed to advance cell-based immunotherapy of diseases such as cancer," said James A. Cour, President and Chief Operating Officer of Aastrom. "It also supports our long-term business goal of establishing the AastromReplicell System as the key technology foundation for the continuing development of our proprietary cell products."

The results of this Phase I SBIR study, if positive, will be used as the preclinical information needed to pursue a subsequent Phase II SBIR grant that will focus on the clinical evaluation of the new DC product.

About Aastrom`s Products

Aastrom produces its proprietary Tissue Repair Cells – adult stem and progenitor cell products for applications including bone grafting, peripheral vascular tissue regeneration, jaw bone reconstruction and spine fusions – in the System. In addition, the Company`s Cell Production Products – the System and disposable dendritic cell production kits – may be sold to third party therapeutic cell developers for the production of cell-based cancer vaccines.

About Aastrom Biosciences, Inc.

Aastrom Biosciences, Inc. (NasdaqSC: ASTM) is developing proprietary stem cell-based products for the regenerative repair of damaged human tissues and other medical disorders. Aastrom`s strategic position in the tissue regeneration and cell therapy sectors is enabled by its proprietary Tissue Repair Cells (TRCs), a mix of bone marrow stem and progenitor cells, and the AastromReplicell® System, an industry-unique automated cell production platform used to produce cells for clinical use. Together TRCs and the AastromReplicell System provide a foundation that the Company is leveraging to produce multiple Prescription Cell Products (PCPs), the first of which is now in the clinical stage in the U.S. and EU.

TRCs are the core component of the PCPs Aastrom is developing for bone grafting, peripheral vascular disease, jaw bone reconstruction and spine fusion markets. The Company also markets the AastromReplicell System and disposable dendritic cell production kits to researchers and institutions developing vaccines to treat cancer and infectious diseases, under its Cell Production Products line.

For more information, visit Aastrom`s website at www.aastrom.com.

This document contains forward-looking statements, including without limitation, statements regarding the anticipated results of clinical trials, product development objectives, and potential advantages and applications of the AastromReplicell® System, which involve certain risks and uncertainties. The forward-looking statements are also identified through use of the words "intended," "may," and other words of similar meaning. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are the results obtained from research and development activities, regulatory approval requirements and the availability of resources. These and other significant factors are discussed in greater detail in Aastrom`s Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.

CONTACTS:
Kris M. Maly or Becky Anderson
Investor Relations Department
Aastrom Biosciences, Inc.
Phone: [phone]

Kevin McGrath
Cameron Associates
Phone: [phone]

[xwin]

noch jemand hier? Soweit ich es verstanden habe sind die Ergebnisse aus Spanien tendenziell positiv, jedoch benötigt die Genesung der Patienten noch einige Zeit (wie üblich bei solchen Verletzungen). Die sonst üblichen Komplikationen konnten sich bei der Aastrom Technik wohl vermeiden lassen. Warten wir ab, wie die USA Börse drauf reagiert:

AASTROM BIOSCIENCES ANNOUNCES PLANS TO EXPAND BONE GRAFT STUDY BASED ON RESULTS OF SEVERE FRACTURE TREATMENTS

Ann Arbor, Michigan, October 18, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) and the Institut de Teràpia Regenerativa Tissular (ITRT) announced today that their clinical trial in Barcelona, Spain will be expanded based on initial results from the first phase of patient treatments. The trial involved 5 patient treatments using Aastrom`s Tissue Repair Cells (TRCs) for the bone graft repair of severe long bone non-union fractures, and was completed at the Hospital General de l`Hospitalet, Centro Médico Teknon and Hospital de Barcelona-SCIAS. The results to date show that Aastrom`s TRCs were safe, with no adverse events reported, and that patients are exhibiting various early stages of healing. Aastrom will continue monitoring the progressive bone regeneration in these patients, while expanding the trial to include additional patients and formalizing a plan for the registration of its TRC product for use in bone graft surgery in the EU.

This trial, one of three clinical studies of Aastrom`s bone graft TRC product currently underway, was initiated in March 2004 in cooperation with ITRT (Barcelona, SP), who coordinated the trial implementation. This proof of concept feasibility clinical trial was designed to evaluate the safety and effectiveness of the Company`s TRCs to regenerate new, healthy bone in the repair of long bone non-union fractures. All of the patients who received TRC treatment had previously failed to repair their non-union fractures using standard of care procedures, during the preceding 6 to 16 months. The results to date are interim, as complete bone fusion typically takes many months.

The trial was completed under the direction of Principal Investigators, Dr. Carlos Solano-Puerta and Dr. Lluís Orozco. These physicians reported that each patient is exhibiting increased mobility and freedom from pain as a result of the healing process at the fracture site. Non-union fractures often present problems related to their repair due to the severity of the fracture in which the bone pieces are completely separated. This type of fracture usually requires various mechanical fixations and bone graft processes for repair. However, standard procedures may fail, requiring the patients to undergo additional surgery and bone grafting approaches. This was the situation for all of the patients in the Barcelona trial, who having failed to heal their fractures after standard of care treatments, received TRCs mixed with a synthetic commercial matrix, directly at the fracture site.

Dr. Lluís Orozco, Scientific Director of ITRT, commented on the study, "We are very satisfied with the results that we have seen in these first five patient treatments, and with the process, utilizing Aastrom`s Tissue Repair Cell technology. We are motivated to now expand the trial to treat additional patients with this new adult stem cell-based approach. We believe the potential ability of TRCs to eliminate the standard surgical process of autograft bone chip collection would offer a better procedure for our patients."

"Completing these first 5 patient treatments, and observing positive safety and patient progress are very important milestones for the Company, and we believe represent the first such results in the clinic using an ex vivo-produced bone marrow stem cell product," said R. Douglas Armstrong, Ph.D., Chairman and Chief Executive Officer of Aastrom. "While additional clinical data must be collected in continued trials of our TRC product to provide conclusive evidence, we are confident that this data is sufficient proof of concept for the Company to aggressively pursue the clinical trials and activities needed for EU product registration."

Typical bone grafting procedures are used to repair major fractures of legs and arms, as well as to reconstruct bone in the jaw and to fuse spine vertebrae. The long-time standard treatment procedure, called autograft, involves surgically chiseling out bone chips and marrow from the patient`s hip to obtain the necessary quantities of bone graft material. This process generally results in substantial acute and chronic pain and complications at the hip collection site. In an attempt to eliminate this clinical problem, various bone matrix substitutes have been developed and are sometimes used as an alternative to autograft procedures. These alternatives are not as effective because bone matrix substitutes lack the cellular components needed to generate bone. In this study, Aastrom`s TRCs, which have been shown to contain large numbers of adult stem and other cells needed to generate bone, are combined with a synthetic matrix product, and applied directly at the fracture site. The application of TRCs is intended to form an optimized bone graft, without the after effects of the autograft procedure.

About Tissue Repair Cells

Tissue Repair Cells (TRCs) are Aastrom`s proprietary mixture of bone marrow stem and progenitor cells produced using patented single-pass perfusion technology in the AastromReplicell® System. The clinical procedure begins with the collection of a small sample of bone marrow from the patient`s hip in an outpatient setting. TRCs are then produced in the automated AastromReplicell System over a 12-day period. It has been demonstrated in the laboratory that TRCs are able to develop into different types of tissue lineages in response to inductive signals, including blood, bone, cartilage, adipose and vascular tubules. In previous clinical trials, TRCs have been shown to be safe and reliable in regenerating certain normal healthy bone marrow tissues.

About Aastrom Biosciences, Inc.

Aastrom Biosciences, Inc. (NasdaqSC: ASTM) is a regenerative medicine company developing proprietary adult stem cell-based products for the repair or generation of damaged human tissues and other medical disorders. Aastrom`s strategic position in the tissue regeneration and cell therapy sectors is enabled by its proprietary Tissue Repair Cells (TRCs), a mix of bone marrow stem and progenitor cells, and the AastromReplicell® System, an industry-unique automated cell production platform used to produce cells for clinical use. Together TRCs and the AastromReplicell System provide a foundation that the Company is leveraging to produce multiple Prescription Cell Products (PCPs), the first of which is now in the clinical stage in the U.S. and EU. TRCs are the core component of the PCPs Aastrom is developing for bone grafting, peripheral vascular disease, jaw bone reconstruction and spine fusion markets. The Company has also developed the AastromReplicell System for dendritic cell production for researchers and institutions developing vaccines to treat cancer and infectious diseases, under its Cell Production Products line.

For more information, visit Aastrom`s website at www.aastrom.com.

This document contains forward-looking statements, including without limitation, statements concerning planned clinical trials, product development objectives, potential product applications, and potential advantages of the AastromReplicell® System, which involve certain risks and uncertainties. The forward-looking statements are also identified through use of the words "intended," "plan," "potential," "believe," and other words of similar meaning. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are clinical trial results, potential product development difficulties, the effects of competitive therapies, regulatory approval requirements, the availability of financial and other resources and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom`s Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.

CONTACTS:

Kris M. Maly or Becky Anderson
Investor Relations Department
Aastrom Biosciences, Inc.
Phone: [phone]

Kevin McGrath
Cameron Associates
Phone: [phone]

[microby]

Anscheinend kommt es in den Staaten gut an?
Immerhin 5 % rauf. Reicht erstmal wieder.

[xwin]

wieder über ein Euro in FFM

[xwin]

neue klinische Studie in Spanien zum Wachstum von Kieferknochen mit der TRC Methode.

10/21/2004

AASTROM BIOSCIENCES ANNOUNCES INITIATION OF CLINICAL TRIAL FOR SINUS LIFT BONE GRAFT PROCEDURES IN SPAIN

-- Aastrom`s Proprietary TRCs to be Utilized to Build New Bone Tissue for Dental Implants --

Ann Arbor, Michigan, October 21, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM), and the Institut de Teràpia Regenerativa Tissular (ITRT) announced today that they have initiated patient enrollment in a clinical trial with Instituto de Cirugía Maxilofacial e Implantología in Barcelona, Spain to determine the safety and efficacy of Aastrom`s proprietary Tissue Repair Cells (TRCs) in maxillary sinus lift bone graft procedures necessary for dental implants. The study is being conducted at Centro Medico Teknon under the direction of Principal Investigator, Dr. Federico Hernández-Alfaro.

The trial will target regions in the upper (maxillary) jaw where premature tooth loss has thinned the bone to such an extent that surgery for tooth replacement cannot be effectively completed. To address this clinical problem, this new study will evaluate the ability of TRCs to regenerate and thicken the maxillary sinus bone needed for a dental implant post. Dental implant surgery can improve function and dental aesthetics in patients suffering from tooth loss. In the initial phase of this trial, five patients will be accrued to compare the outcome of the innovative Aastrom TRC treatment procedure with that of a standard therapy.

This is the fourth clinical trial initiated by Aastrom to evaluate the safety and ability of the Company`s TRC technology to generate local bone tissue. The three previously announced studies focus on the use of TRCs to regenerate bone in severe long bone non-union fractures that had previously failed to heal with conventional therapies. One of the development objectives intended for TRCs is to provide an effective way for surgeons to generate or repair local bone tissue for any bone type, including long bones, spine and facial bones. If this can be achieved, Aastrom`s TRC products may serve as an alternative to autograft, the invasive and painful procedure of surgically carving out bone tissue from the hip.

"With four proof-of-concept feasibility clinical trials now underway, we are diligently working to demonstrate the full value that our TRC technology can bring to the generation of local bone tissue," said R. Douglas Armstrong, Ph.D., Chairman and Chief Executive Officer of Aastrom. "I am proud that our team here at Aastrom has been able to effectively implement these different studies, which should establish our strategic position in these major market areas. We are excited to work in collaboration with Dr. Hernández-Alfaro and his clinical team on a highly innovative therapy that has the potential to represent a breakthrough in maxillofacial bone repair."

About Tissue Repair Cells

Tissue Repair Cells (TRCs) are Aastrom`s proprietary mixture of bone marrow stem and progenitor cells produced using patented single-pass perfusion technology in the AastromReplicell® System. The clinical procedure begins with the collection of a small sample of bone marrow from the patient`s hip in an outpatient setting. TRCs are then produced in the automated AastromReplicell System over a 12-day period. It has been demonstrated in the laboratory that TRCs are able to develop into different types of tissue lineages in response to inductive signals, including blood, bone, cartilage, adipose and vascular tubules. In previous clinical trials, TRCs have been shown to be safe and reliable in regenerating certain normal healthy bone marrow tissues.

About Aastrom Biosciences, Inc.

Aastrom Biosciences, Inc. (NasdaqSC: ASTM) is a regenerative medicine company developing proprietary adult stem cell-based products for the repair or generation of damaged human tissues and other medical disorders. Aastrom`s strategic position in the tissue regeneration and cell therapy sectors is enabled by its proprietary Tissue Repair Cells (TRCs), a mix of bone marrow stem and progenitor cells, and the AastromReplicell® System, an industry-unique automated cell production platform used to produce cells for clinical use. Together TRCs and the AastromReplicell System provide a foundation that the Company is leveraging to produce multiple Prescription Cell Products (PCPs), the first of which is now in the clinical stage in the U.S. and EU. TRCs are the core component of the PCPs Aastrom is developing for bone grafting, peripheral vascular disease, jaw bone reconstruction and spine fusion markets. The Company has also developed the AastromReplicell System for dendritic cell production for researchers and institutions developing vaccines to treat cancer and infectious diseases, under its Cell Production Products line.

[xwin]

AASTROM BIOSCIENCES CEO TO PRESENT AT RODMAN & RENSHAW TECHVEST 6TH ANNUAL HEALTHCARE CONFERENCE

Ann Arbor, Michigan, October 25, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today R. Douglas Armstrong, Ph.D., Chairman and Chief Executive Officer, will present at the Rodman & Renshaw Techvest 6th Annual Healthcare Conference. The conference will be held October 26 – 28, 2004 at the Waldorf Astoria in New York, NY. Dr. Armstrong will present at 2:50 p.m. (EDT) on Wednesday, October 27th.

Rodman & Renshaw, LLC is a privately-held, full-service investment bank committed to fostering the long-term success of emerging growth companies through capital raising, strategic advice, insightful research, and the development of institutional support. Rodman employs dedicated, experienced, and talented professionals within its equity research, corporate finance, and sales and trading divisions.

A live webcast of Aastrom`s presentation can be accessed by logging onto the web at http://www.wallstreetwebcasting.com/webcast/rrshq4/astm/. An archived replay of the presentation will also be available after the conference, at the same site. For more information about the Rodman & Renshaw Techvest 6th Annual Healthcare Conference, please visit Rodman & Renshaw`s website at www.rodmanandrenshaw.com.

About Aastrom Biosciences, Inc.

Aastrom Biosciences, Inc. (NasdaqSC: ASTM) is a regenerative medicine company developing proprietary adult stem cell-based products for the repair of damaged human tissues and other medical disorders, or the generation of normal human tissues. Aastrom`s strategic position in the tissue regeneration and cell therapy sectors is enabled by its proprietary Tissue Repair Cells (TRCs), a mix of bone marrow stem and progenitor cells, and the AastromReplicell® System, an industry-unique automated cell production platform used to produce cells for clinical use. Together TRCs and the AastromReplicell System provide a foundation that the Company is leveraging to produce multiple Prescription Cell Products (PCPs), which are now in the clinical stage in the U.S. and EU. TRCs are the core component of the PCPs Aastrom is developing for bone grafting, peripheral vascular disease, jaw bone reconstruction and spine fusion markets. The Company has also developed the AastromReplicell System for dendritic cell production for researchers and institutions developing vaccines to treat cancer and infectious diseases, under its Cell Production Products line.

[xwin]

da steigt ne Aktie um locker 30% und im Board interessiert es niemanden. In Frankfurt fällt der Wert sogar um 1 Cent.

[diegutefee]

Hallo xwin,

ich habe Aastrom vor langer Zeit mehrmals empfohlen und
sie eingesammelt und heute freue ich mich darüber, daß
ich sie im Depot habe!

Herzliche Grüße

diegutefee

[xwin]

hi gute fee

naja...wir werden dann wohl wieder hier mit dem Kopf schütteln wenn irgendwelche Pusher bei 2,50 ins Board kommen...ist immer das gleiche...

[meislo]

bin schon seit 2001 dabei. habe aber den grössren teil meines depots in 2003 nach geron geschaufelt.

gruss meislo

[diegutefee]

Hallo xwin,

genauso ist es!



Herzliche Grüße

diegutefee

[goasi]

Hallo Leute,
es schauen doch öfters mal alte bekannte vorbei
bin auch schon seit 2001 investiert, der Einstandskurs war
natürlich dementsprechend, aber ich lasse sie im Depot, weil ich mir bei dieser Aktie eines Tages den grossen Knall erwarte, dann können sich die Glücklich schätzen die unter 1 EUR gekauft haben.

Ein Hoch auf die Stammzellen

mfg goasi

[diegutefee]

Hallo goasi,

ganz genau!

Die Weitsichtigen werden reich sein!

Herzliche Grüße

diegutefee



P.S.:
The trend is your friend!

[Sugar2000]

Moin moin!
Ich melde mich auch mal wieder
Habe gerade die heutige Entwicklung von StemCells und Aastrom in meiner Watchlist gesehen! Nicht schlecht
Ich denke auch die große Zeit wird noch kommen, aber bin leider zu Tiefsständen raus Aastrom zu knapp 0,30€ und Stemcells zu 0,75€ verkauft... naja da steckt man nicht drin! Dachte die wären kurz vor der Pleite...
ich werde noch ein paar Jahre abwarten bis man die Entwicklung besser nachvollziehen kann, auch auf die Gefahr hin, dass ich erst zu Kursen um 10-20€ einsteigen kann
Wünsche euch viel Glück mit eueren Positionen! Jedoch rate ich euch SL zu seten, da meist bei starken Anstiegen der Stammzellentitel eine Abwärtswelle folgte...
Schönen Abend!
Sugar

[steinuel]

.. und nächste woche wird bush gewählt und dann fangen wieder alle an zu weinen.

[xwin]

@steinuel - das ist möglich ja. Aber nicht logisch und an der Börse wiederholt sich nicht immer alles zwangsläufig. Vielleicht erkennt der Markt diesmal dass ASTM in der Entwicklung was die Marktreife angeht deutlich vor STEM und GERN ist und vorallem NUR ADULTE STAMMZELLEN verwendet was keinen Konflikt mit der Bush-Doktrin darstellt.

Im Gegenteil könnte ASMT dadurch vielleicht sogar erst profitieren.

Ich persönlich neige zu der Überzeugung das dieser Kranke Affe nicht noch einmal gewählt werden sollte aber für ASTM ist es sagen wir mal von weniger grosser Bedeutung als für die Umwelt, Afghanistan, Irak, Iran, Nordkorea...

[ab@h]

Was ist hier eigentlich los? Der Wert explodiert ja förmlich! (Werden fast zwei Jahre warten doch noch belohnt...? *seufz)

Gruße an alle, die hier noch dabei sind...

[diegutefee]

Hallo abah,

ich bin noch dabei und sehe heute schon, daß Aastrom
eines Tages nicht unter 10 $ zu haben ist!

Herzliche Grüße

diegutefee



P.S.:
Wir müssen diese Firmen fördern, um überleben zu können!

[worldcup]

Hallo Gute Fee,
was war denn die Begründung für den Ausbruch.
gab es irgendwelche news.

[diegutefee]

Hallo worldcup,

gestern hat Aastrom wieder positive Nachrichten über
die Phasen 1/2 ihrer Testversuche mitgeteilt betreffend
Knochenheilung usw.

Weitere Infos unter www.aastrom.com!

Außerdem sieht es charttechnisch sehr gut aus!

Nächstes Kursziel: 3 $ - 5 $

Der Vorstand kauft laufend Aktien nach.

Herzliche Grüße

diegutefee



P.S.: Aastrom macht sehr gute Fortschritte in der
Forschung und Entwicklung ihrer Produkte betr.
Heilung von Haut, Knochen und Zellen...

[xwin]

ich sehe es genauso. Leider habe ich ein wenig gefrustet Anfang Dezember geschmissen obwohl ich an den Wert geglaubt habe. Sieht aber so aus als wenn es kein Zock ist. Der Wert hat definitv Potential.

Wünsche euch weiterhin viel Erfolg mit ASTM. Vielleicht kaufe ich wieder ein wenn der Wert etwas zurückgekommen ist. Sieht aber momentan nicht danach aus.

xwin

[diegutefee]

Hallo xwin,

Aastrom betrachte ich als langfristige Anlage!

Selbstverständlich kann jeder kaufen und verkaufen wann
immer er will!

Entscheidend ist jedoch das Kursziel!

Im vergangenen Jahr waren die Nanotech-Werte in und
in diesem Jahr sind es die Stammzellen-Aktien!

Endlich haben die Anleger erkannt, daß die Stammzellen-
Aktien noch sehr viel Potential haben.

Welches Medikament kann so viel heilen (ohne Neben-
wirkungen)?

Stammzellen sind die Wunderheiler der Zukunft!

Herzliche Grüße

diegutefee

[ollihat]

Habt Ihr schon gemerkt:

Aastrom zieht jetzt prozentual massiv an Stemcells vorbei!

[[KERN]Codex]

Bin bei ASTM dabei seit Donnerstag Nachmittag, Kaufkurs 1,905$

Ich lasse sie einfach laufen..



schönes we,

gruß codex

[meislo]

und es geht weiter

vorbörse bei 2,55 Dollar


gruss meislo

[HetfieId]

Symbol: ASTM
Last Trade: 2.77 9:35AM ET
After Hours Change: N/A
Today`s Change: 0.49 (21.49%)

Sehr geil!

[HetfieId]

3.00 $

[diegutefee]

Hallo Aastrom-Freunde,

charttechnisch ist das nächste Kursziel mindestens 5 $!

Herzliche Grüße

diegutefee

[covino02]

...habe zu 2,18eur heute gekauft.

meint ihr,das war zu teuer ??

[mfierke]

schei..... verpasst

[covino02]

glaub ich nicht...

die dampflok stampft nach vorn.
der zug kommt ins`s rollen!!!

[covino02]

intraday:

runter auf 1,77usd -> jetzt wieder 1,87usd !!

der wert geht nicht weiter runter...

[diegutefee]

Hallo Freunde,

da ist was im Busch!

Die züchten erfolgreich Gewebe usw. außerhalb des Körpers
und innerhalb von 2 - 3 Wochen.

Ich habe nachgeschaut. Es werden ständig kleinere Stück-
zahlen verkauft. Die großen sammeln hier ein!

Kaufempfehlung für diese Woche lautet: week buy!

Herzliche Grüße

diegutefee

[diegutefee]

Hallo covino,

Du meinst wohl 2,87 $!

Herzliche Grüße

diegutefee

[covino02]

und wieder rauf auf 3usd.

da ist was sehr großes im busch!!

freitag: 4USD

[[KERN]Codex]

so bin mit einem Gewinn von knapp 55% vorerst raus
Danke ASTM

[diegutefee]

Hallo Freunde,

wir lassen die Bären nicht mehr rein!

Schaut auf den Chart!

Warum Perlen verschleudern, um Schrott zu kaufen?

Herzliche Grüße

diegutefee

[fifastar]

Hallo zusammen,

mal eine Frage ich habe gesehen das in den USA in den letzten vier Tagen über 100 Mio. Anteile gehandelt wurden. Kann mir mal jemand sagen wieviele Anteile es überhaupt gibt? Danke.

FS

[mfierke]

sie kommt aber jetzt recht kräftig zurück

[covino02]

...geht aber nicht mehr unter 2,80usd.

wer kauft da in so großem stil ein??

[[KERN]Codex]

Den Rücksetzer hab ich genutzt, bin wieder drinnnnn

[covino02]

@kern codex

auf wieviel usd könnte es deiner meinung nach in den nächsten tagen gehen?

[fifastar]

Stimmt es das es ca. 80 Mio. handelbare Shares gibt?

FS

[covino02]

ASTM
Aastrom Biosciences, Inc. NASDAQ-SCM


Back to Headlines | Previous Story



Bellwether Report Identifies Lucrative Growth Opportunity


NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by The Bellwether Report.


TORONTO -- (MARKET WIRE) -- 01/10/05 -- The Bellwether Report strives to introduce aggressive growth opportunities to investors at the very earliest stages, allowing for optimal entry points and profitable exit points.

Our success includes companies like Aastrom Biosciences (NASDAQ: ASTM), JDS Uniphase (NASDAQ: JDSU) and StemCell Inc (NASDAQ: STEM) to name just a few.

The BWR analysts have come across a company that they feel holds many of the characteristics they look for when deeming a company undervalued. Biotelemetric Signaling (OTC: BTLGF), is the company that we feel in the short term could be a very lucrative opportunity for small cap investors.....

Quelle:
10.01.2005

Contact:
The Bellwether Report
1 866 702 5511
[e-mail]

[Octavian]

92.232.000 Aktien gibt es!

[fifastar]

Und davon wurden heute ca. 75.000.000 Anteile gehandelt. Sprich nahezu der gesamte handelbare Aktienbestand. Was geht da ab? Wie auch immer ich habe mir ein paar Anteile ins Depot gelegt.

Fs

[[KERN]Codex]

bin wieder raus, mein stoplos hat gezogen..

kann ich Dir nicht sagen wie weit astm uns tragen wird, vielleicht surf ich morgen nochmal mit

[fifastar]

Merkwürdig ist das ich hier auf Wallstreet-online angezeigt bekomme das gestern ca. 50 Mio. Anteile in den USA gehandelt wurden, wohigegen Comdirekt mir ca. 74 Mio. gehandelte Anteile anzeigt und Consors exakt 73.856.255 gehandelte Anteile Anzeigt.

Wie auch immer bei den Umsätzen bleibe ich vorerst dabei.

FS

[Flashpompa]

hoooppppaaaaaaaaaaaaaa

Was geht den hir ab gucke heute in mein depo erstelt vor 4 jahren.
und aastrom ist nur noch 13% im minus dieser schei.... währungs wechsel.
habe meine damals für 2,41 euro gekauft und das nicht wenig der aktuelle dollar kurs war damals bei 1$=0.80€.. aber ich freue mich für euch das einige hier mit 55% und so aus gestopt denn sie haben ihre basis geschützt das sind gute gewinne. und wenn die gesamte aktien an einem tag gehandelt wurde kann es eigentlich nur sein das sie was bald auf den markt bringen. Und ich denke es wird noch steigen keiner reumt die aktien vom markt um sie wieder günstiger zu verkaufen es sei den das ist eine feindliche übernahme, 73mio aktien sind nicht wenig.

mfg flashpompa

[covino02]

...genau das vermute ich auch.

bleibe dabei, denn was hier in den letzten tagen umgesetzt worden ist, kann nur ein vorbote für eine meganews sein.

viele grüße
covino

[diegutefee]

Hallo Flashpompa,

Du hast Recht!

Es sieht nach einer feindlichen Übernahme aus!

Dabei ist es egal, wer auch immer meine Aktien übernehmen
will. So billig bekommt er sie nicht!

Nach jedem Absturz wird wieder kräftig eingesammelt!

Herzliche Grüße

diegutefee



P.S.:
Ich fördere die Stammzellen-Forschung!
Wer weiß, vielleicht werden die Stammzellen eines Tages
unser Leben retten!

Vielen Dank an die Stammzellen-Forscher!

[[KERN]Codex]

Denkt ihr wirklich an eine Übernahme ??
Ich denke die Amierikaner haben uns einmal mehr ihren neuen staubsauger vorgeführt, mehr nicht

Naja heute sehen wir weiter, vielleicht wird ja wieder gekauft wie blöd :P

[[KERN]Codex]

Name
Aastrom
Last Price
2.3800
Net Change
+0.1000
0.0000 (AH)
Orders Entered
134,079
423 (AH)
Last Match Time
19:58:06.186
Market
SC
Previous Close
2.2800
Percent Change
+4.39%
0.00 (AH)
Shares Entered
89,470,277
2,552,360 (AH)
Shares Matched
20,672,031
453,836 (AH)

[fifastar]

@[KERN]Codex

Sorry, aber was sagt mir das?

FS

[diegutefee]

Vorbörslich 2,69 $
+ 13 % gegenüber Vortag!

Die Shorties (Shortseller) werden gekocht!



Herzliche Grüße

diegutefee



P.S.:
Ich melde mich später wieder!

[fifastar]

Hallo zusammen,

Consors und Comdirekt zeigen mir an das zur Zeit ca. 21 Mio. Anteile gehandelt wurden bei Wallstreet-online sind es aber nur ca 9 Mio Anteile?????

Weiß hier jemand welche der Zahlen denn nunstimmt?

Danke

FS

[diegutefee]

Hallo Freunde,

ich bin bei wallstreet-online die ganze Zeit nicht rein
gekommen!

Rechenbeispiel:
Eine Imclone-Aktie kostete in 2004 ca. 90 $
Im Tief lagen sie bei ca. 5 $
Durch FDA-Zulassung eines Medikamentes stiegen sie wieder
bis ca. 90 $.

Aastrom hat wesentlich mehr Produkte in der Pipeline und
kostet momentan nur 2 Euro!

Fazit:
Ich sehe heute schon, daß Aastrom eines Tages Imclone
überholen wird!

Begründung:
- Heilung von Hautkrebs sowie andere Krebsarten
- Heilung von Alzheimer
- Heilung von Haut und Knochen
- Heilung von defekten Geweben
- Heilung von kranken Zellen
usw.

Frage:
Was müßte eine Aastrom-Aktie demnach kosten?

Antwort:
Auf gar keinen Fall 2 Euro!

Herzliche Grüße

diegutefee

[diegutefee]

Hallo fifastar,

es wurden in USA weit über 21 Mio. Stück gehandelt!

Starke Nachfrage!

Herzliche Grüße

diegutefee

[fifastar]

@dieguteFee

Danke für die Info.

Leider glaube ich langsam das wir hier alle verarscht werden. In den letzten 6 Handelstagen wurden ca. 200 Mio. Anteile gehandelt, von einer Firma von der es nur ca. 100. Mio Anteile gibt. Wenn ein großer Aufkäufer im Markt wäre, dann müßte die Anzahl der handelbaren Anteile mit der Zeit abnehmen und bei gleichbleibend hoher Nachfrage an Aktien der Kurs immer weiter steigen(100% Kurssteigerung wäre dann gar nichts). Stattdessen habe ich das Gefühl das jeder der diese Aktie kauft diese innerhalb von Stunden wieder verkauft, sprich niemand kauft hier wirklich mit einem Anlagehorizont von mehr als ein paar Tagen. Wenn diese Vermutung stimmt, dann wird es in Kürze für die hier investierten ziemlich was auf die Fresse geben.

FS

[diegutefee]

Hallo Freunde,

es sieht charttechnisch sehr gut aus!

Bodenbildung bei 2,5 $ (Doppelboden)

Bei 2,5 $ starker Widerstand!

Kleinanleger (Angsthasen) verkaufen.

Großanleger sammeln ein!

Nicht nur Fonds haben Interesse an Aastrom, sondern
es könnten durchaus auch Pharma-Konzerne dabei sein.

Herzliche Grüße

diegutefee

[diegutefee]

Hallo Fifastar,

es sind leider nunmal auch Hedgefonds dabei!

Aber rein charttechnisch sieht es gut aus!

Herzliche Grüße

diegutefee

[fifastar]

PS

Ich habe vergleichbare Umsätze noch nie bei einer andern Aktie gesehen. Das will aber nichts heißen.

FS

[diegutefee]

Hallo Freunde,

Schlußkurs: 2,58 $

gehandelte Stückzahl: 39.192.812

Nachbörslich: 2,60 $

Herzliche Grüße und gute Nacht!

diegutefee

[meislo]

hallu fifastar

wue lange bist du schon an der börse tätig?


Das sind in amerika ganz normale vorhänge.

Die frage ist nur

Wie lange hält dieser trend an?


gruss meislo

[fifastar]

@meislo,

ich habe bisher zumeist in europäische Firmen investiert und habe mir hier am Montag lediglich mal eine kleine Position zugelegt.

Inzwischen frage ich mich jedoch was hinter den exorbitanten Umsätzen und den im Vergleich dazu moderaten Kurssteigerungen steckt. Vielleicht haben die in USA ja sowas wie einen Über-Frick der die Marktteilnehmer in derartige Rauschzustände(ich gebe zu ich muß wohl auch ein wenig benebelt gewesen sein als ich den Wert am Montag gekauft habe) versetzen kann, so dass die alles kaufen würden.

Aber mal im Ernst, ich kenne wirklich keine Aktie, bei der der gesamte Aktienbestand an 6 Handelstagen dreimal umgesetzt wurde. Fundamental ist der Rummel der letzten Tage doch sicherlich nicht zu begründen oder?

FS

PS
[KERN]Codex hat hier mal folgendes gepostet: "Ich denke die Amierikaner haben uns einmal mehr ihren neuen staubsauger vorgeführt, mehr nicht". Ich glaube ich verstehe so langsam was er meint. Wie auch immer am Ende werde ich um eine interessante Erfahrung reicher und vermutlich um ein paar Euro ärmer sein.

[covino02]

Aastrom Biosciences, Inc.
...heute wird die 3usd marke in angriff genommen.


Pre-Market | After Hours Market Jan. 11, 2005 Market Close: $ 2.58


After Hours Trade Reporting Tuesday January 11

After Hours
Last: $2.65 After Hours
Best Bid: N/A After Hours
High: $2.82
After Hours
Volume: 420,670 After Hours
Best Ask: N/A After Hours
Low: $2.52


After Hours
Time (ET) After Hours
Price After Hours
Share Volume
18.28 $ 2.65 1000
18.28 $ 2.65 1000
18.27 $ 2.64 595
18.24 $ 2.63 100
18.24 $ 2.63 4846
18.23 $ 2.64 1000
18.23 $ 2.64 5000
18.22 $ 2.65 3405
18.22 $ 2.65 1595
18.22 $ 2.64 3000
18.21 $ 2.64 1923
18.21 $ 2.64 1000
18.21 $ 2.64 804
18.21 $ 2.64 6273
18.20 $ 2.65 1000
18.20 $ 2.65 3000
18.20 $ 2.65 300
18.20 $ 2.65 1680
18.20 $ 2.65 100
18.20 $ 2.65 2000
....


Viele Grüße
covino

[herrring]

war drin und bin wieder raus. habe in 2 tagen 50 prozent verdient. was will man mehr. ihr muesst mal anschauen wieviel stueck die leute kaufen. die meisten kaufen 100 stueck, 200 stueck, 300 stueck, da sammelt keiner ein.wenn die leute nicht mehr kaufen, dann faellt ASTM fuerchterlich. alle wollen nur die schnelle mark machen.

[diegutefee]

Hallo Freunde,

da werden die Shortseller aber momentan gegrillt!

Herzliche Grüße

diegutefee

[diegutefee]

Hallo Freunde,

charttechnisch sieht es gut aus!

Vergleicht einmal den heutigen Chart mit dem Chart
von 1999 bis 2000.

Ich kann mir nicht vorstellen, weshalb Aastrom abstürzen
soll. Es liegen überhaupt keine Gründe vor!

Im Gegenteil!
Die Stammzellen-Firmen werden Fördergelder erhalten!
Aastrom ist sehr erfolgreich in der Forschung und
Entwicklung!

Nein!
Hier wird sehr stark manipuliert!

Herzliche Grüße

diegutefee



P.S.:
Ich melde mich später wieder!

[herrring]

letzter kurs:
4400 kauf 2.66
3500 verkauf 2.67, na die werden es schwer haben jetzt noch zu steigen

[fifastar]

@herrring

ich verstehe Dich nicht! Warum sollte es nicht möglich sein das der Kurs in den nächsten Tagen noch steigt? Es ist oftmals das nicht Vorstellbare, das am Ende an der Böerse eintrifft.

Das Aastrom zur Zeit eine Spielwiese für Kleinanleger ist halte ich für totalen Blödsinn, nicht bei den Umsätzen.

FS

[diegutefee]

Hallo Aastrom-Freunde,

vermutlich sind hier einige Anleger beim Höhenrausch von

- chinesischen Aktien in 2002 - 2003
- Nanotechs in 2003 - 2004

nicht dabei gewesen!

Schade!
Wer nicht dabei war, kann auch nicht wissen, was ihm
entgangen ist!

Die Aktien stiegen bis zu 4000 % und mehr!

Danach kamen die Nanotechs!

Nun sind es die Stammzellen-Aktien, die gefördert werden.
Denn das Know-how ist unbezahlbar und von unschätzbarem
Wert!

Die Milliarden werden diese Firmen eines Tages verdienen.

Und dann sehen alle anstatt alt, wesentlich jünger aus!

Herzliche Grüße

diegutefee



P.S.:
Ich weiß, worüber ich schreibe!

[worldcup]

Gute Fee,
du bist mir sehr sympathisch
asth wird seinen weg gehen - da bin ich überzeugt.

[diegutefee]

Hallo worldcup,

danke!

Auch Du bist mir sehr sympathisch, weil wir auf der
gleichen Wellenlänge sind!

Denn "Wissen" ist Macht!

Herzliche Grüße

diegutefee

[fifastar]

@diegutefee

viele verwechseln Wissen mit Glauben.

FS

[diegutefee]

Hallo Freunde,

ich habe heute einige Termine und werde mich erst heute
abend wieder melden.

Herzliche Grüße

diegutefee

[covino02]

...hier noch einmal ein Artikel zu diesen gigantischen Zukunftsmarkt:

Kalifornische Wähler stimmen für Stammzellenforschung

Kalifornien wird nach dem Wunsch der Wähler zu einem Vorreiter der umstrittenen Stammzellenforschung.
Bei einer Volksabstimmung wurden Fördermittel in Milliardenhöhe bewilligt.



Ersten Hochrechnungen zufolge haben sich die Wähler des Westküstenstaates mit deutlicher Mehrheit für die " Proposition 71" ausgesprochen.
Damit wird der Staat Kalifornien die Forschung an embryonalen Stammzellen mit insgesamt 3 Mrd.USD fördern .

Das Geld sollen wissenschaftlichen Instituten über zehn Jahre hinweg zufließen.


Gouverneur Arnold Schwarzenegger befürwortet die Forschung an embryonalen Stammzellen


Zahlreiche Nobelpreisträger, Gouverneur Arnold Schwarzenegger, Microsoft-Gründer Bill Gates und der an Parkinson erkrankte Schauspieler Michael J. Fox hatten sich für das Referendum stark gemacht.
Auch Schauspieler Christopher Reeve hatte kurz vor seinem Tod einen Werbespot aufgezeichnet, in dem er sich für die staatliche Förderung der Stammzellenforschung aussprach. " Stammzellen haben schon Lähmungen in Tieren geheilt" , sagt Reeve in dem Spot.

"Stammzellen sind die Zukunft der Medizin".


Forschung, die wir heute betreiben, könnte in der Zukunft ein Heilmittel liefern" , so stellte sich der Republikaner Schwarzenegger hinter die Initiative. Der Gouverneur distanzierte sich damit vom Kurs der Bush-Regierung, die die Forschung mit Stammzellen nur ganz begrenzt unterstützen will.

Quelle: Financial Times 03.11.04

[Super-Girl]

macht es sinn jetzt noch einzusteigen, ganz ehrlich....
der chart sieht ziemlich gruselig aus. schön für die, die schön positioniert sind. herzlichen gückwunsch...
lg sg

[fifastar]

@SG

Ganz ehrlich ...ich habe keine Ahnung!

FS

[covino02]

also,wenn man danach geht, was in den letzten tagen an positiven nachrichten so kommt sind solche kurse erst der anfang:

11.01.2005 15:30:00 (BUSINESS WIRE NEWS EXPRESS)

U.S. BioDefense Clarifies 3:1 Split Date of January 31 and Announces Stem Cell Initiative


U.S. BioDefense (OTCBB:UBDF) announced Friday that it has adopted a resolution to seek stockholder approval for authority to implement a forward split.
The Board wishes to clarify to its shareholders that its CEO David Chin will vote in favor of the proposed grant of authority to the board with respect to the forward stock split and will have the power to pass the proposed corporate actions without the concurrence of any of our other stockholders. The forward split exchange ratio that the board of directors approved and deemed advisable and for which it is seeking stockholder approval is three post-split shares for each one pre-split share, with the forward split to occur as of January 31, 2005.

According to CEO David Chin, "We are positioning to leverage our new Stem Cell technology transfer focus in response to the potential of California`s $3 Billion Stem Cell Research Fund and a Department of Defense BioDefense Grant available related to Embryonic Stem Cell technology commercialization. The board of directors believes that the lower share price could help generate further interest in our operations from relationships with Universities, Research Labs, and Wall Street thereby adding more fundamental value and creating a more liquid market for our shareholders. A white paper analyzing California University Stem Cell technology resources and industry participants StemCells, Inc. (NASDAQ:STEM), Geron Corp. (NASDAQ:GERN), and Aastrom Biosciences (NASDAQ:ASTM) will be released in coming weeks."

About U.S. BioDefense, Inc.

U.S. BioDefense recently sponsored the Project T2 Technology Transfer Conference, the nation`s leading showcase of new university technologies, being hosted at the Wilshire Grand Hotel in Los Angeles, CA. Other sponsors (http://www.projectt2.org/sponsors.htm) include Southern California Edison, Latham & Watkins, Morrison & Foerster, PricewaterhouseCoopers, Canadian Consulate General, and Genzyme. U.S. BioDefense is a Department of Defense central contractor that researches, develops, and commercializes leading-edge biotechnology. U.S. BioDefense, Inc. recently entered into a Commercial Evaluation License Agreement with the National Institutes of Health (NIH). The biotechnology is related to a method for universal inactivation of viruses, parasites and tumor cells.

These inactivated agents can be used as vaccines against the diseases caused by such viruses, parasites and tumor cells. Hence, the immunogenic of the agent as a whole is maintained and can be safely used for vaccination without the threat of infection. U.S. BioDefense, Inc. intends to conduct laboratory experiments under this Agreement to evaluate the suitability for commercial development. Furthermore, U.S. BioDefense, Inc. has agreed to provide the facilities, personnel, and expertise to evaluate the commercial applications. NIH`s bioterrorism budgets have jumped from $53 million in 2001 to $1.7 Billion in 2005.

Safe Harbor Statement Forward-Looking Statements

Included in this release are certain "forward-looking" statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company`s financial performance. Such statements are based on management`s current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, the success of enhancements to the Company`s brand image, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political conditions, such as terrorism. Information with respect to important factors that should be considered is contained in the Company`s Annual Report on Form 10-K as filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.

Quelle: BUSINESS WIRE NEWS EXPRESS


Viele Grüße
Covino

[covino02]

...und noch `ne meldung!!


13.01.2005 17:00:00 (BUSINESS WIRE NEWS EXPRESS)

U.S. BioDefense Signs Agreement with DuPont Director of Technology Commercialization and TechIAConnect as Stem Cell Technology Transfer Consultants


U.S. BioDefense, Inc. (OTCBB:UBDF) is pleased to announce today that it has retained the services of Dr. Robert R. Gruetzmacher and TechIAConnect and Associates as its Stem Cell Technology Transfer Consultants.
The company has engaged the consultants` services to assist U.S. BioDefense in its Stem Cell technology transfer and commercialization initiative including a white paper in progress on industry participants Geron Corp. (Nasdaq:GERN), Aastrom Biosciences (Nasdaq:ASTM), and StemCells, Inc. (Nasdaq:STEM).

Dr. Gruetzmacher is the Director of Intellectual Property and Licensing in DuPont`s Center for Collaborative Research and Education. For a recent interview with Dr. Gruetzmacher on Licensing at DuPont visit http://www.yet2.com/app/insight/insight/20011021_gruetzmache… .

David Chin, U.S. BioDefense CEO, stated: "We have aligned with experts to accelerate our stem cell technology transfer initiative. By forming strategic relationships with leading tech transfer organizations like TechIAConnect and Associates, we are accelerating our growth strategy for stem cell technology transfer and commercialization while maximizing shareholder value."

Dr. Gruetzmacher`s professional tenure includes leading DuPont`s (NYSED) technology commercialization efforts at its Center for Collaborative Research and Education. During his 30-year career with DuPont, his responsibilities included research, development, manufacturing and marketing in the imaging products and medical diagnostic businesses. He has served as a trustee of the Licensing Executives Society and chairs international forums dealing with topics such as university/company transactions, knowledge management and the management and valuation of intellectual assets. He has authored publications and is invited frequently to give talks on these topics. He is also a member of the American Chemical Society, the Association of University Technology Managers and the American Association for the Advancement of Science He serves on the advisory board of the Larta Instititue and Authored the publication, "Innovation Matters."

[diegutefee]

Hallo Freunde,

nur keine unnötige Aufregung!

Wir haben einen sehr starken Widerstand bei 2,5 $!

Realtime momentan: 2,59 $

Vielleicht sind wir bis Börsenende wieder im Plus!

Charttechnisch sieht es jedenfalls gut aus!

Herzliche Grüße

diegutefee

[covino02]

amex biotech index: -2,5%
nasdaq biotech index: -1,7%

beide indizes standen im gestrigen tagesverlauf wesentlich besser - astm hingegen hat sich kaum verändert.

das spricht für relative stärke und der starken unterstützung bei 2,5usd.

heute geht`s wieder aufwärts...

[diegutefee]

Hallo Freunde,

wir haben heute einen starken Widerstand bei 2,70 $.
Danach geht es weiter bergauf!

Aastrom ist aufgrund der Vielseitigkeit ihrer Produkte
sehr interessant!

Es befinden sich derzeit mehrere Produkte in klinischen
Phasen.

Herzliche Grüße

diegutefee



P.S.:
Ich melde mich später wieder!

[covino02]

...der (positive) newsflow hält an...

14.01.2005 14:05:
Aastrom Biosciences Receives Patent Expanding Coverage for its Single-Pass Perfusion Technology

ANN ARBOR, Mich., Jan. 14 /PRNewswire-FirstCall/ -- Aastrom Biosciences (Nachrichten) (NasdaqSC: ASTM) announced today that it has received patent number 6,835,566 from the United States Patent and Trademark Office. The patent provides expanded coverage for the Company`s single-pass perfusion technology to cover enhancing the biological functionality of human dendritic cells produced in cell culture. Dendritic cells are in clinical trials and experimental evaluations as vaccines for numerous forms of cancer and infectious diseases at various academic institutions and companies.

Aastrom is currently engaged in on-going clinical trial collaborations at Stanford University evaluating dendritic cells produced with this technology.

"This patent further expands Aastrom`s coverage of our single-pass perfusion technology for growing human cells from bone marrow stem cells, to now include dendritic cells," said R. Douglas Armstrong, Ph.D., Chairman and Chief Executive Officer of Aastrom.

"Our industry-unique technology continues to supportAastrom`s position as a leader in the production of novel cell- based therapeutics."


Viele Grüße
covino

[diegutefee]

Hallo Aastrom-Freunde,

kurz und bündig:

Die einzigartige Technologie von Aastrom bestätigt
immer mehr die Führungsposition von Aastrom auf dem
Gebiet von "novel cell-based Therapeutics"!

Fazit:
Wie bereits erwähnt, wird Aastrom eines Tages unbe-
zahlbar sein!

Herzliche Grüße und ein schönes Wochenende!

diegutefee



P.S.:
Meine absoluten Favoriten in der Stammzellen-Forschung
sind:

- Aastrom und
- Stemcells

[meislo]

die favoriten sibd ccel und gern

werden sehn!

gruss meislo

[covino02]

nachbörslich weiter aufwärts...

Aastrom Biosciences, Inc.

Pre-Market | After Hours Market Jan. 13, 2005 Market Close: $ 2.70


After Hours Trade Reporting Friday January 14

After Hours
Last: $2.75 After Hours
Best Bid: N/A After Hours
High: $2.75
After Hours
Volume: 148,433 After Hours
Best Ask: N/A After Hours
Low: $2.66


After Hours
Time (ET) After Hours
Price After Hours
Share Volume
18.29 $ 2.75 3787
18.29 $ 2.75 1211
18.29 $ 2.75 2000
18.29 $ 2.74 1000
18.28 $ 2.75 6789
18.28 $ 2.75 5500
18.27 $ 2.75 3000
18.25 $ 2.75 1500
18.24 $ 2.74 1175
18.24 $ 2.74 1750
18.24 $ 2.74 2686
18.21 $ 2.74 250
18.21 $ 2.74 500
18.16 $ 2.73 1186
18.16 $ 2.74 3814
18.15 $ 2.73 500
18.15 $ 2.73 1314
18.15 $ 2.73 686
18.14 $ 2.73 4614
18.14 $ 2.73 386
18.13 $ 2.73 200
18.12 $ 2.73 2000
18.12 $ 2.73 2000
18.11 $ 2.73 1000

... allen noch ein schönes wochenende !!

[fifastar]

Ich finde es ist hier seltsam ruhig! Dabei sieht es so aus als ob wir heute die 3 Dollar nehmen könnten.

FS

[[KERN]Codex]

[covino02]

schaffen wir diese woche noch den ausbruch über das allzeithoch ?!?!?

heute wieder riesige kauforders !!

[diegutefee]

Hallo Aastrom-Freunde,

bei Aastrom sehe ich nur Insider-Käufe!

Bei Cryo-Cell haben Insider in 2004 verkauft!
Verkaufspreis lag bei ca. 2,50 $.

Charttechnisch sieht es bei Aastrom sehr gut aus!

Herzliche Grüße

diegutefee



P.S.:
Ich melde mich später wieder!

[meislo]

Stem-cell firms rise on funding news
By Val Brickates Kennedy, CBS.MarketWatch.com
Last Update: 4:09 PM ET Jan. 18, 2005
BOSTON (CBS.MW) -- Shares of the three largest publicly traded stem-cell researchers rose notably Tuesday, amid reports that lawmakers in both New York and New Jersey were considering broad funding initiatives to promote stem-cell research in their states.





NEWS FOR ASTM
Stem-cell stocks higher on potential state funding
Schering-Plough takes hit on rating
Highlights of rising and falling U.S. stocks
More news for ASTM

Quote & News Charts Financials Analysts Options SEC Filings




Aastrom Biosciences (ASTM: news, chart, profile) was the highest climber, gaining 14.44 percent to $3.09, with shares of Stem Cells Inc. (STEM: news, chart, profile) right behind, gaining 11.64 percent to $5.85. Geron (GERN: news, chart, profile) stock also advanced, up 4.91 percent to $8.97.

The stem-cell companies appeared to be bolstered by reports over the holiday weekend that New Jersey`s acting governor, Richard Codey, has proposed spending $380 million on funding stem-cell research in his state. Codey has argued that New Jersey must spend the money so that it would not lose scientific talent to other states that are planning to offer lucrative funding for the emerging scientific field, such as California, Illinois and Wisconsin.

Likewise, some New York state lawmakers have been pushing for a major bond offering similar to one recently passed by voters in California.

New York is mulling whether to offer $1 billion in bonds that would fund sizable grants to stem-cell researchers over a 10-year period.

In November, California voters blazed the trail for such initiatives when they approved a $3 billion bond offering to fund stem-cell research.

[diegutefee]

Hallo Freunde,

nun ist der Weg frei!

Damit haben die Shortseller nicht gerechnet, daß wir
heute die 3 $-Marke überschreiten würden!

Herzliche Grüße und gute Nacht
and good evening nach USA!

diegutefee



P.S.:
Die Perlen und Juwelen sollte man pflegen!

[HetfieId]

Today`s Change: Up 0.80 (29.63%)

[meislo]

Nachbörslich 3,60 Dollar!


gruss meislo

[[KERN]Codex]

Strooong Buy!!

hab mir gerad nochmal ne position gegönnt

[[KERN]Codex]

Waaaahnsinn

3,65$

[[KERN]Codex]

4,15$

[pulp_fiction]

Hallo,

echt unglaublich der kurs - hoffe das geht noch lange weiter so.

Aber weswegen ich eigentlich poste: Weiß jemand, wo es kostenlose realtimekurse an der nasd. gibt. Danke für ne antwort!

Gruß

pulp

[Flashpompa]

jeppppaaaaaaaaaaaaaaaaa

4€ ist geknackt..
seit 4 jahren das 2. mal im plus aber diesmal deutlich.
grins

mfg flach
:-)

[HetfieId]

pulp
Bei Yahoo http://finance.yahoo.com/q/ecn?s=ASTM
oder hier
http://www.island.com/bookviewer/javaversion.asp

[[KERN]Codex]

http://www.island.com



3,55 rein => 4,16 raus

[covino02]

...wer jetzt raussgeht schaut dem kurs richtung 5usd hinterher

hier sind große adressen dabei, die sich eindecken!!

zurücklehnen und geniessen.

viele grüße
covino

[diegutefee]

Hallo Freunde,

das Ziel ist noch lange nicht erreicht!

Der Weg nach oben ist frei!

Kein Insider verkauft schon jetzt!

Herzliche Grüße

diegutefee

[fifastar]

Ich gebe kein Stück ab. Am 10.01 dachte ich wären schon unvorstellbare 75 Mio. Stück gehandelt worden und heute sind in der ersten Handelsstunde schon ca. 40 Mio. Stück gehandelt worden. Wahnsinn, unvorstellbarer Wahnsinn. Dabei soll es doch nicht mal 100 Mio. frei handelbare Stücke geben.

FS

[pulp_fiction]

@ hetfield (james?)
@ kerncodex

Vielen Dank für Eure Info!

@ all

War vor Jahren mal bei stem und astm dabei. Habe mir mal die finger verbrannt. Hoffe diesmal hält der Aufwärtstrend länger. Wenn jetzt alle ihre SL-Marken nachziehen, dann kann schnell ne Abwärtslawine in Gang getreten werden!

Kennt Ihr gute Internetseiten die über astm und stem berichten?

Prost,

pulp

[Moos30]

Jetzt noch einsteigen???

[diegutefee]

Hallo Freunde,

ich sehe heute schon:

Der neue Kandidat an der Nasdaq 100 lautet: "Aastrom"!

Bei den hohen Stückzahlen, die täglich gehandelt werden,
besteht zumindest die Wahrscheinlichkeit, daß Aastrom
große Chancen hat!

Herzliche Grüße

diegutefee



P.S.:
Ich melde mich später wieder!

[fifastar]

@Moos30

schau dir mal #241 an.

FS

[covino02]

...und #192

[[KERN]Codex]

Bei Gelegenheit steige ich morgen wieder ein, mal schaun

[[KERN]Codex]

Da hab ich mit 4,16$ den Ausstiegspunkt Heute ja ganz gut getimed, das Ding ist aber so heiß, wenn wir nahe dem TH oder auf Th schließen bin ich wieder drinnnn

Was meint ihr, wie weit steigt ASTM bei der Dynamik noch?
6-7 ?

[[KERN]Codex]

Eben gabs nen heftigen Sprung auf Tageshoch, meine Order steht

GOIL das Teil läuft morgen bis 6$

[[KERN]Codex]

In ein paar Minuten könnt ihr den JUMP auf dem Chart sehen, bin wieder rein zu 4,20$ => Morgen geht es Richtung 5$

Ich wette wir schließen auf TH bzw. in der Nähe bei
4,40$

Noch jemand eingestiegen?

gruß codex

[[KERN]Codex]

1 QQQQ NM 30,961,280 38.4490 14:45:00.6 1,115 -0.2710 -0.70
2 SIRI NM 29,713,906 5.8560 14:45:01.1 1,291 -0.3840 -6.15
3 ASTM SC 27,045,091 4.2100 14:44:56.3 608 +0.8600 +25.67
4 SPY AM 14,023,473 119.1100 14:44:54.8 878 -0.3600 -0.30
5 SUNW NM 13,208,357 4.3430 14:44:56.4 865 -0.1070 -2.40
6 INTC NM 12,238,043 22.7000 14:45:01.9 1,533 -0.2400 -1.05
7 CSCO NM 11,662,324 18.2900 14:44:59.4 1,324 -0.4500 -2.40
8 YHOO NM 10,373,804 37.3100 14:45:01.9 565 +0.1300 +0.35
9 MSFT NM 9,489,372 26.0700 14:45:01.0 1,337 -0.2500 -0.95
10 ORCL NM 9,425,625 13.5300 14:44:54.0 915 -0.2500 -1.81

[[KERN]Codex]

Im Moment gibt es ASTM wieder für knapp 4$

gn8 codex

[diegutefee]

Hallo Freunde,

und die Shortseller werden wieder einmal gegrillt!

Traumhafter Chart!

Herzliche Grüße und gute Nacht
and good evening nach USA!

diegutefee

[coulibaly3]

aastrom. das heißeste Teil seit 1999/2000

so schnell ist noch selten was gestiegen, was bei ericsson 2Jahre gedauert hat lief hier innnerhalb drei Wochen, hab viel Kohle verbrannt durch "neuen Markt" usw. aber von aastrom gebe ich keine Aktie ab. Was in den 90igern Nokia und Microsoft waren, könnte diesmal Stammzellen sein. Nicht nur für einen kurzfristigen Zock, sondern als 10 jähriges Investment. Gestern abend noch rumgeeiert um die drei Dollar, heute locker über vier. Es kann auch langsamer weitergehen, wenn die Richtung bleibt,

allen Investierten Viel Glück und cool bleiben

coulibaly

[meislo]

Das Ding ist doch schon mächtig heissgefahren!!

100 millionen aktien an einem tag getradet, öbwohl die kaum umsatz machen!!! mittlerweile besitz aastrom eine marktkapitalisierung von jenseits gut und bösem!! sagenhafte 300 millionen dollar und mehr ist die klitsche nun wert und das bei einem umsatz im unteren einstelligen millionenbereich!! ich habe heute verkauft und denke wenn es noch ein paar prozente hoch geht. Na und!! was steil szeigt fällt auch tief! Es dauert Jahre bis die mal wirklisch ein paar pfennige verdienen!!!! Man kann der Ausrufezeichen nicht genug setzen!!!!


Dieser Anstieg war eine gelegenheit um aus und nicht einzusteigen! auch wenn da andere anderer meinung sind!


Morgen ergibt sich bochmal eine chance bei srammzellen abzuzocken und zwar ein neues ipo

Viacell

Auf wochensicht wird sich deren ipopreis von 7-9 Dollar verdreifachen! Es ist eben Stammzellenzeit.

gruss meislo

[fifastar]

@Meislo

gestern wurden über 100 Mio. Anteile zu fast 400 Mio. Dollar umgesetzt!!! Man kann der Ausrufezeichen nicht genügend setzten!!!!!

Und das soll alles ein einziger großer Zock sein, hey super dann wird Frick mir vielleicht bald schon meine Telekom auf ein neues Alltime High pushen!!!!!

Wie ich schon mal schrieb, so was wie das hier habe ich noch nie gesehen. Ich kenne keine Aktien bei der jemals die gesamte Anzahl an Aktien an einem Tag gehandelt wurde. Kennt Ihr Werte bei denen das passiert ist?

Also was ist hier los? Eine Horde wilder Kleinanleger? Wohl kaum, denn die müsste dann schon enorm groß und finanzstark sein. Also doch die Profis und da sicherlich auch mehr als ein Investmenthaus.

Was wird also nun heute passieren? Ich habe keine Ahnung und alle anderen hier auch nicht wirklich.

FS

[JoeUp]

hallo,

ich wundere mich auch über die Anzahl der gehandelten Aktien. Aber bei dieser Dynamik kann man innerhalb eines Handelstages einen ordentlichen Gewinn machen und die Aktien am Ende des Tages wieder los sein.
Genau wie die Nanotechnologie steckt die Stammzellenforschung vom wirtschaftlichen Nutzen betrachtet noch in den Anfängen; von daher erscheint eine derzeitige MK von ca. 350 Mio. ohne grosse Einnahmen als übertrieben. Allerdings stellt sich die Frage, was die Patente und die F&E wert sind. Vor allem wenn sie kommerzialisiert werden können.
Ich finde, das wäre eine Frage, der man nachgehen sollte und nicht immer nur den Kurs im Auge zu haben.

Joe

[JoeUp]

Aastrom Biosciences, Inc. (NasdaqSC: ASTM) ist eine Firma für regenerative Medizin; das Unternehmen entwickelt Behandlungsmöglichkeiten zur Reparatur von beschädigter menschlicher Haut, und anderer medizinischer Störungen oder die Erzeugung von normaler menschlicher Haut; dabei werden die proprietäreuf der Zellenbasis erwachsener Stammzellen verwendet. Aastroms strategische Position in den Sektoren der Haut-Regeneration und der Zelltherapie wird ermöglicht durch die proprietären Tissue Repair Cells (TRCs); dabei handelt es sich um einen Mix aus Knochenmarkstamm- und "Eltern"-Zellen (progenitor cell) und dem AastromReplicell(R)-System, einer in der Industrie einmaligen auto­ma­ti­schen Produktions-Plattform zur Produktion von Zellen für den klinischen Einsatz. Zusammen bilden TRCs und das AastromReplicell-System eine Grundlage welche die Firma in die Lage versetzt, verschiedene "Prescription Cell"-Produkte (PCPs) zu produzieren, die zur Zeit in den U.S.A. und Europa in der klinischen Erprobung sind. Bei den TRCs handelt es sich um die Kernprodukte der PCPs, die Aastrom für die Märkte der Knochenveredelung, periphere Gefässerkrankungen, Kieferknochen-Re­kon­struktion und Wirbelsäulen-Fusion herstellt. Die Firma entwickelte in ihrer Produktlinie der Cell Production Products auch das AastromReplicell-System für die dendritische Zellenproduktion für Forscher und Institutionen, die an Impf­stoffen zur Behandlung von Krebs und infektiösen Erkrankungen forschen.

[Sugar2000]

ich würde auch mit einem Einstieg abwarten... Geron ist weitaus interessanter, weil die noch nicht heiß gelaufen sind...
Ich könnte mich auch mal wieder in den Arsch treten, dass ich bei ASTM zu Kursen um 0,35$ ausgestiegen bin...
aber so ist Börse! Sehe auch ganz klar die Zukunft in Stammzellen, aber das wird noch ein wenig dauern...

[HetfieId]

Vorbörse schaut gut aus!
Ich hätte meinen Arsch verwettet, daß es heute
erst mal runter rauscht!

[[KERN]Codex]

hm ich stimme dem hier gesagten teilweise zu, keiner weiß wie weit uns ASTM noch treibt, das ipo von Viacell dürfte nocheinmal die Aufmerksamkeit auf den sektor lenken, also vielleicht geht es heute noch ein stück weiter nach oben.. nicht mehr lange und wir werden sehen

1 EBAY NM 1,786,573 86.9800 9:14:58.5 500 -16.0700 -15.59
2 ASTM SC 1,359,097 4.0600 9:15:04.3 210 +0.0100 +0.25
3 RMBS NM 938,962 21.1600 9:15:04.6 197 +3.3100 +18.54
4 SIRI NM 629,502 5.5610 9:14:59.5 1,016 -0.2490 -4.29
5 QQQQ NM 531,111 37.6400 9:14:17.2 526 -0.4400 -1.16
6 AVII NM 380,965 3.4000 9:14:41.5 152 -0.7400 -17.87
7 CYTR SC 294,123 1.6700 9:13:52.1 35 +0.5000 +42.74
8 VIGN NM 272,800 1.5100 9:14:13.4 94 +0.2100 +16.15
9 ERICY NM 159,626 29.1500 9:01:08.3 37 -0.5800 -1.95
10 SPY AM 127,779 117.8500 9:11:02.5 136 -0.3700 -0.31
11 WLDA SC 116,880 7.0500 9:14:43.6 44 +1.1000 +18.49

Viel Glück,

gruß codex

[[KERN]Codex]

Es ist 16:10 und es haben bereits knapp 6.000.000 Aktien den Besitzer gewechselt! Wir waren vorhin über 10% im Minus, jetzt leicht im Plus, die Seller ziehen sich zurück

da geht noch was

[[KERN]Codex]

@hetfield

man verwettet doch nicht seinen arsch

[meislo]

ich wundere mich auch über die Anzahl der gehandelten Aktien. Aber bei dieser Dynamik kann man innerhalb eines Handelstages einen ordentlichen Gewinn machen und die Aktien am Ende des Tages wieder los sein.
Genau wie die Nanotechnologie steckt die Stammzellenforschung vom wirtschaftlichen Nutzen betrachtet noch in den Anfängen; von daher erscheint eine derzeitige MK von ca. 350 Mio. ohne grosse Einnahmen als übertrieben. Allerdings stellt sich die Frage, was die Patente und die F&E wert sind. Vor allem wenn sie kommerzialisiert werden können.
Ich finde, das wäre eine Frage, der man nachgehen sollte und nicht immer nur den Kurs im Auge zu haben.











Dem ist nichts hinzuzufügen!


Ich hatte AASREOM schon seit Juni 2001 und hatte 2002 zu kursen von 30 cent eingesammelt. einen grossen teil der position hatte ich bei 60 cent wieder verscherbelt und moch 2000 aktien behalten die ich gestern veräussert hatte.

Ich denke nicht dass das gestern ein fehler war.

gruss meislo

[diegutefee]

Hallo Freunde,

ich habe im vergangenen Jahr die Aktien von Geron verkauft
und Aastrom behalten!

Begründung:
In 2004 haben Insider Geron-Aktien bei über 5,20 $ ver-
kauft.

Bei Aastrom konnte ich keine Insider-Verkäufe feststellen.

Außerdem sind die großen institutionellen Anleger massiv
bei Aastrom eingestiegen!

Bei Geron sind einige Großanleger in 2004 ausgestiegen.

Die Produkt-Pipeline von Aastrom ist wesentlich interes-
santer als von Geron.

Aastrom hat mehrere Blockbuster in der Pipeline, die
mehrere Milliarden US$ wert sind!

Herzliche Grüße

diegutefee



P.S.:
Vorhin hat wieder jemand fast 100000 Aastrom-Aktien
gekauft.

[covino02]

hallo leute,

bin heute auch erstmal raus.

habe in antisoma 917 990 umgeschichtet, denn da steht demnächst eine gewaltige gap-schliessung an.

allen investierten weiterhin gute nerven und viel glück.


viele grüße
covino

ps: astm bleibt natürlich ganz oben auf meiner wl.

[meislo]

Hallo Freunde,

ich habe im vergangenen Jahr die Aktien von Geron verkauft
und Aastrom behalten!

Begründung:
In 2004 haben Insider Geron-Aktien bei über 5,20 $ ver-
kauft.

Bei Aastrom konnte ich keine Insider-Verkäufe feststellen.

Außerdem sind die großen institutionellen Anleger massiv
bei Aastrom eingestiegen!

Bei Geron sind einige Großanleger in 2004 ausgestiegen.

Die Produkt-Pipeline von Aastrom ist wesentlich interes-
santer als von Geron.

Aastrom hat mehrere Blockbuster in der Pipeline, die
mehrere Milliarden US$ wert sind!

Herzliche Grüße

diegutefee



P.S.:
Vorhin hat wieder jemand fast 100000 Aastrom-Aktien
gekauft.






Versuchst Du die Aktie zu pushen!!


Irgendwie kann ich deiner argumentationskette nicht folgen!




Konkret

Welche blockbuster hat AASTROM!!

Ist AASTROM nicht nur ein Zulieferer??


Welche Grossaktionäre sind bei Geron ausgestiegen!!

Du sprichst doch wohl nicht den merixdeal an!


Du bist mir suspekt!!!


gruss meislo

[meislo]

Ich glaube auch, du kannst noch nicht mal erklären was der unterschied zwischen stem, astm und gern ist !

Auf welchen feldern sie beheimatet sind und wie sie ihr buisebess vorantreiben!


gruss meislo

[diegutefee]

Hallo meislo,

ich empfehle Dir, erst einmal richtig schreiben zu lernen,
bevor Du mich unterrichtest!

Morgen werde ich Dir Bescheid geben, wer bei Geron ver-
kauft hat!

Außerdem empfehle ich Dir Englisch-Unterricht, damit Du
Dich bei Aastrom besser informieren kannst!

Ich habe nicht behauptet, daß Geron schlecht ist, aber
die Insider-Verkäufe gefallen mir nicht!

Unter Reuters kannst Du Dich auch informieren!
Dort wirst Du die Bestätigung bekommen!

Gute Nacht!

diegutefee

[meislo]

Was soll im englischen stehen(was wohl nur andere verstehen ,aber ich eben nicht)..dass diese aktie so einzigartig macht!!!


gruss meislo

[[KERN]Codex]

Sieht so aus als ob es nächste Woche weiter aufwärts geht, oder was meint ihr?

[fifastar]

Ich schätze die Chancen bei 60 zu 40 das es nächste Woche weiter gen Norden geht.

FS

[ab@h]

Bin eigentlich nicht mehr so optimistisch, was die kommende Woche angeht. Kann das einfach so weitergehen...?

Andererseits ist Skepsis oft ein guter Nährboden für steigende Kurse... also einfach mal abwarten.

Gruß, ab

[Flashpompa]

@alle

Der aktien split war doch zum 31. 1 oderund wie wird gesplittet? (verhältnis)

[meislo]

Da sind wohl einige am verkaufen die dass nicht verstehen mit den vielen blockbustern.

Oder sind die nur einfach des englischen nicht mächtig.

http://finance.yahoo.com/q/ecn?s=ASTM


3,30 dollar minus 17%

nahe altimehoch

ähh, habe ich da wieder was nicht verstanden?

[[KERN]Codex]

Die Konsolidierung ist wohl mehr als Gesund

1 QQQQ NM 33,973,461 36.8290 13:00:06.4 930 -0.2210 -0.60
2 SPY AM 14,268,387 117.0800 13:00:06.5 429 +0.3000 +0.26
3 INTC NM 13,094,154 22.2800 13:00:06.3 1,368 -0.1400 -0.62
4 SIRI NM 12,828,988 6.0390 13:00:02.6 1,356 +0.2090 +3.58
5 ASTM SC 11,921,776 3.1900 13:00:06.5 494 -0.8100 -20.25



gruß codex

[HetfieId]

Es geht wieder aufwärts!
Leider hat mir der Mut zum Nachkaufen gefehlt bei 2,98$!

[mulle34]

Habe bei 3,05 nachgekauft, hoffentlich wars das fürs erste mit der Korrektur.

[diegutefee]

Hallo Aastrom-Freunde,

Gap wurde heute geschlossen!

Nun ist der Weg nach oben frei!

Charttechnisch sieht es jetzt wieder sehr gut aus!

Trotz positiver Meldung wurde Aastrom heute nieder
geprügelt!

Dies war für mich eine gute Gelegenheit, um nachzu-
kaufen.

Strong buy!

Herzliche Grüße

diegutefee

[meislo]

Charttechnisch sieht es jetzt wieder sehr gut aus! Trotz positiver Meldung wurde Aastrom heute nieder geprügelt



Hier erübrigt sich jeder kommentar!


gruss meislo

[diegutefee]

Hallo meislo,

Du bist offensichtlich kein Charttechniker!

Schau auf den Chart, dann wirst Du erkennen, daß das
offene "GAP" heute geschlossen wurde!

Früher habe ich auch nicht darauf geachtet.
Das war ein großer Fehler!
Aber jeder Anfänger macht einmal Fehler!
Aus Fehlern kann man nur lernen!

Am Chart kannst Du die Kauf- und Verkaufssignale
erkennen!

Herzliche Grüße

diegutefee



P.S.:
Außerdem waren viele Shortseller dabei!

[diegutefee]

Hallo Aastrom-Freunde,

Kaufsignal!

Doppelboden hat gehalten!

Starke Unterstützung bei 3,30 $!

Herzliche Grüße

diegutefee



P.S.:
Hedgefonds und Shortseller sind wieder dabei!

[HetfieId]

Starke Unterstützung bei 3,30 $!

Äh,... --> 3.17 !

[Dealer]

Na der Boden war wohl eher bei 3,10 !!

[meislo]

Wieviele gaps werden denn noch geschlossen?

Wo ist der oberpusher der von charts alles versteht?

Gibt es denn noch mehrere gaps zu füllen?

Gibt es da vielleicht noch welche in kursregionen die keiner mehr sehen will?


Genau wie im letzten jahr bei den nanos, so sieht es dieses jahr bei den stammzellen aus. erst hui und dann geht die puste weg!


Hier eine alte analyse aus dem jahr 2002!

und hat sich daran entscheidendes geändert?

http://www.biotech-world.de/archiv/letter/092002.pdf

gruss meislo

[diegutefee]

Zum Nachdenken!

- Der Bettler denkt an heute!
- Der Normalverbraucher denkt an morgen!
- Der Millionär/Milliardär denkt nicht nur an
übermorgen, sondern handelt!

Nun kann jeder nachdenken, was ich damit sagen wollte!

Herzliche Grüße

diegutefee

[HetfieId]

#314
Bin die ganze Nacht wach gelegen und hab
drüber nachgedacht........keine Ahnung

[ab@h]

Mein Bauchgefühl vom Wochenende hat mich doch nicht getrogen. Das Charakteristische am Aastrom-Chart sind gerade die scharfen Zacken...

Ich hoffe auf eine halbwegs weiche Landung irgendwo zwischen 2,50 - 3 $.

lg an alle

[ab@h]

Mein Bauchgefühl vom Wochenende hat mich doch nicht getrogen. Das Charakteristische am Aastrom-Chart sind gerade die scharfen Zacken...

Ich hoffe auf eine halbwegs weiche Landung irgendwo zwischen 2,50 - 3 $.

lg an alle

[Lugano]

So jetzt möchte ich auch wieder einsteigen.

Was würdet ihr mir eher empfehlen zu kaufen.

Aastrom oder Stemcell?

[fifastar]

@All

Ich bin raus, Euch weiterhin viel Erfolg.

PS Ich habe von der Stammzellenforschen null Ahnung und habe einfach mal ein wenig gezockt und Glück gehabt.

FS

[meislo]

Aastrom Biosciences to Hold Investor Conference Call
Monday January 31, 4:30 pm ET


ANN ARBOR, Mich., Jan. 31 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that it will host an investor conference call on Friday, February 4, 2005 at 11:00 a.m. (EST).
Aastrom`s call will begin with brief presentations by R. Douglas Armstrong, Ph.D., Chief Executive Officer and Chairman, Alan M. Wright, Senior Vice President Administrative & Financial Operations and Chief Financial Officer, and James Cour, President and Chief Operating Officer. The balance of the call will be devoted to questions from registered callers.

Interested parties should call [phone], or toll-free (877) 707- 9628, fifteen minutes before the start of the call and identify themselves as registrants of the `Aastrom Conference Call`. The call will be simulcast on the web at http://phx.corporateir.net/playerlink.zhtml?c=85924&s=wm&e=1… and archived for 90 days at the same site.

[Dealer]

Press Release Source: Aastrom Biosciences, Inc.

Aastrom Biosciences Achieves Clinical Milestone in its Phase I/II U.S. Bone Grafting Trial
Tuesday February 1, 8:00 am ET
-- Safety Endpoint for TRC Product Reached; Trial Expanded --

ANN ARBOR, Mich., Feb. 1 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today announced that its U.S. clinical trial of the Company`s Tissue Repair Cell (TRC) product intended for the treatment of long- bone, severe fractures has successfully achieved the first FDA-required clinical benchmark, meeting the clinical safety endpoint for this product when used in bone graft indications. The Company is now able to expand this trial to include a broader range of fracture indications.

ADVERTISEMENT
The first group of patients accrued into the trial suffered with long-term (at least 8 months), non-union tibial fractures. With the safety milestone achieved, the Company is permitted by the FDA-approved IND to now treat appendicular, or fresh, non-union fractures, which opens the trial to a larger patient population.

The sites engaged in this multi-center clinical trial are: Lutheran General Hospital in Park Ridge, IL, the University of Michigan Health System`s Orthopedic Trauma Center, Ann Arbor, MI and the Department of Orthopedic Surgery at William Beaumont Hospital in Royal Oak, MI. The Company anticipates adding additional sites to this U.S. trial. The safety benchmark was achieved in the patient group accrued at Lutheran General Hospital, supplemented with the initial results from the Company`s trial of this same product in Barcelona, Spain.

"We are progressively building the clinical foundation for the safety and usefulness of our Tissue Repair Cell technology for bone regeneration," said R. Douglas Armstrong, Ph.D., Chief Executive Officer and Chairman of Aastrom. "The expansion of this trial to include patients with fresh non-union fractures should accelerate accruals into our bone graft study."

Aastrom`s bone graft TRC product is also in clinical trials in Barcelona, Spain and Bochum, Germany. In October 2004, the Company announced initial results of, and the decision to expand the Barcelona bone graft trial. In addition, the Company is currently engaged in a clinical trial in Barcelona for the use of TRCs in sinus lift procedures, and in 2005 the Company intends to initiate a clinical trial of its TRC product for the treatment of limb ischemia in diabetic patients in Germany. The Company is in the process of preparing an IND application to be filed with the FDA for its TRC product intended for use in spine fusions.

About Aastrom`s TRCs

Tissue Repair Cells (TRCs) are Aastrom`s proprietary mixture of adult bone marrow stem and progenitor cells produced using patented single-pass perfusion technology in the AastromReplicell(R) System. The clinical procedure begins with the collection of a small sample of bone marrow from the patient`s hip in an outpatient setting. TRCs are then produced in the automated AastromReplicell System over a 12-day period. It has been demonstrated in the laboratory that TRCs are able to develop into different types of tissue lineages in response to inductive signals, including blood, bone, cartilage, adipose and vascular tubules. In previous clinical trials, TRCs have been shown to be safe and reliable in regenerating certain normal healthy bone marrow tissues.

About Aastrom Biosciences, Inc.

Aastrom Biosciences, Inc. (NasdaqSC: ASTM) is developing treatments for the repair of damaged human tissues and other medical disorders, or the generation of normal human tissues, utilizing the Company`s proprietary adult stem cell-based products. Aastrom`s strategic position in the tissue regeneration and cell therapy sectors is enabled by its proprietary Tissue Repair Cells (TRCs), a mix of bone marrow stem and progenitor cells, and the AastromReplicell(R) System, an industry-unique automated cell production platform used to produce cells for clinical use. Together TRCs and the AastromReplicell System provide a foundation that the Company is leveraging to produce multiple Prescription Cell Products (PCPs), several of which are now in the clinical stage in the U.S. and EU. TRCs are the core component of the PCPs Aastrom is developing for bone grafting, peripheral vascular disease, jaw bone reconstruction and spine fusion markets. The Company has also developed the AastromReplicell System for dendritic cell production for researchers and institutions developing vaccines to treat cancer and infectious diseases, under its Cell Production Products line.

For more information, visit Aastrom`s website at http://www.aastrom.com.

This document contains forward-looking statements, including without limitation, statements concerning planned clinical trials, product development objective, and potential product applications, which involve certain risks and uncertainties. The forward-looking statements are also identified through use of the words "intended," "should," "anticipates," and other words of similar meaning. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are future clinical trial results, regulatory approval requirements, the availability of resources and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom`s Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.

CONTACTS:
Kris M. Maly or Becky Anderson Kevin McGrath
Investor Relations Department Cameron Associates
Aastrom Biosciences, Inc. Phone: [phone]
Phone: [phone]


Source: Aastrom Biosciences, Inc.

[Dealer]

Morgen @all
Wie sind denn hier die Meinungen zur Bush-Rede und deren Einfluss auf den ASTM-Kurs?

Auszugsweise hat er sich wie folgt geäüßert:

"To build a culture of life, we must also ensure that scientific advances always serve human dignity, not take advantage of some lives for the benefit of others. We should all be able to agree on some clear standards. I will work with Congress to ensure that human embryos are not created for experimentation or grown for body parts, and that human life is never bought and sold as a commodity. America will continue to lead the world in medical research that is ambitious, aggressive, and always ethical".

Wenn Bush gewusst hat, wovon er redet, dann müsste ASTM, die ja nicht mit/an Embryos forschen, jetzt durch die Decke gehen. Wie seht Ihr das???

[telltom]

ASTM ist wahrlich einer der großen interessanten Werte. Man sieht auch, daß der Anteil der institutionellen Unternehmen ständig steigt.

Ich bin davon ausgegangen, bzw habe auch gehofft, das ASTM seine Gewinne der letzten Tage wieder abgibt. Aber nichts davon ist eingetreten.

Auf diesem Niveau könnte man weiterhin ASTM kaufen. Ein Mediziner Freund meinte zwar das die Stammzellenforschung erst in 2-4 Jahren so richtig interessant wird, dann könnten wir hier eine gigantische Hausse erleben.

Man sagt auch, das ASTM die Microsoft der Stammzllenforschung sei. Mal abwarten, aber ich werde ASTM weiter halten, keine meiner Aktien verkaufen, sondern weiter nachkaufen......

[meislo]

Man sagt auch, das ASTM die Microsoft der Stammzllenforschung sei.

Wer sagt dass?

ASTM ist nicht mehr als ein Unternehmen was null umsatz generiert und mit wahnsinnigen 300 millionen dollar absolut überteuert ist!

astm besitzt produkte die seit jahren wie sauerbier anbieten und die keiner haben will!


gruss meislo

[Stemcells]

DIESER VERGLEICH trifft nicht zu,da WIR es hier mit einer wissenschaftlichen Revolution zu tun haben!

[meislo]

wissenschaftlichen Revolution

Was ist dass ?

Da muss ich wohl Einstein fragen!!


gruss meislo

[Stemcells]

GRUSS MEISLO DU ALTER STRATEGE
mich würde mal deine aktuelle Einschätzung zu Stemcells interessieren?

HABE mich im Laufe der Zeit zu Durchschnittskursen von 1.03Dollar in diesem durchaus soliden Wert eingekauft.
Wollte mich dann vielleicht in 3 Jahren bei ungefähr 70 Dollar aus diesem Wert zurückziehen.




GRUSS STEMCELLS

[meislo]

Das sagt alles!

Username: Stemcells
Registriert seit: 06.02.2005
User ist momentan: Offline
Letztes Login: 06.02.2005 21:57:21
Threads: 0
Postings: 4 [ Durchschnittlich 17,4545 Beiträge/Tag ]
Postings der letzten 30 Tage anzeigen
Interessen: keine Angaben

[meislo]

Du meinst also wirklich dass diese aktie in 3 jahren bei 70 dollar steht!

Und das bei zur Zeit etwa 70 millionen ausstehenden Aktien!

Dies entspricht dann einer marktkapitalisierung von etwa 5 Milliarden Dolllar!!!

Stem hat erst ein produkt in die erste klinische phase gebracht, oder sollte ich besser sagen wollte ein produkt in die klinische phase bringen!!



Welcome [Sign In] To track stocks & more, Register
Financial News
Enter symbol(s) BasicPerformanceReal-time MktDetailedChartResearchOptionsOrder Book Symbol Lookup







Associated Press
FDA Puts StemCells Trial on Hold
Tuesday February 1, 12:49 pm ET
StemsCells` Proposed Trial on Hold Until Company Provides FDA With More Information


PALO ALTO, Calif. (AP) -- StemCells Inc. said Tuesday that regulators have placed on hold its proposed phase I trial of a stem cell treatment for a degenerative brain disease until the company provides additional information about the therapy.
ADVERTISEMENT


The stock fell 36 cents, or 7.5 percent, to $4.54 in midday trading on the Nasdaq.

The trial -- which would be the stem cell researcher`s first clinical study -- aims to investigate the safety of a neural cell therapy product called HuCNS to fight Batten disease, an often-fatal neural system disorder that begins in childhood. If the proposed trials gets authorization, it would be the first FDA-approved clinical trial to use a purified composition of human neural stem cells as a potential therapeutic agent, Stem Cells said.

The company said it expects to receive a more detailed, written request from the Food and Drug Administration within 30 days.

Stem Cells said none of the Food and Drug Administration`s suggestions or questions are related to contaminated embryonic stem cells, the subject of recent media reports related to a study done at the University of California in San Diego and the Salk Institute. The company said it does not use embryonic stem cells or mouse feeder cells in preparing its stem cells, but grows its cells in serum-free media that do not have contact with animal cells











Sollte es trotzdem gelingen dieses produkt in die erste klinische phase zu bringen ( woran ich nicht zweifle), wird es noch 6 jahre benötigen bis dieses produkt marktreife hätte!!

Und dieses produkt hat bestimmt keine blockbusterqualität!

klinische phasen sind teuer und diese 6 jahre werden enorm viel geld kosten! Schätzungsweise 500 millionen Dollar, die stem nicht besitzt!

Dieses geld kann über drei wege aufgebracht werden!

1.) über weitere ausgaben von Aktien (darin ist stem sowieso Weltmeister)

2.) über Förderprogramme der nationalen regierungen (diese haben ja gerade den run auf stammzellenfirmen ausgelöst)

3.) über kooperationen mit grossen playern


Wie auch immer es für stem laufen wird. Es wird teuer!!


Und gerade Stammzellen sind noch nicht beherschbar, Man weiss zwar etwas drüber aber längst noch nicht alles.

Einen rückschlag kann es zu jederzeit geben!(Man weiss bis heute nicht ob die zellen entarten können und eine entartung bedeutet hohes krebsrisiko)Auch in fortgeschrittenen stadien der klinischen phasen!

Darauf zu spekulieren dass stem in 3 Jahren bei 70 Dollar steht, klingt absolut abenteuerlich!


gruss meislo

[Stemcells]

GRUSS MEISLO

möchte meine Angaben von vorhin in bezug auf Stemcells noch einmal relativieren.Auch ich bin der Meinung,dass
eine Investition in diese Firma mit enormen Risiken
verbunden ist.Habe nur eine relativ kleine Position.
Mein Hauptaugenmerk liegt bei solideren Aktien.
Dazu gehören:
OSI PHARMACEUTICAL
GILEAD SCIENCES


Gerade bei Osi Pharmaceutical gehe ich weiterhin von einer
soliden Kursentwicklung aus.Denn sollten die Nachrichten
in Bezug auf tarceva(Krebsmittel mit Blockbusterstatus)
weiterhin so positiv verlaufen,sollte einem soliden Aufwärtstrend grundsätzlich nichts im wege stehen.

[HetfieId]

WOW!

[HetfieId]

Sonst alle raus ?

[diegutefee]

Hallo Hetfield,

warum raus?

Ich habe wieder eingesammelt!

Nein! Meine Aastrom-Aktien verschenke ich nicht!

Wer einen ungeschliffenen Diamanten nicht erkennt,
ist selber schuld!

Wir können froh sein, daß es diese Firma gibt!

Herzliche Grüße

diegutefee

[meislo]

scheinbar ist die honsolidierzng beendet.

sieht so aus, obwohl mir der titel unter den stammzellenfirmen am wenigsten zusagt.


gruss meislo

[meislo]

"konsolidierung"

[coulibaly3]

Na also, geht doch wieder
Bilderbuchmäßig zwei mal nahe der 2.50 Dollar aufgesetzt und heute wieder wie ein ping pong ball nach oben. Ehrlich gesagt ging mir das "Zäpfle" (if you know what i mean) und ich dachte es geht wieder runter auf 1 Dollar und warum hast du arsch keinen stoplos gesetzt. Alles wieder gut
forza aastrom

[covino02]

was wir jetzt sehen, ist eine konsolidierung auf gesundem niveau.
eine w-formation zeichnet sich ab und wird uns in neue "alte" höhen bringen.

wer ist mit dabei??

[covino02]

Aastrom Biosciences Issues Statement on Unique Features of its Bone Marrow Tissue Repair Cell Product and Technology



-- The Following is a Statement from R. Douglas Armstrong, Ph.D., Chief
Executive Officer and Chairman of Aastrom Biosciences, Inc. Regarding Recent

Article in New Scientist Magazine --
ANN ARBOR, Mich., April 26 /PRNewswire-FirstCall/ -- R. Douglas Armstrong, Ph.D., Chief Executive Officer and Chairman of Aastrom Biosciences, Inc. (Nasdaq: ASTM) today issued the following statement in response to an article concerning certain aging, research laboratory cultured mesenchymal stem cells and their potential ability to produce tumors in animals, published in the April 21, 2005 edition of New Scientist magazine.

The report noted that mesenchymal stem cells can be managed safely using standard cell culture expansion for 6-8 weeks. However, following multi- passage long-term culture (4 to 5 months), these cells could undergo a spontaneous transformation to cells that may form tumors. This long term culture effect has been known for animal cells, and is now shown for human cells as well.

Aastrom is developing patient-specific bone marrow-based products -- called "Tissue Repair Cells" or TRCs -- for the repair or regeneration of human tissues, utilizing the Company`s proprietary technology.

The Aastrom TRC production process utilizes a small amount of the patient`s own bone marrow, the natural habitat for stem cells in the human body. The sample is placed in a sterile cassette inside the AastromReplicell(R) System, a proprietary, automated cell production system designed to mimic the natural tissue growth environment of the human body. In a short 12-day production cycle the bone marrow grows, filling the cassette and resulting in a much higher number of early-stage stem and progenitor cells, which are then harvested and administered back to the patient for therapeutic treatment.

There are a number of important differences that distinguish Aastrom`s TRCs from the cells that were discussed in the New Scientist article, which synopsized the results of studies cited in an original article in Cancer Research, Vol. 65, Pgs. 3035-3039, published April 15, 2005.

The experiments discussed in the original article used cells obtained from adipose tissue, or fat, not from bone marrow. Once the adipose tissue was collected, the investigators selectively isolated a specific type of cell, removing it from its native tissue environment and thereby eliminating the growth controls that the tissue environment provides. The long-term culture approach used by the investigators was a multiple-passage process that can be preferential for selective outgrowth of transformed cells that can form tumors. Finally, the resultant human cells were administered to mice, a pre- clinical laboratory model which does not always allow for a normal human tissue growth opportunity.

In contrast, Aastrom`s TRCs are produced in a natural mixed-cell environment, in which the bone marrow stem cells remain associated with a portion of the native tissue environment. TRCs are produced over a very short, defined period of 12 days utilizing Aastrom`s proprietary single-pass perfusion technology, which maintains conditions that are conducive to a natural bone marrow growth process. The 12-day process is much less than the 6 to 8 week process that was shown to be safe in the Cancer Research study.

TRCs are not an isolated, pure stem cell product, but a mixture of cells found naturally occurring in bone marrow, and include stem and other cells, which is the natural mixture for augmenting tissue growth. Also, because TRCs are derived from the patient being treated, there are no rejection issues.

Aastrom`s TRCs have been administered safely to over 180 patients to date with no evidence of tumorigenic activity or other serious issues. Aastrom is currently conducting an FDA-approved multi-center human clinical trial of its lead product, intended for the repair of severe long bone fractures, in the United States, and is engaged in similar trials of this lead product in the EU.

->> unterstützungslinie bei 2usd wurde bestätigt

->> große kauforders nach dieser meldung

kaufen.

[covino02]

Aastrom Biosciences` CEO to Present at Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference


ANN ARBOR, Mich., April 29 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) today announced that R. Douglas Armstrong, Ph.D., Chief Executive Officer and Chairman, will present at the Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference. The conference will be held May 4- 5th, at the InterContinental Hotel in Paris, France. Dr. Armstrong will present in the Salon Imperial at 7:00 a.m. (Eastern Time), or 1:00 p.m. (Paris), on Wednesday, May 4th.

Rodman & Renshaw, LLC is a privately-held, full-service investment bank committed to fostering the long-term success of emerging growth companies through capital raising, strategic advice, insightful research, and the development of institutional support. Rodman employs dedicated, experienced, and talented professionals within its equity research, corporate finance, and sales & trading divisions.

A live webcast of Aastrom`s presentation can be accessed by logging onto the web at http://www.wsw.com/webcast/rrshq5/astm/. An archived replay of the presentation will also be available for 90 days after the conference, at the same site. For more information about the Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference, please visit Rodman & Renshaw`s website at http://www.rodmanandrenshaw.com.

[covino02]

Aastrom Biosciences to Hold Investor Conference Call Tomorrow



ANN ARBOR, Mich., May 5 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today that it will host an investor conference call tomorrow, Friday, May 6, 2005 at 11:00 a.m. (ET).

Interested parties should call [phone], or toll-free (877) 707- 9628, fifteen minutes before the start of the call and identify themselves as registrants of the `Aastrom Conference Call`. The call will be simulcast on the web at http://phx.corporate-ir.net/playerlink.zhtml?c=85924&s=wm&e=… and archived for 90 days at the same site.

[covino02]

Aastrom Biosciences, Inc. Reports Third Quarter Fiscal Year 2005 Financial Results



ANN ARBOR, Mich., May 6 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) today reported financial results for the third fiscal quarter ended March 31, 2005. The Company also reported several achievements of the last quarter, both clinically and operationally. For the quarter ended March 31, 2005, these achievements included:

* Clinical progress:

-- Expanded U.S. Phase I/II clinical trial of the Company`s Tissue
Repair Cell (TRC) product for severe long bone fractures to include
a third and fourth site: the Department of Orthopedic Surgery at
William Beaumont Hospital, Royal Oak, MI and Lutheran Medical
Center, Brooklyn, NY
-- Achieved first FDA-required clinical benchmark for our Phase I/II
U.S. clinical trial of the Company`s TRC product intended for the
treatment of severe long bone fractures. Successfully met clinical
safety endpoint for TRCs when used in bone graft indications, which
permits the Company to now treat appendicular, or fresh, non-union
fractures, opening the trial to a larger patient population
-- Completed enrollment in our lead feasibility study for use of TRCs in
jaw bone reconstruction for sinus lifts associated with dental
implants, initiated in Barcelona, Spain

* Patent award:

-- Received patent from the U.S. Patent and Trademark Office that
provides expanded coverage for the Company`s proprietary single-pass
perfusion technology to cover enhancing the biological functionality
of human dendritic cells produced in cell culture

* New board member:

-- Announced appointment of Warren "Chaunce" Bogard, Jr., Ph.D., to the
Company`s Board of Directors. Dr. Bogard is founder and President
of Bogard & Associates, a consulting firm dedicated to assisting
emerging biotechnology and healthcare companies in general
management, strategic planning, business development and new product
marketing

"We are continuing to achieve the operational milestones necessary to move our technology toward the marketplace. In doing so, Aastrom is proactively differentiating itself within the tissue regeneration sector, driven by our ongoing clinical advancement," said R. Douglas Armstrong, Ph.D., Chief Executive Officer and Chairman of Aastrom. "In addition, we continue to build and strengthen the Aastrom team, and are very excited to have Dr. Bogard as the newest member of our Board of Directors."

Fiscal Year 2005 Third Quarter Ended March 31, 2005 Results

Total revenues for the quarter ended March 31, 2005, consisting of grant funding and product sales and rentals, were $252,000 compared to $416,000 for the same period in fiscal year 2004. Total revenues for the nine months ended March 31, 2005 were $0.8 million compared to $1.1 million for the same period in fiscal year 2004.

Grant revenues decreased for the quarter and nine months ended March 31, 2005 to $102,000 and $436,000, respectively, from $331,000 and $1.0 million for the same periods in fiscal year 2004. Grant revenues have decreased from the prior year as a result of reduced grant program activities; however, we continue to pursue grant-funded programs.

Product sales and rentals increased to $150,000 and $377,000 for the quarter and nine months ended March 31, 2005, respectively, from $10,000 and $45,000 for the same periods in fiscal year 2004. The increase is due to increased volume of therapy kit sales for clinical trials and research by others, and revenue from the sale of an AastromReplicell(R) System that was delivered in the first quarter of fiscal year 2005, recognized in this quarter, offset by a terminated rental revenue source of $10,000 and $30,000 for the quarter and nine months, respectively. Rental revenue is not expected in the future, subject to market conditions. In addition, we plan to limit our marketing efforts promoting the AastromReplicell System as a stand-alone product; rather we are focusing on utilizing the AastromReplicell System technology to support our TRC development programs. At such time as we satisfy applicable regulatory approval requirements, we expect that sales of our TRCs and related cell-based products will constitute nearly all of our product sales revenues.

Net loss for the quarter ended March 31, 2005 was $3.3 million, or $.03 per share, compared to a net loss of $2.5 million, or $.03 per share for the same period in fiscal year 2004. Net loss for the nine months ended March 31, 2005, was $8.5 million, or $.09 per share, compared to $7.7 million or $.11 per share for the same period in fiscal year 2004.

Total costs and expenses for the quarter ended March 31, 2005 were $3.8 million compared to $2.9 million for the same period in fiscal year 2004. Total costs and expenses for the nine months ended March 31, 2005 were $9.6 million, compared to $8.9 million for the same period in fiscal year 2004.

Research and development expenses for the quarter ended March 31, 2005 increased to $2.1 million, from $1.7 million for the same period in fiscal year 2004. Research and development expenses for the nine months ended March 31, 2005 increased to $5.3 million, compared to $4.5 million for the same period in fiscal year 2004. This increase reflects our increased research activities to support regulatory submission approvals and anticipated product registrations, product development activities in the area of tissue regeneration, development of product distribution processes, and our ongoing and planned bone grafting clinical trials in the United States and the EU.

Selling, general and administrative expenses increased to $1.6 million for the quarter ended March 31, 2005, compared to $1.3 million for the same period in fiscal year 2004. This increase is due to additional consulting and pre- marketing activities in the United States and internationally, as well as increased costs required for financial internal controls compliance and certification. Selling, general and administrative expenses were $4.2 million for the nine months ended March 31, 2005, unchanged from the same period in fiscal year 2004.

The cost of product sales and rentals increased to $77,000 for the quarter ended March 31, 2005, from $5,000, and increased to $131,000 for the nine months ended March 31, 2005 from $22,000 for the same periods in fiscal year 2004. These increases were due to an increase in volume of product sales.

At March 31, 2005, the Company had $35.4 million in cash, cash equivalents and short-term investments as compared to $16.9 million in cash and cash equivalents at June 30, 2004.

Aastrom Conference Call Information

R. Douglas Armstrong, Ph.D., Chief Executive Officer and Chairman, and Alan M. Wright, Senior Vice President Administrative & Financial Operations and Chief Financial Officer of Aastrom Biosciences, Inc., will review and discuss the third quarter fiscal year 2005 financial results and the Company`s recent progress and future goals today, May 6, 2005, at 11:00 a.m. (ET) when they will host a conference call. Interested parties should call (785) 832- 0326, or toll-free [phone], fifteen minutes before the start of the call to register and identify themselves as registrants of the `Aastrom Conference Call`. The call will be simulcast on the web at http://phx.corporate-ir.net/playerlink.zhtml?c=85924&s=wm&e=… and archived for replay at the same site for 90 days.

About Aastrom Biosciences, Inc.

Aastrom Biosciences, Inc. (Nasdaq: ASTM) is developing patient-specific products for the repair or regeneration of human tissues, utilizing the Company`s proprietary adult stem cell technology. Aastrom`s strategic position in the tissue regeneration sector is enabled by its proprietary Tissue Repair Cells (TRCs), a mix of bone marrow-derived adult stem and progenitor cells, and the AastromReplicell(R) System, an industry-unique automated cell production platform used to produce cells for clinical use. TRCs are the core component of the products Aastrom is developing for severe bone fractures, ischemic vascular disease, jaw reconstruction and spine fusion, with Phase I/II level clinical trials active in the U.S. and EU for some of these indications.

For more information, visit Aastrom`s website at http://www.aastrom.com.

This document contains forward-looking statements, including without limitation, statements concerning clinical trial plans and expectations, intended product development and commercialization objectives, the expected adequacy of capital resources to support planned activities, expected milestones, anticipated components of revenue, plans for the current fiscal year and potential product applications, which involve certain risks and uncertainties. The forward-looking statements are also identified through use of the words "intend," "planned," "planning," "should," and other words of similar meaning. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are the inherent uncertainties associated with clinical trial and product development activities, regulatory approval requirements, the availability of resources and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom`s Annual Report on Form10-K and other filings with the Securities and Exchange Commission.

-- Financial Table Follows --

AASTROM BIOSCIENCES, INC.
(Unaudited)

CONSOLIDATED STATEMENTS OF OPERATIONS DATA:

Quarter ended Nine months ended
March 31, March 31,
------------ -------------
2004 2005 2004 2005
----- ----- ----- -----

REVENUES:
Product sales and
rentals $10,000 $150,000 $45,000 $377,000
Grants and other 406,000 102,000 1,047,000 436,000
----- ----- ----- -----
Total revenues 416,000 252,000 1,092,000 813,000
----- ----- ----- -----

COSTS AND EXPENSES:
Cost of product sales
and rentals 5,000 77,000 22,000 131,000
Cost of product sales
and rentals --
provision for obsolete
and excess inventory -- 9,000 253,000 9,000
Research and
development 1,660,000 2,095,000 4,471,000 5,258,000
Selling, general
and administrative
1,279,000 1,624,000 4,200,000 4,227,000
----- ----- ----- -----
Total costs and
expenses 2,944,000 3,805,000 8,946,000 9,625,000
----- ----- ----- -----

OTHER INCOME 28,000 204,000 113,000 361,000
----- ----- ----- -----

NET LOSS $(2,500,000)$(3,349,000) $(7,741,000) $(8,451,000)
----- ----- ----- -----
----- ----- ----- -----

NET LOSS PER COMMON SHARE
(Basic and Diluted) $ (.03) $ (.03) $ (.11) $ (.09)
----- ----- ----- -----
----- ----- ----- -----

Weighted average number
of common shares
outstanding 72,204,000 100,140,000 71,384,000 90,719,000
----- ----- ----- -----
----- ----- ----- -----



CONSOLIDATED BALANCE SHEET DATA:
June 30, March 31,
2004 2005
----- -----

ASSETS
Cash and investments $16,926,000 $35,435,000
Other current assets 906,000 956,000
Property, net 334,000 614,000
----- -----
Total assets $18,166,000 $37,005,000
----- -----
----- -----

LIABILITIES AND SHAREHOLDERS` EQUITY
Current liabilities $558,000 $801,000
Shareholders` equity 17,608,000 36,204,000
----- -----
Total liabilities and
shareholders` equity $18,166,000 $37,005,000
----- -----
----- -----


CONTACTS:
Kris M. Maly or Becky Anderson Kevin McGrath
Investor Relations Department Cameron Associates
Aastrom Biosciences, Inc. [phone]
[phone]

SOURCE Aastrom Biosciences, Inc.
-0- 05/06/2005
/CONTACT: Kris M. Maly or Becky Anderson, Investor Relations Department
of Aastrom Biosciences, Inc., [phone]; or Kevin McGrath of Cameron
Associates, [phone] /
/Web site: http://www.aastrom.com/
(ASTM)

CO: Aastrom Biosciences, Inc.
ST: Michigan
IN: BIO HEA MTC
SU: ERN CCA MAV

AC-NJ
-- NEF001 --
5762 05/06/200508:00 EDThttp://www.prnewswire.com

[covino02]

vorbörslich

9:04:41.643 S 70 2.2800
8:55:37.185 S 300 2.2800
8:54:20.956 B 5,200 2.3000
8:53:22.839 S 200 2.2900
8:52:41.265 S 1,800 2.2900
8:52:41.265 S 200 2.2900
8:52:09.837 S 2,000 2.2900
8:49:42.354 B 400 2.3000
8:46:57.409 B 2,500 2.2900
8:45:07.338 B 500 2.2800
8:45:06.838 B 1,462 2.2700
8:43:51.390 B 231 2.2600
8:42:45.919 B 350 2.2600
8:41:00.376 B 619 2.2600
8:40:59.906 B 2,500 2.2600

[covino02]

...so, nachdem es am 06.05.05 nicht ganz mit dem anstieg geklappt hat - heute nun der 2. Versuch :


9:06:31.665 B 100 2.4600
9:06:31.448 B 250 2.4500
9:06:30.666 B 500 2.4500
9:06:28.870 B 2,250 2.4500
9:06:18.738 B 200 2.4400
9:06:18.738 B 200 2.4400
9:06:18.738 B 200 2.4400
9:06:18.738 B 200 2.4400
9:06:18.738 B 2,900 2.4400
9:06:10.661 B 200 2.4400
9:06:10.661 B 300 2.4400

[HetfieId]

MarketWatch
Market Pulse: Aastrom shares get a lift from positive trial results
Tuesday May 17, 8:27 am ET
By Michael Baron


NEW YORK (MarketWatch) -- Shares of Aastrom Biosciences jumped 11.7% to $2.30 in pre-market action. Volume of 141,759 made the issue the second most active stock on Instinet. The company early Tuesday reported positive results of a feasibility clinical trial of its Tissue Repair Cells for the treatment of severe long bone non-union fractures. Aastrom said the trial showed five of six patients receiving its TRC treatments showed bone regeneration at the fracture site as determined by radiographic imaging by six months.


Pre-Market (RT-ECN): 2.43 0.37 (17.96%)

[covino02]

...und nochmal auf deutsch:

Aastrom Biosciences meldet aus klinischer Durchführbarkeitsstudie positive Resultate in der Reparatur von Knochengewebe



ANN ARBOR, Michigan, May 17 /PRNewswire/ --

Anzeige:
Ø16-18% im Jahr¹ mit Kapitalabsicherung²! Jetzt kostenloses Infopaket anfordern!


- Resultate zeigen Generation von lokalem Knochengewebe für Knochentransplantate durch Tissue Repair Cells des Unternehmens

Aastrom Biosciences, Inc., (Nasdaq: ASTM) gab heute die Ergebnisse der klinischen Durchführbarkeitsstudie des Unternehmens mit dem Institut de Terapia Regenerativa Tisular (ITRT) in Barcelona, Spanien, bekannt. Die Studie wurde durchgeführt, um die Verwendung von Aastroms Tissue Repair Cells (TRCs) in der Behandlung schwerer, nicht zusammenwachsender Frakturen langer Knochen zu untersuchen. Ein Bericht mit Einzelheiten der klinischen Studie und Informationen zur Behandlung der einzelnen Patienten sowie den erzielten Resultaten wird heute auf Formular 8-K bei der US-amerikanischen SEC eingereicht. Der Bericht besagt, dass alle der Patienten, die mit Aastroms TRCs, einem autologen, aus Knochenmark abgeleiteten Zellprodukt, behandelt wurden, klinische und funktionelle Heilung aufwiesen. Bei fünf von sechs Behandlungen wurde nach sechs Monaten Knochenregeneration an der Frakturstelle durch radiographische bildgebende Verfahren nachgewiesen. Die Resultate waren bemerkenswert, da bei jedem der Patienten Vorbehandlungen mit Standardmethoden der Versorgung versagt hatten und die Patienten bezüglich ihrer Heilung eine schlechte Prognose hatten. Diese Durchführbarkeitsstudie legt nahe, dass Aastroms autologe TRCs möglicherweise ein neues Verfahren zur Erzielung lokaler Knochenregeneration für Knochentransplantate und weitere klinische Indikationen der Knochenreparatur darstellen könnten. Der Bericht mit den Resultaten der Durchführbarkeitsstudie ist auf dem bei der SEC eingereichten Formular 8-K sowie auf Aastroms Website über folgenden Link verfügbar: http://www.aastrom.com/pdf/Whitepaper_Barcelona-051205.pdf.

An der am Hospital General de l`Hospitalet, Centro MedicoTeknon und Hospital de Barcelona-SCIAS durchgeführten Studie nahmen fünf Patienten teil. Ein Patient wurde für zwei separate Frakturen behandelt, d. h. es wurden insgesamt sechs separate Behandlungen vorgenommen. Alle Patienten hatten schwere, nicht zusammenwachsende Frakturen eines langen Knochens erlitten (3 Schienbein- und 2 Oberarmfrakturen, 1 Schlüsselbeinfraktur), die unter traditioneller Standardversorgung nicht heilten. Bei allen Patienten wurde ein offener chirurgischer Eingriff durchgeführt, um eine Metallplatte zur internen Fixierung (im Austausch gegen die alte, erfolglose Fixierung) und Aastrom TRCs einzusetzen und so die lokale Knochenregenerierung zu unterstützen. Die TRCs wurden mit synthetischer kommerzieller Matrix und einem autologen Fibrin gemischt und direkt auf die Frakturstelle aufgebracht. Bei allen Patienten werden laufende postoperative Kontrollen vorgenommen, die klinische und radiographische Standardbeurteilungen der heilenden Frakturstelle beinhalten. Bisher wurden zwei der Patienten länger als ein Jahr postoperativ untersucht, während ein dritter Patient seit länger als acht Monaten kontrolliert wird. Keine Komplikationen oder Nebenwirkungen wurden im Zusammenhang mit der Behandlung beobachtet.

Der Beginn des neuen Knochenwachstums, der durch einen externen Radiologen auf Grundlage von Radiographien beurteilt wurde, schwankte zwischen Patienten. Radiographischer Nachweis von Callusbildung (während der Heilung einer Fraktur gebildetes Knochengewebe) wurde bei fünf von sechs Behandlungen durchschnittlich zuerst nach 11 Wochen beobachtet (Minimum 6 Wochen, Maximum 24 Wochen). Der Callus war im Durchschnitt nach 17 Wochen stabil (Minimum 10 Wochen, Maximum 24 Wochen). Alle Patienten sind in der Lage, den behandelten, gebrochenen Knochen zu belasten. Sie sind schmerzfrei und haben die Beweglichkeit der betroffenen Gliedmasse wiedererlangt. Nur ein Patient (der Patient mit zwei gebrochenen Beinen) bleibt arbeitsunfähig, da seine Arbeit ein hohes Ausmass körperlicher Anstrengung beinhaltet.

Eine unerwartete, günstige klinische Beobachtung bestand darin, dass die für typische, zur Heilung von Frakturen ausgeführte Knochentransplantatverfahren charakteristischen Entzündungen und Ödeme bei allen Patienten am Ort des chirurgischen Eingriffs postoperativ entweder in geringerem Ausmass auftraten oder völlig ausblieben.

"Als behandelnder Arzt dieser Patienten ermutigt mich unser erster Einsatz der TRCs ganz aussergewöhnlich, und ich bin der Ansicht, dass sie ein neues Instrument der orthopädischen Medizin darstellen könnten", so Dr. Carlos Solana-Puerta, der leitende klinische Forscher der Barcelona-Studie. "Obwohl unsere Patienten schwere Frakturen erlitten hatten, die sich zuvor einer Heilung widersetzt hatten, sprachen alle auf die neue Behandlung mit TRCs gut an und erzielten die erwünschten Resultate der Bildung von Knochencallus und neuer Knochenmodellierung. Wir freuen uns darauf, weitere Patienten mit diesem innovativen Zellprodukt behandeln zu können."

Nach Abschluss der Studie bereitet sich Aastrom nun darauf vor, diese Studie zu Frakturen langer Knochen in Barcelona auszuweiten, um verschiedene Verfeinerungen des Verfahrens umzusetzen, die die Verwendung von TRCs in Knochentransplantaten weiter verbessern sollen.

Die von Aastrom auf Formular 8-K eingereichten Studienergebnisse zeigen radiographische Abbildungen der unterschiedlichen behandelten langen Knochen. Abbildungen zeigen den Zustand vor Behandlungsbeginn mit TRCs, den Zustand unmittelbar nach der Behandlung und den Zustand zu einem späteren Zeitpunkt sowie Bilder des chirurgischen Eingriffs. Weitere relevante Daten bezüglich der Verletzungen, der Vorbehandlung und klinischen Erholung wurden ebenfalls zur Verfügung gestellt.

"Die Ergebnisse dieser Durchführbarkeitsstudie sind sowohl bezüglich der Patientenreaktion als auch bezüglich der Umsetzung und des Einsatzes von TRCs im klinischen Umfeld äusserst ermutigend", meinte R. Douglas Armstrong, Ph.D., Aastroms CEO und Vorsitzender. "Jede unserer klinischen Durchführbarkeitsstudien zu Knochentransplantaten soll bestimmen, wie sich TRCs am besten bei chirurgischen Indikationen der lokalen Knochenregeneration einsetzen lassen. Diese Studie ist zwar nur klein, erbrachte aber wesentliche Sicherheitsdaten, Informationen über die beste Verwendung von TRCs im chirurgischen Umfeld und aufregende Resultate zur Genesung."

Aastrom ist derzeit in den USA auch in einer verwandten klinischen Studie zu den TRCs des Unternehmens involviert. Dort wird eine multizentrische Studie ausgeführt, an der derzeit vier Zentren teilnehmen. Diese Studie setzt TRCs zusammen mit einer Knochentransplantat-Allograft-Matrix des Aastrom-Partners MTF (Musculoskeletal Transplant Foundation, Edison, NJ, USA) ein. TRCs werden weiter in einer in Spanien laufenden klinischen Studie am Menschen für eine weitere Anwendung eingesetzt: die Generation von Kieferknochen in Vorbereitung auf Verfahren zum Anheben der Kieferhöhlen. Jede dieser Studien setzt zwar TRCs für die Knochenregeneration ein, aber jede beurteilt einen unterschiedlichen Ansatz zur Verwendung und Anwendung der TRCs. Die Resultate sollen sowohl Aastrom als auch die behandelnden Kliniker zum vorteilhaftesten Verfahren leiten, wie TRCs als neues Instrument der orthopädischen Therapie eingesetzt werden können.

Näheres über Tissue Repair Cells

Tissue Repair Cells (TRCs) sind Aastroms proprietäre Mischung aus Stamm- und Vorläuferzellen aus dem Knochenmark, die im AastromReplicell(R)-System anhand patentierter Single-Class-Perfusionstechnologie gewonnen werden. Das klinische Verfahren beginnt mit der ambulanten Entnahme einer kleinen Knochenmarksprobe aus der Hüfte des Patienten. TRCs werden dann im automatisierten AastromReplicell-System über einen Zeitraum von zwölf Tagen produziert. Im Laborversuch konnte nachgewiesen werden, dass sich TRCs in Reaktion auf induktive Signale zu unterschiedlichen Gewebelinien, darunter Blut, Knochen, Knorpel, Fettgewebe und Gefässröhchen, entwickeln können. In früheren klinischen Studien haben sich TRCs in der Regeneration bestimmter normaler Knochenmarksgewebe als sicher und zuverlässig erwiesen.

Näheres über Aastrom Biosciences, Inc.

Aastrom Biosciences, Inc., (Nasdaq: ASTM) entwickelt patientenspezifische Produkte für die Reparatur bzw. Regeneration humaner Gewebe unter Nutzung der proprietären Technologie adulter Stammzellen des Unternehmens. Aastroms strategische Positionierung in den Sektoren der Geweberegeneration stützt sich auf die proprietären Tissue Repair Cells (TRCs) des Unternehmens, eine Mischung aus Stamm- und Vorläuferzellen des Knochenmarks, sowie auf das AastromReplicell(R)-System, eine innerhalb der Branche einzigartige automatisierte Plattform für die Erzeugung von Zellen, mit deren Hilfe sich Zellen für die klinische Verwendung produzieren lassen. TRCs bilden den zentralen Bestandteil der Produkte, die Aastrom für schwere Knochenfrakturen, ischämische Gefässerkrankungen, Kieferrekonstruktionen und Wirbelfusionen entwickelt. Für einige dieser Indikationen laufen derzeit in den USA und der EU klinische Phase-I/II-Studien.

[covino02]

nach dem schönen anstieg -unter ebenso schönem volumen- gestern ein paar kleinere gewinnmitnahmen.

heute ->> weiter aufwärts !!

ASTM USD

9:51:08.820 B 175 2.3600
9:51:08.820 B 300 2.3600
9:51:08.820 B 300 2.3600
9:51:08.820 B 200 2.3600
9:51:08.437 B 100 2.3500


->

[covino02]

Douglas Armstrong, PhD, Chairman and CEO of Aastrom Biosciences, Inc. (Nasdaq: ASTM) recently granted Wall Street Network an all-new exclusive audio interview profiling the company. Interview highlights include discussions on the following topics:

-- new results from the company`s feasibility study in Spain
-- why the company`s stem-cells are "non-controversial"
-- financials
-- timeline for U.S. clinical trials
-- recently granted expansion in U.S. clinical trials
-- upcoming clinical milestones

To hear the interview in its entirety, visit www.wallst.net . The interview can be accessed by locating the company`s ticker symbol under the exchange on which it trades on the left hand column of the homepage, or by entering the company`s ticker symbol in the Audio Search window.

Quelle: www.nasdaq.de vom 19.05.05

...charttechnisch wird`s jetzt richtig interessant.

der weg bis 3usd ist frei.
die entspricht kurfristigem potential von 17%.

und wenn das volumen weiter so stimmt, kann es auch auf 4usd gehen.

[covino02]

vorbörslich werden wieder fette pakete gekauft:

8:02:51.452 B 1,500 2.7500
8:02:51.312 B 3,000 2.7500
8:02:51.281 B 1,000 2.7500
8:02:50.928 B 1,000 2.7500
8:02:50.342 B 12,500 2.7500
8:02:50.283 B 500 2.7500
8:02:39.269 B 500 2.7500

[Lugano]

Da könnte man doch wieder einsteigen. Vielleicht werden ja die alten Höhen wieder erreicht.

[covino02]

heute doch schon 3usd ??

10:44:06.620 B 90 2.9700
10:44:06.620 B 300 2.9700
10:44:06.620 B 1,710 2.9700
10:44:05.405 B 1,000 2.9700
10:44:01.741 B 1,300 2.9700
10:43:52.119 B 990 2.9700
10:43:52.119 B 10 2.9700
10:43:35.863 B 10 2.9700
10:43:35.863 B 10 2.9700

...echt wahnsinn,was hier abgeht

[covino02]

gestern gingen wir unter dem höchsten handelsvolumen seit
mitte februar um 8,63% nach oben.

im th kratzten wir mit 2,99usd knapp an der 3usd marke.

ein blick auf die letzten handelstage zeigt, dass sich vermehrt größere adressen eingedeckt haben könnten.

eine stabilisierung oberhalb von 2,70usd würde weitere unterstützung für den aufwärtstrend bringen.

wir können uns auf nächste woche freuen!!

After Hours
Last: usd 2.82

After Hours High: usd 2.82
After Hours Volume: 82,524
After Hours Low: usd 2.75


After Hours
Time (ET) After Hours
Price After Hours
Share Volume
18.24 $ 2.82 2200
18.23 $ 2.82 2300
18.23 $ 2.82 500
18.17 $ 2.82 1000
18.17 $ 2.82 1000
18.09 $ 2.82 300
18.08 $ 2.82 200
18.08 $ 2.82 500
18.04 $ 2.82 500
18.00 $ 2.82 200
17.58 $ 2.82 937
17.56 $ 2.80 500
17.55 $ 2.80 870
17.52 $ 2.79 300
17.50 $ 2.79 500
17.50 $ 2.79 100

allen ein schönes und sonniges wochenende.

covino02

[WhiteRabbit]

AP Stem Cell Firms Get Bill Activity Boost
Friday May 20, 4:27 pm ET
Biotech Companies Using Stem Cell Technology Get Boost After Legislative Activity

NEW YORK (AP) -- Biotech companies that use stem cell technologies received a boost Friday after House Republican leaders said they would support a research bill that encouraged harvesting the cells from umbilical cords, in light of a presidential veto threat over a bill calling for the use of embryonic cells.

Aastrom Biosciences Inc. shares rose 22 cents, or 8.6 percent, to close at $2.88 on the Nasdaq, and StemCells Inc. shares rose 42 cents, or 11.7 percent, to close at $4.

Stem cells are template cells found in bone marrow, embryos and umbilical cords that can be coaxed to grow into different cell types using biochemical signals to replace damaged cells that cause a variety of illnesses.

On Thursday, House Speaker Dennis Hastert, R-Ill., and Majority Leader Tom DeLay, R-Texas, said they would pair language encouraging the harvesting stem cells from umbilical cord blood with legislation calling for a lift of President Bush`s 2001 ban on using federal money for research using new embryonic stem cells lines. Bush said Friday he would veto any bill that tried to lift the ban.

One drawback from using umbilical cord blood cells is that they grow into fewer types of tissues than embryonic cells can.

Reps. Mike Castle, R-Del., and Diana DeGette, D-Colo., sponsored the bill that calls for a lift of the ban.

Geron Corp. shares rose 14 cents to close at $7.35 on the Nasdaq, and ViaCell Inc. shares climbed 46 cents, or 7.6 percent, to close at $6.51.

[covino02]

ASTM USD

9:18:29.481 S 3,000 2.9000
9:18:18.616 S 95 2.9000
9:17:43.658 S 1,000 2.9000
9:17:29.310 B 500 2.9000
9:13:49.619 S 100 2.8900
9:13:49.619 S 100 2.8900
9:12:25.303 B 300 2.9200
9:12:25.303 B 200 2.9200
9:08:14.027 B 200 2.9000

[DonauPirat]

Aastrom Biosciences has received the first part of a $740,000 phase II grant from the US National Institute of Diabetes and Digestive and Kidney Diseases, to support research into the use of stem cells in tissue regeneration.

17 Aug 2005, 17:22 GMT - The company is developing its "Tissue Repair Cells" for use in multiple medical indications, and has already received a phase I grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases.

Tissue Repair Cells (TRCs) are Aastrom`s proprietary mixture of bone marrow-derived adult stem and progenitor cells produced using patented technology in the AastromReplicell System. It has been demonstrated in the laboratory that TRCs are able to develop into different types of tissue lineages in response to inductive signals, including blood, bone, cartilage, adipose and vascular tubules.

This new grant will support investigations to further increase the overall numbers of the targeted cells thought to be especially important for bone regeneration.

This includes studies of the cells contained in TRCs, to better understand how accessory cells support the growth of stem and progenitor cells, so they are optimized when the surgeon is ready to use them for bone or vessel regeneration. Another significant goal of this study is the evaluation of Aastrom`s unique cell production process in the AastromReplicell System to facilitate the transition to commercial level cell manufacturing.

Dr Janet Hock, chief science officer and vice president of Global Research at Aastrom stated. "Further understanding how TRCs contribute to the regeneration of blood vessels should allow us to better utilize our cell products for bone regeneration in orthopedic applications, and for other conditions where regulated revascularization is needed."

[Flashpompa]

@all

kann es sein das ein neuer aufschwung kommt ?

lange keine meldung mehr .

:eekdenke 4,5$ sind in den nächsten 2 monaten drinne)

mfg

[Flashpompa]

astm +20%

hat die korrektzr schon begonnen?

mfg viel spass longs

[Flashpompa]

23.03.2006 21:01
Aastrom Biosciences Receives Orphan Drug Designation from the FDA for Proprietary Bone Marrow Cells

ANN ARBOR, Mich., March 23 /PRNewswire-FirstCall/ -- Aastrom Biosciences, (Nachrichten) Inc. , announced today that the Company's proprietary Tissue Repair Cells (TRCs) received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for use in the treatment of osteonecrosis (also known as avascular necrosis). The National Osteonecrosis Foundation indicates that in the U.S. alone, there are at least 20,000 new people diagnosed with this debilitating disease each year, and current therapies are of limited effectiveness.

(Logo: http://www.newscom.com/cgi-bin/prnh/20060302/NETH028LOGO )

Osteonecrosis is a painful medical condition where the tissue inside a bone is dying and unable to regenerate itself through natural processes. Ninety percent of the patients afflicted by this disease have osteonecrosis at the hip, or more specifically the femoral head -- the ball at the top of the femur bone that rotates inside the hip socket. This disease usually attacks young male adults, and left untreated the femoral head eventually collapses, leading to the requirement of a total hip joint replacement. In the U.S., it is estimated that up to 10% of all hip replacements are performed due to osteonecrosis. There are no established pharmaceuticals for the prevention or treatment of osteonecrosis.

The tissues destroyed in the osteonecrosis disease process include bone, bone marrow and vascular (blood vessels). The diverse tissues involved with this disease have complicated the development of effective treatments in the past. Aastrom's TRCs, a proprietary mixture of stem, stromal and progenitor cells derived from a small sample of the patient's own bone marrow, have been used in clinical trials to regenerate all three of these tissues. With this capability, TRCs may offer a novel means to restore healthy tissue at osteonecrotic sites.

Aastrom is currently preparing a clinical trial protocol to evaluate TRCs in the treatment of osteonecrosis at the hip. In general terms, the expected treatment approach will be to remove the necrotic tissue from the interior of the patient's deteriorated bone, and implant the tissue-regenerating TRCs into the femoral head. The expectation is that if the femoral head/hip joint is strengthened by the re-growth of healthy bone, vascular and marrow tissue, the need for a hip replacement could be delayed or eliminated for patients suffering from this disease.

"With our clinical and developmental research progress using TRCs for the regeneration of healthy bone, vascular and bone marrow tissues, we can begin to target new areas of unmet medical need, such as osteonecrosis," said R. Douglas Armstrong, Ph.D., Chairman and Chief Executive Officer of Aastrom. "We are pleased to receive an orphan drug designation for our TRC cell product as a new treatment option for patients with such a significantly debilitating disease. This progress is a part of our strategic plan for the development of a new concept in products for use in complex orthopedic indications."

The orphan drug designation is granted to select approaches that offer potential therapeutic value in the treatment of rare diseases and conditions. Above and beyond assistance from the Office of Orphan Products Development in furthering its TRC tissue regeneration program, Aastrom may receive several other benefits. In particular, Aastrom may be entitled to an expedited FDA review, the reduction or even elimination of filing fees, and the availability of possible tax credits. The Company will also be entitled to marketing exclusivity for seven years once the product receives FDA approval.

About Aastrom Biosciences, Inc.

Aastrom Biosciences, Inc. is developing products for the repair or regeneration of multiple human tissues, based on its proprietary Tissue Repair Cell (TRC) adult stem cell technology. Aastrom's TRC products contain large numbers of stromal, stem and progenitor cells that are produced from a small amount of bone marrow cells originating from the patient. The AastromReplicell(R) System, an industry-unique automated cell product manufacturing platform, was developed for the production of standardized, patient-specific TRC products. TRC products have been used safely in humans as a substitute for bone marrow stem cells, and are currently in clinical trials for bone grafting (long bone fractures and spine fusion) and blood vessel regeneration (diabetic limb ischemia) applications. The Company has recently reported positive interim clinical trial results for its TRCs demonstrating both the clinical safety and ability of TRCs to induce healthy new tissue growth (long bone fractures and jaw bone reconstruction).

For more information, visit Aastrom's website at http://www.aastrom.com/.

This document contains forward-looking statements, including without limitation, statements regarding product development objectives and expected therapeutic value, potential benefits to be received because of the orphan product classification, planned clinical trials and their results, contemplated regulatory filings, potential product applications and potential advantages of Tissue Repair Cells (TRCs), which involve certain risks and uncertainties. The forward-looking statements are also identified through use of the words "plan," "may," "possible," "potential," "could," "expected," "expectation," and other words of similar meaning. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are the results obtained from clinical trial and development activities, regulatory approval requirements, the availability of resources, competitive developments and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom's Annual Report on Form 10-K, and other filings with the Securities and Exchange Commission.

CONTACTS: Kris M. Maly Cameron Associates Investor Relations Department Kevin McGrath Aastrom Biosciences, Inc. Phone: [phone] Phone: [phone]
Photo: http://www.newscom.com/cgi-bin/prnh/20060302/NETH028LOGO
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, [e-mail]

[Flashpompa]

astm 2.33$ +30,17%

wurde auch echt mal zeit

mfg long

[kevin.lomax]

24.03.2006 17:03
Aastrom Biosciences: Trendwechsel
Der bisherige kurzfristige Trend von Aastrom Bioscien (Nachrichten) wird nach oben durchbrochen werden. Die Prognose fr Aastrom Bioscien fr Freitag den 31. Mrz ist 1,72 Euro.

[Flashpompa]

ja aber leider gehts in ami land noch weiter und der ami chart ist er aussagebiger

mfg

[Flashpompa]

ASTM achtung

MANN KÖNNTE DIESE KURSE ALS EINSTIEG BENUTZEN .

in drei monaten gibts ein neues 52week high

mfg

[connyco]

Antwort auf Beitrag Nr.: 21.118.268 von Flashpompa am 07.04.06 12:38:30

Man kann aber auch noch einen Monat warten und dann für unter einem Euro kaufen !!

[evens]

Irgendjemand hier?
Wer kann was Aastrom berichten?
Kaufkurse, oder sieht man noch den euro

[diegutefee]

Hallo Aastrom-Freunde,

gestern war Kaufsignal!

Wiedereinstieg nicht verpassen!

Ich bin dabei!

Herzliche Grüße

diegutefee

[kevin.lomax]

British scientists have reported discovering a gene that may make it possible to take adult stem cells and transform them into embryonic ones with the same properties. If their research proves to be a success, it could the debate about embryonic stem cell research by reducing the need to use it or human cloning for studies.
http://www.lifenews.com/bio1566.html

[kevin.lomax]

15/06/2006 18.46.36
The EU Votes on Stem Cell Research

(15 Jun 06 - RV) In a legislative compromise, the European Parliament today voted to allow researchers working on stem cells to access EU funding for their experiments.

The ruling was made on the proviso that the experiments are not creating human embryos solely for the purpose of research.

Other restrictions on access to EU funding are that the experiments not be directly connected to research into human cloning; for reproductive purposes; or for the modification of human genetic heritage.

Maria Martins of the european peoples’ party was in Brussels for the vote. She says the decisions is questionable on many grounds…

[kevin.lomax]

Religious row over stem cell work

Scientists have condemned a leading Catholic cardinal's calls for those who carry out embryonic stem cell research to be excommunicated.
Cardinal Alfonso Lopez Trujillo, head of the Pontifical Council for the Family, made his comments in Famiglia Cristiana, a Catholic magazine.

He said research carried out on embryos was "the same as abortion".

But scientists called his comments outrageous, and said they amounted to "religious persecution".


This amounts to religious persecution of scientists which has no place in modern liberal societies
Professor Julian Savulescu, University of Oxford

Cardinal Trujillo will open the church's World Meeting of Families in Valencia, Spain, on Saturday.

He told Famiglia Cristiana: "Destroying an embryo is the equivalent of abortion.

"Excommunication applies to all women, doctors and researchers who eliminate embryos."

He added: "Even talking about the defence of life and family rights is being treated as a sort of crime against the state in some countries - a form of social disobedience or discrimination against women."

'God will judge'

But Dr Stephen Minger, leading stem cell expert at Kings College, said: "Having been raised a Catholic I found this stance really outrageous.

"Are they going to excommunicate IVF doctors, nurses and embryologists who routinely put millions of embryos down the sink every year throughout the world?

"It is more ethical to use embryos that are going to be destroyed anyway for the general benefit of mankind than simply putting them down the sink."

Professor Allan Templeton, president of the Royal College of Obstetricians and Gynaecologists, called the cardinal's comments "insensitive and unhelpful".

He added: "I cannot really believe it represents the thinking of the Roman Catholic church."

Professor Julian Savulescu, Uehiro Chair in practical ethics at the University of Oxford, warned: "This amounts to religious persecution of scientists which has no place in modern liberal societies.

"Presumably God will be the one to judge the scientists, not Church leaders."

http://news.bbc.co.uk/2/hi/health/5158760.stm

[kevin.lomax]

Democrats Win Swift Action on Stem Cell Legislation

7/12/2006 11:37:00 AM

To: National Desk

Contact: Jim Manley or Rebecca Kirszner, 202-224-2939, both of the Office of Senate Democratic Leader Harry Reid

WASHINGTON, July 12 /U.S. Newswire/ -- A day after the Senate Democrat Leadership called on him to make House passed stem cell legislation (HR 810) the next bill debated in the U.S. Senate, Senate Majority Leader Bill Frist today agreed and announced the legislation will be considered by the Senate on July 17 and 18. With today's progress on legislation that holds the promise of cures for diseases impacting millions of Americans, Senate Democratic Leader Harry Reid issued the following statement:

"I am extremely pleased Senator Frist has agreed to Democrats' request to take up stem cell legislation next week. The American people have waited long enough for the United States Senate to act on this potentially life-saving legislation. Despite his frequent promises, Senator Frist waited for over a year after the House of Representatives passed the bill before even agreeing to bring it to the Senate floor. There is not another moment left to spare."

http://releases.usnewswire.com/GetRelease.asp?id=69096